Beruflich Dokumente
Kultur Dokumente
BASIC BIOLOGY
AND CURRENT UNDERSTANDING
OF SKELETAL MUSCLE
No part of this digital document may be reproduced, stored in a retrieval system or transmitted in any form or
by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no
expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No
liability is assumed for incidental or consequential damages in connection with or arising out of information
contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in
rendering legal, medical or any other professional services.
BASIC BIOLOGY
AND CURRENT UNDERSTANDING
OF SKELETAL MUSCLE
KUNIHIRO SAKUMA
EDITOR
New York
All rights reserved. No part of this book may be reproduced, stored in a retrieval system or
transmitted in any form or by any means: electronic, electrostatic, magnetic, tape, mechanical
photocopying, recording or otherwise without the written permission of the Publisher.
For permission to use material from this book please contact us:
Telephone 631-231-7269; Fax 631-231-8175
Web Site: http://www.novapublishers.com
NOTICE TO THE READER
The Publisher has taken reasonable care in the preparation of this book, but makes no expressed or
implied warranty of any kind and assumes no responsibility for any errors or omissions. No
liability is assumed for incidental or consequential damages in connection with or arising out of
information contained in this book. The Publisher shall not be liable for any special,
consequential, or exemplary damages resulting, in whole or in part, from the readers use of, or
reliance upon, this material. Any parts of this book based on government reports are so indicated
and copyright is claimed for those parts to the extent applicable to compilations of such works.
Independent verification should be sought for any data, advice or recommendations contained in
this book. In addition, no responsibility is assumed by the publisher for any injury and/or damage
to persons or property arising from any methods, products, instructions, ideas or otherwise
contained in this publication.
This publication is designed to provide accurate and authoritative information with regard to the
subject matter covered herein. It is sold with the clear understanding that the Publisher is not
engaged in rendering legal or any other professional services. If legal or any other expert
assistance is required, the services of a competent person should be sought. FROM A
DECLARATION OF PARTICIPANTS JOINTLY ADOPTED BY A COMMITTEE OF THE
AMERICAN BAR ASSOCIATION AND A COMMITTEE OF PUBLISHERS.
Additional color graphics may be available in the e-book version of this book.
Contents
Preface
vii
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
21
53
87
123
Chapter 6
147
Chapter 7
171
Chapter 8
205
251
Chapter 9
vi
Chapter 10
Index
Contents
Skeletal Muscular Adaptation and Local Steroidogenesis
Katsuji Aizawa
289
303
Preface
Skeletal muscle is a highly plastic tissue that constitutes approximately thirty percent of
total body mass and adapts rapidly to changing functional demands. Skeletal muscle is not
only the generator of force production, but also plays a crucial role in whole body metabolism
and energy consumption. In this book, leading experts in the area of exercise biochemistry
and molecular biology in skeletal muscle provide an up-to-date view of the molecular basis of
various adaptations of skeletal muscle, with emphasis on new biological concepts (muscle
stem cells, muscle steroidogenesis, etc). This book deals with the recent intriguing role of
heat shock protein (HSP), AMPK and reactive oxygen species (ROS) for muscle morphology,
function and metabolism. Discussed also is the molecular mechanism for protein metabolism
and therapeutic application for sarcopenia. The deeper understanding of the signal
transduction and modification in skeletal muscle will develop new therapeutic strategies for
preventing physical disability and increased risk of morbidity/mortality due to the loss of
muscle mass.
Chapter 1 - Satellite cells are muscle stem cells located between the basal lamina and
plasma lemma of myofibres and play important roles in adult skeletal muscle repair and
regeneration as well as postnatal muscle growth. Recent findings indicate that satellite cells
exist as a genetically and functionally heterogeneous population among muscles, which is not
only based on fibre types, but also embryonic origins. Satellite cells are also a heterogeneous
population within a single myofibre. Importantly, only a small population of satellite cells
appears to possess stemness that generates robust myogenic progeny and maintains the
satellite cell pool throughout life. Recent studies have discovered the cellular and molecular
characteristics of satellite cell heterogeneity including Pax7+Myf5- satellite stem cells,
immortal DNA strand-retaining cells, satellite-side population cells, highly Pax7-expressing
cells and slow-dividing cells. In this chapter, the authors discuss emerging findings of satellite
cell heterogeneity and stem cell hierarchies in satellite cell populations in adult muscle.
Further understanding of the hierarchical regulation of satellite cell populations is an
important issue to develop cell-based therapies of muscular dystrophies and age-related
sarcopenia.
Chapter 2 - Skeletal muscle is the largest organ in the human body, making up more than
30-40% of total body weight in healthy adults. The wasting of skeletal muscle mass, which is
induced by unloading, malnutrition, aging or several kinds of diseases, leads to the loss of
functional human performance, long-term health issues and a low quality of life. It has been
viii
Kunihiro Sakuma
generally accepted that the net balance between protein synthesis and degradation is a critical
determinant of the regulation of skeletal muscle mass.
Recent studies indicate that the skeletal muscle protein metabolism in response to the
environmental cues (i.e. physical activity and nutrients) is blunted in the elderly, which then
leads to the age-associated gradual loss of muscle mass. The aim of the present chapter is to
summarize and discuss, 1) recent progress in the understanding of cellular mechanisms in
anabolic (protein synthesis) and catabolic (protein degradation) signaling pathways that
govern the regulation of skeletal muscle mass, 2) altered capacity in the protein metabolism
of aged skeletal muscle in response to exercise and nutrients. A better understanding of the
anabolic and catabolic processes which regulate skeletal muscle mass is critical for the
development of more effective therapeutic interventions to prevent the loss of muscle with
aging and disease.
Chapter 3 - Insulin-like growth factor-I (IGF-I) is an important growth factor mediating
cell proliferation, differentiation and cell survival in skeletal muscles. In humans, there are
three types of IGF-I isoforms derived from the differential E domain, called IGF-I Ea, Eb and
Ec. IGF-I Ec is also called mechano growth factor (MGF), because of the marked
upregulation in exercised and damaged muscles. In rodents, IGF-I isoforms are composed of
two types of IGF-I, IGF-I Ea and MGF. IGF-I isoforms serve as the IGF-I precursor peptides.
IGF-I isoforms have multiple transcriptional initiation sites and derived from some alternative
splicing. After post-translation modification, the IGF-I precursor peptides are grown into a
mature IGF-I. IGF-I isoforms are produced by various tissues, including liver, cartilage and
skeletal muscle, and act through endocrine and autocrine/paracrine pathways. E peptides
derived from the IGF-I isoforms are likely to have different growth-promoting effects on
skeletal muscles.
IGF binding protein (IGFBP) family is composed of six different members, which are
IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6. IGFBPs are characteristic
of high affinity for IGFs binding, whereas IGFBP related proteins with the low affinity
binding are also found and distinguished from IGFBPs. Most of the circulating IGF-I exists in
a large tripartite complex with IGFBP-3 and the acid labile subunit (ALS). IGF-I also exists
in binary or ternary complexes with another member of the IGFBP family. IGF-I is removed
from the complexes, and free IGF-I acts on muscle growth via the IGF-I receptors. IGFBPs
have stimulating and inhibitory effects depending on the IGF-I as well as IGF-independent
actions. The same IGFBP can act to promote or suppress IGF actions in association with
posttranslational modification, such as proteolytic cleavage, dephosphorylation. Gene
expressions and their functions of IGF-I isoforms and IGFBPs in skeletal muscle are
discussed in the present review.
Chapter 4 - The world's elderly population is expanding rapidly, and we are now faced
with the significant challenge of maintaining or improving physical activity, independence,
and quality of life in the elderly. Sarcopenia, the age-related loss of skeletal muscle mass, is
characterized by a deterioration of muscle quantity and quality leading to a gradual slowing of
movement, a decline in strength and power, increased risk of fall-related injury, and often,
frailty. Since sarcopenia is largely attributed to various molecular mediators affecting fiber
size, mitochondrial homeostasis, and apoptosis, the mechanisms responsible for these
deleterious changes present numerous therapeutic targets for drug discovery. Resistance
training combined with amino acid-containing supplements is often utilized to prevent agerelated muscle wasting and weakness. In this chapter, the authors summarize recent
Preface
ix
Kunihiro Sakuma
twitch muscle fibers. These properties potentially affect the mechanical strength and the
signal transduction. The adaptive transformation is postulated on the structural organization
as well as its components, in accordance with the level and the pattern of the muscle activity.
Chapter 8 - Skeletal muscle possesses a great degree of metabolic plasticity, which can be
controlled by exercise, cytokines, pharmaceuticals and nutrients. There are large variations in
the human skeletal muscle metabolic capacity, and they are linked with the prevalence of
chronic metabolic disorders such as obesity, type II diabetes mellitus, hypertension and
dyslipidemia, as well as exercise endurance.
The metabolic profiles of skeletal muscle have been investigated for several decades. 5AMP-activated protein kinase (AMPK) is one of the most important metabolic regulators in
skeletal muscle. AMPK is also activated by energy deprivation (i.e., an increasing AMP:ATP
ratio) and served as a cellular energy sensor. AMPK is activated by muscle contraction (e.g.,
exercise), drugs used to treat type 2 diabetes mellitus, cytokines, nutrients, reactive oxygen
species and other chemically synthesized activators.
Activated AMPK promotes the catabolic pathways that generate ATP (e.g., glucose
uptake, fatty acid uptake and oxidation, and mitochondrial respiration). AMPK promotes the
translocation of glucose transporter 4 (GLUT4) from the cytoplasm to the cell membrane and
the subsequent glucose uptake into a cell independent of the insulin system. AMPK also
accelerates the mitochondrial fatty acid uptake by inhibiting the acetyl-coenzyme A
carboxylase activity. AMPK phosphorylates several downstream transcription factors and
coactivators that regulate energy catabolism. AMPK activation results in the upregulation and
the direct phosphorylation of the peroxisome proliferator-activated receptor coactivator-1
(PGC-1), which is an important regulator for mitochondrial biogenesis. In addition, AMPK
indirectly deacetylates PGC-1 via SIRT1. These characteristics make AMPK a valuable
therapeutic target for chronic metabolic diseases associated with insulin resistance.
Chapter 9 - Mitochondria serve a critical function in the maintenance of cellular energy
supplies, calcium homeostasis, and cell death. Aside from these major roles, several lines of
evidence suggest that mitochondria are involved in cell cycle control, cell growth and
differentiation in a wide variety of cell types including myogenic cells.
When the myoblasts differentiate into myotubes, the abundance, morphology, and
functional properties of mitochondria is being dynamically altered. Mitochondrial mass,
mitochondrial DNA content, mitochondrial enzyme activities, and mitochondrial respiration
are markedly increased during myogenesis.
This strongly suggests that myogenesis is accompanied by increased mitochondrial
biogenesis and that the metabolic shift from glycolysis to oxidative phosphorylation as the
major energy source occurs during myogenesis. Intriguingly, when myoblasts are exposed to
mitochondrial genetic and metabolic stress, they fail to differentiate into multinucleated
myotubes, suggesting that mitochondria may play a certain role in myogenesis.
The process is relatively well understood phenomenologically, but the underlying
molecular mechanisms have been surprisingly slow to emerge. Understanding how
mitochondria are involved in myogenesis will provide a valuable insight into the underlying
mechanisms that regulate the maintenance of cellular homeostasis. Here the authors will
summarize the current knowledge regarding the role of mitochondria as a potential regulator
of myogenesis.
Chapter 10 - The plasticity of skeletal muscle facilitates adaptation to various stimuli.
Exercise training induces skeletal muscle adaptation such as muscle strength and hypertrophy,
Preface
xi
while inactivity leads to muscle atrophy such as sarcopenia. Sex steroid hormones (androgens
and estrogens) often mediate muscle plasticity. Indeed, these hormones induce various effects
including growth, strength, metabolism, and antioxidant levels as well as muscle atrophy.
Though sex steroid hormones play an important role in skeletal muscular homeostasis, the
role of the endocrine system in muscle plasticity is unknown.
Sex steroid hormones are produced by various peripheral target tissues including the
kidney, liver, and brain in addition to endocrine organs such as the testis or ovary. Sex steroid
hormones are synthesized from cholesterol by steroidogenic enzymes, such as cholesterol
side-chain cleavage (P450scc), cytochrome P450 enzyme 17-hydroxylase (P450c17), 3hydroxysteroid dehydrogenase (HSD), and 17-HSD, with testosterone being irreversibly
converted to estrogen by aromatase cytochrome P450 (P450arom). Testosterone is also
converted into its bioactive metabolite dihydrotestosterone (DHT) by 5-reductase.
The functional importance of sex steroid hormones derived from extragonadal tissues has
been gaining support in recent years. For instance, steroidogenic enzymes expressed in
skeletal muscle have been reported to locally synthesize sex steroid hormones from
circulating dehydroepiandrosterone (DHEA) or testosterone in response to exercise. Thus,
local steroidogenesis in skeletal muscle may play an important role in the plasticity of skeletal
muscle. This review focuses on the steroidogenesis of skeletal muscle and discusses the
physiological significance of the sex steroid hormone network of circulation and skeletal
muscle.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 1
Abstract
Satellite cells are muscle stem cells located between the basal lamina and plasma
lemma of myofibres and play important roles in adult skeletal muscle repair and
regeneration as well as postnatal muscle growth. Recent findings indicate that satellite
cells exist as a genetically and functionally heterogeneous population among muscles,
which is not only based on fibre types, but also embryonic origins. Satellite cells are also
a heterogeneous population within a single myofibre. Importantly, only a small
population of satellite cells appears to possess stemness that generates robust myogenic
progeny and maintains the satellite cell pool throughout life. Recent studies have
discovered the cellular and molecular characteristics of satellite cell heterogeneity
including Pax7+Myf5- satellite stem cells, immortal DNA strand-retaining cells, satelliteside population cells, highly Pax7-expressing cells and slow-dividing cells. In this
chapter, we discuss emerging findings of satellite cell heterogeneity and stem cell
hierarchies in satellite cell populations in adult muscle. Further understanding of the
hierarchical regulation of satellite cell populations is an important issue to develop cellbased therapies of muscular dystrophies and age-related sarcopenia.
Corresponding author: Yusuke Ono, Ph.D. Department of Stem Cell Biology, Nagasaki University Graduate
School of Biomedical Science, 1-12-4 Sakamoto, Nagasaki 852-8523 Japan. Tel: +81 (0)95 819 7099; Fax:
+81 (0)95 819 7100.E-mail: yusuke-ono@nagasaki-u.ac.jp.
Yusuke Ono
1. Introduction
Satellite cells are resident muscle stem cells located between the basal lamina and
plasmalemma of myofibres, which were discovered by electron microscopy analysis over 50
years ago [1-3]. Satellite cells play important roles in providing myonuclei for postnatal
muscle growth as well as muscle maintenance, hypertrophy, repair and regeneration in adults
[4, 5]. Satellite cells generate muscle progenitors, termed myoblasts, which extensively
proliferate before fusing with existing myofibres to contribute toward myonuclei, or fuse with
each other to form myotubes that eventually become mature myofibres. Satellite cells also
self-renew to maintain the stem cell pool for future needs [6, 7].
In healthy adult muscle, satellite cells are mitotically quiescent and express the pairedbox transcription factor Pax7. Satellite cells are activated in response to stimulation such as
muscle injury. Activated satellite cells up-regulate MyoD expression and undergo mitosis.
Following cell proliferation, the majority of satellite cells down-regulates Pax7, maintains
MyoD, expresses myogenin and undergoes myogenic differentiation to produce myosin
heavy chain (MyHC)+ new myonuclei. A minority population down-regulates MyoD,
maintains Pax7 and returns to a quiescent state to self-renew [8-10], as observed in mouse
myoblast cell lines [11]. Interestingly, the total number of satellite cells in adult muscle
remains relatively constant following repeated muscle injury and regeneration throughout life,
indicating that self-renewal of satellite cells is carefully regulated. Indeed, failure of satellite
cell functions leads to impaired recovery following muscle damage and severe muscular
dystrophic phenotypes [12-18]. In addition to Pax7 [19], satellite cells can be also identified
by the expression of CD34 [20], caveolin-1 [21], M-cadherin [22], calcitonin receptors [23],
1-integrin [24], c-Met [25], syndecan-3/4 [26], Myf5/ -gal [20], NCAM [27], VCAM-1 [28]
and CXCR4 [29] (Figure 1).
Figure 1. Muscle satellite cells and cell fate choice. (A) Freshly isolated extensor digitorum longus
(EDL) myofibres with their associated satellite cells were immediately fixed and stained for caveolin1(red)+ and Pax7 (green) + satellite cells. (B) Pax7+ quiescent satellite cells become activated to coexpress both Pax7 and MyoD (Pax7+MyoD+). The vast majority of activated satellite cells then
undergoes proliferation before down-regulating Pax7, maintaining MyoD, and differentiating (Pax7MyoD+). The minority of satellite cells maintains Pax7 but lose MyoD to self-renew and become
quiescent. (C) Freshly isolated satellite cells were cultured in differentiation medium for 5 days after
culture in growth medium for 7 days. Mononucleited proliferating cells in growth condition and
multinucleited myotubes in differentiation condition were observed in culture. (D) MyHC+ myotubes
shown in (C) were visualised by immunocytochemistry.
Yusuke Ono
Old age is associated with a significant decline in the mass, strength and regenerative
capacity of skeletal muscles [52]. While the myogenic potential of aged satellite cells is not
compromised [53, 54], their self-renewal appears to fail [55]. This observation may explain
the decline in satellite cell numbers with age [54, 56]. However, it is unlikely that the agerelated decrease in satellite cell numbers occurs in all muscles throughout the body. For
example, age-related decline in rat satellite cell numbers occurs in tibialis anterior muscle,
extensor digitorum longus (EDL) and soleus [56, 57], whereas no significant reduction is
observed in levator ani muscle [58]. Additionally, although the number of Pax7+ satellite cells
per EDL fibre significantly decreases with age, conversely, the number of satellite cells per
masseter fibre almost doubles in aged mice, compared with that in young mice [43]. This
finding may explain that both the structure and function of masseter muscles are preserved
with age, compared with those of limb muscles [59]. These observations, therefore, indicate
that age-dependent changes in satellite cell number and function may not be a universal
property of muscle aging, suggesting distinct alterations in muscle function with age.
Yusuke Ono
Although the majority of SP cells exist outside the satellite cell position, satellite-SP cells
are localized in the satellite cell position and spontaneously fuse to form myotubes and
produce myogenic progeny [71]. When transplanted into regenerating muscle, satellite-SP
cells generate satellite cell progeny more efficiently.
In 1975, the immortal strand hypothesis has been proposed as a protective mechanism
against genomic mutations during DNA replication in stem cells [72]. According to this
hypothesis, a stem cell produces a committed cell with newly synthesized DNA and a
daughter cell that retains older DNA strands by asymmetric cell division. This phenomenon
has been also observed for satellite cells [73, 74]. Recently, using transgenic Tg:Pax7-nGFP
mice, Rocheteau et al showed that a highly Pax7-expressing (Pax7-nGFPhigh) cell population
has a lower metabolic status and delayed first cell division compared with those of a lower
Pax7-expressing (Pax7-nGFPlow) cell population [75]. Pax7-nGFPhigh cells can self-renew and
generate Pax7-nGFPlow cells after serial transplantations. Interestingly, they found that the
majority of Pax7-nGFPhigh cells asymmetrically segregate older DNA strands to renewing
cells during cell division; thus, quiescent Pax7-nGFPhigh cells represent a reversible dormant
stem cell state during muscle repair and regeneration, whereas Pax7-nGFPlow cells perform
random DNA segregation [75].
Yusuke Ono
Figure 2. A slow-dividing cell population present in activated satellite cells. To monitor cell-cycle
frequency, freshly isolated satellite cells were labelled with a fluorescent membrane dye PKH26
(Sigma). PKH26-labelled cells were maintained in growth medium for 4 days. Typical images
immediately (Day 0) or at 4 days (Day 4) after PKH26 staining. The vast majority of activated satellite
cells are PKH26low fast-dividing cells, whereas PKH26high slow-dividing cells are observed as a
minority population [85].
To assess the frequency of cell division, satellite cells isolated from mouse EDL muscle
were labelled with the fluorescent lipophilic dye PKH26 and stimulated to proliferate under a
growth culture condition for several days. The vast majority of activated satellite cells are
PKH26low retaining fast-dividing cells that generate a greater number of both multinucleated
myotubes and self-renewing cells, compared with those of PKH26high retaining slow-dividing
cells as the minority population (Figure 2). However, cells derived from the slow-dividing
cell population efficiently form secondary myogenic colonies after passaging, whereas those
derived from the fast-dividing cell population rapidly commit to myogenic differentiation
after a few rounds of cell division. Thus, the fast-dividing cell population is exhausted after
several passages, but the slow-dividing cell population retains long-term self-renewal ability
[85]. A single satellite cell clonal assay demonstrated that large colonies contain numerous
self-renewable and differentiated progeny, which suggests cells that generate large colonies
possess stem cell characteristics [43]. Importantly, only cells derived from large colonies can
generate highly proliferative progeny with long-term self-renewal, unlike those from small
colonies (our preliminarily observation). Indeed, the satellite cell population that generates
large colonies probably contains slow-dividing cells. Moreover, in vivo transplantation
analysis demonstrated that slow-dividing cells extensively produce regenerative myofibres in
muscles with cardiotoxin-induced injury. Following transplantation, the effect of secondary
cardiotoxin injection to stimulate muscle regeneration was also examined.
Interestingly, after the second cardiotoxin injection, more newly regenerated myofibres
were observed only in slow-dividing cell-transplanted muscle, but not in fast-dividing cell-
transplanted muscle, compared with levels after the first cardiotoxin injection. These findings
indicate that self-renewing cells derived from the slow-dividing cell population undergo a
second round of proliferation within injured muscle after the second muscle injury, and slowdividing cells, therefore, retain stem cell-like properties that extensively contribute to
regeneration in host muscle by repeatedly producing myogenic progeny. A previous study by
Beauchamp et al showed that the majority of immortal myoblasts quickly die after
transplantation into irradiated dystrophic muscles, but a minority, which are slow-dividing in
vitro, efficiently survive and are more successfully engrafted [86], Therefore, the in vivo
regenerating environment appears to directly and preferentially favour engraftment of slowdividing cells.
10
Yusuke Ono
Figure 3. Role of BMP signalling during muscle regeneration in satellite cells. During muscle
regeneration, quiescent Pax7+ satellite cells are activated to co-express Pax7 and MyoD. Satellite cellderived myoblasts proliferate extensively before many cells then downregulate Pax7 and differentiate to
either repair injured muscle fibres or fuse together to generate new myofibres. Other satellite cells
maintain Pax7 expression but lose MyoD, and self-renew to maintain a stem cell pool. Normal BMP
signalling through Smad1/5/8 phosphorylation and Id1 induction is required during muscle regeneration
to allow the satellite cell-derived myoblast population to expand, by preventing precocious myogenic
differentiation. Noggin, a negative regulator for BMP signalling, is up-regulated to antagonise the BMP
signal to facilitate the myogenic differentiation programme [90].
Together, BMP signalling is clearly a part of the programme that regulates satellite cell
numbers and functions from development through to growth and regeneration of muscle
(Figure 3).
It is important to note that some slow-dividing cells tend to differentiate and fuse to form
myotubes at an early time point in culture [85]. This observation indicates that slow-dividing
cells are still a heterogeneous population that may correspond to committed myogenic
progenitors that immediately undergo myogenic differentiation with minimal or no cell
division in vivo [93] and in vitro [43]. As mentioned above, Id1 as a critical target of BMP
signalling plays an important role to maintain the undifferentiated state of activated satellite
cells [90, 91, 94]. Interestingly, Id1 is expressed by all activated satellite cells, but the
expression level varies within the slow-dividing cell population. Because slow-dividing cells
with low levels of Id1 protein tend to undergo myogenic differentiation immediately, longterm self-renewable cells in the slow-dividing cell population are restricted to an
undifferentiated population that expresses high levels of Id1 protein [85]. Thus, slow-dividing
cells with a highly BMP signalling (Id1high) in the activated satellite cells are a minority cell
population that retains long-term self-renewal throughout life, while committed progenitors
that express low levels of Id1 protein may proliferate minimally before differentiation into
muscle.
Speculatively, the small population of satellite cells capable of robust re-population of
satellite cells and efficient muscle regeneration, which is observed in previous studies [6, 31,
32, 68], may also contain cells that generate slow-dividing cells.
11
The cell cycle frequency of satellite-SP cells that are capable of efficiently generating
satellite cell progeny is much lower compared with that of other satellite cells in vitro [71]. In
addition, cell cycle entry for the first cell division by the Pax7high cell population is much
slower than that of the Pax7low cell population [75]. Future studies should be valuable for
defining whether slow-dividing cells correspond to other stem cell-like populations found
previously, such as Pax7+Myf5+ cells, older DNA retaining cells, satellite-SP cells and
Pax7high cells (Figure 4).
Figure 4. A possible model for stem cell hierarchies of satellite cells. Satellite cells within a fibre exist
as a functionally heterogeneous population [43]. There seems to be hierarchical regulation of satellite
cell populations in adult muscle. In activated satellite cells, there are at least two populations; fastdividing cells as a majority and slow-dividing cells as a minority [85]. Slow-dividing cells that express
high levels of Id1 protein retain long-term self-renewal ability and so may be at the top of the satellite
cell hierarchy. As a transit amplifying cells, fast-dividing cells that highly express Id1 protein give rise
to a greater number of multinucleated myotubes and self-renewing cells. Self-renewed cells derived
from the fast-dividing cell population are committed cells that express low levels of Id1 protein and
rapidly undergo myogenic differentiation after a few rounds of cell division without producing any selfrenewing cells when reactivated, whereas cells derived from the slow-dividing cell population that
highly express Id1 protein are capable of generating both slow- and fast-dividing cell populations [85].
It is unclear whether the slow-dividing cells are corresponding to the other stem cell-like populations,
such as Pax7+Myf5- cells [68], Pax7high cells [17], SP-satellite cells [71] and older DNA-retaining cells
[17, 73, 74].
12
Yusuke Ono
Satellite cells in their niche are also regulated by growth factors and cytokines secreted
from myofibres or interstitial cells [97]. Indeed, the satellite cell niche is a critical factor in
the maintenance of stem cell function.Whether or not slow-dividing cell population in
satellite cells is maintained throughout life or affected by aging remained unclear. Recently,
Chakkalakal et al. have shown that the function of slow-dividing cells is partially disrupted
during aging. Using the transgenic mice expressing a histone2B-GFP reporter driven by a
tetracycline-inducible transactivator, they monitored proliferative state of satellite cells
throughout life on the basis of label retention in vivo [98].The study showed that the rate of
satellite cell cycling differed between adult and aged histone2B-GFP mice and found that
aged satellite cells spend less time in a quiescent state compared with adult satellite cells and
aged satellite cells lose robust self-renewal potential after cell cycle entry, suggesting that
aged satellite cells lose their ability to retain a quiescent state. Slow-dividing cell population
in aged muscles displayed reduced cell growth, decreased expression of Pax7 compared with
young slow-dividing cells.However, transplanted slow-dividing cells from aged muscle into
pre-injured adult muscles can give rise to produce more numbers of both myonuclei and
Pax7+satellite cells compared with fast-dividing cells, indicating that aged slow-dividing cells
still retain stemness.
Conclusion
More than 50 years after the discovery of satellite cells, new insights during this decade
have significantly advanced our knowledge of the molecular mechanisms underlying satellite
cell fate choice. Recent studies also indicate that resident satellite cells are directly or
indirectly affected in some types of muscular dystrophy such as DMD, Emery-Dreifuss,
oculopharyngeal and facioscapulohumeral [45]. How distinct genetic networks in muscle
progenitors during the development of different muscles affect satellite cell properties in
adults, and how satellite cells are directly or indirectly compromised by genetic mutations in
specific muscular dystrophies will be emerging research areas in satellite cell biology. In this
chapter, we discussed recent findings of functionally heterogeneous and stem cell-like
subpopulations among satellite cells in adult muscle.
Considering current research progress on satellite cell heterogeneity, we may need to
revise satellite cell criteria, while discovery of new markers to define the satellite cell
population that retains more stem cell-like properties will be important to advance satellite
cell research [99].
There appears to be hierarchical regulation of satellite cell populations in adult muscle.
Slow-dividing cells avoid the risk of DNA mutation by repetitive replication and may be at
the top of the satellite cell hierarchy.
Future in vitro and in vivo studies will be valuable to define stem cell-like populations,
including slow-dividing cells, to better understand the molecular mechanisms of muscle
homeostasis and efficient repeated regeneration of adult muscle throughout life to extend the
window of opportunity for satellite cell-based therapies of muscular dystrophies and
sarcopenia.
13
Acknowledgments
This work was supported by The Nakatomi Foundation, JSPS KAKENHI and Special
Coordination Funds for Promoting Science and Technology from JST.
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol.,
9, 493-495.
Scharner, J. and Zammit, P. S. (2011). The muscle satellite cell at 50: the formative
years. Skeletal muscle, 1, 28.
Yablonka-Reuveni, Z. (2011). The skeletal muscle satellite cell: still young and
fascinating at 50. J. Histochem. Cytochem., 59, 1041-1059.
Bentzinger, C. F., Wang, Y. X. and Rudnicki, M. A. (2012). Building muscle:
molecular regulation of myogenesis. Cold Spring Harb. Perspect. Biol., 4.
Zammit, P. S. (2008). All muscle satellite cells are equal, but are some more equal than
others? J. Cell Sci., 121, 2975-2982.
Collins, C. A., Olsen, I., Zammit, P. S., Heslop, L., Petrie, A., Partridge, T. A., and
Morgan, J. E. (2005). Stem cell function, self-renewal, and behavioral heterogeneity of
cells from the adult muscle satellite cell niche. Cell, 122, 289-301.
Montarras, D., Morgan, J., Collins, C., Relaix, F., Zaffran, S., Cumano, A., Partridge,
T., and Buckingham, M. (2005). Direct isolation of satellite cells for skeletal muscle
regeneration. Science, 309, 2064-2067.
Halevy, O., Piestun, Y., Allouh, M. Z., Rosser, B. W., Rinkevich, Y., Reshef, R.,
Rozenboim, I., Wleklinski-Lee, M., and Yablonka-Reuveni, Z. (2004). Pattern of Pax7
expression during myogenesis in the posthatch chicken establishes a model for satellite
cell differentiation and renewal. Dev. Dyn., 231, 489-502.
Zammit, P. S., Golding, J. P., Nagata, Y., Hudon, V., Partridge, T. A., and Beauchamp,
J. R. (2004). Muscle satellite cells adopt divergent fates: a mechanism for self-renewal?
J. Cell Biol., 166, 347-357.
Olguin, H. C. and Olwin, B. B. (2004). Pax-7 up-regulation inhibits myogenesis and
cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev.
Biol., 275, 375-388.
Yoshida, N., Yoshida, S., Koishi, K., Masuda, K., and Nabeshima, Y. (1998). Cell
heterogeneity upon myogenic differentiation: down-regulation of MyoD and Myf-5
generates 'reserve cells'. J. Cell Sci., 111, 769-779.
Sacco, A., Mourkioti, F., Tran, R., Choi, J., Llewellyn, M., Kraft, P., Shkreli, M., Delp,
S., Pomerantz, J. H., Artandi, S. E., and Blau, H. M. (2010). Short telomeres and stem
cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell, 143,
1059-1071.
Heslop, L., Morgan, J. E. and Partridge, T. A. (2000). Evidence for a myogenic stem
cell that is exhausted in dystrophic muscle. J. Cell Sci., 113, 2299-2308.
Kuang, S., Charge, S. B., Seale, P., Huh, M., and Rudnicki, M. A. (2006). Distinct roles
for Pax7 and Pax3 in adult regenerative myogenesis. J. Cell Biol., 172, 103-113.
14
Yusuke Ono
[15] Lepper, C., Partridge, T. A. and Fan, C. M. (2011). An absolute requirement for Pax7positive satellite cells in acute injury-induced skeletal muscle regeneration.
Development, 138, 3639-3646.
[16] Murphy, M. M., Lawson, J. A., Mathew, S. J., Hutcheson, D. A., and Kardon, G.
(2011). Satellite cells, connective tissue fibroblasts and their interactions are crucial for
muscle regeneration. Development, 138, 3625-3637.
[17] Sambasivan, R., Yao, R., Kissenpfennig, A., Van Wittenberghe, L., Paldi, A., GayraudMorel, B., Guenou, H., Malissen, B., Tajbakhsh, S., and Galy, A. (2011). Pax7expressing satellite cells are indispensable for adult skeletal muscle regeneration.
Development, 138, 3647-3656.
[18] Boldrin, L. and Morgan, J. E. (2012). Human satellite cells: identification on human
muscle fibres. PLoS Curr., 3, RRN1294.
[19] Seale, P., Sabourin, L. A., Girgis-Gabardo, A., Mansouri, A., Gruss, P., and Rudnicki,
M. A. (2000). Pax7 is required for the specification of myogenic satellite cells. Cell,
102, 777-786.
[20] Beauchamp, J. R., Heslop, L., Yu, D. S., Tajbakhsh, S., Kelly, R. G., Wernig, A.,
Buckingham, M. E., Partridge, T. A., and Zammit, P. S. (2000). Expression of CD34
and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J. Cell
Biol., 151, 1221-1234.
[21] Volonte, D., Liu, Y. and Galbiati, F. (2005). The modulation of caveolin-1 expression
controls satellite cell activation during muscle repair. FASEB J., 19, 237-239.
[22] Irintchev, A., Zeschnigk, M., Starzinski-Powitz, A., and Wernig, A. (1994). Expression
pattern of M-cadherin in normal, denervated, and regenerating mouse muscles. Dev.
Dyn., 199, 326-337.
[23] Fukada, S., Uezumi, A., Ikemoto, M., Masuda, S., Segawa, M., Tanimura, N.,
Yamamoto, H., Miyagoe-Suzuki, Y., and Takeda, S. (2007). Molecular signature of
quiescent satellite cells in adult skeletal muscle. Stem Cells, 25, 2448-2459.
[24] Burkin, D. J. and Kaufman, S. J. (1999). The alpha7beta1 integrin in muscle
development and disease. Cell Tissue Res., 296, 183-190.
[25] Tatsumi, R., Anderson, J. E., Nevoret, C. J., Halevy, O., and Allen, R. E. (1998). HGF/
SF is present in normal adult skeletal muscle and is capable of activating satellite cells.
Dev. Biol., 194, 114-128.
[26] Cornelison, D. D., Filla, M. S., Stanley, H. M., Rapraeger, A. C., and Olwin, B. B.
(2001). Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells and
are implicated in satellite cell maintenance and muscle regeneration. Dev. Biol., 239,
79-94.
[27] Mechtersheimer, G., Staudter, M. and Moller, P. (1992). Expression of the natural killer
[NK] cell-associated antigen CD56[Leu-19], which is identical to the 140-kDa isoform
of N-CAM, in neural and skeletal muscle cells and tumors derived therefrom. Ann. N Y
Acad. Sci., 650, 311-316.
[28] Jesse, T. L., LaChance, R., Iademarco, M. F., and Dean, D. C. (1998). Interferon
regulatory factor-2 is a transcriptional activator in muscle where it regulates expression
of vascular cell adhesion molecule-1. J. Cell Biol., 140, 1265-1276.
[29] Ratajczak, M. Z., Majka, M., Kucia, M., Drukala, J., Pietrzkowski, Z., Peiper, S., and
Janowska-Wieczorek, A. (2003). Expression of functional CXCR4 by muscle satellite
cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the
[30]
[31]
[32]
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
15
16
Yusuke Ono
[47] Pavlath, G. K., Thaloor, D., Rando, T. A., Cheong, M., English, A. W., and Zheng, B.
(1998). Heterogeneity among muscle precursor cells in adult skeletal muscles with
differing regenerative capacities. Dev. Dyn., 212, 495-508.
[48] McMullen, C. A., Ferry, A. L., Gamboa, J. L., Andrade, F. H., and DupontVersteegden, E. E. (2009). Age-related changes of cell death pathways in rat
extraocular muscle. Exp. Gerontol., 44, 420-425.
[49] Kaminski, H. J., Al-Hakim, M., Leigh, R. J., Katirji, M. B., and Ruff, R. L. (1992).
Extraocular muscles are spared in advanced Duchenne dystrophy. Ann. Neurol., 32,
586-588.
[50] Karpati, G. and Carpenter, S. (1986). Small-caliber skeletal muscle fibers do not suffer
deleterious consequences of dystrophic gene expression. Am. J. Med. Genet., 25, 653658.
[51] Kallestad, K. M., Hebert, S. L., McDonald, A. A., Daniel, M. L., Cu, S. R., and
McLoon, L. K. (2011). Sparing of extraocular muscle in aging and muscular
dystrophies: a myogenic precursor cell hypothesis. Exp. Cell Res., 317, 873-885.
[52] Gopinath, S. D. and Rando, T. A. (2008). Stem cell review series: aging of the skeletal
muscle stem cell niche. Aging Cell, 7, 590-598.
[53] Conboy, I. M., Conboy, M. J., Smythe, G. M., and Rando, T. A. (2003). Notchmediated restoration of regenerative potential to aged muscle. Science, 302, 1575-1577.
[54] Collins, C. A., Zammit, P. S., Ruiz, A. P., Morgan, J. E., and Partridge, T. A. (2007). A
population of myogenic stem cells that survives skeletal muscle aging. Stem Cells, 25,
885-894.
[55] Day, K., Shefer, G., Shearer, A., and Yablonka-Reuveni, Z. (2010). The depletion of
skeletal muscle satellite cells with age is concomitant with reduced capacity of single
progenitors to produce reserve progeny. Dev. Biol., 340, 330-343.
[56] Shefer, G., Van de Mark, D. P., Richardson, J. B., and Yablonka-Reuveni, Z. (2006).
Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal
muscle. Dev. Biol., 294, 50-66.
[57] Brack, A. S., Bildsoe, H. and Hughes, S. M. (2005). Evidence that satellite cell
decrement contributes to preferential decline in nuclear number from large fibres during
murine age-related muscle atrophy. J. Cell Sci., 118, 4813-4821.
[58] Nnodim, J. O. (2000). Satellite cell numbers in senile rat levator ani muscle. Mech.
Ageing Dev., 112, 99-111.
[59] Norton, M., Verstegeden, A., Maxwell, L. C., and McCarter, R. M. (2001). Constancy
of masseter muscle structure and function with age in F344 rats. Arch. Oral. Biol., 46,
139-146.
[60] Biressi, S. and Rando, T. A. (2010). Heterogeneity in the muscle satellite cell
population. Semin. Cell Dev. Biol., 21, 845-854.
[61] Altschuler, S. J. and Wu, L. F. (2010). Cellular heterogeneity: do differences make a
difference? Cell, 141, 559-563.
[62] Lagord, C., Soulet, L., Bonavaud, S., Bassaglia, Y., Rey, C., Barlovatz-Meimon, G.,
Gautron, J., and Martelly, I. (1998). Differential myogenicity of satellite cells isolated
from extensor digitorum longus [EDL] and soleus rat muscles revealed in vitro. Cell
Tissue Res., 291, 455-468.
17
[63] Rouger, K., Brault, M., Daval, N., Leroux, I., Guigand, L., Lesoeur, J., Fernandez, B.,
and Cherel, Y. (2004). Muscle satellite cell heterogeneity: in vitro and in vivo
evidences for populations that fuse differently. Cell Tissue Res., 317, 319-326.
[64] Baroffio, A., Hamann, M., Bernheim, L., Bochaton-Piallat, M. L., Gabbiani, G., and
Bader, C. R. (1996). Identification of self-renewing myoblasts in the progeny of single
human muscle satellite cells. Differentiation, 60, 47-57.
[65] Schultz, E. and Lipton, B. H. (1982). Skeletal muscle satellite cells: changes in
proliferation potential as a function of age. Mech. Ageing Dev., 20, 377-383.
[66] Knoblich, J. A. (2008). Mechanisms of asymmetric stem cell division. Cell, 132, 583597.
[67] Cornelison, D. D. and Wold, B. J. (1997). Single-cell analysis of regulatory gene
expression in quiescent and activated mouse skeletal muscle satellite cells. Dev. Biol.,
191, 270-283.
[68] Kuang, S., Kuroda, K., Le Grand, F., and Rudnicki, M. A. (2007). Asymmetric selfrenewal and commitment of satellite stem cells in muscle. Cell, 129, 999-1010.
[69] Gayraud-Morel, B., Chretien, F., Jory, A., Sambasivan, R., Negroni, E., Flamant, P.,
Soubigou, G., Coppe, J. Y., Di Santo, J., Cumano, A., Mouly, V., and Tajbakhsh, S.
(2012). Myf5 haploinsufficiency reveals distinct cell fate potentials for adult skeletal
muscle stem cells. J. Cell Sci., 125, 1738-1749.
[70] Le Grand, F., Jones, A. E., Seale, V., Scime, A., and Rudnicki, M. A. (2009). Wnt7a
activates the planar cell polarity pathway to drive the symmetric expansion of satellite
stem cells. Cell Stem Cell, 4, 535-547.
[71] Tanaka, K. K., Hall, J. K., Troy, A. A., Cornelison, D. D., Majka, S. M., and Olwin, B.
B. (2009). Syndecan-4-expressing muscle progenitor cells in the SP engraft as satellite
cells during muscle regeneration. Cell Stem Cell, 4, 217-225.
[72] Cairns, J. (1975). Mutation selection and the natural history of cancer. Nature, 255,
197-200.
[73] Shinin, V., Gayraud-Morel, B., Gomes, D., and Tajbakhsh, S. (2006). Asymmetric
division and cosegregation of template DNA strands in adult muscle satellite cells.
Nature Cell Biol., 8, 677-687.
[74] Conboy, M. J., Karasov, A. O. and Rando, T. A. (2007). High incidence of non-random
template strand segregation and asymmetric fate determination in dividing stem cells
and their progeny. PLoS Biol., 5, e102.
[75] Rocheteau, P., Gayraud-Morel, B., Siegl-Cachedenier, I., Blasco, M. A., and
Tajbakhsh, S. (2012). A subpopulation of adult skeletal muscle stem cells retains all
template DNA strands after cell division. Cell, 148, 112-125.
[76] Tumbar, T., Guasch, G., Greco, V., Blanpain, C., Lowry, W. E., Rendl, M., and Fuchs,
E. (2004). Defining the epithelial stem cell niche in skin. Science, 303, 359-363.
[77] Clayton, E., Doupe, D. P., Klein, A. M., Winton, D. J., Simons, B. D., and Jones, P. H.
(2007). A single type of progenitor cell maintains normal epidermis. Nature, 446, 185189.
[78] Lopez-Garcia, C., Klein, A. M., Simons, B. D., and Winton, D. J. (2010). Intestinal
stem cell replacement follows a pattern of neutral drift. Science, 330, 822-825.
[79] Klein, A. M., Nakagawa, T., Ichikawa, R., Yoshida, S., and Simons, B. D. (2010).
Mouse germ line stem cells undergo rapid and stochastic turnover. Cell Stem Cell, 7,
214-224.
18
Yusuke Ono
[80] Urbanek, K., Cesselli, D., Rota, M., Nascimbene, A., De Angelis, A., Hosoda, T.,
Bearzi, C., Boni, A., Bolli, R., Kajstura, J., Anversa, P., and Leri, A. (2006). Stem cell
niches in the adult mouse heart. Proc. Natl. Acad. Sci. US, 103, 9226-9231.
[81] Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M.,
Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., Li, P., Macdonald, H. R., and
Trumpp, A. (2008). Hematopoietic stem cells reversibly switch from dormancy to selfrenewal during homeostasis and repair. Cell, 135, 1118-1129.
[82] Foudi, A., Hochedlinger, K., Van Buren, D., Schindler, J. W., Jaenisch, R., Carey, V.,
and Hock, H. (2009). Analysis of histone 2B-GFP retention reveals slowly cycling
hematopoietic stem cells. Nat. Biotechnol., 27, 84-90.
[83] Fuchs, E. (2009). The tortoise and the hair: slow-cycling cells in the stem cell race.
Cell, 137, 811-819.
[84] Schultz, E. (1996). Satellite cell proliferative compartments in growing skeletal
muscles. Dev. Biol., 175, 84-94.
[85] Ono, Y., Masuda, S., Nam, H. S., Benezra, R., Miyagoe-Suzuki, Y. and Takeda, S.
(2012). Slow-dividing satellite cells retain long-term self-renewal ability in adult
muscle. J. Cell Sci.,125, 1309-1317.
[86] Beauchamp, J. R., Morgan, J. E., Pagel, C. N., and Partridge, T. A. (1999). Dynamics of
myoblast transplantation reveal a discrete minority of precursors with stem cell-like
properties as the myogenic source. J. Cell Biol., 144, 1113-1122.
[87] Feng, X. H. and Derynck, R. (2005). Specificity and versatility in tgf-beta signaling
through Smads. Annu. Rev. Cell Dev. Biol., 21, 659-693.
[88] Munsterberg, A. E., Kitajewski, J., Bumcrot, D. A., McMahon, A. P., and Lassar, A. B.
(1995). Combinatorial signaling by Sonic hedgehog and Wnt family members induces
myogenic bHLH gene expression in the somite. Genes Dev., 9, 2911-2922.
[89] Reshef, R., Maroto, M. and Lassar, A. B. (1998). Regulation of dorsal somitic cell
fates: BMPs and Noggin control the timing and pattern of myogenic regulator
expression. Genes Dev., 12, 290-303.
[90] Ono, Y., Calhabeu, F., Morgan, J. E., Katagiri, T., Amthor, H., and Zammit, P. S.
(2011). BMP signalling permits population expansion by preventing premature
myogenic differentiation in muscle satellite cells. Cell Death Differ., 18, 222-234.
[91] Ono, Y., Gnocchi, V. F., Zammit, P. S., and Nagatomi, R. (2009). Presenilin-1 acts via
Id1 to regulate the function of muscle satellite cells in a gamma-secretase-independent
manner. J. Cell Sci., 122, 4427-4438.
[92] Wang, H., Noulet, F., Edom-Vovard, F., Tozer, S., Le Grand, F., and Duprez, D.
(2010). Bmp signaling at the tips of skeletal muscles regulates the number of fetal
muscle progenitors and satellite cells during development. Dev. Cell, 18, 643-654.
[93] Rantanen, J., Hurme, T., Lukka, R., Heino, J., and Kalimo, H. (1995). Satellite cell
proliferation and the expression of myogenin and desmin in regenerating skeletal
muscle: evidence for two different populations of satellite cells. Lab. Invest., 72, 341347.
[94] Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L., and Weintraub, H. (1990). The
protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell, 61, 4959.
19
[95] Day, K., Shefer, G., Richardson, J. B., Enikolopov, G., and Yablonka-Reuveni, Z.
(2007). Nestin-GFP reporter expression defines the quiescent state of skeletal muscle
satellite cells. Dev. Biol., 304, 246-259.
[96] LaBarge, M. A. and Blau, H. M. (2002). Biological progression from adult bone
marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to
injury. Cell, 111, 589-601.
[97] Kuang, S., Gillespie, M. A. and Rudnicki, M. A. (2008). Niche regulation of muscle
satellite cell self-renewal and differentiation. Cell Stem Cell, 2, 22-31.
[98] Chakkalakal, J. V., Jones, K. M., Basson, M. A., Brack, A. S. (2012). The aged niche
disrupts muscle stem cell quiescence. Nature, 18, 355-60.
[99] Gnocchi, V. F., White, R. B., Ono, Y., Ellis, J. A., and Zammit, P. S. (2009). Further
characterisation of the molecular signature of quiescent and activated mouse muscle
satellite cells. PLoS One, 4, e5205.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 2
Abstract
Skeletal muscle is the largest organ in the human body, making up more than 3040% of total body weight in healthy adults. The wasting of skeletal muscle mass, which
is induced by unloading, malnutrition, aging or several kinds of diseases, leads to the loss
of functional human performance, long-term health issues and a low quality of life. It has
been generally accepted that the net balance between protein synthesis and degradation is
a critical determinant of the regulation of skeletal muscle mass.
Recent studies indicate that the skeletal muscle protein metabolism in response to the
environmental cues (i.e. physical activity and nutrients) is blunted in the elderly, which
then leads to the age-associated gradual loss of muscle mass. The aim of the present
chapter is to summarize and discuss, 1) recent progress in the understanding of cellular
mechanisms in anabolic (protein synthesis) and catabolic (protein degradation) signaling
pathways that govern the regulation of skeletal muscle mass, 2) altered capacity in the
protein metabolism of aged skeletal muscle in response to exercise and nutrients. A better
understanding of the anabolic and catabolic processes which regulate skeletal muscle
mass is critical for the development of more effective therapeutic interventions to prevent
the loss of muscle with aging and disease.
22
Mitsunori Miyazaki
Introduction
Skeletal muscle is the largest organ in the human body, making up more than 30-40% of
total body weight in healthy adults [1]. The maintenance of skeletal muscle mass is critical for
long-term health and quality of life, because a decrease in muscle mass during aging is highly
associated with functional impairment and disability, which then leads to the loss of
independence and increased risk of morbidity and mortality [2, 3]. Sarcopenia is the term
widely used to describe the age-associated and progressive loss of skeletal muscle mass and
strength. This degenerative loss of skeletal muscle occurs at a rate of 1-2% per each year after
the age of 50 yr. [4-6], and this is accelerated with advancing of age such that lean muscle
mass declines to ~50% when reaching an age of 75-80 yr. compared to the healthy young
adults [7-10]. Particularly, the reduced muscle mass largely reflects a loss of myofibrillar
proteins [11]. Despite the significance of skeletal muscle loss and weakness as inevitable
concomitants with aging, the potential mechanisms underlying the development of sarcopenia
are only partially understood.
The etiology of sarcopenia is very complex and characterized by the combination of
multiple factors including individual muscle fiber atrophy, degenerative loss of fiber number
or preferential loss of type II (fast, glycolytic) muscle fiber (summarized in Table 1). In
addition, situations are more complicated because of changes in elderly such as sedentary life
style, malnutrition or susceptibility to diseases, all of which can accelerate/influence the
potential loss of muscle mass.
Table 1. The potential etiologies leading to age-associated muscle wasting
Mitochondrial dysfunction
Increased oxidative stresses
DNA damage
Increased myonuclei apoptosis
Increased level of pro-inflammatory cytokines
Decreased or altered responsiveness of sex/anabolic hormones
Compromised protein metabolism (reduced protein synthesis / increased protein degradation)
Decreased number of muscle precursor cells
Loss of alpha-motor neuron input
Degenerative loss of muscle fiber number
Individual muscle fiber atrophy
Infiltration with fat and connective tissues
Preferential loss of type II fiber (fast / glycolytic)
Vitamin D deficiency
Increased susceptibility to chronic diseases
Inadequate nutritional intake
Decreased level of physical activity, Sedentary life style
Significant progress has been made over the past decade to identify some of the potential
contributors to the development of age-associated muscle loss. Skeletal muscle mass is
largely determined by the net balance between protein synthesis and protein degradation. In
the catabolic conditions such as aging, disuse or inflammatory diseases, the rate of protein
23
degradation in skeletal muscle exceeds relative to the protein synthesis rates such that there is
a net negative balance in cellular protein contents leading to atrophy of individual muscle
fibers and decreased muscle mass.
Recently, the impaired balance of protein metabolism is indicated as an important factor
that contributes to age-associated muscle loss. Here in this chapter, we will highlight the
advances that have been made over the past few years in our understanding of the cellular and
physiological mechanisms regulating the protein metabolism in the development and
treatment of age-associated muscle loss.
Particular emphasis has been placed on 1) cellular mechanisms regulating mammalian
target of rapamycin (mTOR, also called as mechanistic target of rapamycin)-dependent
signaling and protein synthesis, 2) potential mechanisms govern the protein degradation
through ubiquitin-proteasome system, 3) age-associated alteration of protein metabolism in
skeletal muscle.
24
Mitsunori Miyazaki
Figure 1. Simplified schema depicting signaling networks regulating mTORC1 activity and protein
synthesis in skeletal muscle. Insulin or IGF-1 activates class I PI3K, which then leads to the
phosphorylation and activation of Akt. Akt directly phosphorylates TSC2 on multiple residues and
inhibits its GAP activity, thereby allowing Rheb to accumulate in its active GTP-bound form and
leading to activation of mTORC1 and its downstream effectors S6K1 and 4EBP1. Activated Akt also
phosphorylates PRAS40, thereby releasing its inhibitory function toward mTORC1. Activation of
MEK/ERK pathway leads to TSC2 phosphorylation at S664 may contributes to mTORC1 activation. A
heterodimeric complex of the Rag proteins plays a fundamental role in amino acid-induced regulation
of mTORC1 signaling. Rag GTPases are heterodimers of either RagA or RagB with either RagC or
RagD. In the presence of amino acids, the Rag GTPases are converted to the active conformation, in
which RagA/B is loaded with GTP and RagC/D is loaded with GDP. The active form of the Rag
heterodimer physically interacts and relocalizes mTORC1 to a perinuclear membrane-bound
compartment that contains the mTORC1 activator Rheb. REDD1 and REDD2 function by inhibiting
the interaction of TSC2 with the scaffold protein 14-3-3, thereby promoting assembly of the
TSC1/TSC2 complex and subsequent inhibition of Rheb, which then lead to mTORC1 inhibition.
Under energy-deprived conditions (increased AMP to ATP ratio), activated AMPK phosphorylates
TSC2 and enhances its inhibitory function leading to decreased mTORC1 activity. AMPK also directly
phosphorylate the Raptor and inhibit mTORC1 activity.
25
26
Mitsunori Miyazaki
S1798 site or raptor, a component of mTORC1 [60, 61]. MEK/ERK signaling can also
enhance protein synthesis independent of the mTORC1 pathway through RSK regulation
toward rpS6 [63, 64] or MAP kinase-interacting kinase 1 (MNK1) signaling to eIF4E [16, 65,
66].
Nutrient-Dependent Pathway
In addition to growth factors, availability of amino acids, particularly leucine, has also
been shown to play an important role in the regulation of mTORC1 signaling and protein
synthesis rate [21, 67-70]. Unlike the growth factor-dependent pathway, it has been suggested
that amino acids activate mTORC1 pathway through independent of a canonical class I
PI3K/Akt signaling [70-72]. Currently the precise mechanisms regulating amino aciddependent activation of mTORC1 signaling in skeletal muscle are largely unknown, however,
some potential candidates have been implicated. A class III PI3K, human vacuolar proteinsorting-associated protein 34 (Vps34) has been suggested as a mediator of amino acidinduced activation of mTORC1 signaling, as siRNA knockdown of Vps34 blocks amino acidinduced S6K1 activation but has no effect on Akt activation [71, 73, 74]. A heterodimeric
complex of the Rag proteins, subfamily of Ras small GTPases, has also been implicated as an
effecter of amino acid availability upstream of mTORC1 [75, 76]. In the presence of amino
acids, the Rag GTPases are converted to the active conformation, in which RagA or RagB is
loaded with GTP and RagC or RagD is loaded with GDP. The active form of Rag
heterodimer physically binds to mTORC1 and promotes its translocation to a membranebound compartment that contains the mTORC1 activator Rheb through regulation of the
Ragulator protein complex (trimeric protein complex encoded by the MAPKSP1, ROBLD3
and c11orf59 genes) [75-77].
Cellular Stresses and mTORC1 Inhibition
It has been indicated that mTORC1-dependent signaling is negatively regulated by the
cellular stresses such as hypoxia or energy deprivation, which then leads to the diminished
rate of protein synthesis. Recently, stress response genes designated as regulated in
development and DNA damage responses 1 (REDD1) and REDD2 have been suggested as
important molecules that negatively regulate mTORC1 signaling in skeletal muscle [78-84].
Both REDD1 and REDD2 are indicated as inhibitor of mTORC1 signaling and cell growth in
response to several cellular stresses such as hypoxia, energy stress, or glucocorticoid
treatment [85-88]. REDD1/REDD2 functions by inhibiting the interaction of TSC2 with the
scaffold protein 14-3-3, thereby promoting assembly of the TSC1/TSC2 complex and
subsequent inhibition of Rheb, which then lead to mTORC1 inhibition [83, 89]. Interestingly,
gene expression profiles have indicated the skeletal muscle-enriched expression of REDD2
vs. the ubiquitous expression of REDD1 both in mouse and human tissues [83, 90]. It is of
great interest in REDD2 function in skeletal muscle because gene expression of REDD2 has
been shown to be significantly sensitive in response to the mechanical loading state of
skeletal muscle: REDD2 mRNA expression was down-regulated approximately 50% in both
young and old human skeletal muscle in response to an anabolic stimulus [90] and by 90%
following mechanical overload of the mouse plantaris muscle by synergist ablation (Miyazaki
et al., unpublished observation), whereas increased expression of REDD2 in response to
unloading, a model of muscle atrophy that is associated with diminished mTORC1 activity
[91-93].
27
28
Mitsunori Miyazaki
In addition to Atrogin1 and MuRF1, another RING-type ubiquitin ligase Cbl-b has also
been suggested as the primary ubiquitin ligase responsible for microgravity-induced skeletal
muscle atrophy [125, 126]. Another E3 ubiquitin ligase found to play a critical role in skeletal
muscle atrophy is tripartite motifcontaining protein 32 (Trim32), which mediates the
ubiquitination of thin filament (actin, tropomyosin, troponins) and Z-band (-actinin)
components and promotes their degradation [127]. Tumor necrosis factor receptor-associated
factor 6 (TRAF6) is also suggested as another E3 ubiquitin ligase, which intercedes
starvation-induced skeletal muscle atrophy [128].
29
30
Mitsunori Miyazaki
myogenic regulatory factors are essential for muscle cell differentiation and formation of
myofiber, Atrogin1-dependent degradation of MyoD and myogenin likely contribute to the
loss of myofibrillar proteins such as myosin heavy chain [144, 145].
The regulatory subunit of the eIF3 (eukaryotic Initiation Factor 3) complex; eIF3f, has
been also identified as a major target of Atrogin1 for ubiquitination and degradation by the
proteasome during skeletal muscle atrophy [146, 147]. Ectopic expression of Atrogin1 in
skeletal muscle cells induces atrophy and degradation of eIF3f, whereas blockade of Atrogin1
prevents eIF3f degradation undergoing atrophy [147]. Interestingly, the eIF3f has also been
indicated as a scaffold protein that interconnects mTORC1 and downstream S6K1 to
coordinate a promotion of protein synthesis, and genetic activation of eIF3f is sufficient to
induce skeletal muscle hypertrophy and blockade of atrophy [146-148]. The central role of
eIF3f in both pathways regulating protein synthesis and degradation is attractive as a
therapeutic target.
In contrast, it appears that MuRF1 may directly targets contractile and/or myofibrillar
proteins for degradation. MuRF1 associates with titin at the M band of the sarcomere and
potentially contributes titin-dependent signaling [149-151]. A yeast two-hybrid screening of
skeletal muscle cDNA libraries with MuRF1 baits has identified eight myofibrillar proteins as
potential binding partner of MuRF1: titin, nebulin, the nebulin-related protein NRAP,
troponin-I, troponin-T, myosin light chain 2, myotilin and T-cap [152]. Within these potential
candidates, troponin-I has been confirmed as the direct substrate of MuRF1 for
polyubiquitination in cardiac muscle [153]. It has also been indicated that protein components
of thick filaments including myosin heavy chain proteins, myosin-binding protein C, myosin
light chain-1 and myosin light chain-1 are directly degraded through MuRF1-dependent
polyubiquitination [154, 155].
31
32
Mitsunori Miyazaki
blunted phosphorylation of two key downstream targets of mTORC1, S6K1 and 4EBP1 at 1
hr. after exercise [170]. Recently, Fry et al. have also confirmed that age-associated decline in
protein synthesis rates and blunted responses of mTORC1 signaling persist for at least 24 hrs.
following resistance exercise in elderly subjects [179]. These data clearly suggest that proper
control of mTORC1-dependent signaling in response to anabolic stimuli is critical key factor
for developing more effective therapeutic interventions to prevent the loss of muscle with
aging.
33
34
Mitsunori Miyazaki
Conclusion
Significant progresses have been made over a past decade to identify some of the
potential mechanisms contributing to the development of sarcopenia. In elderly individuals,
impaired balance of protein metabolism has been indicated as a critical factor which
contributing age-associated muscle loss. Although basal rates of protein synthesis and protein
degradation are essentially unchanged with advancing of age, skeletal muscle in elderly
individuals may have an impaired ability to properly respond to anabolic stimuli. This
imbalance of protein metabolism results in a minor and daily muscle protein loss, which leads
to the long-term gradual muscle wasting in the elderly. At this time, only proven and effective
intervention to counteract to this age-associated anabolic resistance and the subsequent
muscle loss is the resistance exercise in combination with adequate nutrients supplementation.
However, considering the multifactorial nature of muscle loss and weakness in elderly
populations such as potential disease status or sedentary life style, more comprehensive
interventions will be necessary. It is quite possible that precise understanding of cellular
mechanisms that govern protein metabolism in skeletal muscle will develop new therapeutic
strategies for preventing physical disability and increased risk of morbidity/mortality due to
the loss of muscle mass with aging.
Acknowledgments
This work was supported by the JSPS KAKENHI Grant Number 24800056 and the
research grant provided from The Uehara Memorial Foundation.
35
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
Lee, R. C., Wang, Z., Heo, M., Ross, R., Janssen, I. & Heymsfield, S. B. (2000). Totalbody skeletal muscle mass: development and cross-validation of anthropometric
prediction models. Am. J. Clin. Nutr, 72, 796-803.
Janssen, I., Heymsfield, S. B. & Ross, R. (2002). Low relative skeletal muscle mass
(sarcopenia) in older persons is associated with functional impairment and physical
disability. J. Am. Geriatr. Soc, 50, 889-896.
Doherty, T. J. (2003). Invited review: Aging and sarcopenia. J. Appl. Physiol, 95, 17171727.
Hughes, V. A., Frontera, W. R., Roubenoff, R., Evans, W. J. & Singh, M. A. (2002).
Longitudinal changes in body composition in older men and women: role of body
weight change and physical activity. Am. J. Clin. Nutr, 76, 473-481.
Sehl, M. E. & Yates, F. E. (2001). Kinetics of human aging: I. Rates of senescence
between ages 30 and 70 years in healthy people. J. Gerontol. A. Biol. Sci. Med. Sci, 56,
B198- B208.
Peake, J., Della Gatta, P. & Cameron-Smith, D. (2010). Aging and its effects on
inflammation in skeletal muscle at rest and following exercise-induced muscle injury.
Am. J. Physiol. Regul. Integr. Comp. Physiol, 298, R1485-R1495.
Short, K. R. & Nair, K. S. (2000). The effect of age on protein metabolism. Curr. Opin.
Clin. Nutr. Metab. Care, 3, 39-44.
Koopman, R. & van Loon, L. J. (2009). Aging, exercise, and muscle protein
metabolism. J. Appl. Physiol, 106, 2040-2048.
Short, K. R., Vittone, J. L., Bigelow, M. L., Proctor, D. N. & Nair, K. S. (2004). Age
and aerobic exercise training effects on whole body and muscle protein metabolism.
Am. J. Physiol. Endocrinol. Metab, 286, E92-E101.
Lexell, J. (1995). Human aging, muscle mass, and fiber type composition. J. Gerontol.
A Biol. Sci. Med. Sci, 50 Spec No, 11-16.
Evans, W. (1997). Functional and metabolic consequences of sarcopenia. J. Nutr, 127,
998S-1003S.
Welle, S., Thornton, C., Statt, M. & McHenry, B. (1994). Postprandial myofibrillar and
whole body protein synthesis in young and old human subjects. Am. J. Physiol, 267,
E599-E604.
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R.,
Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J. & Yancopoulos, G. D.
(2001). Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and
can prevent muscle atrophy in vivo. Nat. Cell Biol, 3, 1014-1019.
Hornberger, T. A., Stuppard, R., Conley, K. E., Fedele, M. J., Fiorotto, M. L., Chin, E.
R. & Esser, K. A. (2004). Mechanical stimuli regulate rapamycin-sensitive signalling
by a phosphoinositide 3-kinase-, protein kinase B- and growth factor-independent
mechanism. Biochem. J, 380, 795-804.
Nader, G. A., McLoughlin, T. J. & Esser, K. A. (2005). mTOR function in skeletal
muscle hypertrophy: increased ribosomal RNA via cell cycle regulators. Am. J. Physiol.
Cell Physiol, 289, C1457-C1465.
36
Mitsunori Miyazaki
[16] Drummond, M. J., Fry, C. S., Glynn, E. L., Dreyer, H. C., Dhanani, S., Timmerman, K.
L., Volpi, E. & Rasmussen, B. B. (2009). Rapamycin administration in humans blocks
the contraction-induced increase in skeletal muscle protein synthesis. J. Physiol, 587,
1535-1546.
[17] Jacinto, E. & Hall, M. N. (2003). Tor signalling in bugs, brain and brawn. Nat. Rev.
Mol. Cell Biol, 4, 117-126.
[18] Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M.,
Gray, N. S. & Sabatini, D. M. (2009). DEPTOR is an mTOR inhibitor frequently
overexpressed in multiple myeloma cells and required for their survival. Cell, 137, 873886.
[19] Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C.,
Avruch, J. & Yonezawa, K. (2002). Raptor, a binding partner of target of rapamycin
(TOR), mediates TOR action. Cell, 110, 177-89.
[20] Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat,
J., Brown, M., Fitzgerald, K. J. & Sabatini, D. M. (2006). Ablation in mice of the
mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for
signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11, 859-871.
[21] Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage,
H., Tempst, P. & Sabatini, D. M. (2002). mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell, 110, 163-175.
[22] Oshiro, N., Takahashi, R., Yoshino, K., Tanimura, K., Nakashima, A., Eguchi, S.,
Miyamoto, T., Hara, K., Takehana, K., Avruch, J., Kikkawa, U. & Yonezawa, K.
(2007). The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate
of mammalian target of rapamycin complex 1. J. Biol. Chem, 282, 20329-20339.
[23] Wang, L., Harris, T. E., Roth, R. A. & Lawrence, J. C., Jr. (2007). PRAS40 regulates
mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J.
Biol. Chem, 282, 20036-20044.
[24] Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R., ErdjumentBromage, H., Tempst, P. & Sabatini, D. M. (2004). Rictor, a novel binding partner of
mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates
the cytoskeleton. Curr. Biol, 14, 1296-1302.
[25] Risson, V., Mazelin, L., Roceri, M., Sanchez, H., Moncollin, V., Corneloup, C.,
Richard- Bulteau, H., Vignaud, A., Baas, D., Defour, A., Freyssenet, D., Tanti, J. F.,
Le- Marchand-Brustel, Y., Ferrier, B., Conjard-Duplany, A., Romanino, K., Bauche, S.,
Hantai, D., Mueller, M., Kozma, S. C., Thomas, G., Ruegg, M. A., Ferry, A., Pende,
M., Bigard, X., Koulmann, N., Schaeffer, L. & Gangloff, Y. G. (2009). Muscle
inactivation of mTOR causes metabolic and dystrophin defects leading to severe
myopathy. J. Cell Biol, 187, 859-874.
[26] Bentzinger, C. F., Romanino, K., Cloetta, D., Lin, S., Mascarenhas, J. B., Oliveri, F.,
Xia, J., Casanova, E., Costa, C. F., Brink, M., Zorzato, F., Hall, M. N. & Ruegg, M. A.
(2008). Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic
changes and results in muscle dystrophy. Cell Metab, 8, 411-424.
[27] Bentzinger, C. F., Lin, S., Romanino, K., Castets, P., Guridi, M., Summermatter, S.,
Handschin, C., Tintignac, L. A., Hall, M. N. & Ruegg, M. A. (2013). Differential
response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy.
Skelet Muscle, 3, 6.
37
[28] Laplante, M. & Sabatini, D. M. (2012). mTOR signaling in growth control and disease.
Cell, 149, 274-293.
[29] Pallafacchina, G., Calabria, E., Serrano, A. L., Kalhovde, J. M. & Schiaffino, S. (2002).
A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal
muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. U S A, 99, 92139218.
[30] Bodine, S. C. (2006). mTOR signaling and the molecular adaptation to resistance
exercise. Med. Sci. Sports Exerc, 38, 1950-1957.
[31] Dennis, M. D., Kimball, S. R. & Jefferson, L. S. (2013). Mechanistic target of
rapamycin
complex 1 (mTORC1)-mediated phosphorylation is governed by
competition between substrates for interaction with raptor. J. Biol. Chem, 288, 10-19.
[32] Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N. & Sonenberg, N. (1996).
Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation
of translation. EMBO J, 15, 658-664.
[33] Dowling, R. J., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B. D., Petroulakis, E.,
Wang, X., Larsson, O., Selvaraj, A., Liu, Y., Kozma, S. C., Thomas, G. & Sonenberg,
N. (2010). mTORC1-mediated cell proliferation, but not cell growth, controlled by the
4E-BPs. Science, 328, 1172-1176.
[34] Wang, X. & Proud, C. G. (2006). The mTOR pathway in the control of protein
synthesis. Physiology (Bethesda), 21, 362-369.
[35] Ruvinsky, I., Sharon, N., Lerer, T., Cohen, H., Stolovich-Rain, M., Nir, T., Dor, Y.,
Zisman, P. & Meyuhas, O. (2005). Ribosomal protein S6 phosphorylation is a
determinant of cell size and glucose homeostasis. Genes Dev, 19, 2199-2211.
[36] Ruvinsky, I. & Meyuhas, O. (2006). Ribosomal protein S6 phosphorylation: from
protein synthesis to cell size. Trends Biochem. Sci, 31, 342-348.
[37] Wang, X., Li, W., Williams, M., Terada, N., Alessi, D. R. & Proud, C. G. (2001).
Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J,
20, 4370-4379.
[38] Redpath, N. T., Foulstone, E. J. & Proud, C. G. (1996). Regulation of translation
elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J,
15, 2291-2297.
[39] Hay, N. & Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev, 18,
1926-1945.
[40] Ma, X. M. & Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational
control. Nat. Rev. Mol. Cell Biol, 10, 307-318.
[41] Proud, C. G. (2007). Signalling to translation: how signal transduction pathways control
the protein synthetic machinery. Biochem. J, 403, 217-234.
[42] Mahoney, S. J., Dempsey, J. M. & Blenis, J. (2009). Cell signaling in protein synthesis
ribosome biogenesis and translation initiation and elongation. Prog. Mol. Biol. Transl.
Sci, 90, 53-107.
[43] Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N.,
Yancopoulos, G. D. & Glass, D. J. (2001). Mediation of IGF-1-induced skeletal
myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat.
Cell Biol, 3, 1009-1013.
[44] Shepherd, P. R., Withers, D. J. & Siddle, K. (1998). Phosphoinositide 3-kinase: the key
switch mechanism in insulin signalling. Biochem. J, 333 (Pt 3), 471-490.
38
Mitsunori Miyazaki
39
[60] Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P. & Blenis, J. (2004). Tumor-promoting
phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor
complex via p90 ribosomal S6 kinase. Proc. Natl. Acad. Sci. U S A, 101, 13489-13494.
[61] Carriere, A., Cargnello, M., Julien, L. A., Gao, H., Bonneil, E., Thibault, P. & Roux, P.
P. (2008). Oncogenic MAPK signaling stimulates mTORC1 activity by promoting
RSK- mediated raptor phosphorylation. Curr. Biol, 18, 1269-1277.
[62] Miyazaki, M., McCarthy, J. J., Fedele, M. J. & Esser, K. A. (2011). Early activation of
mTORC1 signalling in response to mechanical overload is independent of
phosphoinositide 3-kinase/Akt signalling. J. Physiol, 589, 1831-1846.
[63] Roux, P. P., Shahbazian, D., Vu, H., Holz, M. K., Cohen, M. S., Taunton, J.,
Sonenberg, N. & Blenis, J. (2007). RAS/ERK signaling promotes site-specific
ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent
translation. J. Biol. Chem, 282, 14056-14064.
[64] Pende, M., Um, S. H., Mieulet, V., Sticker, M., Goss, V. L., Mestan, J., Mueller, M.,
Fumagalli, S., Kozma, S. C. & Thomas, G. (2004). S6K1(-/-)/S6K2(-/-) mice exhibit
perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA
translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.
Mol. Cell Biol, 24, 3112-3124.
[65] Fluckey, J. D., Knox, M., Smith, L., Dupont-Versteegden, E. E., Gaddy, D., Tesch, P.
A. & Peterson, C. A. (2006). Insulin-facilitated increase of muscle protein synthesis
after resistance exercise involves a MAP kinase pathway. Am. J. Physiol. Endocrinol.
Metab, 290, E1205-E1211.
[66] Wang, X., Yue, P., Chan, C. B., Ye, K., Ueda, T., Watanabe-Fukunaga, R., Fukunaga,
R., Fu, H., Khuri, F. R. & Sun, S. Y. (2007). Inhibition of mammalian target of
rapamycin
induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated
eukaryotic translation initiation factor 4E phosphorylation. Mol. Cell Biol, 27, 74057413.
[67] Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B. & Pan,
D. (2002). Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat.
Cell Biol, 4, 699-704.
[68] Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C. & Avruch, J.
(1998). Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1
through a common effector mechanism. J. Biol. Chem, 273, 14484-14494.
[69] Long, X., Ortiz-Vega, S., Lin, Y. & Avruch, J. (2005). Rheb binding to mammalian
target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem, 280,
23433-23436.
[70] Smith, E. M., Finn, S. G., Tee, A. R., Browne, G. J. & Proud, C. G. (2005). The
tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian
target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem, 280,
18717-18727.
[71] Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M.
P., Backer, J. M., Natt, F., Bos, J. L., Zwartkruis, F. J. & Thomas, G. (2005). Amino
acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol
3OH-kinase. Proc. Natl. Acad. Sci. U S A, 102, 14238-14243.
[72] Gulati, P. & Thomas, G. (2007). Nutrient sensing in the mTOR/S6K1 signalling
pathway. Biochem. Soc. Trans, 35, 236-238.
40
Mitsunori Miyazaki
41
[87] Schwarzer, R., Tondera, D., Arnold, W., Giese, K., Klippel, A. & Kaufmann, J. (2005).
REDD1 integrates hypoxia-mediated survival signaling downstream of
phosphatidylinositol 3-kinase. Oncogene, 24, 1138-1149.
[88] Sofer, A., Lei, K., Johannessen, C. M. & Ellisen, L. W. (2005). Regulation of mTOR
and cell growth in response to energy stress by REDD1. Mol. Cell Biol, 25, 5834-5845.
[89] DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D. & Ellisen, L. W. (2008). Hypoxia
regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated
14- 3-3 shuttling. Genes Dev, 22, 239-251.
[90] Drummond, M. J., Miyazaki, M., Dreyer, H. C., Pennings, B., Dhanani, S., Volpi, E.,
Esser, K. A. & Rasmussen, B. B. (2009). Expression of growth-related genes in young
and older human skeletal muscle following an acute stimulation of protein synthesis. J.
Appl. Physiol, 106, 1403-1411.
[91] Hornberger, T. A., Armstrong, D. D., Koh, T. J., Burkholder, T. J. & Esser, K. A.
(2005). Intracellular signaling specificity in response to uniaxial vs. multiaxial stretch:
implications for mechanotransduction. Am. J. Physiol. Cell Physiol, 288, C185-C194.
[92] Pisani, D. F., Leclerc, L., Jarretou, G., Marini, J. F. & Dechesne, C. A. (2005). SMHS1
is involved in oxidative/glycolytic-energy metabolism balance of muscle fibers.
Biochem. Biophys. Res. Commun, 326, 788-793.
[93] Cros, N., Tkatchenko, A. V., Pisani, D. F., Leclerc, L., Leger, J. J., Marini, J. F. &
Dechesne, C. A. (2001). Analysis of altered gene expression in rat soleus muscle
atrophied by disuse. J. Cell Biochem, 83, 508-519.
[94] Shaw, R. J. (2009). LKB1 and AMP-activated protein kinase control of mTOR
signalling and growth. Acta Physiol. (Oxf), 196, 65-80.
[95] Mounier, R., Lantier, L., Leclerc, J., Sotiropoulos, A., Pende, M., Daegelen, D.,
Sakamoto, K., Foretz, M. & Viollet, B. (2009). Important role for AMPKalpha1 in
limiting skeletal muscle cell hypertrophy. FASEB J, 23, 2264-2273.
[96] Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Makela, T. P., Alessi,
D. R. & Hardie, D. G. (2003). Complexes between the LKB1 tumor suppressor,
STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated
protein kinase cascade. J. Biol, 2, 28.
[97] Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G., Neumann, D.,
Schlattner, U., Wallimann, T., Carlson, M. & Carling, D. (2003). LKB1 is the upstream
kinase in the AMP-activated protein kinase cascade. Curr. Biol, 13, 2004-2008.
[98] Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M.,
Frenguelli, B. G. & Hardie, D. G. (2005). Calmodulin-dependent protein kinase kinasebeta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab, 2,
9-19.
[99] Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R. & Witters,
L. A. (2005). The Ca2+/calmodulin-dependent protein kinase kinases are AMPactivated protein kinase kinases. J. Biol. Chem, 280, 29060-29066.
[100] Woods, A., Dickerson, K., Heath, R., Hong, S. P., Momcilovic, M., Johnstone, S. R.,
Carlson, M. & Carling, D. (2005), Ca2+/calmodulin-dependent protein kinase kinasebeta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab, 2,
21-33.
42
Mitsunori Miyazaki
[101] Momcilovic, M., Hong, S. P. & Carlson, M. (2006). Mammalian TAK1 activates Snf1
protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J.
Biol. Chem, 281, 25336-25343.
[102] Kahn, B. B., Alquier, T., Carling, D. & Hardie, D. G. (2005). AMP-activated protein
kinase: ancient energy gauge provides clues to modern understanding of metabolism.
Cell Metab, 1, 15-25.
[103] Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D. &
Hardie, D. G. (1996). Characterization of the AMP-activated protein kinase kinase from
rat liver and identification of threonine 172 as the major site at which it phosphorylates
AMP-activated protein kinase. J. Biol. Chem, 271, 27879-27887.
[104] Sanders, M. J., Ali, Z. S., Hegarty, B. D., Heath, R., Snowden, M. A. & Carling, D.
(2007). Defining the mechanism of activation of AMP-activated protein kinase by the
small molecule A-769662, a member of the thienopyridone family. J. Biol. Chem, 282,
32539-32548.
[105] Davies, S. P., Helps, N. R., Cohen, P. T. & Hardie, D. G. (1995). 5'-AMP inhibits
dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein
kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and
native bovine protein phosphatase-2AC. FEBS Lett, 377, 421-425.
[106] Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett,
C., Harada, Y., Stankunas, K., Wang, C. Y., He, X., MacDougald, O. A., You, M.,
Williams, B. O. & Guan, K. L. (2006). TSC2 integrates Wnt and energy signals via a
coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell, 126,
955-968.
[107] Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez,
D. S., Turk, B. E. & Shaw, R. J. (2008). AMPK phosphorylation of raptor mediates a
metabolic checkpoint. Mol. Cell, 30, 214-226.
[108] Thomson, D. M. & Gordon, S. E. (2005). Diminished overload-induced hypertrophy in
aged fast-twitch skeletal muscle is associated with AMPK hyperphosphorylation. J.
Appl. Physiol, 98, 557-564.
[109] Dreyer, H. C., Fujita, S., Cadenas, J. G., Chinkes, D. L., Volpi, E. & Rasmussen, B. B.
(2006). Resistance exercise increases AMPK activity and reduces 4E-BP1
phosphorylation and protein synthesis in human skeletal muscle. J. Physiol, 576, 613624.
[110] Bolster, D. R., Crozier, S. J., Kimball, S. R. & Jefferson, L. S. (2002). AMP-activated
protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem, 277,
23977- 23980.
[111] Pruznak, A. M., Kazi, A. A., Frost, R. A., Vary, T. C. & Lang, C. H. (2008). Activation
of AMP-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-beta-Dribonucleoside prevents leucine-stimulated protein synthesis in rat skeletal muscle. J.
Nutr, 138, 1887-1894.
[112] Williamson, D. L., Bolster, D. R., Kimball, S. R. & Jefferson, L. S. (2006). Time course
changes in signaling pathways and protein synthesis in C2C12 myotubes following
AMPK activation by AICAR. Am. J. Physiol. Endocrinol. Metab, 291, E80-E89.
[113] Deshmukh, A. S., Treebak, J. T., Long, Y. C., Viollet, B., Wojtaszewski, J. F. &
Zierath, J. R. (2008). Role of adenosine 5'-monophosphate-activated protein kinase
43
44
Mitsunori Miyazaki
[128] Paul, P. K., Bhatnagar, S., Mishra, V., Srivastava, S., Darnay, B. G., Choi, Y. & Kumar,
A. (2012). The E3 ubiquitin ligase TRAF6 intercedes in starvation-induced skeletal
muscle atrophy through multiple mechanisms. Mol. Cell Biol, 32, 1248-1259.
[129] Dehoux, M. J., van Beneden, R. P., Fernandez-Celemin, L., Lause, P. L. & Thissen, J.
P. (2003). Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle
after LPS injection. FEBS Lett, 544, 214-217.
[130] Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R.,
Mitch, W. E. & Goldberg, A. L. (2004). Multiple types of skeletal muscle atrophy
involve a common program of changes in gene expression. FASEB J, 18, 39-51.
[131] Wray, C. J., Mammen, J. M., Hershko, D. D. & Hasselgren, P. O. (2003). Sepsis
upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int. J.
Biochem. Cell Biol, 35, 698-705.
[132] Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K.,
Schiaffino, S., Lecker, S. H. & Goldberg, A. L. (2004). Foxo transcription factors
induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Cell, 117, 399-412.
[133] Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O.,
Gonzalez, M., Yancopoulos, G. D. & Glass, D. J. (2004). The IGF-1/PI3K/Akt pathway
prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO
transcription factors. Mol. Cell, 14, 395-403.
[134] Furuyama, T., Kitayama, K., Yamashita, H. & Mori, N. (2003). Forkhead transcription
factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal
muscle during energy deprivation. Biochem. J, 375, 365-371.
[135] Moylan, J. S., Smith, J. D., Chambers, M. A., McLoughlin, T. J. & Reid, M. B. (2008).
TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKTFoxo1/3 signaling. Am. J. Physiol. Cell Physiol, 295, C986-C993.
[136] Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J.,
Arden, K. C., Blenis, J. & Greenberg, M. E. (1999). Akt promotes cell survival by
phosphorylating and inhibiting a Forkhead transcription factor. Cell, 96, 857-868.
[137] Ladner, K. J., Caligiuri, M. A. & Guttridge, D. C. (2003). Tumor necrosis factorregulated biphasic activation of NF-kappa B is required for cytokine-induced loss of
skeletal muscle gene products. J. Biol. Chem, 278, 2294-2303.
[138] Li, Y. P., Chen, Y., John, J., Moylan, J., Jin, B., Mann, D. L. & Reid, M. B. (2005).
TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase
atrogin1/MAFbx in skeletal muscle, FASEB J, 19, 362-370.
[139] Hunter, R. B., Stevenson, E., Koncarevic, A., Mitchell-Felton, H., Essig, D. A. &
Kandarian, S. C. (2002). Activation of an alternative NF-kappaB pathway in skeletal
muscle during disuse atrophy. FASEB J, 16, 529-538.
[140] Cai, D., Frantz, J. D., Tawa, N. E., Jr., Melendez, P. A., Oh, B. C., Lidov, H. G.,
Hasselgren, P. O., Frontera, W. R., Lee, J., Glass, D. J. & Shoelson, S. E. (2004).
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119, 285298.
[141] Moresi, V., Williams, A. H., Meadows, E., Flynn, J. M., Potthoff, M. J., McAnally, J.,
Shelton, J. M., Backs, J., Klein, W. H., Richardson, J. A., Bassel-Duby, R. & Olson, E.
N. (2010). Myogenin and class II HDACs control neurogenic muscle atrophy by
inducing E3 ubiquitin ligases. Cell, 143, 35-45.
45
[142] Bricceno, K. V., Sampognaro, P. J., Van Meerbeke, J. P., Sumner, C. J., Fischbeck, K.
H. & Burnett, B. G. (2012). Histone deacetylase inhibition suppresses myogenindependent atrogene activation in spinal muscular atrophy mice. Hum. Mol. Genet, 21,
4448-4459.
[143] Jogo, M., Shiraishi, S. & Tamura, T. A. (2009). Identification of MAFbx as a
myogenin-engaged F-box protein in SCF ubiquitin ligase. FEBS Lett, 583, 2715-2719.
[144] Tintignac, L. A., Lagirand, J., Batonnet, S., Sirri, V., Leibovitch, M. P. & Leibovitch, S.
A. (2005). Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J.
Biol. Chem, 280, 2847-2856.
[145] Lagirand-Cantaloube, J., Cornille, K., Csibi, A., Batonnet-Pichon, S., Leibovitch, M. P.
& Leibovitch, S. A. (2009). Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis
prevents skeletal muscle atrophy in vivo. PLoS One, 4, e4973.
[146] Csibi, A., Cornille, K., Leibovitch, M. P., Poupon, A., Tintignac, L. A., Sanchez, A. M.
& Leibovitch, S. A. (2010). The translation regulatory subunit eIF3f controls the
kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy
in mouse. PLoS One, 5, e8994.
[147] Lagirand-Cantaloube, J., Offner, N., Csibi, A., Leibovitch, M. P., Batonnet-Pichon, S.,
Tintignac, L. A., Segura, C. T. & Leibovitch, S. A. (2008). The initiation factor eIF3-f
is a major target for atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J, 27,
1266-1276.
[148] Holz, M. K., Ballif, B. A., Gygi, S. P. & Blenis, J. (2005). mTOR and S6K1 mediate
assembly of the translation preinitiation complex through dynamic protein interchange
and ordered phosphorylation events. Cell, 123, 569-580.
[149] Gregorio, C. C., Perry, C. N. & McElhinny, A. S. (2005). Functional properties of the
titin/connectin-associated proteins, the muscle-specific RING finger proteins (MURFs),
in striated muscle. J. Muscle Res. Cell Motil, 26, 389-400.
[150] McElhinny, A. S., Kakinuma, K., Sorimachi, H., Labeit, S. & Gregorio, C. C. (2002).
Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and
thick filament structure and may have nuclear functions via its interaction with
glucocorticoid modulatory element binding protein-1. J. Cell Biol, 157, 125-136.
[151] Centner, T., Yano, J., Kimura, E., McElhinny, A. S., Pelin, K., Witt, C. C., Bang, M. L.,
Trombitas, K., Granzier, H., Gregorio, C. C., Sorimachi, H. & Labeit, S. (2001).
Identification of muscle specific ring finger proteins as potential regulators of the titin
kinase domain. J. Mol. Biol, 306, 717-726.
[152] Witt, S. H., Granzier, H., Witt, C. C. & Labeit, S. (2005). MURF-1 and MURF-2 target
a specific subset of myofibrillar proteins redundantly: towards understanding MURFdependent muscle ubiquitination. J. Mol. Biol, 350, 713-722.
[153] Kedar, V., McDonough, H., Arya, R., Li, H. H., Rockman, H. A. & Patterson, C.
(2004). Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades
cardiac troponin I. Proc. Natl. Acad. Sci. U S A, 101, 18135-18140.
[154] Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E.,
Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E. & Glass, D. J. (2007). The E3
ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal
muscle. Cell Metab, 6, 376-385.
[155] Cohen, S., Brault, J. J., Gygi, S. P., Glass, D. J., Valenzuela, D. M., Gartner, C., Latres,
E. & Goldberg, A. L. (2009). During muscle atrophy, thick, but not thin, filament
46
Mitsunori Miyazaki
47
[170] Kumar, V., Selby, A., Rankin, D., Patel, R., Atherton, P., Hildebrandt, W., Williams, J.,
Smith, K., Seynnes, O., Hiscock, N. & Rennie, M. J. (2009). Age-related differences in
the dose-response relationship of muscle protein synthesis to resistance exercise in
young and old men. J. Physiol, 587, 211-217.
[171] Mayhew, D. L., Kim, J. S., Cross, J. M., Ferrando, A. A. & Bamman, M. M. (2009).
Translational signaling responses preceding resistance training-mediated myofiber
hypertrophy in young and old humans. J. Appl. Physiol, 107, 1655-1662.
[172] Phillips, S. M., Tipton, K. D., Aarsland, A., Wolf, S. E. & Wolfe, R. R. (1997). Mixed
muscle protein synthesis and breakdown after resistance exercise in humans. Am. J.
Physiol, 273, E99-E107.
[173] Kosek, D. J., Kim, J. S., Petrella, J. K., Cross, J. M. & Bamman, M. M. (2006).
Efficacy of 3 days/wk resistance training on myofiber hypertrophy and myogenic
mechanisms in young vs. older adults. J. Appl. Physiol, 101, 531-544.
[174] Yarasheski, K. E., Pak-Loduca, J., Hasten, D. L., Obert, K. A., Brown, M. B. &
Sinacore, D. R. (1999). Resistance exercise training increases mixed muscle protein
synthesis rate in frail women and men >/=76 yr old. Am. J. Physiol, 277, E118-E125.
[175] Sheffield-Moore, M., Paddon-Jones, D., Sanford, A. P., Rosenblatt, J. I., Matlock, A.
G., Cree, M. G. & Wolfe, R. R. (2005). Mixed muscle and hepatic derived plasma
protein metabolism is differentially regulated in older and younger men following
resistance exercise. Am. J. Physiol. Endocrinol. Metab, 288, E922-E929.
[176] Smith, K., Barua, J. M., Watt, P. W., Scrimgeour, C. M. & Rennie, M. J. (1992).
Flooding with L-[1-13C]leucine stimulates human muscle protein incorporation of
continuously infused L-[1-13C]valine. Am. J. Physiol, 262, E372-E376.
[177] Chesley, A., MacDougall, J. D., Tarnopolsky, M. A., Atkinson, S. A. & Smith, K.
(1992). Changes in human muscle protein synthesis after resistance exercise. J. Appl.
Physiol, 73, 1383-1388.
[178] Drummond, M. J., Dreyer, H. C., Pennings, B., Fry, C. S., Dhanani, S., Dillon, E. L.,
Sheffield-Moore, M., Volpi, E. & Rasmussen, B. B. (2008). Skeletal muscle protein
anabolic response to resistance exercise and essential amino acids is delayed with
aging. J. Appl. Physiol, 104, 1452-1461.
[179] Fry, C. S., Drummond, M. J., Glynn, E. L., Dickinson, J. M., Gundermann, D. M.,
Timmerman, K. L., Walker, D. K., Dhanani, S., Volpi, E. & Rasmussen, B. B. (2011)
Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and
protein synthesis. Skelet Muscle, 1, 11.
[180] Miyazaki, M. & Esser, K. A. (2009). Cellular mechanisms regulating protein synthesis
and skeletal muscle hypertrophy in animals. J. Appl. Physiol, 106, 1367-1373.
[181] Baar, K. & Esser, K. (1999). Phosphorylation of p70(S6k) correlates with increased
skeletal muscle mass following resistance exercise. Am. J. Physiol, 276, C120-C127.
[182] Kubica, N., Bolster, D. R., Farrell, P. A., Kimball, S. R. & Jefferson, L. S. (2005).
Resistance exercise increases muscle protein synthesis and translation of eukaryotic
initiation factor 2Bepsilon mRNA in a mammalian target of rapamycin-dependent
manner. J. Biol. Chem, 280, 7570-7580.
[183] Rennie, M. J., Bohe, J. & Wolfe, R. R. (2002). Latency, duration and dose response
relationships of amino acid effects on human muscle protein synthesis. J. Nutr, 132,
3225S-3227S.
48
Mitsunori Miyazaki
[184] Wolfe, R. R. (2002). Regulation of muscle protein by amino acids. J. Nutr, 132, 3219S3224S.
[185] Volpi, E., Kobayashi, H., Sheffield-Moore, M., Mittendorfer, B. & Wolfe, R. R. (2003).
Essential amino acids are primarily responsible for the amino acid stimulation of
muscle protein anabolism in healthy elderly adults. Am. J. Clin. Nutr, 78, 250-258.
[186] Anthony, J. C., Yoshizawa, F., Anthony, T. G., Vary, T. C., Jefferson, L. S. & Kimball,
S. R. (2000). Leucine stimulates translation initiation in skeletal muscle of
postabsorptive rats via a rapamycin-sensitive pathway. J. Nutr, 130, 2413-2419.
[187] Anthony, J. C., Anthony, T. G., Kimball, S. R., Vary, T. C. & Jefferson, L. S. (2000).
Orally administered leucine stimulates protein synthesis in skeletal muscle of
postabsorptive rats in association with increased eIF4F formation. J. Nutr, 130, 139145.
[188] Garlick, P. J. (2005). The role of leucine in the regulation of protein metabolism. J.
Nutr, 135, 1553S-1556S.
[189] Fujita, S., Dreyer, H. C., Drummond, M. J., Glynn, E. L., Cadenas, J. G., Yoshizawa,
F., Volpi, E. & Rasmussen, B. B. (2007). Nutrient signalling in the regulation of
human muscle protein synthesis. J. Physiol, 582, 813-823.
[190] Guillet, C., Prod'homme, M., Balage, M., Gachon, P., Giraudet, C., Morin, L., Grizard,
J. & Boirie, Y. (2004). Impaired anabolic response of muscle protein synthesis is
associated with S6K1 dysregulation in elderly humans. FASEB J, 18, 1586-1587.
[191] Fiatarone, M. A., O'Neill, E. F., Ryan, N. D., Clements, K. M., Solares, G. R., Nelson,
M. E., Roberts, S. B., Kehayias, J. J., Lipsitz, L. A. & Evans, W. J. (1994). Exercise
training and nutritional supplementation for physical frailty in very elderly people. N.
Engl. J. Med, 330, 1769-1775.
[192] Welle, S. & Thornton, C. A. (1998). High-protein meals do not enhance myofibrillar
synthesis after resistance exercise in 62- to 75-yr-old men and women. Am. J. Physiol,
274, E677-83.
[193] Biolo, G., Tipton, K. D., Klein, S. & Wolfe, R. R. (1997). An abundant supply of amino
acids enhances the metabolic effect of exercise on muscle protein. Am. J. Physiol, 273,
E122-E129.
[194] Tipton, K. D., Borsheim, E., Wolf, S. E., Sanford, A. P. & Wolfe, R. R. (2003). Acute
response of net muscle protein balance reflects 24-h balance after exercise and amino
acid ingestion. Am. J. Physiol. Endocrinol. Metab, 284, E76-E89.
[195] Rasmussen, B. B., Tipton, K. D., Miller, S. L., Wolf, S. E. & Wolfe, R. R. (2000). An
oral essential amino acid-carbohydrate supplement enhances muscle protein anabolism
after resistance exercise. J. Appl. Physiol, 88, 386-392.
[196] 196. Fujita, S., Dreyer, H. C., Drummond, M. J., Glynn, E. L., Volpi, E. & Rasmussen,
B. B. (2009). Essential amino acid and carbohydrate ingestion before resistance
exercise does not enhance postexercise muscle protein synthesis. J. Appl. Physiol, 106,
1730-1739.
[197] Dreyer, H. C., Drummond, M. J., Pennings, B., Fujita, S., Glynn, E. L., Chinkes, D. L.,
Dhanani, S., Volpi, E. & Rasmussen, B. B. (2008). Leucine-enriched essential amino
acid and carbohydrate ingestion following resistance exercise enhances mTOR
signaling and protein synthesis in human muscle. Am. J. Physiol. Endocrinol. Metab,
294, E392-E400.
49
[198] Koopman, R., Wagenmakers, A. J., Manders, R. J., Zorenc, A. H., Senden, J. M.,
Gorselink, M., Keizer, H. A. & van Loon, L. J. (2005). Combined ingestion of protein
and free leucine with carbohydrate increases postexercise muscle protein synthesis in
vivo in male subjects. Am. J. Physiol. Endocrinol. Metab, 288, E645-E653.
[199] Smith, M. A., Moylan, J. S., Smith, J. D., Li, W. & Reid, M. B. (2007). IFN-gamma
does not mimic the catabolic effects of TNF-alpha. Am. J. Physiol. Cell Physiol, 293,
C1947-C1952.
[200] Saini, A., Faulkner, S., Al-Shanti, N. & Stewart, C. (2009). Powerful signals for weak
muscles. Ageing Res. Rev, 8, 251-267.
[201] Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E. & Kumar, A. (2007).
TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting
cytokine. FASEB J, 21, 1857-1869.
[202] White, J., Puppa, M., Gao, S., Sato, S., Welle, S. & Carson, J. (2013). Muscle mTORC1
suppression by IL-6 during cancer cachexia: A role for AMPK, Am. J. Physiol.
Endocrinol. Metab.
[203] Adams, V., Mangner, N., Gasch, A., Krohne, C., Gielen, S., Hirner, S., Thierse, H. J.,
Witt, C. C., Linke, A., Schuler, G. & Labeit, S. (2008). Induction of MuRF1 is essential
for TNF-alpha-induced loss of muscle function in mice. J. Mol. Biol, 384, 48-59.
[204] Frost, R. A., Nystrom, G. J., Jefferson, L. S. & Lang, C. H. (2007). Hormone, cytokine,
and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in
skeletal muscle. Am. J. Physiol. Endocrinol. Metab, 292, E501-E512.
[205] Kandarian, S. C. & Jackman, R. W. (2006). Intracellular signaling during skeletal
muscle atrophy. Muscle Nerve, 33, 155-165.
[206] Jackman, R. W. & Kandarian, S. C. (2004). The molecular basis of skeletal muscle
atrophy. Am. J. Physiol. Cell Physiol, 287, C834-C843.
[207] Doucet, M., Russell, A. P., Leger, B., Debigare, R., Joanisse, D. R., Caron, M. A.,
LeBlanc, P. & Maltais, F. (2007). Muscle atrophy and hypertrophy signaling in patients
with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med, 176, 261269.
[208] Rutten, E. P., Franssen, F. M., Engelen, M. P., Wouters, E. F., Deutz, N. E. & Schols,
A. M. (2006). Greater whole-body myofibrillar protein breakdown in cachectic patients
with chronic obstructive pulmonary disease. Am. J. Clin. Nutr, 83, 829-834.
[209] Cesari, M., Penninx, B. W., Pahor, M., Lauretani, F., Corsi, A. M., Rhys Williams, G.,
Guralnik, J. M. & Ferrucci, L. (2004). Inflammatory markers and physical performance
in older persons: the InCHIANTI study. J. Gerontol. A. Biol. Sci. Med. Sci, 59, 242248.
[210] Cohen, H. J., Pieper, C. F., Harris, T., Rao, K. M. & Currie, M. S. (1997). The
association of plasma IL-6 levels with functional disability in community-dwelling
elderly. J. Gerontol. A. Biol. Sci. Med. Sci, 52, M201-M208.
[211] Ershler, W. B., Sun, W. H., Binkley, N., Gravenstein, S., Volk, M. J., Kamoske, G.,
Klopp, R. G., Roecker, E. B., Daynes, R. A. & Weindruch, R. (1993). Interleukin-6 and
aging: blood levels and mononuclear cell production increase with advancing age and
in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res, 12,
225- 230.
50
Mitsunori Miyazaki
[212] Fagiolo, U., Cossarizza, A., Scala, E., Fanales-Belasio, E., Ortolani, C., Cozzi, E.,
Monti, D., Franceschi, C. & Paganelli, R. (1993). Increased cytokine production in
mononuclear cells of healthy elderly people. Eur. J. Immunol, 23, 2375-2378.
[213] Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D. D., Guralnik,
J. M. & Longo, D. L. (2005). The origins of age-related proinflammatory state. Blood,
105, 2294-2299.
[214] Franceschi, C., Bonafe, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E. & De
Benedictis, G. (2000). Inflamm-aging. An evolutionary perspective on
immunosenescence. Ann. N Y Acad. Sci, 908, 244-254.
[215] Visser, M., Pahor, M., Taaffe, D. R., Goodpaster, B. H., Simonsick, E. M., Newman, A.
B., Nevitt, M. & Harris, T. B. (2002). Relationship of interleukin-6 and tumor necrosis
factor-alpha with muscle mass and muscle strength in elderly men and women: the
Health ABC Study. J. Gerontol. A. Biol. Sci. Med. Sci, 57, M326-M332.
[216] Schaap, L. A., Pluijm, S. M., Deeg, D. J., Harris, T. B., Kritchevsky, S. B., Newman, A.
B., Colbert, L. H., Pahor, M., Rubin, S. M., Tylavsky, F. A. & Visser, M. (2009).
Higher inflammatory marker levels in older persons: associations with 5-year change in
muscle mass and muscle strength. J. Gerontol. A. Biol. Sci. Med. Sci, 64, 1183-1189.
[217] Payette, H., Roubenoff, R., Jacques, P. F., Dinarello, C. A., Wilson, P. W., Abad, L. W.
& Harris, T. (2003). Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in
very old community-living men and women: the Framingham Heart Study. J. Am.
Geriatr. Soc, 51, 1237-1243.
[218] Roubenoff, R., Harris, T. B., Abad, L. W., Wilson, P. W., Dallal, G. E. & Dinarello, C.
A. (1998). Monocyte cytokine production in an elderly population: effect of age and
inflammation. J. Gerontol. A. Biol. Sci. Med. Sci, 53, M20-M26.
[219] Barbieri, M., Ferrucci, L., Ragno, E., Corsi, A., Bandinelli, S., Bonafe, M., Olivieri, F.,
Giovagnetti, S., Franceschi, C., Guralnik, J. M. & Paolisso, G. (2003). Chronic
inflammation and the effect of IGF-I on muscle strength and power in older persons.
Am. J. Physiol. Endocrinol. Metab, 284, E481-E487.
[220] Elosua, R., Bartali, B., Ordovas, J. M., Corsi, A. M., Lauretani, F. & Ferrucci, L.
(2005).
Association between physical activity, physical performance, and
inflammatory biomarkers in an elderly population: the InCHIANTI study. J. Gerontol.
A. Biol. Sci. Med. Sci, 60, 760-767.
[221] Schrager, M. A., Metter, E. J., Simonsick, E., Ble, A., Bandinelli, S., Lauretani, F. &
Ferrucci, L. (2007). Sarcopenic obesity and inflammation in the InCHIANTI study. J.
Appl. Physiol, 102, 919-925.
[222] Foletta, V. C., Prior, M. J., Stupka, N., Carey, K., Segal, D. H., Jones, S., Swinton, C.,
Martin, S., Cameron-Smith, D. & Walder, K. R. (2009). NDRG2, a novel regulator of
myoblast proliferation, is regulated by anabolic and catabolic factors. J. Physiol, 587,
1619-1634.
[223] Leger, B., Derave, W., De Bock, K., Hespel, P. & Russell, A. P. (2008). Human
sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of
Akt phosphorylation. Rejuvenation Res, 11, 163-175B.
[224] Welle, S., Burgess, K., Thornton, C. A. & Tawil, R. (2009). Relation between extent of
myostatin depletion and muscle growth in mature mice. Am. J. Physiol. Endocrinol
Metab, 297, E935-E940.
51
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 3
Abstract
Insulin-like growth factor-I (IGF-I) is an important growth factor mediating cell
proliferation, differentiation and cell survival in skeletal muscles. In humans, there are
three types of IGF-I isoforms derived from the differential E domain, called IGF-I Ea, Eb
and Ec. IGF-I Ec is also called mechano growth factor (MGF), because of the marked
upregulation in exercised and damaged muscles. In rodents, IGF-I isoforms are composed
of two types of IGF-I, IGF-I Ea and MGF. IGF-I isoforms serve as the IGF-I precursor
peptides. IGF-I isoforms have multiple transcriptional initiation sites and derived from
some alternative splicing. After post-translation modification, the IGF-I precursor
peptides are grown into a mature IGF-I. IGF-I isoforms are produced by various tissues,
including liver, cartilage and skeletal muscle, and act through endocrine and
autocrine/paracrine pathways. E peptides derived from the IGF-I isoforms are likely to
have different growth-promoting effects on skeletal muscles.
IGF binding protein (IGFBP) family is composed of six different members, which
are IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6. IGFBPs are
characteristic of high affinity for IGFs binding, whereas IGFBP related proteins with the
low affinity binding are also found and distinguished from IGFBPs. Most of the
circulating IGF-I exists in a large tripartite complex with IGFBP-3 and the acid labile
subunit (ALS). IGF-I also exists in binary or ternary complexes with another member of
the IGFBP family. IGF-I is removed from the complexes, and free IGF-I acts on muscle
growth via the IGF-I receptors. IGFBPs have stimulating and inhibitory effects
54
Introduction
Skeletal muscle results from morphological and biochemical changes in response to
different environments and stimuli. Skeletal muscle is also influenced by hormonal
conditions, such as growth hormone (GH) and testosterone, and mechanical loading, such as
exercise, and results from the changes of muscle mass and protein synthesis. Insulin-like
growth factor-I (IGF-I) is one of the most important growth-promoting factors mediating
numerous gene expressions in the skeletal muscles. Originally, somatic growth is thought to
be controlled by pituitary GH and its action was mediated by circulating IGF-I, which is
mostly derived from the liver. It has been well-established as GH/IGF-I axis. The GH/IGF-I
axis is important for normal growth, and the disruption leads to the retardation of body and
muscle growth. Most of the circulating IGF-I exists in a large tripartite complex with IGF
binding protein (IGFBP)-3 and the acid labile subunit (ALS) [1]. IGF-I also exists in binary
or ternary complexes with another member of the IGFBP family [1]. IGF-I is removed from
the complexes, and the free IGF-I exerts various biological functions via the IGF-I receptors.
The large complex of IGF-I in circulation cannot cross the vascular endothelium unless this
complex is broken down and therefore acts to regulate the endocrine actions of IGF-I. In
contrast, the remaining IGF/IGFBP complex is easily cross the vascular endothelium and is
thought to be locally bioavailable to the target tissues [1]. Thus, it is thought that IGFBPs
function as carrier proteins for circulating IGFs and regulate IGF turnover, transport, and
tissue distribution [2].
IGF-I gene expression in the liver is tightly regulated by GH, whereas IGF-I expression
in skeletal muscle is regulated by mechanical stimuli in addition to GH [3]. Enhanced IGF-I
expression in skeletal muscle induces various growth-promoting actions, such as cell
proliferation and differentiation [4, 5]. Local IGF-I expression in response to mechanical
overloading is thought to be a most important factor for regulating muscle hypertrophy. The
multiplicity of growth-promoting actions of IGF-I is related to the diversity of intracellular
signaling, and proceeds on to the differential cascades [4, 5]. The multiplicity is also related
to a variety of IGF-I isoforms and IGFBPs expressed in the skeletal muscle. Several studies
have shown that IGF-I isoforms are expressed at the point of differential timing in response to
exercise and injury [6, 7]. IGFBPs are also expressed individually in response to various
stimuli [8, 9, 10]. The differential expressions and distinct roles of IGF-I isoforms and
IGFBPs in skeletal muscle would be discussed in the present review.
IGF-I Isoforms
Human insulin-like growth factor-I (IGF-I) gene originally called somatomedin C is
located within a region of the long arm of chromosome 12 [11]. It contains two promoters and
six exons, and yields multiple and heterogeneous mRNA transcripts. The multiple mRNA
55
transcripts result from multiple transcriptional initiation sites, alternative splicing and
different polyadenylation signals [12]. The IGF-I mRNA transcripts receive post-translation
modification and grow a mature IGF-I of 70-amino acid peptide.
IGF-I gene contains two promoters initiating at alternate 5' exons, exon 1 or 2. Promoter
1 initiates at exon 1 and produces IGF-I transcripts called class 1. Promoter 2 initiating at
exon 2 results from class 2 IGF-I transcripts. The transcripts of class 2 are predominantly
expressed in the liver, and thought to be highly responsive to a GH [13]. In contrast,
transcripts of class 1 are widely expressed in all tissues. Each promoter initiating at exon 1
and 2 is spliced to the common exon 3 and 4, and also spliced to exon 5 and/or 6 according to
various combinations (Figure 1).
Exon 3 and 4 of IGF-I gene are common to all transcripts and encode to the mature IGF-I
peptide. First 16-amino acids common to all E peptide of IGF-I are encoded by exon 4. The
remainder of E peptide is encoded by exon 5 and/or 6. Alternative splicing of IGF-I gene at
exon 5 and 6 yields different IGF-I isoforms. The isoforms, which contain exon 5, are
classified as IGF-I Eb and those of exon 6 are classified as IGF-I Ea. Transcripts of IGF-I Eb
are thought to be abundant in the liver, whereas transcripts of IGF-I Ea are predominantly
expressed in extra-hepatic tissues [14]. In the human skeletal muscle, as well as other tissues,
a third alternative splicing variant is also produced. The transcript is named IGF-I Ec, which
is alternatively called mechano-growth factors (MGF), and contains both exon 5 and 6 [15].
As IGF-I Ec transcript contains only the first 49 base pairs from exon 5, it leads to a reading
frame shift of carboxyl terminal ends during the translation process. Thus, IGF-I Ea, IGF-I Eb
and IGF-I Ec mRNA transcripts are composed of exons 3-4-6, exons 3-4-5 and exons 3-4-5
(49 bp insert)-6, respectively (Figure 1). IGF-I Eb isoform in humans has been identified in
the liver [18] and the skeletal muscle [19], however, its role still remains unclear.
Figure 1. IGF-I isoforms in humans. IGF-I gene consists of six exons including two promoters. The
isoforms of mRNA and precursor peptides are produce by the combination of alternate promoters and
different E domains. A mature IGF-I peptide is composed of B, C, A, and D domains, which are
derived from exon 3 and 4. There are three different E peptides in humans, called Ea, Eb and Ec (MGF)
peptides. The Ea, Eb and Ec peptides in humans are derived from exons 4-6, exons 4-5 and exons 4-56, respectively. The translated parts into proteins are described as the gray and black boxes. Numbers
described in parenthesis represent the numbers of amino acid in proteins.
56
IGF-I mRNA transcripts encode several IGF-I precursor peptides. The IGF-I precursor
peptides differ in the length of the amino-terminal (N-terminal) ends and the structure of
carboxyl-terminal (C-terminal) ends, called the E-domain. There are two types of IGF-I
precursor peptides derived from different promoters, called class 1 IGF-I and class 2 IGF-I.
There are three types of IGF-I precursor proteins derived from differential E domains, called
IGF-I Ea, IGF-I Eb and IGF-I Ec in humans. Taken together, the number of IGF-I mRNAs
and precursor peptides are expected to consist of six types of the isoforms. To date, four types
of splicing variants have been identified (Figure 1). The E-domains in the different IGF-I
precursor peptides share only 50% similarity [20, 21].
A mature IGF-I polypeptide is composed of a B-, C-, A- and D-domains. The E-domain
of mature IGF-I is trimmed off the precursor peptides through post-translational modification
by proteolytic cleavage. The mature IGF-I has a 70-amino acid long single chain polypeptide
and a 7,649 Da of the molecular weight [22]. The identical mature IGF-I peptide results from
all precursor peptides via post-translational modification (Figure 1).
The transcriptional and post-transcriptional regulation, alternative splicing, and posttranslational modification of IGF-I gene have given rise to several IGF-I precursor peptides,
and mature IGF-I and E peptide. The different E-peptides are thought to be removed from the
precursor IGF-I intracellularly [23]. Several studies have shown that these peptides have their
multiple biological roles [24, 25]. The different E-peptides have been shown to modulate IGF
actions and exert IGF-independent bioactivities [25, 26, 27].
57
Figure 2. The structure of IGFBPs and biological actions of their domains. IGFBPs are composed of Nterminal domain, L-domain and C-terminal domain. The N-terminal and C-terminal domains are
cysteine rich, and sharing high similarity in their amino acid sequences. The L-domain is poorly
conserved and contains a number of proteolysis, glycosylation and phosphorylation sites. The Cterminal domain contains heparin-binding motifs, which are associated with the binding to cell surfaces
and the extracellular matrix, nuclear localization sequence, integrin binding sequence as well as IGF
binding site. IGF-independent actions are also associated with the C-terminal domain. Arrowhead
indicates cysteine residue.
The L-domains of IGFBPs contain 55-94 amino acid residues, and share less than 15%
similarity. It is thought that this region structurally acts as a hinge between the N-terminal and
C-terminal domains. The L-domain contains a number of proteolysis, glycosylation and
phosphorylation sites. All IGFBPs can be cleaved by specific protease. The IGF binding
activities in IGFBPs are reduced by the proteolytic cleavages. IGFBP-3 and IGFBP-4 are Nglycosylated, and IGFBP-5 and IGFBP-6 are O-glycosylated [34]. The glycosylation of
IGFBPs influences the resistance to proteolysis of IGFBPs [35], and makes the molecule less
susceptible to proteolysis [36]. Potential phosphorylation sites are found in IGFBPs, only
phosphoisoforms of IGFBP-1, IGFBP-3 and IGFBP-5 have been reported so far [37].
Phosphorylation of IGFBP-1 has been shown to increase IGF binding by at least 5-fold [38].
Phosphorylated IGFBP-1 inhibits IGF-I actions, whereas the dephosphorylated IGFBP-1
appears to enhance IGF-I-induced DNA synthesis [39, 40]. Thus, the post-translational
modification in the L-domain would alter the property of IGFBPs to modulate IGF
bioactivity.
The C-terminal domains of IGFBPs, like the N-terminal domains, are highly conserved,
and share approximately 34% similarity. The C-terminal domain contains six cysteines of the
total 16-20 cysteines in IGFBPs (Figure 2). The amino acid residues including the last 5
cysteines in the C-terminal domain share 37% similarity with the thyroglobulin-type-I domain
[41]. The thyroglobulin-type-I domain is composed of about 65 amino acid residues, found in
a number of proteins with various physiological functions in different organisms [41]. In
IGFBPs, the C-terminal domain is involved in the bindings to IGFs, cell surfaces,
extracellular matrix (ECM) and other ligands. The C-terminal domains of IGFBP-3, IGFBP-5
and IGFBP-6 contain heparin-binding motifs, which are associated with the binding to cell
58
surfaces and ECM [42, 43, 44, 45]. The C-terminal domains of IGFBP-3 and IGFBP-5 also
have a functional nuclear localization sequence (NLS) and demonstrate localization in the
nucleus [46]. The C-terminal domains of IGFBP-1 and IGFBP-2 have an arginie-glycineglutamate (RGD) motif, which are involved in binding to integrins, located on the cell surface
[47]. The C-terminal domains of IGFBP-3 and IGFBP-5 have a nuclear localization sequence
(NLS) [48].
59
domain have been shown to be related to IGF binding [63, 64]. Forbes et al. [65] has reported
that Lys222-Asn236 in bovine IGFBP-2, which is corresponding to those of 224-238 of human
IGFBP-2, was important for IGF binding, and speculated that these residues must lie in close
proximity to the N-terminal domain to allow both domains to interact with IGFs. Kibbey et al
[66] have confirmed that upstream and downstream regions contained the residues of 247-250
in the C-terminal domain of human IGFBP-2 participate in IGF-I binging. Thus, it is thought
that the C-terminal domain of IGFBP-2 plays a key role in IGF binding and inhibition of IGF
binding to the IGF-IR [67].
Some studies have been reported that both the N-terminal and C-terminal domains need
for high affinity of IGF binding in IGFBP-2 [68] and IGFBP-3 [69]. By using biosensor
analysis of IGFBP-2 fragments, Carrick et al. [68] have reported that the N-terminal domain
has a fast association component, and the C-terminal domain contributes to the stability of
IGF/IGFBPs complex, and that these domains must be combined to form one high affinity
binding site [68]. In IGFBP-3, Payet et al. [69] have shown that each fragment of N-terminal
or C-terminal domains has a low affinity binding site, but co-incubating the fragments of
these domains can form high affinity binding site for IGFs. In addition, the ternary complexes
containing the N-terminal and C-terminal fragments and IGF appear to show some binding to
ALS, but not able to bind with ALS in the binary complexes between N-terminal or Cterminal fragments and IGF [69]. Headey et al [70] have reported that the presence of both
the N-terminal and C-terminal domains in IGFBP-6 is insufficient to hold high affinity IGF
binding using the coincubation technique. They have discussed that linkage of the N-terminal
and C-terminal domains, such as an intact IGFBP, is necessary for high affinity IGF binding.
The L-domain of IGFBPs does not directly bind IGFs, but appears to modulate the IGF
binding by post-translational modification. It has been reported that phosphorylation in the Ldomain changes the property of IGFBPs to modulated IGF binding [71]. Its contribution to
IGF binding is likely related to its ability to promote a tertiary structure, which permits
optimal relationships between the N-terminal and C-terminal domains. In a chimeras study
constructed between IGFBP-3 and IGFBP-2, Hashimoto et al. [72] have shown that IGF-II
binding of IGFBP-3 does not change, when the C-terminal domain of IGFBP-3 is exchanged
for the C-terminal domain of IGFBP-2. In contrast, replacement of IGFBP-3 L-domain to the
IGFBP-2 L-domain reduces the relative affinity of the resultant chimera for IGF-II by 37%. It
is possible that the different L-domain of IGFBPs influences the properties of IGF binding of
specific IGFBP.
60
superfamily [33]. Consequently, the IGFBP superfamily can be classified into IGFBP family
proteins with high affinities for IGFs and IGFBP-rPs with low affinities.
IGFBP-rP1 is firstly named Mac 25 [73], and provisionally IGFBP-7 [74]. This protein is
similar to tumor adhesion factor (TAF) [75] or prostacyclin stimulating factor (PSF) [76].
Structurally, IGFBP-rP1 consists of the N-terminal domain, Kazal-type serine proteinase
inhibitor and immunoglobulin-like domain. The region of similarity to the IGFBPs is
confined to the N-terminal domain. The IGFBP-rP1 appears to have multiple roles including
the ability to bind IGFs and insulin. It has been reported that Mac mRNA expression is higher
in dividing mouse myoblasts than in undivided, undifferentiated myotubes [77]. It suggests
that IGFBP-rP1 may play a role in differentiation of muscles. IGFBP-rP1 appears to
specifically accumulate in new blood vessels of various human cancer tissues and in cultured
vascular endothelial cells [78], suggesting that IGFBP-rP1 may also be involved in the
formation of new capillary vessels. IGFBP-rP1 is also capable of stimulating and enhancing
IGF and insulin mediated fibroblast cell growth [79]. Thus, IGFBP-rP1 has diverse biological
roles.
CCN family proteins are a group of cysteine rich proteins, which is coined by Bork [80].
The nomenclature of CCN family is based on the initial letters of main members: Cystein-rich
61 (Cyr61, CCN1), Connective tissue growth factor (CTGF, CCN2), and Nephroblastoma
Overexpressed gene (Nov, CCN3). CCN family proteins are shown to contain a N-terminal
domain of similarity to those of IGFBPs, and consist of six members: CTGF, Nov, Cyr61,
WISP-2, WISP-1 and WISP-3. These proteins are alternatively named IGFBP-rP2, IGFBPrP3, IGFBP-rP4 IGFBP-rP7, IGFBP-rP8 and IGFBP-rP9, respectively. WISP-1, WISP-2 and
WISP-3 are regulated by Wnt-1, which is a glycosylated signaling protein critical in the
developmental process [81, 82]. Each protein of the CCN family is composed of four
domains: the N-terminal domain similar to IGFBPs, the Von Willebrand factor type C repeat
(VWC), the thrombospondin type I repeat, and the C-terminal domain with cysteine knot and
heparin binding sites. IGFBP-rP7 only has the first three conserved protein domains: the Nterminal domain, the VWC and the thrombospondin type I repeat, and lacks the last Cterminal domain unlike the other CCN family proteins. In general, it is thought that the
members of the CCN family have 1,000-fold lower affinity for IGF-I as compared with
IGFBP family [83].
It is now thought that CCN family proteins are not growth factors but matricellular
proteins that modify signaling of other molecules, in particular those associated with ECM
[84]. CCN family proteins appear to be involved to mitosis, adhesion, apoptosis, extracellular
matrix production, growth arrest and migration of multiple cell types. [84]. CCN family
proteins are induced by growth factors and cytokines such as transforming growth factor
(TGF)- and endothelin 1 and cellular stress such as hypoxia, and integrate communication
between ECM and the cell surface [85]. It has been reported that IGFBP-rP2 is selectively
upregulated by TGF- in fibroblast cells, which is a potent stimulator of fibroblast cell
proliferation [86]. Some of the biological effects of TGF- on fibroblast and endothelial cells
appear to be mediated by the upregulated IGFBP-rP2 [87, 88, 89, 90]. It has been known that
IGFBP-rP4 is associated with the ECM and cell surfaces, probably through its heparin
binding sites [91, 92]. IGFBP-rP4 promotes the adhesion of fibroblasts and epithelial cells,
enhances chemotaxis of fibroblasts, and enhances growth factor-stimulated DNA synthesis in
fibroblast and endothelial cells [92, 93]. It is thought that the interactions between integrins or
61
heparin sulfate proteoglycans and CCN family proteins are important for the adhesive and
mitogenic functions [85, 94, 95].
IGFBP-rP5 is structurally composed of three domains: a N-terminal domain similar to
those of the IGFBPs, Kazal-type serine proteinase inhibitor and immunoglobulin-like domain,
and a large domain having similarity with bacterial serine protease of HtrA class [96].
IGFBP-rP5 is known to be serine protease specifically cleaving IGFBP-5 [83]. IGFBP-rP6 is
alternatively named an endothelial cell-specific molecule-1 (ESM-1) and endocan. Expression
of this molecule appears to be restricted to human lung tissue. IGFBP-rP6 is composed of two
potential protein domains: a N-terminal domain similar to those of the IGFBPs and a Cterminal domain that does not share the similarity with any known proteins. It has been
reported that IGFBP-rP6 is upregulated by cytokines, TNF, interleukin 1 [97], and growth
factors such as vascular endothelial growth factor-A (VEGF-A) [98].
The IGFBP-rPs are regulated by a variety of growth factors and cytokines, and involved
in various biological functions independent of IGF actions. As IGFBP-rPs have at 100-fold
lower affinity for IGFs as compared with IGFBPs, the modulation for IGF action may be
weak from the properties with the low affinity binding. The biological function of IGFBP-rPs
for IGF actions is obscure at present. The details of IGFBP superfamily and CCN family
proteins are discussed in other reviews [33, 84, 85].
62
of muscle mass at 3 weeks of age [106]. Although the MKR mice were treated with
recombinant human GH for 4weeks, MKR mice failed to exhibit the GH-induced increases of
muscle fibers and myogenic regulatory factors observed in wild-type mice. The proliferation
of satellite cells in MKR mice also failed to exhibit the effects of GH administration [106].
Thus, growth-promoting action of GH is mainly mediated by IGF-I action via IGF-IR.
Local IGF-I production in the skeletal muscle is regulated by GH-dependent and GHindependent stimuli and is thought to act in autocrine or paracrine manners. Several
investigators have reported that hypophysectomy induces a decreased expression of IGF-I
mRNA in the skeletal muscle [99, 107], and that GH treatment in hypophysectomized rats
cause the increases of IGF-I mRNA expression in skeletal muscle [108]. In contrast,
compensatory overload due to synergic ablation increases the expression of IGF-I mRNA in
hypophysectomized muscle as well as in the controls [108, 109]. IGF-I is composed of two
different isoforms, called IGF-I Ea and MGF, in rodent skeletal muscles. Lowe et al. [110]
have reported that the expressions of IGF-I Ea and MGF mRNAs in the kidney, lung, and
heart are coordinately increased by the administration of GH. Iida et al. [111] have shown that
exogenous GH administration to GH-deficient mice increased the expressions of IGF-I Ea
and MGF mRNAs in the skeletal muscle. Administration of recombinant human GH to
hypophysectomized rats caused a marked increase in both MGF and IGF-I Ea muscle mRNA
levels [112]. In addition, Yamaguchi et al. [113] have also shown that both IGF-I Ea and
MGF mRNAs exhibit an increased expression following compensatory overload independent
of the GH status. Thus, local IGF-I expressions are thought to be modulated through both
GH-dependent and GH-independent manners.
Different expression patterns of the IGF-I isoforms have been shown in overloaded or
damaged muscles. Owino et al. [17] have reported that MGF mRNA expression, but not IGFI Ea mRNA, is specifically stimulated by mechanical overloading. Cheema et al. [114] have
also reported that using an in vitro culture system, the distinct expression responses between
MGF and IGF Ea mRNAs are induced by mechanical signals, static load, ramp stretch or
cyclical stretches. In humans, Hameed et al. [16] have shown that a single bout of highresistance exercise in young subjects results in a significant increase in MGF mRNA, but not
in IGF-I Ea mRNA. Thus, MGF appear to be more susceptible to the mechanical stimuli than
IGF Ea.
Muscle hypertrophy is caused by mechanical overloading, but circulating IGF-I hardly
changes in spite of the increased expression of IGF-I in skeletal muscle [115]. Exogenous
administration of GH induces the increase of serum IGF-I, but does not stimulate muscle
hypertrophy in the absence of mechanical loading [116]. In the liver IGF-I deficient mouse
model, a severe deficiency of serum IGF-I did not prevent muscle hypertrophy in response to
resistance exercise [117]. Mechanical overloading to hypophysectomized muscles also
induced the increases of muscle fiber areas and IGF-I expression [115]. In addition, a greater
hypertrophied portion in a muscle following mechanical overloading has exhibited a larger
increase of muscle IGF-I expression [109]. Thus, exercise-induced localized muscle
hypertrophy is thought to be associated with locally produced IGF-I in the skeletal muscle.
In humans, GH levels start to increase 10 to 20 min after the onset of exercise. The GH
levels reach their peak at the end of the exercise, and remain elevated for up to 2h after
exercise [118, 119, 120]. The serum GH levels are increased according to the intensity of
exercise [121]. GH secretion correlates positively with duration of exercise, when the
intensity is maintained at a constant state [122]. Total IGF-I, IGFBP-3 and ALS in serum
63
increase slightly during exercise, and free IGF-I does not change during and after exercise
[123]. The physiological meaning of these changes is unknown. It has been known that IGF-I
stimulates glucose transport as potently as insulin in addition to involving of skeletal muscle
remodeling. IGF-I deficiency results in an impaired insulin action in skeletal muscle [124].
Circulating IGF-I as well as locally produced IGF-I would also have an impact on these
metabolic effects.
64
Figure 3. Local IGF/IGFBPs complex, IGFBPs and IGF signaling in skeletal muscle. IGF/IGFBPs
complex is prompted to bind IGF-IR after post-translational modification of IGFBPs, including
proteolytic cleavage, de-phosphorylation, ECM binding, and interaction to cell surface. IGFBPs also
have cellular bioactivity through IGF-independent manner. IGF-I signaling processes three different
cascades, called MAP kinase, PI3-K/AKT, and calcineurin signaling pathways. IGF-I signaling in
skeletal muscle modulates the proliferation and differentiation as well as protein synthesis and
degradation through these different pathways, and result from muscle hypertrophy.
Either inhibitory or stimulatory effect of IGFBPs for IGF actions is influenced by the
specific cleavage of IGFBP protease (Figure 3). Parker et al. [133] have shown that a
calcium-dependent serine protease activated by IGFs specifically cleaves IGFBP-4 into
fragments with a low affinity for IGF-I, and that the IGFBP-4 fragments decreases the
inhibitory effects for IGF-I actions in comparison with intact IGFBP-4. In addition, a
protease-resistant mutation of IGFBP-4 has been shown to inhibit DNA synthesis, cell
migration, and muscle growth in response to IGFs [134, 135]. Proteolyzed IGFBP-5 could not
modulate IGF growth stimulation in cultured fibroblasts [136]. Protease resistant mutation of
IGFBP-5 inhibits IGF-I stimulated DNS and protein synthesis and migration of porcine
smooth muscle cells [137]. Proteolyzed IGFBP-3 fragments have also been shown to lose the
binding affinity for IGFs and diminish the inhibitory effects of IGFBP-3 [51, 138].
The modulation of IGFBPs for IGF actions is also dependent upon ECM association and
interactions with cell surface proteins (Figure 3). IGFBP-5 is known to contain ECM binding
sites, which are located on amino acid residues of Arg201-Arg218 [45]. IGFBP-5 interacts
65
specifically with thrombospondin-1 and osteopontin, which are ECM proteins [139]. ECMbound IGFBP-5 has a several-fold decrease of IGF-I affinity [136]. Binding to ECM of
IGFBP-5 results from the increased interaction between IGF-I and IGF-IR, and potentiates
IGF actions. Disruption of the ECM binding sites in IGFBP-5 abolishes ECM binding, and
the potentiated IGF actions in smooth muscle [140].
As the affinity of IGFBP-1 for IGF-I is higher than that of IGF-I for the IGF-IR, IGFBP1 reduces free IGF-I levels and inhibits a signaling through IGF-IR. IGFBP-1 is secreted as a
phosphoprotein, and contains three serine phosphorylation sites in humans. The affinity of
phosphorylated IGFBP-1 for IGF-I is several-fold higher than that of a non-phosphorylated
one [71]. Some studies have shown that dephosphorylated IGFBP-1 enhances IGF-I-induced
DNA synthesis, but phosphorylated IGFBP-1 inhibits IGF-I actions [39, 40]. Phosphorylation
of IGFBP-3 has also been shown to reduce IGF binding [141, 142]. The phosphorylation of
IGFBP-3 inhibits cell surface interaction and proteolytic cleavage [142]. Thus, it is thought
that phosphorylation of IGFBPs is associated with the modulation of IGF binding (Figure 3).
Intriguingly, in rats, the phosphorylation of IGFBP-1 has been reported not to change the
affinity for IGF-I [143].
66
67
68
69
In in vivo gene transfer and transgenic approaches, overexpression of IGF-I Ea has been
reported to promote the increase of muscle mass and strength in adult mice [196]. In the
combination of overexpression of IGF-I Ea and resistance training in rats, the hypertrophic
effects of IGF-I Ea have been demonstrated [104]. E peptides of IGF-I appear to have
biological activities. Pfeffer et al. [27] demonstrated that IGF-I Ea and Eb did not modulate
IGF-I secretion, but that they increased cell entry of IGF-I compared with the mature IGF-I
alone. Overexpressions of IGF-I Ea and Eb promote muscle hypertrophy, but the
overexpression of mature IGF-I fails to increase muscle mass [197]. When several
recombinant Ea peptides derived from rainbow trout are synthesized and administrated to
three types of cell lines, all Ea peptides have been shown to exert the mitogenic activities
[26]. The Eb peptide also has growth-promoting effects in human bronchial epithelial cells
[198]. Thus, it is thought that E peptides retain the function of growth-promoting factors.
In C2/C12 cell cultures treated with IGF-I Ea and MGF, Yang & Goldspink [25] have
demonstrated that IGF-I Ea-treated cells initiates the fusion of myoblasts to form myotubes,
and that MGF-treated cells show evidence of proliferation, but remains in the mononucleated
state. Mills et al. [199] have also reported that synthesized E peptide of MGF induced the
proliferation of human myogenic precursor cells and inhibit the differentiation. To compare
the actions of IGF-I isoforms, Barton [24] performed viral mediated delivery of IGF-I Ea and
MGF into the skeletal muscle of young and adult mice. The injection of IGF-I Ea in young
and adult mice produced the increases of muscle IGF-I protein and induced the increases of
muscle mass. In contrast, MGF injection increased the IGF-I protein and muscle mass in
young mice, but did not in adult mice. Shavlakadze et al. [200] have reported that the overexpression of IGF-I Ea in transgenic mice do not stimulate the early regeneration after whole
muscle grafts, suggesting that another IGF-I such as MGF may play a role in the early stages
of skeletal muscle regeneration. Taken together, IGF-I Ea and MGF would play differential
roles on muscle growth. IGF-IR on muscle fibers would be required for the hypertrophy,
regardless of which isoform is expressed. Barton et al. [197] have shown that overexpressions
of IGF-I Ea and Eb result in the increase of muscle mass in wild mice, but could not cause
hypertrophy after injection into the muscles of MKR mice, which lack functional IGF-IR. In
contrast, there are some evidences that the signaling of the E peptides is not mediated by the
IGF-IR [25, 197, 198, 199, 201]. Siegfried et al. [198] have reported that a monoclonal
antibody antagonist to the IGF-IR could not suppress the proliferating response induced by
IGF-I Eb. An antibody against IGF-IR abolished the proliferating and migrating effects of
IGF-I on myoblasts, but did not influence the mitogenic activities in E peptide of MGF [25,
199, 201]. Barton et al. [197] have shown that MGF, but not IGF-I Ea, acts through an IGFIR-independent pathway to cause increased MMP-13, a member of collagenase sub-family
and a potent degrading enzyme of the muscle extracellular matrix. Thus, the different actions
of E peptides may be modulated by the distinct receptor regulation. It remains unclear
whether specific receptors and intracellular signaling for each E peptide exists, or not.
70
not in IGFBP-5 mRNA [8]. In contrast, IGFBP-5 mRNA expression is increased in unloaded
muscle but not in IGFBP-4 mRNA [8]. Awede et al. [202] have shown that IGFBP-4 and
IGFBP-5 mRNA is increased by clenbutenol-induced muscle hypertrophy. Denervation
results in upregulation of IGFBP-4 and IGFBP-5 transcripts, but there was no change in
IGFBP-6 [203]. In rat regenerating muscles, all members of the IGFBPs appear to be
upregulated after muscle damage [9, 10]. Jennische and Hall [9] have reported that IGFBP-3,
IGFBP-4, IGFBP-5 and IGFBP-6 mRNAs were upregulated in the regenerating skeletal
muscle. Yamaguchi et al. [10] have shown that all members of IGFBPs are upregulated with
different timings during the regenerating process after muscle damage. In humans, prolonged
exercise induced a marked increase of serum IGFBP-1 level, but did not change IGFBP-3
[204, 205]. Dall et al. [206] have reported that serum IGFBP-1 and IGFBP-6 levels increase
after submaximal rowing exercise, whereas IGFBP-2 and IGFBP-4 do not change after the
exercise. Schwarz et al. [207] have shown that serum IGFBP-3 is increased after low and high
intensity exercises.
It has been reported that overexpressions of IGFBP-1, IGFBP-2, IGFBP-3 and IGFBP-5
in transgenic mice lead to various growth retardations [208, 209]. In contrast, IGFBP-2 null
mice exhibit normal body weight gains during pre-natal and post-natal growth [210, 211].
IGFBP-5 deficient mice have also shown indistinguishable changes of body weights in
comparison with wild-type mice from birth through postnatal 42 days [212]. In IGFBP-2 null
mice, mRNA expression of IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5 and IGFBP-6
were significantly increased as compared with the control [211]. In IGFBP-5 deficient mice,
IGFBP-3 was upregulated according to the loss of IGFBP-5 [212]. Thus, null mutation of an
IGFBP induces the elevated expression of the other members. It is thought that the
expressions of IGFBPs in various conditions would be regulated in harmony with the other
members of the IGFBP family.
In skeletal muscle, it has been well known that IGFBP-4 has an inhibitory effect [213,
214]. In contrast, IGFBP-5 has either an inhibitory or stimulatory effect for IGF actions [215,
216]. In C2C12 myoblast culture system, IGFBP-5 expression is increased during myoblast
differentiation [203]. In the cultured myoblast, Knockdown of IGFBP-5 decreases the
expression of myogenin and impairs the myoblast differentiation [217]. In the IGFBP-5
overexpressing mice, whole body growth inhibition and retarded muscle development are
observed [209]. Further, IGFBP-5 has been shown to inhibit muscle differentiation by
blocking IGF actions in cultured myoblasts [152, 218]. Thus, the same IGFBP could act to
potentiate or inhibit IGF actions depending on various conditions such as culture conditions,
cell type and IGFBP dose [129, 130, 131, 132].
Bach et al. [219] have reported that IGF-II-induced proliferation and differentiation are
inhibited by IGFBP-6 in L6A1 rat myoblasts, and that the inhibition levels depend upon the
affinities of IGFBP-6. All IGFBPs can be cleaved by specific protease. The IGF binding
activities in IGFBPs are reduced by the cleavage. Dephosphorylation of IGFBPs and
interaction of IGFBPs with cellular surface and ECM also reduce IGF-I binding affinity. The
reduced affinity of IGFBPs would be easy to interact IGF-I with IGF-IR. It is thought that
these changes result from an inhibitory or stimulatory effect for the IGF actions [34]. In
humans, both increased [207] and unchanged [206] IGFBP-3 proteolytic activities have been
reported after exercise. Interestingly, Rosendal et al. [220] have reported that prolonged
physical training increases IGFBP-3 proteolysis in previously untrained individuals, but not
in trained individuals, indicating an association with the level of training in the individuals.
71
Yamaguchi et al. [10] have showed that the expressions of specific IGFBPs are
associated with those of specific myogenic markers in regenerating muscles in vivo. The time
course expression of IGFBP-3 and IGFBP-2 mRNA was significantly correlated with those of
MyoD and PCNA. In contrast, the expression of IGFBP-1 and IGFBP-5 mRNAs was
significantly correlated with those of myogenin and p21. These suggest that IGFBP-2 and
IGFBP-3 are associated with the proliferating process in regenerating muscles and that
IGFBP-1 and IGFBP-5 are related to the differentiation process but not to proliferation. James
et al. [32] have reported that IGFBP-5 is expressed during myoblast differentiation in a
culture system. Ren et al. [217] have shown that knockdown of IGFBP-5 inhibits myogenic
differentiation in vitro. Despite the significant sequence homology among the six IGFBPs,
each IGFBP exhibit distinct structural and biochemical properties [48]. For example, IGFBP1 and IGFBP-2 have RGD sequences, which are associated with binding to integrins. IGFBP3 and GFBP-5 have a NLS in their sequence, and IGFBP-3, IGFBP-5 and IGFBP-6 have a
heparin-binding motif. These distinct characteristics of IGFBPs may support the various
biological effects of IGF-I.
It has been known that IGFBP-6 binds IGF-II with an affinity 100--fold higher than those
for IGF-I, and predominantly inhibits IGF-II action [36, 128]. Yamaguchi et al. [10] have
shown that the expression of IGFBP-2, IGFBP-3 and IGFBP-6 in IGFBP family is only
correlated with the expression of MGF in regenerating muscles. However, the relationships
between IGFBPs and IGF-I isoforms are still unknown.
Conclusion
Insulin-like growth factor-I (IGF-I) plays important roles for various developmental
processes in skeletal muscles. IGF-I is known as an inter-mediator regulated by GH. IGF-I in
skeletal muscle is regulated in a GH-independent manner as well as a GH-dependent manner.
IGF-I locally produced in skeletal muscle is thought to play an important role for muscle
growth in response to mechanical stimuli. Mechanical overloading increases IGF-I expression
in the skeletal muscle via a GH-independent manner. IGFBPs have a characteristically high
affinity for IGFs binding, and form binary or ternary complexes with IGFs. In the case when
IGF-I is removed from the complexes, then free IGF-I acts on muscle growth via the IGF-I
receptors. IGFBPs in skeletal muscle are expressed individually in response to various
stimuli.
IGFBPs have stimulating and inhibitory effects depending on the IGF-I as well as IGFindependent actions. IGFBPs can act to promote or suppress IGF actions in association with
the posttranslational modification, such as proteolytic cleavage and dephosphorylation. There
are three different cascades of IGF-I intracellular signaling, which are MAP kinase, PI3K/AKT, and calcineurin signaling pathways. Several IGF-I isoforms are produced by multiple
transcriptional initiation sites and alternative splicing, and developed a mature IGF-I after
post-translation modification. Each IGF-I isoform appears to play distinct roles for the
growth-promoting effects. Proliferation and differentiation in the skeletal muscle are thought
to be associated with the multiplicity of the IGF isoforms, the diversity and various
posttranslational modifications of IGFBPs, and the multiple and complicated intracellular
signaling.
72
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
Mohan, S. & Baylink, D. J. (2002). IGF-binding proteins are multifunctional and act via
IGF-dependent and -independent mechanism. J. Endocrinol., 175, 19-31.
Jones, J. I. & Clemons, D. R. (1995). Insulin-like growth factors and their binding
proteins: biological actions. Endocr. Rev., 16, 3-13.
Yakar, S., Liu, J. -L. & Le Roith, D. (2000). The growth hormone-insulin-like growth
factor-I system: implications for organ growth and development. Pediatr. Nephrol., 14,
544-549.
Glass, D. J. (2005). Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J.
Biochem. Cell Biol., 37, 1974-1984.
Mourkioti, F. & Rosenthal, N. (2005). IGF-1, inflammation and stem cells: interactions
during muscle regeneration. TRENDS Immunol., 26, 535-542.
Hill, M. & Goldspink, G. (2003). Expression and splicing of the insulin-like growth
factor gene in rodent muscle is associated with muscle satellite (stem) cell activation
following local tissue damage. J. Physiol., 549, 409-418.
McKay, B. R., O'Reilly C. E., Phillips, S. M., Tarnopolsky, M. A. & Parise, G. (2008).
Co-expression of IGF-1 family members with myogenic regulatory factors following
acute damaging muscle lengthening contractions in humans. J. Physiol., 586, 55495560.
Awede, B., Thissen, J. -P., Gailly, P. & Lebacq, J. (1999). Regulation of IGF-I, IGFBP4 and IGFBP-5 gene expression by loading in mouse skeletal muscle. FEBS Lett., 461,
263-267.
Jennische, E. & Hall, C. M. (2000). Expression and localization of IGF-binding protein
mRNAs in regenerating rat skeletal muscle. Acta Pathol. Microbiol. Immunol. Scand.,
108, 747-755.
Yamaguchi, A., Sakuma, K., Fujikawa, T. & Morita, I. (2013). Expression of specific
IGFBPs is associated with those of the proliferating and differentiating markers in
regenerating rat plantaris muscle. J. Physiol. Sci., 63, 71-77.
Kim, S. W., Lajara, R. & Rotwein, P. (1991). Structure and function of a human
insulin-like growth factor I gene promoter. Mol. Endocrinol., 5, 1964-1972.
Tang, L. -L., Wang, Y. -L. & Sun, C. -X. (2004). The stress reaction and its molecular
events: splicing variants. Biochem. Biophys. Res. Commun., 320, 287-291.
LeRoith, D. & Roberts C. T. Jr. (1991). Insulin-like growth factor I (IGF-I): a
molecular basis for endocrine versus local action? Mol. Cell Endocrinol., 77, C57-C61.
Stewart, C. E. & Rotwein, P. (1996). Growth, differentiation, and survival: multiple
physiological functions for insulin-like growth factors. Physiol. Rev., 76, 1005-1026.
Chew, S. L., Lavender, P., Clark, J. L. & Ross R. J. M. (1995). An alternatively spliced
human insulin-like growth factor-I transcript with hepatic tissue expression that diverts
away from the mitogenic IBE1 peptide. Endocrinology, 136, 1939-1944.
Hameed, M., Orrell R. W., Cobbold, M., Goldspink, G. & Harridge, D. R. (2003).
Expression of IGF-I splice variants in young and old human skeletal muscle after high
resistance exercise. J. Physiol., 547, 247-254.
73
[17] Owino, V., Yang, S. Y. & Goldspink, G. (2001). Age-related loss of skeletal muscle
function and the inability to express the autocrine form of insulin-like growth factor-1
(MGF) in response to mechanical overload. FEBS let., 505, 259-263.
[18] Rotwein, P. (1986). Two insulin-like growth factor I messenger RNAs are expressed in
human liver. Proc. Natl. Acad. Sci. U S A, 83, 77-81.
[19] Hameed, M., Lange, K. H., Andersen, J. L., Schjerling, P., Kjaer, M. & Harridge, D. R.
(2003). The effect of recombinant human growth hormone and resistance training on
IGF-I mRNA expression in the muscles of elderly men. J. Physiol., 555, 231-240.
[20] Adamo, M. L., Neuenschwander, S., LeRoith, D. & Roberts, C. T. Jr. (1993). Structure,
expression, and regulation of the IGF-I gene. Adv. Exp. Med. Biol., 343, 1-11.
[21] Barton, E. R. (2006). The ABCs of IGF-I isoforms: impact on muscle hypertrophy and
implications of repair. Appl. Physiol. Nutr. Metab., 31, 791-797.
[22] Shavlakadze, T., Winn, N., Rosenthal, N. & Grounds, M. D. (2005). Reconciling data
from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth
Horm. IGF Res., 15, 4-18.
[23] Velloso, C. P. & Harridge, S. D. R. (2010). Insulin-like growth factor-I E peptides:
implications for aging skeletal muscle. Scand. J. Med. Sci. Sports, 20, 20-27.
[24] Barton, E. R. (2006). Viral expression of insulin-like growth factor-I isoforms promote
different response in skeletal muscle. J. Appl. Physiol., 100, 1778-1784.
[25] Yang, S. Y. & Goldspink, G. (2002). Different roles of IGF-I Ec peptide (MGF) and
mature IGF-I in myoblast proliferation and differentiation. FEBS Lett., 522, 156-160.
[26] Tian, X. C., Chen, M. J., Pantschenko, A. G., Yang, T. J. & Chen, T. T. (1999).
Recombinant E-peptides of pro-IGF-I have mitogenic activity. Endocrinology, 140,
3387-3390.
[27] Pfeffer, L. A., Brisson, B. K., Lei, H. & Barton, E. R. (2009). The insulin-like growth
factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Mol. Biol.
Cell, 20, 3810-3817.
[28] Sara, V. R. & Hall, K. (1990). Insulin-like growth factors and their binding proteins.
Physiol. Rev., 70, 591-614.
[29] Funk, B., Kessler, U., Eisenmenger, W., Hansmann, A., Kolb, H. J & Kiess, W. (1992).
The expression of insulin-like growth factor binding proteins is tissue specific during
human fetal life and early infancy. Acta Endocrinol., 127, 107-114.
[30] Shimasaki, S. & Ling, N. (1991). Identification and molecular characterization of
insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, -6). Prog. Growth
Factor Res., 3, 243-266.
[31] Schuller, A. G. P., Zwarthff, E. C. & Drop, S. L. S. (1993). Gene expression of the six
insulin-like growth factor binding proteins in the mouse conceptus during mid- and late
gestation. Endocrinology, 132, 2544-2550.
[32] James, P. L., Jones, S. B., Busby, W. H. Jr., Clemmons, D. R. & Rotwein, P. (1993). A
highly conserved insulin-like growth factor-binding protein (IGFBP-5) is expressed
during myoblast differentiation. J. Biol. Chem., 268, 22305-22312.
[33] Hwa, V., Oh, Y. & Rosenfeld, R. G. (1999). The insulin-like growth factor-binding
protein (IGFBP) superfamily. Endocr. Rev., 20, 761-787.
[34] Firth, S. M. & Baxter, R. C. (2002). Cellular actions of the insulin-like growth factor
binding proteins. Endocr. Rev., 23, 824-854.
74
[35] Neumann, G. M., Marinaro, J. A. & Bach, L. A. (1998). Identification of Oglycosylation sites and partial characterization of carbohydrate structure and disulfide
linkages of human insulin-like growth factor binding protein 6. Biochem. J., 37, 65726585.
[36] Bach, L. A. (1999). Insulin-like growth factor binding protein-6: the "forgotten"
binding protein? Horm. Metab. Res., 31, 226-234.
[37] Coverley J. A. & Baxter, R. C. (1997). Phosphorylation of insulin-like growth factor
binding proteins. Mol. Cell Endocrinol., 128, 1-5.
[38] Jones, J. I., DErcle, A. J., Camacho-Hubner, C. & Clemons, D. R. (1991).
Phosphorylation of insulin-like growth factor (IGF)-binding protein-1 in cell culture
and in vivo: effects on affinity for IGF-I. Proc. Natl. Acad. Sci. U S A, 88, 7481-7485.
[39] Busby Jr, W. H., Klapper, D. G. & Clemmons D. R. (1988). Purification of a 31,000dalton insulin-like growth factor binding protein from human amniotic fluid. Isolation
of two forms with different biologic actions. J. Biol. Chem., 263, 1402-1410.
[40] Yu, J., Iwashita, M., Kudo, Y. & Takeda, Y. (1998). Phosphorylated insulin-like growth
factor (IGF)-binding protein-1 (IGFBP-1) inhibits while non-phosphorylated IGFBP-1
stimulates IGF-I-induced amino acid uptake by cultured trophoblast cells. Growth
Horm. IGF Res., 8, 65-70.
[41] Lenarcic, B. & Bevec, T. (1998). Thyropins - new structurally related proteinase
inhibitors. Biol. Chem., 379, 105-111.
[42] Andress, D. (1995). Heparin modulates the binding of insulin-like growth factor (IGF)
binding protein-5 to a membrane protein in osteoblastic cells. J. Biol. Chem., 270,
28289-28296.
[43] Booth, B., Boes, M., Dake, B., Linhardt, R., Caldwell, E., Weiler, J. & Bar, R. (1996).
Structure-function relationships in the heparin-binding c-terminal region of insulin-like
growth factor binding protein-3. Growth Regul., 6, 206-213.
[44] Fowlkes, I. L., Thrailkill, K. M., George-Nascimento, C., Rosenberg, C. K. & Serra, D.
M. (1997). Heparin-binding, highly basic regions within the thyroglobulin type-I repeat
of insulin-like growth factor (IGF)-I binding proteins (IGFBPs) -3, -5, -6 inhibit
IGFBP-4 degradation. Endocrinology, 138, 2280-2285.
[45] Parker, A., Rees, C., Clarke, J., Busby Jr, W. H. & Clemmons D. R. (1998). Binding of
insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular
matrix is a major determinant of the cellular response to IGF-I. Mol. Biol. Cell, 9, 23832392.
[46] Schedlich, L. J., Le Page, S. L., Firth, S. M., Briggs, L. J., Jans, D. A. & Baxter, R. C.
(2000). Nuclear import of insulin-like growth factor-binding protein-3 and -5 is
mediated by the importin subunit. J. Biol. Chem., 275, 23462-23470.
[47] Jones, J. I., Doerr, M. E. & Clemons, D. R. (1995). Cell migration: interactions among
integrins, IGFs and IGFBPs. Prog. Growth Factor Res., 6, 319-327.
[48] Duan, C. & Xu, Q. (2005). Roles of insuli-like growth factor (IGF) binding proteins in
regulating IGF actions. Gen. Comp. Endocrinol., 142, 44-52.
[49] Cohen, P., Graves, H., Peehl, D., Kamerei, M., Giudice, L. & Rosenfeld R. (1992).
Prostate specific antigen is an IGF binding protein-3 (IGFBP-3) protease found in
seminal plasma. J. Clin. Endocrinol. Metab., 75, 1046-1053.
[50] Fielder, P. J., Rosenfeld, R. G., Graves, H. C., Grandbois, K., Maack, C. A., Sawamura,
S., Ogawa, Y., Sommer, A. & Cohen, P. (1994) Biochemical analysis of prostate
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
[60]
[61]
[62]
[63]
75
76
[64] Wang, J. F., Hampton, B., Mehlman, T., Burgess, W. H. & Rechler, M. M. (1988).
Isolation of a biologically active fragment from the carboxy terminus of the fetal rat
binding protein for insulin-like growth factors. Biochem. Biophys. Res. Commun., 157,
718-726.
[65] Forbes, B. E., Turner, D., Hodge, S. J., McNeil, K. A., Forsberg, G. & Wallace, J. C.
(1998). Localization of an insulin-like growth factor (IGF) binding site of bovine IGF
binding protein-2 using disulfide mapping and deletion mutation analysis of the Cterminal domain. J. Biol. Chem., 273, 4647-4652.
[66] Kibbey, M. M., Jameson, M. J., Eaton, E. M. & Rosenzweig, S. A. (2006). Insulin-like
growth factor binding protein-2: contributions of the C-terminal domain to insulin-like
growth factor-1 binding. Mol. Pharmacol., 69, 833-845.
[67] Carrick F. E., Hinds, M. G., McNeil, K. A., Wallace, J. C., Forbes, B. E. & Norton, R.
S. (2005). Interaction of insulin-like growth factor (IGF)-I and II with IGF binding
protein-2: mapping the binding surfaces by nuclear magnetic resonance. J. Mol.
Endocrinol., 34, 685-698.
[68] Carrick F. E., Forbes, B. E. & Wallace, J. C. (2001). BIAcore analysis of bovine
insulin-like growth factor (IGF)-binding protein-2 identifies major IGF binding site
determinants in both the amino- and carboxyl-terminal domains. J. Biol. Chem., 276,
27120-27128.
[69] Payet, L. D., Wang, X. -H., Baxter, R. C. & Firth, S. M. (2003). Amino- and carboxylterminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to
bind IGFs with high affinity and inhibit IGF receptor interactions. Endocrinology, 144,
2797-2806.
[70] Headey, S. J., Leeding K. S., Norton, R. S. & Bach, L. A. (2004). Contributions of the
N- and C-terminal domains of IGF binding protein-6 to IGF binding. J. Mol.
Endocrinol., 33, 377-386.
[71] Jones, J. I., Busby, W. H. Jr., Wright, G., Smith, C. E., Kimack, N. M. & Clemmons D.
R. (1993). Identification of the sites of phosphorylation in insulin-like growth factor
binding protein-1. Regulation of its affinity by phosphorylation of serine 101. J. Biol.
Chem., 268, 1125-1131.
[72] Hashimoto, R., Ono, M., Fujiwara, H., Higashihashi, N., Yoshida, M., Enjoh-Kimura,
T. & Sakano, K. (1997). Binding sites and binding properties of binary and ternary
complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid
labile subunit. J. Biol. Chem., 272, 27936-27942.
[73] Murphy, M., Pykett, M. J., Harnish, P., Zang, K. D. & George, D. L. (1993).
Identification and characterization of genes differentially expressed in meningiomas.
Cell Growth Differ., 4, 715-755.
[74] Oh, Y., Nagalla, S. R., Yamanaka, Y., Kim, H. -S., Wison, E. & Rosenfeld, R. G.
(1996). Synthesis and characterization of insulin-like growth factor binding protein
(IGFBP-7). J. Biol. Chem., 271, 30322-30325.
[75] Akaogo, K., Okabe, Y., Funahashi, K., Yoshitake, Y., Nishikawa, K., Yasumitsu, H.,
Umeda, M. & Miyazaki, K. (1994). Cell adhesion activity of a 30-kDa major secreted
protein from human bladder carcinoma cells. Biochem. Biophys. Res. Commun., 198,
1046-1053.
[76] Yamauchi, T., Umeda, F., Masakado, M., Isaji, M., Mizushima, S. & Nawata, H.
(1994). Purification and molecular cloning of prostacyclin-stimulating factor from
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]
77
serum-free conditioned medium of human diploid fibroblast cells. Biochem. J., 303,
591-598.
Damon, S. E., Haugk, K. L., Swisshelm, K. & Quinn, L. S. (1997). Developmental
regulation of Mac25/insulin-like growth factor-binding protein-7 expression in skeletal
myogenesis. Exp. Cell Res., 237, 192-195.
Akaogo, K., Okabe, Y., Sato, J., Nagashima, Y., Yasumitsu, H., Sugahara, K. &
Miyazaki, K. (1996). Specific accumulation of tumor-derived adhesion factor in tumor
vascular endothelial cells. Proc. Natl. Acad. Sci. U S A, 93, 8384-8389.
Akaogo, K., Sato, J., Okabe, Y., Sakamoto, Y., Yasumitsu, H. & Miyazaki, K. (1996).
Synergistic growth stimulation of mouse fibroblasts by tumor-derived adhesion factor
with insulin-like growth factors and insulin. Cell Growth Differ., 7, 1671-1677.
Bork, P. (1993). The modular architecture of a new family of growth regulators related
to connective tissue growth factor. FEBS Lett., 327, 125-1300.
Cadigan, K. M. & Nusse, R. (1997). Wnt signaling: a common theme in animal
development. Genes Dev., 11, 3286-3305.
Dale T. C. (1998). Signal transduction by the Wnt family of ligands. Biochem. J., 329,
209-223.
Hou, J., Clemmons, D. R. & Smeekens, S. P. (2005). Expression and characterization of
a serine protease that preferentially cleaves insulin-like growth factor binding protein-5.
J. Cell Biol., 94, 470-484.
Yeger, H. & Perbal, B. (2007). The CCN family of genes: a perspective on CCN
biology and therapeutic potential. J. Cell Commun. Signal, 1, 159-164.
Leask, A. & Abraham, D. J. (2006). All in the CCN family: essential matricellular
signaling modulators emerge from the bunker. J. Cell Sci., 119, 4803-4810.
Igarashi, A., Okoshi, H., Bradham, D. M. & Grotendorst, G. R. (1993). Regulation of
connective tissue growth factor gene expression in human skin fibroblast and during
wound repair. Mol. Biol. Cell, 4, 637-645.
Frazier, K., Williams, S., Kothapalli, D., Klapper, H. & Grotendorst, G. R. (1996).
Stimulation of fibroblast cell growth, matrix production, and granulation tissue
formation by connective tissue growth factor. J. Invest. Dermatol., 107, 404-411.
Kothapalli, D., Frazier, K., Welply, A., Segarini, P. R. & Grotendorst, G. R. (1997).
Transforming growth factor induces anchorage-independent growth of NRK
fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell
Growth Differ., 8, 61-68.
Kothapalli, D., Hayashi, N. & Grotendorst, G. R. (1998). Inhibition of TGF-stimulated CTGF gene expression and anchorage-independent growth by camp
identifies a CTGF-dependent restriction point in the cell cycle. FASEB J., 12, 11511161.
Shimo, T., Nakanishi, T., Kimura, Y., Nishida, T., Ishizeki, K., Matsumura, T. &
Takigawa, M. (1998). Inhibition of endogenous expression of connective tissue growth
factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and
migration of vascular endothelial cells. J. Biochem., 124, 130-140.
Yang, G. P. & Lau, L. F. (1991). Cyr61, product of a growth factor-inducible
immediate early gene, is associated with the extracellular matrix and the cell surface.
Cell Growth Differ., 2, 351-357.
78
[92] Kireeva, M. L., Mo, F. -E., Yang, G. P. & Lau, L. F. (1996). Cyr61, a product of a
growth factor-inducible immediate-early gene, promotes cell proliferation, migration,
and adhesion. Mol. Cell Biol., 16, 1326-1334.
[93] Kireeva, M. L., Latinkic, B. V., Kolesnikova, T. V., Chen, C. C., Yang, G. P., Abler, A.
S. & Lau, L. F. (1997). Cyr61 and Fisp12 are both ECM-associated signaling molecule:
activities, metabolism, and localization during development. Exp. Cell Res., 233, 63-77.
[94] Chen, Y., Abraham, D. J., Shi-wen, X., Pearson, J. D., Black, C. M., Lyons, K. M. &
Leask, A. (2004). CCN2 (connective tissue growth factor) promotes fibroblast adhesion
to fibronectin. Mol. Biol. Cell, 15, 5635-5646.
[95] Chen, N., Leu, S. -J., Todorovic, V., Lam, S. C. -T. & Lau, L. F. (2004). Identification
of a novel integrin v3 binding site in CCN1 (CYR61) critical for pro-angiogenic
activities in vascular endothelial cells. J. Biol. Chem., 279, 44166-44176.
[96] Lipinska, B., Fayet, O., Baird, L. & Georgopoulos, C. (1989). Identification,
characterization, and mapping of the Escherichia coli htrA gene, whose product is
essential for bacterial growth only at elevated temperatures. J. Bacteriol., 171, 15741584.
[97] Lassalle P., Molet, S., Janin, A., Heuden, J. V., Tavernier, J., Fiers, W., Devos, R. &
Tonnel, A. -B. (1996). ESM-1 is a novel human endothelial cell-specific molecule
expressed in lung and regulated by cytokines. J. Biol. Chem., 271, 20458-20464.
[98] Roudnicky, F., Poyet, C., Wild, P., Krampitz, S., Negrini, F., Huggenberger, R., Rogler,
A., Stohr, R., Hartmann, A., Provenzano, M., Otto, V. I. & Detmar, M. (2013). Endocan
is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A
induced angiogenesis. Cancer Res., 73, 1097-1106.
[99] Yamaguchi, A., Fujikawa, T., Tateoka, M., Soya, H., Sakuma, K., Sugiura, T., Morita,
I., Ikeda, Y. & Hirai, T. (2006). The expression of IGF-I and myostatin mRNAs in
skeletal muscle of hypophysectomized and underfed rats during postnatal growth. Acta
Physiol., 186, 291-300.
[100] Naranjo, W. M., Yaker, S., Sanchez-Gomez, M., Perez, A. U., Setser, J. & LeRoith, D.
(2002). Protein calorie restriction affects nonhepatic IGF-I production and the lymphoid
system: studies using the liver-specific IGF-I gene-deleted mouse model.
Endocrinology, 143, 2233-2241.
[101] Sonksen, P. H. (2001). Insulin, growth hormone and sport. J. Endocrinol., 170, 13-25.
[102] Palmer, R. M., Loveridge, N., Thomson, B. M., Mackie, S. C. & Tonner, E. (1994).
Effects of a polyclonal antiserum to rat growth hormone on circulating insulin-like
growth factor (IGF)-I and IGF-binding protein concentrations and the growth of muscle
and bone. J. Endocrinol., 142, 85-91.
[103] Yaker, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. -L., Ooi,
G. T., Setser, J., Frystyk, J., Boisclair, Y. R. & LeRoith, D. (2002). Circulating levels of
IGF-I directly regulated bone growth and density. J. Clin. Invest., 110, 771-781.
[104] Lee, S., Barton, E. R., Sweeney, H. L. & Farrar, R. P. (2004). Viral expression of
insulin-like growth factor-I enhances muscle hypertrophy in resistance-trained rats. J.
Appl. Physiol., 96, 1097-1104.
[105] Liu, J. -L. & LeRoith, D. (1999). Insulin-like growth factor I is essential for postnatal
growth in response to growth hormone. Endocrinology, 140, 5178-5184.
[106] Kim, H., Barton, E., Muja, N., Yaker, S., Pennisi, P. & LeRoith, D. (2005). Intact
insulin and insulin-like growth factor-I receptor signaling is required for growth
79
hormone effects on skeletal muscle growth and function in vivo. Endocrinology, 146,
1772-1779.
[107] Isgaard, J., Nilsson, A., Vikman, K. & Isaksson, O. G. P. (1988). Growth hormone
regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J.
Endocrinol., 120, 107-112.
[108] DeVol, D. L., Rotwein, P., Sadow, J. L., Novakofski, J. & Bechtel, P. J. (1990).
Activation of insulin-like growth factor gene expression during work-induced skeletal
muscle growth. Am. J. Physiol., 259, E89-E95.
[109] Yamaguchi, A., Ikeda, Y., Hirai, T., Fujikawa, T. & Morita, I. (2003). Local changes of
IGF-I mRNA, GH receptor mRNA, and fiber size in rat plantaris muscle following
compensatory overload. Jpn. J. Physiol., 53, 53-60.
[110] Lowe, W. L., Lasky, S. R., LeRoith D. & Roberts, C. T. Jr. (1988). Distribution and
regulation of rat insulin-like growth factor I messenger ribonucleic acids encoding
alternative carboxyterminal E-peptides: evidence for differential processing and
regulation in liver. Mol .Endocrinol., 2, 528-535.
[111] Iida, K., Itoh E., Kim, D. -S., del Rincon, J. P., Coschigano, K. T., Kopchick, J. J. &
Thorner, M. O. (2004). Muscle mechano growth factor is preferentially induced by
growth hormone in growth hormone-deficient lit-lit mice. J. Physiol., 560, 341-349.
[112] Rigamonti, A. E., Locatelli, L., Cella, S. G., Bonomo, S. M., Giunta, M., Molinari, F.,
Sartorio, A. & Mller, E. E. (2009). Muscle expressions of MGF, IGF-I Ea, and
myostatin in intact and hypophysectomized rats: effects of rhGH and testosterone alone
or combined. Horm. Metab. Res., 41, 23-29.
[113] Yamaguchi, A., Fujikawa, T., Shimada, S., Kanbayashi, I., Tateoka, M., Soya, H.,
Takeda, H., Morita, I., Matsubara, K. & Hirai, T. (2006). Muscle IGF-I Ea, MGF, and
myostatin mRNA expressions after compensatory overload in hypophysectomized rats.
Pflgers Arch., 453, 203-210.
[114] Cheema, U., Brown, R., Mudera, V., Yang, S. Y., Mcgrouther, G. & Goldspink, G.
(2005). Mechanical signals and IGF-I gene splicing in vitro in relation to development
of skeletal muscle. J. Cell Physiol., 202, 67-75.
[115] Adams, G. R. & Haddad, F. (1996). The relationships among IGF-1, DNA content, and
protein accumulation during skeletal muscle hypertrophy. J. Appl. Physiol., 81, 25092516.
[116] Bamman, M. M., Clarke, M. S. F., Feeback, D. L., Talmadge, R. J., Stevens, B. R.,
Lieberman, S. A. & Greenisen, M. C. (1998). Impact of resistance exercise during bed
rest on skeletal muscle sarcopenia and myosin isoform distribution. J. Appl. Physiol.,
84, 157-163.
[117] Matheny, W., Merritt, E., Zannikos, S. V., Farrar, R. P. & Adamo, M. L. (2009). Serum
IGF-I-deficiency does not prevent compensatory skeletal muscle hypertrophy in
resistance exercise. Exp. Biol. Med., 234, 164-170.
[118] Lassarre, C., Girard, F., Durand, J. & Raynaud, J. (1974). Kinetics of human growth
hormone during submaximal exercise. J. Appl. Physiol., 37, 826-830.
[119] Raynaud J., Drouet, L., Martineaud, J. P., Bordachar, J., Coudert, J. & Durand, J.
(1981). Time course of plasma growth hormone during exercise in humans at altitude.
J. Appl. Physiol., 50, 229-233.
[120] Viru, A., Karelson, K. & Smirnova, T. (1992). Stability and variability in hormonal
responses to prolonged exercise. Int. J. Sports Med., 13, 230-235.
80
[121] Pritzlaff, C. J., Wideman, L., Weltman, J. Y., Abbott, R. D., Gutgesell, M. E., Hartman,
M. L., Veldhuis, J. D. & Weltman, A. (1999). Impact of acute exercise intensity on
pulsatile growth hormone in men. J. Appl. Physiol., 87, 498-504.
[122] Wideman, L., Consitt, L., Patrie, J., Swearingin, B., Bloomer, R., Davis, P. & Weltman,
A. (2006). The impact of sex and exercise duration on growth hormone secretion. J.
Appl. Physiol., 101, 1641-1647.
[123] Wallace, J. D., Cuneo, R. C., Baxter, R., Orskov, H., Keay, N., Pentecost, C., Dall, R.,
Rosn, T., Jrgensen, J. O., Cittadini, A., Longobardi, S., Sacca, L., Christiansen, J. S.,
Bengtsson, B. -. & Snksen, P. H. (1999). Responses of the growth hormone (GH)
and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal
in trained adult males: potential test for GH abuse in sport. J. Clin. Endocrinol. Metab.,
84, 3591-3601.
[124] Yaker, S., Liu, J. -L., Fernandez, A. M., Wu, Y., Schally, A. V., Frystyk, J.,
Chernausek, S. D., Megia, W. & Le Roith, D. (2001). Liver-specific igf-1 gene deletion
leads to muscle insulin insensitivity. Diabetes, 50, 1110-1118.
[125] Baserga, R., Hongo, A., Rubini, M., Prisco, M. & Valentinis, B. (1997). The IGF-I
receptor in cell growth, transformation and apoptosis. Biochim. Biophys. Acta, 1332,
F105-F126.
[126] Ikezu, T., Okamoto, T., Giambarella, U., Yokota, T. & Nishimoto, I. (1995). In vivo
coupling of insulin-like growth factor II/mannose 6-phosphate receptor to heteromeric
G proteins. Distinct roles of cytoplasmic domains and signal sequestration by the
receptor. J. Biol. Chem., 270, 29224-29228.
[127] El-Sewy, H. M., Lee, M. -H., Obeid, L. M., Jaffa, A. A. & Luttrell, L. M. (2007). The
insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J. Biol.
Chem., 282, 26150-26157.
[128] Martin, J. L., Willetts, K. E. & Baxter, R. C. (1990). Purification and properties of a
novel insulin-like growth factor-II binding protein from transformed human fibroblasts.
J. Biol. Chem., 265, 4124-4130.
[129] Kelley, K., Oh. Y., Gargosky, S., Gucev, Z., Matsumoto, T., Hwa, V., Ng, L., Simpson,
D. & Rosenfeld, R. (1996). Insulin-like growth factor-binding proteins (IGFBPs) and
their regulatory dynamics. Int. J. Biochem. Cell Biol., 28, 619-637.
[130] Rajaram, S., Baylink, D. J. & Mohan, S. (1997). Insulin-like growth factor-binding
proteins in serum and other biological fluids: regulation and functions. Endocr. Rev.,
18, 801-831.
[131] Clemmons, D. R. (1998). Role of insulin-like growth factor-binding proteins in
controlling IGF actions. Mol. Cell Endocrinol., 140, 19-24.
[132] Baxter, R. C. (2000). Insulin-like growth factor (IGF)-binding proteins: interactions
with IGFs and intrinsic bioactivities. Am. J. Physiol., 278, E967-E976.
[133] Parker, A., Gockerman, A., Busby, W. H. & Clemmons D. R. (1995). Properties of an
insulin-like growth factor-binding protein-4 protease that is secreted by smooth muscle
cells. Endocrinology, 136, 2470-2476.
[134] Rees, C., Clemmons D. R., Horvitz, G. D., Clarke, J. B. & Busby, W. H. (1998). A
protease-resistant form of insulin-like growth factor (IGF) binding protein 4 inhibits
IGF-1 actions. Endocrinology, 139, 4182-4188.
81
[135] Zhang, M., Smith, E. P., Kuroda, H., Banach, W., Chernausek, S. D. & Fagin, J. A.
(2002). Targeted expression of a protease-resistance IGFBP-4 mutant in smooth muscle
of transgenic results in IGFBP-4 stabilization and smooth muscle hypertrophy. J. Biol.
Chem., 277, 21285-21290.
[136] Jones, J. I., Gockerman, A., Busby, W. H. Jr., Camacho-Hubner, C. & Clemmons, D. R.
(1993). Extracellular matrix contains insulin-like growth factor binding protein-5:
potentiation of the effects of IGF-I. J. Cell Biol., 121, 679-687.
[137] Imai, Y., Busby, W. H. Jr, Smith, C. E., Clarke, J. B., Garmong, A. J., Horwitz, G. D.,
Rees, C. & Clemmons, D. R. (1997). Protease-resistant form of insulin-like growth
factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine
smooth muscle cells in culture. J. Clin. Invest., 100, 2596-2605.
[138] Cohen, P., Peehl, D. M., Graves, H. C. & Rosenfeld, R. G. (1994). Biological effects of
prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J.
Endocrinol., 142, 407-415.
[139] Nam, T. J., Busby, W. H., Rees, C. & Clemmons D. R. (2000). Thrombospondin and
osteopntin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an
alteration in IGF-I-stimulated cell growth. Endocrinology, 141, 1100-1106.
[140] Clemmons, D. R. (2001). Use of mutagenesis to probe IGF-binding protein structurefunction relationships. Endocrine Rev., 22, 800-817.
[141] Schedlich, L. J., Nilsen, T., John, A. P., Jans, D. A. & Baxter, R. C. (2003).
Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic
acid-dependent protein kinase reduces ligand binding and enhances nuclear
accumulation. Endocrinology, 144, 1984-1993.
[142] Coverley, J. A., Martin J. L. & Baxter, R. C. (2000). The effect of phosphorylation by
casein kinase 2 on the activity of insulin-like growth factor-binding protein-3.
Endocrinology, 141, 564-570.
[143] Peterkofsky, B., Gosiewska, A., Wilson, S. & Kim, Y. -R. (1998). Phosphorylation of
rat insulin-like growth factor binding protein-1 does not affect its biological properties.
Arch. Biochem. Biophys., 357, 101-110.
[144] Jones, J. I., Gockerman, A., Busby, W. H. Jr., Wright, G. & Clemmons, D. R. (1993).
Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the
51 integrin by means of its Arg-Gly-Asp sequence. Proc. Natl. Acad. Sci. U S A, 90,
10553-10557.
[145] Schutt, B. S., Langkamp, M., Rauschnabel, U., Ranke, M. B. & Elmlinger, M. W.
(2004). Integrin-mediated action of insulin-like growth factor binding protein-2 in
tumor cells. J. Mol. Endocrinol., 32, 859-868.
[146] Frommer, K. W., Reichenmiller, K., Schutt, B. S., Hoeflich, A., Ranke, M. B., Dodt, G.
& Elmlinger, M. W. (2006). IGF-independent effects of IGFBP-2 on the human breast
cancer cell line Hs578T. J. Mol. Endocrinol., 37, 13-23.
[147] Valentinis, B., Bhala, A., DeAngelis, T., Baserga, R. & Cohen, P. (1995). The human
insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts
with a targeted disruption of the IGF-I. Mol. Endocrinol., 9, 361-367.
[148] Lalou, C., Lassarre, C. & Binoux, M. (1996). A proteolytic fragment of insulin-like
growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic
effects of IGF-I and insulin. Endocrinology, 137, 3206-3212.
82
[149] Zadeh, S. M. & Binoux, M. (1997). The 16-kDa proteolytic fragment of insulin-like
growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth
factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene.
Endocrinology, 138, 3069-3072.
[150] Gill, Z. P., Perks, C. M., Newcomb, P. V. & Holly, J. M. P. (1997). Insulin-like growth
factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell
death in a non-IGF-dependent manner. J. Biol. Chem., 272, 25602-25607.
[151] Miyakoshi, N., Richman, C., Kasukawa, Y., Linkhart, T. A., Bayllink, D. J. & Mohan,
S. (2001). Evidence that IGF-binding protein-5 functions as a growth factor. J. Clin.
Invest., 107, 73-81.
[152] Cobb, L. J., Salih, D. A. M., Gonzalez, I., Tripathi, G., Carter, E. J., Lovett, F., Holding,
C. & Pell, J. M. (2004). Partitioning of IGFBP-5 actions in myogenesis: IGFindependent anti-apoptosis function. J. Cell Sci., 117, 1737-1746.
[153] Tripathi, G., Salih, D. A. M., Drozd, A. C., Cosgrove, R. A., Cobb, L. J. & Pell, J. M.
(2009). IGF-independent effects of insulin-like growth factor binding protein-5 (igfbp5)
in vivo. FASEB J., 23, 2616-2626.
[154] Coolican, S. A., Samuel, D. S., Ewton, D. Z., McWade, F. J. & Florini, J. R. (1997).
The mitogenic and myogenic actions of insulin-like growth factors utilize distinct
signaling pathway. J. Biol. Chem., 272, 6653-6662.
[155] Latres, E., Amni, A. R., Amini, A. A., Griffiths, J., Martin, F. J., Wei, M. Y., Lin, H.
C., Yancopoulos, G. D. & Glass, D. J. (2005). Insulin-like growth factor-1 (IGF-1)
inversely regulates atrophy-induced genes via the phosphatidylinositol 3kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol.
Chem., 280, 2737-2744.
[156] Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N.,
Yancopoulos, G. D. & Glss, D. J. (2001). Mediation of IGF-1-induced skeletal myotube
hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol., 3,
1009-1013.
[157] Musaro, A. & Rosenthal, N. (2002). The role of local insulin-like growth factor-I
isoforms in the pathophysiology of skeletal muscle. Curr. Genomics, 3, 149-162.
[158] Semsarian, C., Wu, M. -J., Ju, Y. -K., Marciniec, T., Yeoh, T., Allen, D. G., Harvey, R.
P. & Graham, R. M. (1999). Skeletal muscle hypertrophy is mediated by a Ca2+dependent calcineurin signaling pathway. Nature, 400, 576-581.
[159] Sakuma, K., Nishikawa, J., Nakao, R., Watanabe, K., Totsuka, T., Nakano, H., Sano,
M. & Yasuhara, M. (2003). Calcineurin is a potent regulator for skeletal muscle
regeneration by association with NFATc1 and GATA-2. Acta Neurophathol., 105, 271280.
[160] Delling, U., Tureckova, J., Lim, H. W., De Windt, L. J., Rotwein, P. & Molkentin, J. D.
(2000). A calcineurin-NFATc3-dependent pathway regulates skeletal muscle
differentiation and slow myosin heavy-chain expression. Mol. Cell Biol., 20, 66006611.
[161] Friday, B. B., Mitchell, P. O., Kegley, K. M. & Pavlath, G. K. (2003). Calcineurin
initiates skeletal muscle differentiation by activating MEF2 and MyoD. Differentiation,
71, 217-227.
83
[162] Perks, C. M., Newcomb, P. V., Norman, M. R. & Holly, J. M. P. (1999). Effect of
insulin-like growth factor binding protein-1 on integrin signaling and the induction of
apoptosis in human breast cancer cells. J. Mol. Endocrinol., 22, 141-150.
[163] Gleeson, L. M., Chakraborty, C., Mckinnon, T. & Lala, P. K. (2001). Insulin-like
growth factor-binding protein 1 stimulates human trophoblast migration by signaling
through 51 integrin via mitogen-activated protein kinase pathway. J. Clin.
Endocrinol. Metab., 86, 2484-2493.
[164] Huang, D., Cheung, A. T., Parsons, J. T. & Bryer-Ash, M. (2002). Focal adhesion
kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes. J. Biol.
Chem., 277, 18151-18160.
[165] Perks, C. M., Vernon, E. G., Rosendahl, A. H., Tonge, D. & Holly, J. M. P. (2007).
IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells.
Oncogene, 26, 5966-5972.
[166] Amaar, Y. G., Thompson, G. R., Linkhart, T. A., Chen, S. -T., Baylink, D. J. & Mohan,
S. (2002). Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four
and half LIM protein 2 (FHL2). J. Biol. Chem., 277, 12053-12060.
[167] Leal, S. M., Liu, Q., Huang, S. S. & Huang J. S. (1997). The type V transforming
growth factor receptor is the putative insulin-like growth factor-binding protein 3
receptor. J. Biol. Chem., 272, 20572-20576.
[168] Liu, B., Lee, H. -Y, Weinzimer, S. A., Powell, D. R., Clifford, J. L., Kurie, J. M. &
Cohen, P. (2000). Direct functional interactions between insulin-like growth factorbinding protein-3 and retinoid X receptor- regulate transcriptional signaling and
apoptosis. J. Biol. Chem., 275, 33607-33613.
[169] Schultz, E. & McCormick, K. M. (1994). Skeletal muscle satellite cells. Rev. Physiol.
Biochem. Pharmacol., 123, 213-257.
[170] Allen, D. L., Monke, S. R., Talmadge, R. J., Roy, R. R. & Edgerton, V. R. (1995).
Plasticity of myonuclear number in hypertrophied and atrophied mammalian skeletal
muscle fibers. J. Appl. Physiol., 78, 1969-1976.
[171] Adams, G. R., Haddad, F. & Baldwin, K. M. (1999). Time course of changes in
markers of myogenesis in overloaded rat skeletal muscles. J. Appl. Physiol., 87, 17051712.
[172] Ishido, M., Kami, K. & Masuhara, M. (2004). Localization of MyoD, myogenin and
cell cycle regulatory factors in hypertrophying rat skeletal muscles. Acta Physiol.
Scand., 180, 281-289.
[173] Kadi, F., Eriksson, A., Holmner, S., Butler-Browne, G. S. & Thornell, L. -E. (1999).
Cellular adaptation of the trapezius muscle in strength-trained athletes. Histochem. Cell
Biol., 111, 189-195.
[174] Kadi, F., Schjerling, P., Andersen, L. L., Charifi., N., Madsen, J. L., Christensen, L. R.
& Andersen, J. L. (2004). The effects of heavy resistance training and detraining on
satellite cells in human skeletal muscles. J. Physiol., 558, 1005-1012.
[175] Rosenblatt, J. D. & Parry, D. J. (1992). Gamma irradiation prevents compensatory
hypertrophy of overloaded mouse extensor digitorum longus muscle. J. Appl. Physiol.,
73, 2538-2543.
[176] Phelan, J. N. & Gonyea, W. J. (1997). Effect of radiation on satellite cell activity and
protein expression in overloaded mammalian skeletal muscle. Anat. Rec., 247, 179-188.
84
[177] Zammit, P. S., Partridge, T. A. & Yablonka-Reuveni, Z. (2006). The skeletal muscle
satellite cell: the stem cell that came in from the cold. J. Histochem. Cytochem., 54,
1177-1191.
[178] Sabourin, L. A. & Rudnicki, M. A. (2000). The molecular regulation of myogenesis.
Clin. Genet., 57, 16-25.
[179] Wang, J. & Walsh, K. (1996). Resistance to apoptosis conferred by cdk inhibitors
during myocyte differentiation. Science, 273, 359-361.
[180] Zhang, P., Wong, C., Liu, D., Finegold, M., Harper, J. W. & Elledge, S. J. (1999).
p21CIP1 and p57KIP2 control muscle differentiation at the myogenin step. Genes Dev.,
13, 213-224.
[181] Kadi, F., Eriksson, A., Holmner, S. & Thornell, L. -E. (1999). Effects of anabolic
steroids on the muscle cells of strength-trained athletes. Med. Sci. Sport Exerc., 31,
1528-1534.
[182] Petrella, J. K., Kim, J. -S., Cross, J. M., Kosek, D. J. & Bamman, M. M. (2006).
Efficacy of myonuclear addition may explain differential myofiber growth among
resistance-trained young and older men and women. Am. J. Physiol. Endocrinol.
Metab., 291, E937-E946.
[183] Petrella, J. K., Kim, J. -S., Mayhew, D. L., Cross, J. M. & Bamman, M. M. (2008).
Potent myofiber hypertrophy during resistance training in human is associated with
satellite cell-mediated myonuclear addition: a cluster analysis. J. Appl. Physiol., 104,
1736-1742.
[184] Rosenthal, S. M. & Cheng, Z. -Q. (1995). Opposing early and late effects of insulin-like
growth factor I on differentiation and cell cycle regulatory retinoblastoma protein in
skeletal myoblasts. Proc. Natl. Acad. Sci. U S A, 92, 10307-10311.
[185] Engert, J. C., Berglund, E. B. & Rosenthal, N. (1996). Proliferation precedes
differentiation in IGF-I-stimulated myogenesis. J. Cell Biol., 135, 431-440.
[186] Chakravarthy, M. V., Abraha, T. W., Schwartz, R. J., Fiorotto, M. L. & Booth, F. W.
(2000). Insulin-like growth factor-I extends in vitro replicative life span of skeletal
muscle satellite cells by enhancing G1/S cell cycle progression via the activation of
phosphatidylinositol 3-kinase/Akt signaling pathway. J. Biol. Chem., 275, 3594235952.
[187] Jacquemin, V., Furling, D., Bigot, A., Butler-Browne, G. S. & Mouly, V. (2004). IGF-1
induces human myotube hypertrophy by increasing cell recruitment. Exp. Cell Res.,
299, 148-158.
[188] Florini, J. R., Ewton, D. Z. & Coolican S. A. (1996). Growth hormone and the insulinlike growth factor system in myogenesis. Endocr. Rev., 17, 481-517.
[189] Vandenburgh, H. H., Karlisch, P., Shansky, J. & Feldstein, R. (1991). Insulin and IGF-I
induce pronounced hypertrophy of skeletal myofibers in tissue culture. Am. J. Physiol.,
260, C475-C484.
[190] Barton-Davis, E. R., Shoturma, D. I. & Sweeney H. L. (1999). Contribution of satellite
cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol. Scand., 367, 301305.
[191] Bamman, M. M., Shipp, J. R., Jiang, J., Gower, B. A., Hunter, G. R., Goodman, A.,
McLafferty, C. L. Jr. & Urban, R. J. (2001). Mechanical load increases muscle IGF-I
and androgen receptor mRNA concentrations in human. Am. J. Physiol. Endocrinol.
Metab., 280, E383-E390.
85
[192] Haddad, F. & Adams, G. R. (2002). Exercise effects on muscle insulin signaling and
action selected contribution: acute cellular and molecular response to resistance
exercise. J. Appl. Physiol., 93, 394-403.
[193] Kim, J. -S., Kosek, D. J., Petrella, J. K., Cross, J. M. & Bamman, M. M. (2005).
Resting and load-induced levels of myogenic gene transcripts differ between older
adults with demonstrable sarcopenia and young men and women. J. Appl. Physiol., 99,
2149-2158.
[194] Psilander, N., Damsgaard, R. & Pilegaard, H. (2003). Resistance exercise alters MRF
and IGF-I mRNA content in human skeletal muscle. J. Appl. Physiol., 95, 1038-1044.
[195] Bamman, M. M., Petrella, J. K., Kim, J. -S., Mayhew, D. L. & Cross, J. M. (2007).
Cluster analysis tests the importance of myogenic gene expression during myofiber
hypertrophy in humans. J. Appl. Physiol., 102, 2232-2239.
[196] Barton-Davis, E. R., Shoturma, D. I., Musaro, A., Rosenthal, N. & Sweeney, H. L.
(1998). Viral mediated expression of insulin-like growth factor I blocks the agingrelated loss of skeletal muscle function. Proc. Natl. Acad. Sci. U S A, 95, 15603-15607.
[197] Barton, E. R., DeMeo, J. & Lei, H. (2010). The insulin-like growth factor (IGF)-I Epeptides are required for isoform-specific gene expression and muscle hypertrophy after
local IGF-I production. J. Appl. Physiol., 108, 1069-1076.
[198] Siegfried, J. M., Kasprzyk, P. G., Treston, A. M. & Mulshine, J. L. (1992). A mitogenic
peptide amide encoded within the E peptide domain of the insulin-like growth factor IB
prohormone. Proc. Natl. Acad. Sci. U S A, 89, 8107-8111.
[199] Mills, P., Dominique, J. C., Lafrenire, J. F., Bouchentouf, M. & Tremblay, J. P.
(2007). A synthetic mechano growth factor E peptide enhances myogenic precursor cell
transplantation success. Am. J. Transplant., 7, 2247-2259.
[200] Shavlakadze, T., Davies, M., White, J. D. & Grounds, M. D. (2004). Early regeneration
of whole skeletal muscle grafts is unaffected by overexpression of IGF-1in
MLC/mIGF-1 transgenic mice. J. Histochem. Cytochem., 52, 873-883.
[201] Mills, P., Lafrenire, J. -F., Bouchentouf, M., Benabdallah, B. F., El Fahime, E. M. &
Tremblay, J. -P. (2007). A new pro-migratory activity on human myogenic precursor
cells for a synthetic peptide within the E domain of the mechano growth factor. Exp.
Cell Res., 313, 527-537.
[202] Awede B. L., Thissen, J. -P. & Lebacq, J. (2002). Role of IGF-I and IGFBPs in the
changes of mass and phenotype induced in rat soleus muscle by clenbutenol. Am. J.
Physiol. Endocrinol. Metab., 282, E31-E37.
[203] Bayol, S., Loughna, P. T. & Brownson, C. (2000). Phenotypic expression of IGF
binding protein transcripts in muscle, in vitro and in vivo. Biochem. Biophys. Res.
Commun., 273, 282-286.
[204] Koistinen, H., Koistinen, R., Selenius, L., Ylikorkala, Q. & Seppala, M. (1996). Effect
of marathon run on serum IGF-I and IGF-binding protein 1 and 3 levels. J. Appl.
Physiol., 80, 760-764.
[205] Chicharro, J. L., Lopez-Calderon, A., Hoyos, J., Martin-Velasco, A. I., Villa, G.,
Villana, M. A. & Luca, A. (2001). Effects of an endurance cycling competition on
resting serum insulin-like growth factor I (IGF-I) and its binding proteins IGFBP-1 and
IGFBP-3. Br. J. Sports Med., 35, 303-307.
[206] Dall, R., Lange, K. H., Kaer, M., Jorgensen, J. O., Christiansen, J. S., Orskov, H. &
Flyvbjerg, A. (2001). No evidence of insulin-like growth factor-binding protein 3
86
proteolysis during a maximal exercise test in elite athletes. J. Clin. Endocrinol. Metab.,
86, 669-674.
[207] Schwarz, A. J., Brasel, J. A., Hintz, R. L., Mohan, S. & Cooper, D. M. (1996). Acute
effect of brief low- and high-intensity exercise on circulating insulin-like growth factor
(IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J. Clin.
Endocrinol. Metab., 81, 3492-3497.
[208] Silha, J. V. & Murphy, L. J. (2002). Minireview: Insights from insulin-like growth
factor binding protein transgenic mice. Endocrinology, 143, 3711-3714.
[209] Salih, D. A. M., Tripathi, G., Holding, C., Szestak, T. A. M., Gonzalez, M. I., Carter, E.
J., Cobb, L. J., Eisemann, J. E. & Pell, J. M. (2004). Insulin-like growth factor-binding
protein 5 (Igfbp5) compromises survival, growth, muscle development, and fertility in
mice. Proc. Natl. Acad. Sci. U S A, 101, 4314-4319.
[210] Wood, T. L., Rogler, L. E., Czick, M. E., Schuller, A. G. P. & Pintar, J. E. (2000).
Selective alterations in organ sizes in mice with a targeted distribution of the insulinlike growth factor binding protein-2 gene. Mol. Endocrinol., 14, 1472-1482.
[211] DeMambro, V. E., Clemmons, D. R., Horton, L. G., Bouxsein, M. L., Wood, T. L.,
Beamer, W. G., Canalis, E. & Rosen, C. J. (2008). Gender-specific changes in bone
turnover and skeletal architecture in Igfbp-2-null mice. Endocrinology, 149, 2051-2061.
[212] Ning, Y., Hoang, B., Schuller, A. G. P., Cominski, T. P., Hsu, M. -S., Wood, T. L. &
Pntar, J. E. (2007). Delayed mammary gland involution in mice with mutation of the
insulin-like growth factor binding protein 5 gene. Endocrinology, 148, 2138-2147.
[213] Ewton, D. Z. & Florini, J. R. (1995). IGF binding protein-4, -5 and -6 may play
secialized roles during L6 myoblast proliferation and differentiation. J. Endocrinol.,
144, 539-553.
[214] Silverman, L. A., Cheng, Z. Q., Hsiao, D. & Rosenthal, S. M. (1995). Skeletal muscle
cell-derived insulin-like growth factor (IGF) binding proteins inhibit IGF-I-induced
myogenesis in rat L6E9 cells. Endocrinology, 136, 720-726.
[215] Ewton, D. Z., Coolican, S. A., Mohan, S., Chernausek, S. D. & Florini, J. R. (1998).
Modulation of insulin-like growth factor actions in L6A1 myoblasts by insulin-like
growth factor binding protein (IGFBP)-4 and IGFBP-5: a dual role for IGFBP-5. J. Cell
Physiol., 177, 47-57.
[216] James, P. L., Stewart, C. E. H. & Rotwein, P. (1996). Insulin-like growth factor binding
protein-5 modulates muscle differentiation through an insulin-like growth factordependent mechanism. J. Cell Biol., 133, 683-693.
[217] Ren, H., Yin, P. & Duan, C. (2008). IGFBP-5 regulates muscle cell differentiation by
binding to IGF-II and switching on the IGF-II auto-regulation loop. J. Cell Biol., 182,
979-991.
[218] Mukherjee, A., Wilson, E. M. & Rotwein, P. (2008). Insulin-like growth factor (IGF)
binding protein-5 blocks skeletal muscle differentiation by inhibiting IGF actions. Mol.
Endocrinol., 22, 206-215.
[219] Bach, L. A., Salemi, R. & Leeding, K. S. (1995). Roles f insulin-like growth factor
(IGF) receptors and IGF-binding proteins in IGF-II-induced proliferation and
differentiation of L6A1 rat myoblasts. Endocrinology, 136, 5061-5069.
[220] Rosendal, L., Langberg, H., Flyvbjerg, A., Frystyk, J., Orskov, H. & Kjr, M. (2002).
Physical capacity influences the response of insulin-like growth factor and its binding
proteins to training. J. Appl. Physiol., 93, 1669-1675.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 4
Abstract
The world's elderly population is expanding rapidly, and we are now faced with the
significant challenge of maintaining or improving physical activity, independence, and
quality of life in the elderly. Sarcopenia, the age-related loss of skeletal muscle mass, is
characterized by a deterioration of muscle quantity and quality leading to a gradual
slowing of movement, a decline in strength and power, increased risk of fall-related
injury, and often, frailty. Since sarcopenia is largely attributed to various molecular
mediators affecting fiber size, mitochondrial homeostasis, and apoptosis, the mechanisms
responsible for these deleterious changes present numerous therapeutic targets for drug
discovery. Resistance training combined with amino acid-containing supplements is often
utilized to prevent age-related muscle wasting and weakness. In this chapter, we
summarize recent therapeutic strategies using supplemental, pharmacological, and
hormonal approach for counteracting sarcopenia. Treatment with ghrelin seems to be an
interesting approach for preventing sarcopenia in the near future. EPA and ursolic acid
seem to be effective as therapeutic aqgents, because they attenuate the degenerative
symptoms of muscular dystrophy and cachexic muscle. The activation of peroxisome
proliferator-activated receptor coactivator 1 (PGC-1) in skeletal muscle by exercise
and/or unknown supplementation would be an intriguing approach to attenuating
sarcopenia. In contrast, muscle loss with age may not be influenced positively by
treatment with a proteasome inhibitor or antioxidant.
Corresponding author: Kunihiro Sakuma, Ph.D., Research Center for Physical Fitness, Sports and Health,
Toyohashi University of Technology, 1-1 Hibarigaoka, Tenpaku-cho, Toyohashi, 441-8580, Japan. E-mail:
ksakuma@las.tut.ac.jp; Tel: 81-532-44-6630; Fax: 81-532-44-6947.
88
Abbreviations
ACE
ActRIIB
ALK
BCAA
CR
CrM
DHEA
DMD
eIF
EPA
FOXO
GH
IGF-I
IKK
IL
mTOR
MuRF1
NF-B
PGC-1
PI3-K
p70S6K
RDA
Rheb
ROS
TNF-
TSC
angiotensin-converting enzyme
activin receptor IIB
activin receptor-like kinase
branched chain amino acid
calorie restriction
creatine monohydrate
dehydroepiandrosterone
Duchenne muscular dystrophy
eukaryotic initiation factor
eicosapentaenoic acid
forkhead box O
growth hormone
insulin-like growth factor-I
inhibitor of B kinase
interleukin
mammalian target of rapamycin
muscle ring-finger protein 1
nuclear factor-kappaB
peroxisome proliferator-activated receptor coactivator 1
phosphatidylinositol 3-kinase
p70 ribosomal protein S6 kinase
recommended dietary allowance
Ras homolog enriched in brain
reactive oxidative species
tumor necrosis factor-
tuberous sclerosis complex
1. Introduction
Skeletal muscle contractions power human body movements and are essential for
maintaining stability. Skeletal muscle tissue accounts for almost half of the human body mass
and, in addition to its power-generating role, is a crucial factor in maintaining homeostasis.
Given its central role in human mobility and metabolic function, any deterioration in the
contractile, material, and metabolic properties of skeletal muscle has an extremely important
effect on human health. Aging is associated with a progressive decline of muscle mass,
quality, and strength, a condition known as sarcopenia [1]. Although this term is applied
clinically to denote loss of muscle mass, it is often used to describe both a set of cellular
processes (denervation, mitochondrial dysfunction, inflammatory and hormonal changes) and
a set of outcomes, such as decreased muscle strength, decreased mobility and function [2],
89
increased fatigue, a greater risk of falls [3], and reduced energy needs [4]. In most countries,
there has been a rapid and continuing increase in life expectancy. By the year 2030, 20% of
the adult US population will be older than 65 years [5]. In the 27 member states of the EU,
the percentage of people aged 65 years and older will rise from 17.1 in 2008 to 25.4 in 2035
and to 30 in 2060 [6], therefore, age-related losses in skeletal muscle mass and function
present an extremely important current and future public health issue.
Lean muscle mass generally contributes up to ~50% of total body weight in young adults
but declines with aging to be 25% at 75-80 years old [7, 8]. Loss of muscle mass is typically
offset by gains in fat mass. Loss of muscle mass is most notable in the lower limb muscle
groups, with the cross-sectional area of the vastus lateralis being reduced by as much as 40%
between the age of 20 and 80 years old [9]. On a muscle fiber level, sarcopenia is
characterized by specific type II muscle fiber atrophy, fiber necrosis, and fiber-type grouping
[10-12]. In elderly men, Verdijk et al. [12] showed a reduction in type II muscle fiber satellite
cell content with aging. Although several investigators support such an age-related decrease
in the number of satellite cells [12-15], some reports [16, 17] indicate no such change. In
contrast, most studies point to an age-dependent reduction in muscle regenerative capacity
due to reduced satellite cell proliferation and differentiation.
Another morphologic aspect of sarcopenia is fat accumulation. In the US, it was
estimated that the prevalence of obesity in elderly Americans, aged 60 years and older, would
increase from 23.6% in 1990 to 37.4% in 2010 [18]. Obesity is associated with increased
morbidity and mortality, and there is unchallenged evidence that obesity increases the risk of
hypertension, dislipidemia, type 2 diabetes mellitus, and several cancers [19-21]. Although
the methods used to classify sarcopenic obesity vary [22-25], sarcopenic obesity has been
attributed as a major cause of disability in old age. Indeed, Bouchard et al. [24] demonstrated
that obesity contributed more to lower physical capacity than sarcopenia. Fat distribution
changes with age such that there is an increase in visceral fat, which is more marked in
women than in men. Also, fat is increasingly deposited in skeletal muscle [26, 27] and in the
liver. Higher visceral fat is a main determinant of impaired glucose tolerance in the elderly.
Increased intramuscular and intrahepatic fat contributes to impaired insulin action through
locally released adipokines and fat free fatty acids. Broadwin et al. [23] have illustrated that
an increased percentage of fat mass was associated with greater functional disability in older
adults.
Several possible mechanisms of age-related muscle atrophy have been described;
however, the precise contribution of each is unknown. Age-related muscle loss is a result of
reductions in the size and number of muscle fibers [28], possibly due to a multi-factoral
process that involves physical activity, nutritional intake, oxidative stress, and hormonal
changes [3, 29]. The specific contribution of each of these factors is unknown but there is
emerging evidence that the disruption of several positive regulators (Akt and serum response
factor) of muscle hypertrophy with age is an important feature in the progression of
sarcopenia [30-32]. In contrast, many investigators have failed to demonstrate an age-related
enhancement in levels of common negative regulators [Atrogin-1, myostatin, and calpain] in
senescent mammalian muscles [31, 32].
Resistance training combined with amino acid-containing supplements is an effective
candidate to prevent age-related muscle wasting and weakness [31-33]. In particular,
sarcopenia has been most attenuated by treatment with many essential amino acids plus high
leucine [31-33]. In addition, many researchers have focused on inhibiting myostatin to treat
90
various muscle disorders such as muscular dystrophy, cachexia, and sarcopenia [34, 35].
Furthermore, more recent studies have indicated the possible application of new supplements
to prevent muscle atrophy [36, 37]. This chapter aims to address strategies using exercise, and
hormonal, pharmacological, and supplemental approaches for inhibiting muscle wasting, in
particular sarcopenia. Figure 1 indicates a summary of therapeutic approach for sarcopenia.
2. Exercise
2.1. Resistance Training
One resistance exercise bout can, within 1 hour, increase muscle protein synthesis [38],
which can last up to 72 hour after exercise [39]. Resistance training has shown the most
promise among interventions aimed to decrease the effects of sarcopenia, as it enhances
strength, power, and mobility function and induces varing degrees of skeleteal muscle
hypertrophy [40-42]. For example, 12 weeks of whole-body resistance training resulted in an
increase in type II muscle fiber area in men aged 64-86 year [43] and 65-72 year [44, 45]. A
2-year longituidinal trial of resistance training found increases in leg press (32%) and military
press (90%) 1 repetition maximum and kneee extensor muscle cross-sectional area (9%) in
60-80 year old men and women [46]. The functional benefits of resistance training have been
evaluated in a large-scale trial of 72- to 98-year olds and frail nursing home residents, with
resistance training increasing muscle strength (113%), gait velocity (12%), stair-climbing
power (28%), and spontaneous physical activity [41]. In addition, 6 weeks of training for
elderly persons (68.45.4 years) improved their physical activity profile (6-min walk, 30second chair stand, chair sit and reach and back scratch) as well as muscle strength.
91
In the elderly, resistance training induces the muscle expression of insulin-like growth
factor-I (IGF-I) [47], myogenic regulatory factors [48], and interleukin (IL)-6 [49], which
contribute to muscular hypertrophy by regulating the activation, proliferation, and
differentiation of satellite cells. In addition, resistance training decreases oxidative DNA
damage and improves the electron transport chain function [50]. One bout of resistance
exercise for elders can enhance the rate of synthesis of muscle protein [51, 52]. However,
several studies using humans and rodents indicated a lower degree of activation in mitogenactivated protein kinase and Akt-mammalian target of rapamycin (mTOR) pathways after
muscle contraction or mechanical overload than occurs in young adults [51, 53, 54]. More
recently, Mathew et al. [55] indicated that one bout of resistance exercise elicited a similar
extent of activation in translational signaling [Akt, p70 ribosomal protein S6 kinase
(p70S6K), ribosomal protein S6, and 4E-binding protein 1] between young and old subjects.
In contrast, physical activity can affect muscle inflammation. Recent evidence shows that
chronic resistance physical training contributes to the control of locally-derived inflammation
through adaptations to repeated and acute increases in proinflammatory mRNA within muscle
[56]. Several studies [47, 57] have shown that excess intensive strength training for the
elderly impairs the effective gain of muscle strength and mass particularly in women.
Therefore, careful attention should be paid when determining the amount and frequency of
resistance training for the elderly.
92
3. Supplemental Approach
3.1. Amino Acid Supplementation
Many Americans consume more than the recommended dietary allowance (RDA) of
protein; however, research shows that a significant number of elderly people do not meet the
estimated average requirement, let alone the RDA [74]; 32% to 41% of women and 22% to
38% of men aged 50 and older consume less than the RDA of protein [75]. Epidemiological
studies show that protein intake is positively associated with preservation of muscle mass. For
example, in a recent study, 38 healthy, normal-weight, sedentary women aged 57 to 75 were
recruited to determine whether a higher muscle mass index was associated with animal or
vegetal protein intake [76].
93
Many reviews indicate that certain nutritional interventions such as a high protein intake
or an increased intake of essential amino acids and the branched chain amino acid (BCAA)
leucine with resistance training may help to attenuate fiber atrophy in sarcopenic muscle by
the modulation of both anabolic and catabolic pathways [77-79]. In particular, leucine can be
considered a regulatory amino acid with unique characteristics. It plays several roles in
muscle metabolism regulation, which includes translational control of protein synthesis [80]
and glucose homeostasis [81]. In addition, leucine has been demonstrated to be a nitrogen
donor for the synthesis of muscle alanine and glutamine [80]. Considering these findings, the
use of leucine as an anti-atrophic agent is biologically justified.
It has been documented that oral post-exercise amino acid supplementation had a
synergistic effect on the contraction-induced escalation of muscle protein synthesis following
an acute resistance exercise bout [82-84]. Treatment with amino acids has been shown to
induce additive hypertrophy in response to continuous resistance training [85]. Recent human
studies have shown that amino acids play a role in the phosphorylation of translational factors
called eukaryotic initiation factors, especially eukaryotic initiation factor (eIF)4F and
p70S6K, through an mTOR-mediated mechanism [84, 86] On the other hand, several studies
have not found benefits from protein supplementation [87-89]. These studies utilized a single
bout or short-term (10 days) ingestion to examine the rate of myofibrillar synthesis [89] or
protein synthesis [87]. In contrast, Godard et al. [88] tried to investigate the long-term
supplementation of several amino acids and carbohydrate with resistance training.
Unfortunately, they conducted the examination of total muscle cross-sectional areas by only
magnetic resonance imaging, and did not perform a detailed morphological analysis (crosssectional area of muscle fiber by biopsy sample). Since the evaluation of muscle crosssectional area by magnetic resonance imaging appears to be influenced by the inner amount
of adipose tissue, connective tissue, or water, it is unknown whether their protein
supplementation actually failed to elicit positive effects on the morphometry of muscle fiber.
More recently, the administration of many essential amino acids tends to achieve a
positive effect on muscle mass and protin synthesis both under normal conditions [90-92] and
with resistance training [86]. Although a positive attenuating effect on sarcopenia has been
observed in almost all studies utilizing many essential amino acids plus a high amount of
leucine, supplementation with essential amino acids not enriched with leucine may fail to
enhance muscle protein synthesis in the elderly. In addition, a higher amount of leucine
should be supplemented along with large amounts of isoleucine and valine in order to avoid
an imbalance of BCAA levels, as pointed out by Nicastro et al. [91] in their recent review.
94
unclear whether or not creatine content is altered by the aging process, different to the marked
reduction of phosphocreatine in muscle of metabolic myopathic patients [99]. Although some
studies did not show a beneficial effect from CrM supplementation during resistance training
for elderly individuals [100, 101], many studies have reported that CrM supplementation
during resistance training increases muscle mass and muscular strength, endurance, and
power in older individuals [99, 101-104]. Rawson et al. [101] reported that 1 month of CrM
supplementation (20 g/d 10 d 4 g/d 20 d) did not enhance fat-free mass, total body
mass, or upper extremity strength gains, yet there was less leg fatigue in the CrMsupplemented group.
In addition, a 2-month resistance exercise program (67-80 years) supplemented with CrM
(20 g/d 5 d 3 g/d) did not influence training-induced increases in total body mass or
strength gain [100]. In contrast, studies of longer duration (> 4 months) reported beneficial
effects of CrM supplementation in further enhancing the strength and muscle mass gains
attained with a resistance-training program [101, 102, 105]. There are several effects of CrM
administration that may enhance resistance exercise-induced strength gains in elderly
including activation of myogenic determination factors [106], enhancement of satellite cell
activation and recruitment [107], and reduction of amino acid oxidation and protein
breakdown [108]. There are a number of important mechanistic questions that remain to be
answered, including whether the gains are maintained over a longer period (i.e., > 6 months)
post-study and if there is a true enhancement of functional capacity, what is the mechanism of
action (i.e., more contractions over time vs. activation of satellite cells [109]. CrM
supplementation without resistance training in older adults has also been shown to have
minimal benefits [101, 109].
95
[114] studied serum-starved skeletal myotubes and found that ursolic acid rapidly stimulated
IGF-I receptor and insulin receptor activity, but only if IGF-I or insulin was also present.
Taken together, their data suggest that ursolic acid first enhances the capacity of pre-existing
IGF-I and insulin to activate skeletal muscle IGF-I receptors and insulin receptors,
respectively. Importantly, ursolic acid alone was not sufficient to increase phosphorylation of
the IGF-I receptor or insulin receptor. Rather, its effects also required IGF-I and insulin,
respectively. This suggests that ursolic acid either facilitates hormone-mediated receptor
autophosphorylation or inhibits receptor dephosphorylation. The latter possibility is supported
by previous in vitro data showing that ursolic acid directly inhibits protein tyrosine
phosphatase 1B [115], a tyrosine phosphatase that dephosphorylates (inactivates) the IGF-I
and insulin receptors [116]. Further research is needed to elucidate the effect of
supplementation with ursolic acid in skeletal muscle and to attenuate muscle wasting (ex.
sarcopenia).
96
Figure 2. Supplementation with ursolic acid upregulates the amount of IGF-I and insulin and then
stimulates protein synthesis by activating Akt/mTOR/p70S6K pathway. Amino acid supplementation
enhances protein synthesis by stimulating mTOR. Akt blocks the nuclear translocation of FOXO to
inhibit the expression of Atrogin-1 and MuRF1 and the consequent protein degradation. In cachexic
muscle, supplementation with EPA downregulates the amount of TNF- and NF-B. Resistance
training also induces IGF-I expression and activates mTOR. Both resitstance and endurance exercise
inhibit TNF- expression. Endurance training increases the amount of PGC-1 through calcineurin- or
CaMK-dependent signaling. Activated PGC-1 protects several mitochondrial disorders (apoptosis,
oxidative damage, etc.) elicited by the increase in NF-B and Bax and/or the decrease in Bcl-2 in
senescent muscle.
97
4. Hormonal Supplementation
4.1. Testosterone
In males, levels of testosterone decrease by 1% per year, and those of bioavailable
testosterone by 2% per year from age 30 [141, 142]. In women, testosterone levels drop
rapidly from 20 to 45 years of age [143]. Testosterone increases muscle protein synthesis
[144] and its effects on muscle are modulated by several factors including genetic
background, nutrition and exercise [145]. Numerous studies of treatment with testosterone in
the elderly have been performed over the past few years [146-148]. In 1999, Snyder et al.
[148] suggested that increasing the level of testosterone in old men to that seen in young men
increased muscle mass but did not result in functional gains in strength. Systemic reviews of
the literature [149] have concluded that testosterone supplementation attenuates several
sarcopenic symptoms including decreases in muscle mass [147, 148] and grip strength [146].
For instance, a recent study of 6 months of supraphysiological dosage of testosterone in a
randomized placebo-controlled trial reported increased leg lean body mass and leg and arm
strength [150]. Although there are significant increases in strength among elderly males given
high doses of testosterone, the potential risks may outweigh the benefits. Risks associated
with testosterone therapy in older men include sleep apnea, thrombotic complications, and the
increased risk of prostate cancer [151].
These side effects have driven the necessity for drugs that demonstrate improved
therapeutic profiles. Novel, non-steroidal compounds, called selective androgen receptor
98
4.2. Estrogen
It has been hypothesized that menopause transition and the subsequent decline in
estrogen may play a role in muscle mass loss [156]. Van Geel et al. [157] reported a positive
relationship between lean body mass and estrogen levels. Similarly, Iannuzzi-Sucich et al.
[158] observed that muscle mass is correlated significantly with plasma estrone and estradiol
levels in women. However, Baumgartner et al. [159] reported that estrogen levels were not
associated with muscle mass in women aged 65 years and older. The mechanisms by which
decrease in estrogen levels may have a negative effect on muscle mass are not well
understood but may be associated with an increase in pro-inflammatory cytokines, such as
TNF- and IL-6, which might be implicated in the apparition of sarcopenia [160].
Furthermore, estrogen could have a direct effect on muscle mass since it has been shown that
skeletal muscle has estrogen beta-receptors on the cell membrane [161]. Therefore, a direct
potential mechanistic link could exist between low estrogen levels and a decrease in protein
synthesis. Further studies are needed to investigate this hypothesis. Neverthless, before
reaching a conclusion on the contribution of estrogens to the onset of sarcopenia, it would be
important to measure urinary estrogen metabolites since a relationship between breast cancer
and urinary estrogen metabolites has been shown [162].
99
4.4. Ghrelin
Ghrelin, is a 28-amino acid peptide mainly produced by cells in the stomach, intestines,
and hypothalamus [180]. Ghrelin is a natural ligand for the GH-secretagogue receptor, which
possesses a unique fatty acid modification, an n-octanoylation, at Ser 3 [181]. Ghrelin plays a
critical role in a variety of physiological processes, including the stimulation of GH secretion
and regulation of energy homeostasis by stimulating food intake and promoting adiposity via
a GH-independent mechanism [180].
In contrast, ghrelin inhibits the production of anorectic proinflammatory cytokines,
including IL-1, IL-6 and TNF- [182]. Because of their combined anabolic effects on
skeletal muscle and appetite, ghrelin and low molecular weight agonists of the ghrelin
receptor are considered attractive candidates for the treatment of cachexia [183]. For example,
Nagaya et al. [184] gave human ghrelin (2 g/Kg twice daily intravenously) for 3 weeks to
cachexic patients with chronic obstructive pulmonary disease in an open-label study. After
ghrelin therapy, significant increases from baseline measurements were observed for body
weight, lean body mass, food intake, hand grip strength, maximal inspiratory pressure, and
Karnofsky performance score [184]. In another unblinded study, the same group
demonstrated that treatment with human ghrelin (2 g/Kg twice daily intravenously, 3 weeks)
significantly improved several parameters (e.g., Lean body mass measured by Dual-energy
X-ray Absorption and left ventricular ejection fraction) in 10 patients with chronic heart
failure [185]. In a 1-year placebo-controlled study in healthy older adults over the age of 60
100
years given an oral ghrelin-mimetic (MK-677), an increase in appetite was observed [186].
The study did not show a significant increase in strength or function in the ghrelin-mimetic
treatment group, when compared to the placebo group, however a tendency was observed
[186]. As pointed out in a recent review by Nass et al., [187], the use of this compound
induces the potential deterioration of insulin sensitivity and development of diabetes mellitus
in older adults with impaired glucose tolerance.
5. Pharmacological Approach
5.1. Myostatin Inhibition
Myostatin was first discovered during screening for novel members of the transforming
growth factor- superfamily, and shown to be a potent negative regulator of muscle growth
[188, 189]. Mutations in myostatin can lead to massive hypertrophy and/or hyperplasia in
developing animals, as evidenced by knockout experiments in mice. Moreover, mouse
skeletal muscles engineered to overexpress the myostatin propeptide, the naturally occurring
myostatin inhibitor follistatin, or a dominant-negative form of activin receptor IIB (ActRIIB:
the main myostatin receptor [193]) all display similar, if not greatr, increase in size [190].
Myostatin levels increase with muscle atrophy due to unloading in mice and humans
[191, 192], and with severe muscle wasting in HIV ptients [193]. The increased levels of
myostatin are widely accepted to lead to muscle wasting [194]. Although many researchers
consider myostatin levels to increase with age, studies using sarcopenic muscles have yielded
conflicting results [53, 195, 196]. Intriguingly, Carlson et al. [195] showed enhanced levels of
Smad3 (possible myostatin-downstream regulator) but not myostatin in sarcopenic muscles of
mice. More recently, McKay et al. [197] observed more abundant myostatin-positive type IIassociated stem cells in older than younger males after muscle loading in spite of no
difference in stem cell-specific myostatin levels at baseline. Therefore, it is possible that
myostatin-dependent signaling is activated in sarcopenic mammalian muscles.
Many researchers have conducted experiments to inhibit myostatin in models of muscle
disorders such as DMD, amyotrophic lateral sclerosis, and cancer cachexia [34, 35]. In
addition, several investigators examined the effect of inhibiting myostatin to counteract
sarcopenia using animals only. A lack of myostatin caused by gene manipulation increased
the number of satellite cells, and enlarged the cross-sectional area of predominant type IIB/X
fibers in tibialis anterior muscles of mice [198]. In addition, these myostatin-null mice
showed prominent regenerative potential including accelerated fiber remodeling after an
injection of notexin [198]. Lebrasseur et al. [199] reported several positive effects of 4 weeks
of treatment with PF-354 (24 mg/Kg), a drug for myostatin inhibition, in aged mice. They
showed that PF-354-treated mice exhibited significantly greater muscle mass (by 12%), and
increased performance such as treadmill time, distance to exhaustion, and habitual activity.
Furthermore, PF-354-treated mice exhibited decreased levels of phosphorylated Smad3 and
MuRF1 in aged muscle. More recently, Murphy et al. [200] showed, by way of once weekly
injections, that a lower dose of PF-354 (10 mg/Kg) significantly increased the fiber crosssectional area (by 12%) and in situ force of tibialis anterior muscles (by 35%) of aged mice
(21-mo-old). Blocking myostatin enhances muscle protein synthesis [201] by potentially
101
relieving the inhibition normally imposed on the Akt/ mTOR signaling pathway by myostatin
[202]. These lines of evidence clearly highlight the therapeutic potential of antibody-directed
inhibition of myostatin for treating sarcopenia. However careful attention would be payed for
the myostatin inhibition, as mice with null mutation of myostatin revealed to impair tendon
structure and function [203].
102
was very limited (1.5-2.5 fold) as compared with other catabolic situations (10-fold). In
addition, the major peptidase activities of the proteasome (i.e. chymotrypsin-like, trypsin-like,
and caspase-like activities) were always reduced or unchanged with aging [212, 215, 221].
Altogether, these observations clearly suggest that activation of the ubiquitin-proteasome
system contributed little to the establishment of sarcopenia in accordance with very slow
muscle mass erosion.
There are several chemical classes of compounds that inhibit proteasomal activity,
including peptide analogs of substrates with different C-terminal groups, such as aldehydes,
epoxyketones, boronic acids, and vinyl sulfones [222]. A selective boronic acid proteasome
inhibitor, Velcade (also known as PS-341 and bortezomib), directly inhibits the proteasome
complex without direct effects on ubiquitination. Velcade is orally active and is presently
approved by the Food and Drug Administration and the European Medicines Agency [223,
224]. Gazzerro et al. [225] suggested that treatment with Velcade (0.8 mg/Kg) over a 2-week
period reduced muscle degeneration and necrotic features in mdx muscle fibers, as evaluated
with Evans blue dye. In addition, they observed many myotubes and/or immature myofibers
expressing embryonic myosin heavy chain in mdx muscle after Velcade administration.
Furthermore, Gazzerro et al. [225] also demonstrated that MG-132 increased dystrophin,
alpha-sarcoglycan and beta-dystroglycan protein levels in explants from Becker muscular
dystrophy patients, whereas it increased the proteins of the dystrophin glycoprotein complex
in DMD cases. Strangely, there has been no rodent study examining the effect of these
proteasome inhibitors to prevent muscle atrophy with aging; therefore, proteasome inhibitors
do not seem to attenuate muscle wasting in cases of sarcopenia.
5.4. Vitamin D
Vitamin D has been traditionally considered a key regulator of bone metabolism, and
calcium and phosphorus homeostasis through negative feedback with the parathyroid
hormone [226]. It is also well established that vitamin D deficiency causes rickets in children
and osteomalacia and osteoporosis in adults. A large and growing body of evidence suggests
that vitamin D is not only necessary for bone tissue and calcium metabolism, but may also
represent a crucial determinant for the development of major (sub)clinical conditions and
health-related events [226, 227].
Today, approximately 1 billion, mostly elderly people, worldwide have vitamin D
deficiency. The prevalence of low vitamin D concentrations in subjects older than 65 years of
age has been estimated at approximately 50% [228, 229], but this figure is highly variable
because it is influenced by sociodemographic, clinical, therapeutic and environmental factors.
Similarly there is an age-dependent reduction in vitamin D receptor expression in skeletal
muscle [230]. Prolonged vitamin D deficiency has been associated with severe muscle
weakness, which improves with vitamin D supplementation [231]. The histological
examination of muscle tissue from subjects with osteomalacia is characterized by increased
interfibrillar space, intramuscular adipose tissue infiltrates and fibrosis [232].
A large body of evidence currently demonstrates that low vitamin D concentrations
represent an independent risk factor for falls in the elderly [233-235]. Supplementation with
vitamin D in double-blind randomized-controlled trials has been shown to increase muscle
strength and performance and reduce the risk of falling in community-living elderly and
103
nursing home residents with low vitamin D levels [236-238]. In contrast, several groups
found no positive effect of vitamin D supplementation on fall event outcomes [239-241].
Cesari et al., [242] attributed these contradictory findings to the selection criteria adopted to
recruit study populations, adherence to the intervention, or the extreme heterogeneity of cutpoints defining the status of deficiency. A more comprehensive knowledge on vitamin Drelated mechanisms may provide a very useful tool preventing muscle atrophy for older
persons (sarcopenia). Figure 3 represents an overview of hormonal and pharmacological
strategies for sarcopenia.
104
Figure 3. Myostatin signals through the ActRIIB-ALK4/5 heterodimer activate Smad2/3 with blocking
of MyoD transactivation in an autoregulatory feedback loop. Recent findings suggest that myostatinSmad pathway inhibit protein synthesis probably due to blocking the functional role of Akt. Treatment
with ACE inhibitor and testosterone upregulates the amount of IGF-I and then stimulates protein
synthesis by activating Akt/mTOR/p70S6K pathway. Testosterone also enhances protein synthesis by
stimulating mTOR. Abundant serum GH, which is induced by ghrelin, activates JAK2-STAT5
signaling to promote muscle-specific gene transcription necessary to hypertrophy. More recent finding
indicates that vitamin D enhances follistatin expression, in turn blocks the functional role of myostatin
in vitro. The direct role of vitamin D on muscle fiber remains to be elucidated.
105
Acknowledgments
This work was supported by a research Grant-in-Aid for Scientific Research C (No.
23500778) from the Ministry of Education, Culture, Sports, Science and Technology of
Japan.
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
106
[15] Shefer, G., Van de Mark, D. P., Richardson, L. B., and Yablonka-Reuveni, Z. (2006).
Satellite-cell pool size does matter: defining the myogenic potency of aging skeletal
Muscle. Dev. Biol., 294, 50-66.
[16] Conboy, I. M., Conboy, M. J., Smythe, G. M., and Rando, T. A. (2003). Notchmediated restoration of regenerative potential to aged muscle. Science, 302, 1575-1577.
[17] Wagners, A. J. and Conboy, I. M. (2005). Cellular and molecular signatures of muscle
regeneration: current concepts and controversies in adult myogenesis. Cell, 122, 659667.
[18] Arterburn, D. E., Crane, P. K. and Sullivan, S. D. (2004). The coming epidemic of
obesity in elderly Americans. J. Am. Geriatr. Soc., 52, 1907-1912.
[19] Bellanger, T. M. and Bray, G. A. (2005). Obesity related morbidity and mortality. J.
Louisiana State Med. Soc., 157, S42-S49.
[20] Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., and Heath, C. E. Jr. (1999).
Body-mass index and mortality in a prospective cohort of US adults. N Engl. J. Med.,
341, 1097-1105.
[21] Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, S., Hong, Y.,
and Eckel, R. H. (2004). Clinical implications of obesity with specific focus on
cardiovascular disease. A statement for professionals from the American Heart
Association Council on Nutrition, Physical Activity, and Metabolism. Endorsed by the
American College of Cardiology Foundation. Circulation, 110, 2952-2967.
[22] Baumgartner, R. N., Wayne, S. J., Waters, D. L., Janssen, I., Gallagher, D., and Morley,
J. E. (2004). Sarcopenic obesity predicts instrumental activities of daily living disability
in the elderly. Obese. Res., 12, 1995-2004.
[23] Broadwin, J., Goodman-Gruen, D. and Slymen, D. (2001). Ability of fat and fat-free
mass percentages to predict functional disability in older men and women. J. Am.
Geriatr. Soc., 49, 1641-1645.
[24] Bouchard, D. R., Pickett, W. and Janssen, I. (2010). Association between obesity and
unintentional injury in older adults. Obesity Facts, 3, 363-369.
[25] Rolland, Y., Lauwers-Cances, V., Cristini, C., Abellan Van Kan, G., Janssen, I.,
Morley, J. E., and Velas, B. (2009). Difficulties with physical function associated with
obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women:
The EPIDOS (EPIDemiologie de IOSteoporose) study. Am. J. Clin. Nutr., 89, 18951900.
[26] Dube, J. and Goodpaster, B. H. (2006). Assessment of intramuscular triglycerides:
contribution to metabolic abnormalities. Curr. Opin. Clin. Nutr. Metab. Care, 9, 553559.
[27] Kraegen, E. W. and Cooney, G. J. (2008). Free fatty acids and skeletal muscle insulin
resistance. Curr. Opin. Lipidol., 19, 235-241.
[28] Lexell, J. (1993). Ageing and human muscle: observations from Sweden. Can. J. Appl.
Physiol., 18, 2-18.
[29] Roubenoff, R. and Hughes, V. A. (2000). Sarcopenia: current concepts. J. Gerontol. A
Biol. Sci. Med. Sci., 55, M716-M724.
[30] Sakuma, K., Akiho, M., Nakashima, H., Akima, H., and Yasuhara, M. (2008). Agerelated reductions in expression of serum response factor and myocardin-related
transcription factor A in mouse skeletal muscles. Biochim. Biophys. Acta Mol. Basis
Dis., 1782, 453-461.
107
[31] Sakuma, K. and Yamaguchi, A. (2010). Molecular mechanisms in aging and current
strategies to counteract sarcopenia. Curr. Aging Sci., 3, 90-101.
[32] Sakuma, K. and Yamaguchi, A. (2011). Sarcopenia: Molecular mechanisms and current
therapeutic strategy. Cell Aging, 93-152, ed: Perloft, J. W. and Wong, A. H. Nova
Science Publisher, NY.
[33] Paddon-Jones, D. and Rasmussen, B. B. (2009). Dietary protein recommendations and
the prevention of sarcopenia. Curr. Opin. Nutr. Metab. Care, 12, 86-90.
[34] Bradley, L., Yaworsky, P. J. and Walsh, F. S. (2008). Myostatin as a therapeutic target
for musculoskeletal disease. Cell Mol. Life Sci., 65, 2119-2124.
[35] Sakuma, K. and Yamaguchi, A. (2011). Inhibitors of myostatin- and proteasomedependent signaling for attenuating muscle wasting. Recent Pat. Regenerat. Med., 1,
284-298.
[36] Kunkel, S. D., Suneja, M., Ebert, S. M. Bongers, K. S., Fox, D. K., Malmberg, S. E.,
Alipour, F., Shields, R. K., and Adams, C. M. (2011). mRNA expression signatures of
human skeletal muscle atrophy identify a natural compound that increases muscle mass.
Cell Metab., 13, 627-638.
[37] Smith, G. I., Atherton, P. and Reeds, D. N. (2011). Dietary omega-3 fatty acid
supplementation increases the rate of muscle protein synthesis in older adults: a
randomized controlled trial. Am. J. Clin. Nutr., 93, 402-412.
[38] Dreyer, H. C., Fujita, S., Cadenas, J. G., Chinkes, D. L., Volpi, E., and Rasmussen, B.
B. (2006). Resistance exercise increases AMPK activity and reduces 4E-BP1
phosphorylation and protein synthesis in human skeletal muscle. J. Physiol., 576, 613624.
[39] Miller, B. F., Olesen, J. L., Hansen, M., Dossing, S., Crameri, R. M., Welling, R. J.,
Langberg, H., Flyvbjerg, A., Kjaer, M., Babraj, J. A., Smith, K., and Rennie, M. J.
(2005). Coordinated collagen and muscle protein synthesis in human patella tendon and
quadriceps muscle after exercise. J. Physiol., 567, 1021-1033.
[40] Esmarck, B., Andersen, J. L., Olsen, S., Richter, E. A., Mizuno, M., and Kjaer, M.
(2001). Timing of postexercise protein intake is important for muscle hypertrophy with
resistance training in elderly humans. J. Physiol., 535, 301-311.
[41] Fiatarone, M. A., ONeil, E. F., Ryan, N. D., Clements, K. M., Solares, G. R., Nelson,
M. E., Roberts, S. B., Kehayias, J. J., Lipsitz, L. A., and Evans, W. J. (1994). Exercise
training and nutritional supplementation for physical frailty in very elderly people. N
Engl. J. Med., 330, 1769-1775.
[42] Lenk, K., Schuler, G. and Adams, V. (2010). Skeletal muscle wasting in cachexia and
sarcopenia: Molecular pathophysiology and impact of exercise training. J. Cachexia
Sarcopenia Muscle, 1, 9-21.
[43] Charette, S. L., McEvoy, L., Pyka, G., Snow-Harter, C., Guido, D., Wiswell, R. A., and
Marcus, R. (1991). Muscle hypertrophy response to resistance training in older women.
J. Appl. Physiol., 70, 1912-1916.
[44] Frontera, W. R., Meredith, C. N., OReilly, K. P., Knuttgen, H. G., and Evans, W. J.
(1988). Strength conditioning in older men: Skeletal muscle hypertrophy and improved
function. J. Appl. Physiol., 64, 1038-1044.
[45] Campbell, W. W., Joseph, L. J., Davey, S. L., Cyr-Campbell, D., Anderson, R. A., and
Evans, W. J. (1999). Effects of resistance training and chromium picolinate on body
composition and skeletal muscle in older men. J. Appl. Physiol., 86, 29-39.
108
[46] McCartney, N., Hicks, A. L., Martin, J., and Webber, C. E. (1996). A longituidinal trial
of weight training in the elderly: Continued improvements in year 2. J. Gerontol. A
Biol. Sci. Med. Sci., 51, B425-B433.
[47] Singh, M. A., Ding, W., Manfredi, T. J., Solares, G. S., ONeil, E. F., Clements, K. M.,
Ryan, N. D., Kehayias, J. J., Fielding, R. A., and Evans, W. J. (1999). Insulin-like
growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am. J.
Physiol. Endocrinol. Metab., 277, E135-E143.
[48] Raue, U., Slivka, D., Jemiolo, B., Hollon, C., and Trappe, S. (2006). Myogenic gene
expression at rest and after a bout of resistance exercise in young (18-30 yr) and old
(80-89 yr) women. J. Appl. Physiol., 101, 53-59.
[49] Pedersen, B. K. (2006). The anti-inflammatory effect of exercise: Its role in diabetes
and cardiovascular disease control. Essay Biochem., 42, 105-117.
[50] Parise, G., Brose, A. N. and Tarnopolsky, M. A. (2005). Resistance exercise training
decreases oxidative damage to DNA and increases cytochrome oxidase activity in older
adults. Exp. Gerontol., 40, 173-180.
[51] Hasten, D. L., Pak-Loduca, J., Obert, K. A., and Yarasheski, K. E. (2000). Resistance
exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and
23-32 yr olds. Am. J. Physiol. Endocrinol. Metab., 278, E620-E626.
[52] Yarasheski, K. E., Pak-Loduca, J., Hasten, D. L., Obert, K. A., Brown, M. B., and
Sinacore, D. R. (1999). Resistance exercise training increases mixed muscle protein
synthesis rate in frail women and men > 76 yr old. Am. J. Physiol. Endocrinol. Metab.,
277, E118-E125.
[53] Haddad, F. and Adams, G. R. (2006). Aging-sensitive cellular and molecular
mechanisms associated with skeletal muscle hypertrophy. J. Appl. Physiol., 100, 11881203.
[54] Thomson, D. M. and Gordon, S. E. (2006). Impaired overload-induced muscle growth
is associated with diminished translational signaling in aged rat fast-twitch skeletal
muscle. J. Physiol., 574, 291-305.
[55] Mayhew, D. L., Kim, J. S., Cross, J. M., and Bamman, M. M. (2009). Translational
signaling responses preceding resistance training-mediated myofibers hypertrophy in
young and old humans. J. Appl. Physiol., 107, 1655-1662.
[56] Smart, N. A. and Steele, M. (2011). The effect of physical training on systemic
proinflammatory cytokine expression in heart failure patients: A systematic review.
Congest Heart Fail., 17, 110-114.
[57] Kosek, D. J., Kim, J. S., Petrella, J. K., Cross, J. M., and Bamman, M. M. (2006).
Efficacy of 3 day/wk resistance training on myofiber hypertrophy and myogenic
mechanisms in young vs. older adults. J. Appl. Physiol., 101, 531-544.
[58] Holloszy, J. O. (1967). Biochemical adaptations in muscle. Effects of exercise on
mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle. J.
Biol. Chem., 242, 2278-2282.
[59] Chow, L. S., Greenlund, L. J., Asmann, Y. W., Short, K. R., McCrady, S. K., Levine, J.
A., and Nair, K. S. (2007). Impact of endurance training on murine spontaneous
activity, mitochondrial DNA abundance, gene transcripts, and function. J. Appl.
Physiol., 102, 1078-1089.
[60] Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A.
L., and Spiegelman, B. M. (2006). PGC-1 protects skeletal muscle from atrophy by
[61]
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
109
suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad.
Sci. U. S. A., 103, 16260-16265.
Payne, G. W. (2006). Effect on inflammation on the aging microcirculation: impact on
skeletal muscle blood flow control. Microcirculation, 13, 343-352.
Arany, Z. (2008). PGC-1 coactivators and skeletal muscle adaptations in health and
disease. Curr. Opin. Genet. Dev., 18, 426-434.
Arany, Z., Foo, S. Y., Ma, Y., Ruas, J. L., Bommi-Reddy, A., Girnun, G., Cooper, M.,
Laznik, D., Chinsomboon, J., Rangwala, S. M., Baek, K. H., Rosenzweig, A., and
Spiegelman, B. M. (2008). HIF-independent regulation of VEGF and angiogenesis by
the transcriptional coactivator PGC-1. Nature, 451, 1008-1012.
Handschin, C., Chin, S., Li, P., Liu, F., Maratos-Flier, E., Lebrasseur, N. K., Yan, Z.,
and Spiegelman, B. M. (2007). Skeletal muscle fiber-type switching, exercise
intolerance, and myopathy in PGC-1 muscle-specific knock-out animals. J. Biol.
Chem., 282, 30014-30021.
Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M., and Moraes, C. T. (2009).
Increased muscle PGC-1 expression protects from sarcopenia and metabolic disease
during aging. Proc. Natl. Acad. Sci. U. S. A., 106, 20405-20410.
Anderson, R. and Prolla, T. (2009). PGC-1 in aging and anti-aging interventions.
Biochim. Biophys. Acta, 1790, 1059-1066.
Handschin, C., Kobayashi, Y. M., Chin, S., Seale, P., Campbell, K. P., and Spiegelman,
B. M. (2007). PGC-1 regulates the neuromuscular junction program and ameliorates
Duchenne muscular dystrophy. Genes Dev., 21, 770-783.
Wenz, T., Diaz, F., Hernandez, D., and Moraes, C. T. (2008). Activation of the PPAR/
PGC-1 pathway prevents a bioenergetic deficit and effectively improves a
mitochondrial myopathy. J. Appl. Physiol., 106, 1712-1719.
Haskel, W. L., Lee, I. M., Pate, R. R., Powell, K. E., Blair, S. N., Franklin, B. A.,
Macera, C. A., Heath, G. W., Thompson, P. D., and Bauman, A. (2007). Physical
activity and public health: Updated recommendation for adults from the American
College of Sports Medicine and the American Heart Association. Med. Sci. Sports
Exerc., 39, 1423-1434.
Liu, C. J. and Latham, N. K. (2009). Progressive resistance strength training for
improving physical function in older adults. Cochrane Database Systemic Review,
CD002759.
Davidson, L. E., Hudson, R., Kilpatrick, K., Kurk, J. L., McMillan, K., Janiszewski, P.
M., Lee, S., Lam, M., and Ross, R. (2009). Effects of exercise modality on insulin
resistance and functional limitations in older adults: A randomized controlled trial.
Arch. Int. Med., 169, 122-131.
Leveritt, M., Abernethy, P. J., Barry, B. K., and Logan, P. A. (1999). Concurrent
strength and endurance training. A review. Sports Med., 28, 413-427.
Leveritt, M., Abernethy, P. J., Barry, B., and Logan, P. A. (2003). Concurrent strength
and endurance training: The influence of dependent variable selection. J. Strength
Cond. Res., 17, 503-508.
Fulgoni, V. L. III. (2008). Current protein intake in America. Analysis of the National
Health and Nutrition Examination Survey, 2003-2004. Am. J. Clin. Nutr., 87, 1554S1557S.
110
[75] Kerstetter, J. E., OBrien, K. O. and Insogna, K. L. (2003). Low protein intake. The
impact on calcium and bone homeostasis in humans. J. Nutr., 133, 855S-861S.
[76] Lord, C., Chaput, J. P., Aubertin-Leheure, M., Labont, M., and Dionne, I. J. (2007).
Dietary animal protein intake: Association with muscle mass index in older women. J.
Nutr. Health Aging, 11, 383-387.
[77] Timmerman, K. L. and Volpi, E. (2008). Amino acid metabolism and regulatory effets
in aging. Curr. Opin. Clin. Nutr. Metab. Care, 11, 45-49.
[78] Henderson, G. C., Irving, B. A. and Nair, K. S. (2009). Potential application of essential
amino acid supplementation to treat sarcopenia in elderly people. J. Clin. Endocrinol.
Metab., 94, 1524-1526.
[79] Paddon-Jones, D. and Rasmussen, B. B. (2009). Dietary protein recommendations and
the prevention of sarcopenia. Curr. Opin. Nutr. Metab. Care, 12, 86-90.
[80] Norton, L. E. and Layman, D. K. (2006). Leucine regulates translation initiation of
protein synthesis in skeletal muscle after exercise. J. Nutr., 136, 533S-537S.
[81] Nair, K. S., Woolf, P. D., Welle, S. L., and Matthews, D. E. (1987). Leucine, glucose,
and energy metabolism after 3 days of fasting in health human subjects. Am. J. Clin.
Nutr., 46, 557-562.
[82] Walker, D. K., Dickinson, J. M., Timmerman, K. L., Drummond, M. J., Reidy, P. T.,
Fry, C. S., Gundermann, D. M., and Rasmussen, B. B. (2011). Exercise, amino acids,
and aging in the control of human muscle protein synthesis. Med. Sci. Sports Exerc., 43,
2249-2258.
[83] Tipton, K. D., Ferrando, A. A., Phillips, S. M., Doyle, D., Jr and Wolfe, R. R. (1999).
Postexecise net protein synthesis in human muscle from orally administered amino
acids. Am. J. Physiol. Endocr. Metab., 276, E628-E634.
[84] Dreyer, H. C., Drummond, M. J., Pennings, B., Fujita, S., Glynn, E. L., and Chinkes, D.
L. (2008). Leucine-enriched essential amino acid and carbohydrate ingestion following
resistance exercise enhances mTOR signaling and protein synthesis in human muscle.
Am. J. Physiol. Endocr. Metab., 294, E392-E400.
[85] Esmarck, B., Andersen, J. L., Olsen, S., Richter, E. A., Mizuno, M., and Kjaer, M.
(2005). Timing of postexercise protein intake is important for muscle hypertrophy with
resistance training in elderly humans. J. Physiol., 567, 301-311.
[86] Drummond, M. J., Dreyer, H. C., Pennings, B., Fry, C. S., Dhanani, S., Dillon, E. L.,
Sheffield-Moore, M., Volpi, E., and Rasmussen, B. B. (2008). Skeletal muscle protein
anabolic response to resistance exercise and essential amino acids is delayed with
aging. J. Appl. Physiol., 104, 1452-1461.
[87] Walrand, S., Short, K. R., Bigelow, M. L., Sweatt, A. J., Hutson, S. M., and Nair, K. S.
(2008). Functional impact of high protein intake on healthy elderly people. Am. J.
Physiol. Endocrinol. Metab., 295, E921-E928.
[88] Godard, M. P., Williamson, D. L. and Trappe, S. W. (2002). Oral amino-acid provision
does not affect muscle strength or size gains in older men. Med. Sci. Sports Exerc., 34,
1126-1131.
[89] Welle, S. and Thornton, C. A. (1998). High-protein meals do not enhance myofibrillar
synthesis after resistance exercise in 62- to 75-yr-old men and women. Am. J. Physiol.
Endocrinol. Metab., 274, E677-E683.
[90] Dillon, E. L., Sheffield-Moore, M., Paddon-Jones, D., Gilkison, C., Sanford, A. P.,
Casperson, S. L., Jiang, J., Chinkes, D. L., and Urban, R. J. (2009). Amino acid
111
supplementation increases lean body mass, basal muscle protein synthesis, and insulinlike growth factor-I expression in older women. J. Clin. Endocrinol. Metab., 94, 16301637.
[91] Nicastro, H., Artioli, G. G., Dos Santos Costa, A., Sollis, M. Y., Da Luz, C. R.,
Blachier, F., and Lancha, A. H. Jr. (2011). An overview of the therapeutic effects of
leucine supplementation on skeletal muscle under atrophic conditions. Amino Acids, 40,
287-300.
[92] Solerte, S. B., Gazzaruso, C., Bonacasa, R., Rondanelli, M., Zamboni, M., Basso, C.,
Locatelli, E., Schifino, N., Giustina, A., and Fioravanti, M. (2008). Nutritional
supplements with oral amino acid mixtures increases whole-body lean mass and insulin
sensitivity in elderly subjects with sarcopenia. Am. J. Cardiol., 101, 69E-77E.
[93] Jacobs, I. (1999). Dietary creatine monohydrate supplementation. Can. J. Appl.
Physiol., 24, 503-514.
[94] Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M.,
Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., and Beal, M. F.
(1999). Neuroprotective effects of creatine in a transgenic animal model of amyotrophic
lateral sclerosis. Nat. Med., 5, 347-350.
[95] Passaquin, A. C., Renard, M., Kay, L., Challet, C., Mokhtarian, A., Wallimann, T., and
Ruegg, U. T. (2002). Creatine supplementation reduces skeletal muscle degeneration
and enhances mitochondrial function in mdx mice. Neuromuscul. Disord., 12, 174-182.
[96] Guthmiller, P., Van Pilsum, J. F., Boen, J. R., and McGuire, D. M. (1994). Cloning and
sequencing of rat kidney L-arginine:glycine amidinotransferase. Studies on the
mechanism of regulation by growth hormone and creatine. J. Biol. Chem., 269, 1755617560.
[97] Heinnen, K., Nnt-Salonen, K., Komu, M., Erkintalo, M., Heinonen, O. J., Pulkki,
K., Nikoskelainen, E., Sipil, I., and Simell, O. (1999). Muscle creatine phosphate in
gyrate atrophy of the choroids and retina with hyperornithinaemia-clues to
pathogenesis. Eur. J. Clin. Invest, 29, 426-431.
[98] Levine, S., Tikunov, B., Henson, D., LaManca, J., and Sweeney, H. L. (1996). Creatine
depletion elicits structural, biochemical, and physiological adaptations in rat costal
diaphragm. Am. J. Physiol., 271, C1480-C1486.
[99] Tarnopolsky, M. and Martin, J. (1999). Creatine monohydrate increases strength in
patients with neuromuscular disease. Neurology, 52, 854-857.
[100] Bermon, S., Venembre, P., Sachet, C., Valour, S., and Dolisi, C. (1998). Effects of
creatine monohydrate ingestion in sedentary and weight-trained older adults. Acta
Physiol. Scand., 164, 147-155.
[101] Rawson, E. S., Wehnert, M. L. and Clarkson, P. M. (1999). Effects of 30 days of
creatine ingestion in older men. Eur. J. Appl. Physiol. Occup. Physiol., 80, 139-144.
[102] Brose, A., Parise, G. and Tarnopolsky, M. A. (2003). Creatine supplementation
enhances isometric strength and body composition improvements following strength
exercise training in older adults. J. Gerontol. A Biol. Sci. Med. Sci., 58, 11-19.
[103] Chrusch, M. J., Chilibeck, P., Chad, K. E., Davison, K. S. and Burke, D. G. (2001).
Creatine supplementation combined with resistance training in older men. Med. Sci.
Sports Exerc., 33, 2111-2117.
112
[104] Gotshalk, L. A., Volek, J. S., Staron, R. S., Denegar, C. R., Hagerman, F. C., and
Kraemer, W. J. (2002). Creatine supplementation improves muscular performance in
older men. Med. Sci. Sports Exerc., 34, 537-543.
[105] Tarnopolsky, M. A., Parise, G., Yardley, N. J., Ballantyne, C. S., Olatinji, S., and
Phillips, S. M. (2001). Creatine-dextrose and protein-dextrose induce similar strength
gains during training. Med. Sci. Sports Exerc., 33, 2044-2052.
[106] Chilibeck, P. D., Chrusch, M. J., Chad, K. E., Shawn Davidson, K., and Burke, D. G.
(2005). Creatine monohydrate and resistance training increase bone mineral content and
density in older men. J. Nutr. Health Aging, 9, 352-353.
[107] Hespel, P., OPt Eijnde, B., Van Leemputte, M., Urs, B., Greenhalf, P. L., Labarque,
V., Dymarkowski, S., Van Hecke, P., and Richter, E. A. (2001). Oral creatine
supplementation facilitates the rehabilitation of disuse atrophy and alters the expression
of muscle myogenic factors in humans. J. Physiol., 536, 625-633.
[108] Olsen, S., Aagaard, P., Kadi, F., Tufekovic, G., Verney, J., Olsen, J. L., Suetta, C., and
Kjaer, M. (2006). Creatine supplementation augments the increase in satellite cell and
myonuclei number in human skeletal muscle induced by strength training. J. Physiol.,
573, 525-534.
[109] Parise, G., Mihic, S., MacLennan, D., Yarasheski, K. E., and Tarnopolsky, M. A.
(2001). Effects of acute creatine monohydrate supplementation on leucine kinetics and
mixed-muscle protein synthesis. J. Appl. Physiol., 91, 1041-1047.
[110] Frighetto, R. T. S., Welendorf, R. M., Nigro, E. N., Frighetto, N., and Siani, A. C.
(2008). Isolation of ursolic acid from apple peels by high speed countr-current
chromatography. Food Chemist., 106, 767-771.
[111] Liu, J. (1995). Pharmacology of oleanolic acid and ursolic acid. J. Ethnopharmacol.,
49, 57-68.
[112] Wang, Z. H., Hsu, C. C., Huang, C. N., and Yin, M. C. (2009). Anti-glycative effects of
oleanolic acid and ursolic acid in kidney of diabetic mice. Eur. J. Pharmacol., 628,
255-260.
[113] Liu, J. (2005). Oleanolic acid and ursolic acid: Research perspectives. J.
Ethnopharmacol., 100, 92-94.
[114] Kunkel, S. D., Suneja, M., Ebert, S. M. Bongers, K. S., Fox, D. K., Malmberg, S. E.,
Alipour, F., Shields, R. K., and Adams, C. M. (2011). mRNA expression signatures of
human skeletal muscle atrophy identify a natural compound that increases muscle mass.
Cell Metab., 13, 627-638.
[115] Zhang, W., Hong, D., Zhou, Y., Zhang, Y., Shen, Q., Li, J. Y., Hu, L. H., and Li, J.
(2006). Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B,
enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim.
Biophys. Acta, 1760, 1505-1512.
[116] Kenner, K. A., Anyanwu, E., Olefsky, J. M., and Kusari, J. (1996). Protein-tyrosine
phosphatase 1B is a negative regulator of insulin-and insulin-like growth factor-Istimulated signaling. J. Biol. Chem., 271, 19810-19816.
[117] Arterburn, L. M., Hall, E. B. and Oken, H. (2006). Distribution, interconversion, and
dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr., 83, 1467S-1476S.
[118] Fearon, K. C., Von Meyenfeldt, M. F., Moses, A. G., Van Geenen, R., Roy, A., Gouma,
D. J., Giacosa, A., Van Gossum, A., Bauer, J., Barber, M. D., Aaronson, N. K., Voss,
A. C., and Tisdale, M. J. (2003). Effect of a protein and energy dense N-3 fatty acid
113
enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A
randomised double blind trial. Gut, 52, 1479-1486.
[119] Harper, C. R. and Jacobson, T. A. (2005). Usefulness of omega-3 fatty acids and the
prevention of coronary heart disease. Am. J. Cardiol., 96, 1521-1529.
[120] Bloomer, R. J., Larson, D. E., Fisher-Wellman, K. H., Calpin, A. J., and Schilling, B.
K. (2009). Effect of eicosapentaenoic and docosahexaenoic acid on resting and
exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo
controlled, cross-over study. Lipids Health Dis., 8, 36.
[121] Babcock, T. A., Helton, W. S. and Espat, N. J. (2000). Eicosapentaenoic acid (EPA):
An anti-inflammatory -3 fat with potential clinical applications. Nutrition, 16, 11161118.
[122] Singer, P., Shapiro, H., Theilla, M., Anbar, R., Singer, J., and Cohen, J. (2008). antiinflammatory properties of omega-3 fatty acids in critical illness: Novel mechanisms
and an integrative perspective. Intensive Care Med., 34, 1580-1592.
[123] Babcock, T. A., Helton, W. S., Hong, D., and Espat, N. J. (2002). Omega-3 fatty acid
lipid emulsion reduces LPS-stimulated macrophage TNF- production. Surg. Infect., 3,
145-149.
[124] Magee, P., Pearson, S. and Allen, J. (2008). The omega-3 fatty acid, eicosapentaenoic
acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha
during murine skeletal muscle cell differentiation. Lipids Health Dis., 7, 24.
[125] Machado, R. V., Mauricio, A. F., Tiemi Taniguti, A. P., Ferretti, R., Santo Neto, H.,
and Marques, M. J. (2011). Eicosapentaenoic acid decreases TNF- and protects
dystrophic muscles of mdx mice from degeneration. J. Neuroimmunol., 232, 145-150.
[126] Smith, G. I., Atherton, P. and Reeds, D. N. (2011). Dietary omega-3 fatty acid
supplementation increases the rate of muscle protein synthesis in older adults: A
randomized controlled trial. Am. J. Clin. Nutr., 93, 402-412.
[127] Halliwell, B. H. and Gutteridge, J. M. C. (1989). Free Radicals in Biology and
Medicine, Oxford University Press, Oxford, UK.
[128] Beckman, K. B. and Ames, B. N. (1998). The free radical theory of aging matures.
Physiol. Rev., 78, 547-581.
[129] Vasilaki, A., McArdle, F., Iwanejko, L. M., and McArdle, A. (2006). Adaptive response
of mouse skeletal muscle to contractile activity: The effect of age. Mech. Ageing Dev.,
127, 830-839.
[130] Shigenaga, M. K., Hagen, T. M. and Ames, B. N. (1994). Oxidative damage and
mitochondrial decay in aging. Proc. Natl. Acad. Sci. U. S. A., 91, 10771-10778.
[131] Marzetti, E., Hwang, J. C., Lees, H. A., Wohlgemuth, S. E., Dupont-Versteegden, E.
E., Carter, C. S., Bernabei, R., and Leeuwenburgh, C. (2010). Mitochondrial death
effectors: Relevance to sarcopenia and disuse muscle atrophy. Biochim. Biophys. Acta
Gen. Subj., 1800, 235-244.
[132] Bonetto, A., Penna, F., Muscaritoli, M., Minero, V. G., Fanelli, F. R., Baccino, F. M.,
and Costelli, P. (2009). Are antioxidants useful for treating skeletal muscle atrophy?
Free Radic. Biol. Med., 47, 906-916.
[133] Leoncini, S., Rossi, V., Signorini, C., Tanganelli, C. E., Comporti, M., and Ciccoli, L.
(2008). Oxidative stress, erythrocyte ageing and plasma non-protein-bound iron in
diabetic patients. Free Radic. Res., 42, 716-724.
114
[134] Mastrocola, R., Reffo, P., Penna, F., Tomasinelli, C. E., Boccuzzi, G., Baccino, F. M.,
Aragano, M., and Costelli, P. (2008). Muscle wasting in diabetic and tumor-bearing
rats: Role of oxidative stress. Free Radic. Biol. Med., 44, 584-593.
[135] Boots, A. W., Haenen, G. R. and Bast, A. (2008). Health effects of quercetin: From
antioxidant to nutraceutical. Eur. J. Pharmacol., 44, 126-131.
[136] Harikumar, K. B. and Aggarwal, B. B. (2008). Resveratrol: A multi-targeted agent for
age-associated chronic diseases. Cell Cycle, 7, 1020-1035.
[137] Baur, J. A. and Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo
evidence. Nature Rev. Drug Discov., 5, 493-506.
[138] Cerullo, F., Gambassi, G. and Cesari, M. (2012). Rationale for antioxidant
supplementation in sarcopenia. J. Aging Res., 2012, Article ID 316943, 8 pages.
[139] Bonetto, A., Penna, F., Muscaritoli, M., Minero, V. G., Fanelli, F. R., Baccino, F. M.,
and Costelli, P. (2009). Are antiocidants useful for treating skeletal muscle atrophy?
Free Radic. Biol. Med., 47, 906-916.
[140] Morley, J. E., Abbatecola, A. M., Argiles, J. M., Baracos, V., Bauer, J., Bhasin, S.,
Cederholm, T., Coats, A. J., Cummings, S. R., Evans, W. J., Fearon, K., Ferrucci, L.,
Fielding, R. A., Guralnik, J. M., Harris, T. B., Inui, A., Kalantar-Zadeh, K., Kirwan, B.
A., Mantovani, G., Muscaritoli, M., Newman, A. B., Rossi-Fanelli, F., Rosano, G. M.,
Roubenoff, R., Schambelan, M., Sokol, G. H., Storer, T. W., Vellas, B., von Haehling,
S., Yeh, S. S., and Anker, S. D., Society on Sarcopenia, Cachexia and Wasting
Disorders Trialist Workshop. (2011). Sarcopenia with limited mobility: An
international consensus. J. Am. Med. Dir. Assoc., 12, 403-409.
[141] Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello,
A. D., Bremner, W. J., and McKinlay, J. B. (2002). Age trends in the level of serum
testosterone and other hormones in middle-aged men: Longitudinal results from the
Massachusetts male aging study. J. Clin. Endocrinol. Metab., 87, 589-598.
[142] Morley, J. E., Kaiser, F. E., Perry III, H. M., Patrick, P., Morley, P. M., Stauber, P. M.,
Vellas, B., Baumgartner, R. N., and Garry, P. J. (1997). Longitudinal changes in
testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older
men. Metabolism, 46, 410-413.
[143] Morley, J. E. and Perry III, H. M. (2003). Androgens and women at the menopause and
beyond. J. Gerontol. A Biol. Sci. Med. Sci., 58, M409-M416.
[144] Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R.
R., and Ferrando, A. (1995). Testosterone administration to elderly men increases
skeletal muscle strength and protein synthesis. Am. J. Physiol., 269, E820-E826.
[145] Bhasin, S., Woodhouse, K. and Storer, T. W. (2001). Proof of the effect of tstosterone
on skeletal muscle. J. Endocrinol., 170, 27-38.
[146] Bakhshi, V., Elliott, M., Gentili, A., Godschalk, M., and Mulligan, T. (2000).
Testosterone improves rehabilitation outcomes in ill older men. J. Am. Geriatr. Soc.,
48, 550-553.
[147] Ferrando, A. A., Sheffield-Moore, M., Yeckel, C. W., Gilkison, C., Jiang, J., Achacosa,
A., Lieberman, S. A., Tipton, K., Wolfe, R. R., Urban, R. J. (2002). Testosterone
administration to older men improves muscle function: molecular and physiological
mechanisms. Am. J. Physiol. Endocrinol. Metab., 282, E601-E607.
[148] Snyder, P. J., Peachey, H., Hannoush, P., Berlin, J. A., Loh, L., Lenrow, D. A., Holmes,
J. H., Dlewati, A., Santanna, J., Rosen, C. J., and Strom, B. L. (1999). Effect of
115
testosterone treatment on body composition and muscle strength in men over 65 years
of age. J. Clin. Endocrinol. Metab., 84, 2647-2653.
[149] Bhasin, S., Calof, O., Storer, T. W., Lee, M. L., Mazer, N. A., Jasuja, R., Montori, V.
M., Gao, W., and Dalton, J. T. (2006). Drug insight: Testosterone and selective
androgen receptor modulators as anabolic therapies for physical dysfunction in chronic
illness and ageing. Nature Clin. Pract. Endocrinol. Metab., 2, 146-159.
[150] Sinha-Hikim, I., Cornford, M., Gaytan, H., Lee, M. L., and Bhasin, S. (2006). Effects of
testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in
community-dwelling older men. J. Clin. Endocrinol. Metab., 91, 3024-3033.
[151] Mudali, S. and Dobs, A. S. (2004). Effects of testosterone on body composition of the
aging male. Mech. Ageing Dev., 125, 297-304.
[152] Cadilla, R. and Turnbull, P. (2006). Selective androgen receptor modulators in drug
discovery: Medicinal chemistry and therapeutic potential. Curr. Top Med. Chem., 6,
245-270.
[153] Labrie, F., Luu-The, V. and Belanger, A. (2005). Is dehydroepiandrosterone a
hormone? J. Endocrinol., 187, 169-196.
[154] Baulieu, E. E., Thomas, G. and Legrain, S. (2000). Dehydroepiandrosterone (DHEA),
DHEA sulfate, and aging: Contribution of the DHEAge study to a sociobiomedical
issue. Proc. Natl. Acad. Sci. U. S. A., 97, 4279-4284.
[155] Dayal, M., Sammel, M. D., Zhao, J., Hummel, A. C., Vandenbourne, K., and Barnhart,
K. T. (2005). Supplementation with DHEA: Effect on muscle size, strength, quality of
life, and lipids. J. Womens Health, 14, 391-400.
[156] Thomas, D. R. (2007). Loss of skeletal muscle mass in aging: Examining the
relationship of starvation, sarcopenia and cachexia. Clin. Nutr., 26, 389-399.
[157] Van Geel, T. A., Geusens, P. P., Winkens, B., Sels, J. P., and Dinant, G. J. (2009).
Measures of bioavailable serum testosterone and estradiol and their relationships with
muscle mass, muscle strength and bone mineral density in postmenopausal women: A
cross-sectional study. Eur. J. Endocrinol., 160, 681-687.
[158] Iannuzzi-Sucich, M., Prestwood, K. M. and Kenny, K. M. (2002). Prevalence of
sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J.
Gerontol. A Biol. Sci. Med. Sci., 57, M772-M777.
[159] Baumgartner, R. N., Waters, D. L., Gallagher, D., Morley, J. E., and Garry, P. J. (1999).
Predictors of skeletal muscle mass in elderly men and women. Mech. Ageing Dev., 107,
123-136.
[160] Roubenoff, R. (2003). Catabolism of aging: Is it an inflammatory process? Curr. Opin.
Clin. Nutr. Metab. Care, 6, 295-299.
[161] Brown, M. (2008). Skeletal muscle and bone: Effect of sex steroids and aging. Adv.
Physiol. Education, 32, 120-126.
[162] Falk, R. T., Rossi, S. C., Fears, T. R., Sepkovic, D. W., Migella, A., Adlercreutz, H.,
Donaldson, J., Bradlow, H. L., and Ziegler, R. G. (2000). A new ELISA kit for
measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio:
Reproducibility, validity, and assay performance after freeze-thaw cycling and
preservation by boric acid. Cancer Epidemiol. Biolarkers Prevent., 9, 81-87.
[163] Florini, J. R., Ewton, D. Z. and Coolican, S. A. (1996). Growth hormone and the
insulin-like growth factor system in myogenesis. Endocrine Rev., 17, 481-517.
116
[164] Giustina, A., Mazziotti, G. and Canalis, E. (2008). Growth hormone, insulin-like
growth factors, and the skeleton. Endocrine Rev., 29, 535-559.
[165] Hermann, M. and Berger, P. (2001). Hormonal changes in aging men: A therapeutic
indication? Exp. Gerontol., 36, 1075-1082.
[166] Ryall, J. G., Schertzer, J. D. and Lynch, G. S. (2008). Cellular and molecular
mechanisms underlying age-related skeletal muscle wasting and weakness.
Biogerontology, 9, 213-228.
[167] Veldhuis, J. D. and Iranmanesh, A. (1996). Physiological regulation of the human
growth hormone (GH)-insulin-like growth factor type I (IGF-I) axis: Predominant
impact of age, obesity, gonadal function, and sleep. Sleep, 19, S221-S224.
[168] Giovannini, S., Marzetti, E., Borst, S. E. and Leeuwenburgh, C. (2008). Modulation of
GH/IGF-I axis: Potential strategies to counteract sarcopenia in older adults. Mech.
Ageing Dev., 129, 593-601.
[169] Andersen, N. B., Andreassen, T. T., Orskov, H., and Oxlund, H. (2000). Growth
hormone and mild exercise in combination increases markedly muscle mass and tetanic
tension in old rats. Eur. J. Endocrinol., 143, 492-503.
[170] Blackman, M. R., Sorkin, J. D., Mnzer, T., Bellantoni, M. F., Busby-Whitehead, J.,
Stevens, T. E., Jayme, J., O'Connor, K. G., Christmas, C., Tobin, J. D., Stewart, K. J.,
Cottrell, E., St Clair, C., Pabst, K. M., and Harman, S. M. (2002). Growth hormone and
sex steroid administration in healthy aged women and men: A randomized controlled
trial. JAMA, 288, 2282-2292.
[171] Giannoulis, M. G., Sonksen, P. H., Umpleby, M., Breen, L., Pentecost, C., Whyte, M.,
McMillan, C. V., Bradley, C., and Martin, F. C. (2006). The effects of growth hormone
and/or testosterone in health elderly men: A randomized controlled trial. J. Clin.
Endocrinol. Metab., 91, 477-484.
[172] Marcell, T. J., Harman, S. M., Urban, R. J., Metz, D. D., Rodgers, B. D., and Blackman,
M. R. (2001). Comparison of GH, IGF-I, and testosterone with mRNA of receptors and
myostatin in skeletal muscle in older men. Am. J. Physiol. Endocrinol. Metab., 281,
E1159-E1164
[173] Ferrucci, L., Penninx, B. W., Volpato, S., Harris, T. B., Bandeen-Roche, K., Balfour, J.,
Leveille, S. G., Fried, L. P., and Md, J. M. (2002). Change in muscle strength explains
accelerated decline of physical function in older women with high interleukin-6 serum
levels. J. Am. Geriatr. Soc., 50, 1947-1954.
[174] Philippou, A., Maridaki, M., Halapas, A., and Koutsilieris, M. (2007). The role of the
insulin-like growth factor-I (IGF-I) in skeletal muscle physiology. In Vivo, 21, 45-54.
[175] Butterfield, G. E., Thompson, J., Rennie, M. J., Marcus, R., Hintz, R. L., and Hoffman,
A. R. (1997). Effect of rhGH and rhIGF-I treatment on protein utilization in elderly
women. Am. J. Physiol. Endocrinol. Metab., 272, E94-E99.
[176] Evans, W. J., Paolisso, G., Abbatecola, A. M., Corsonello, A, Bustacchini, S., Strollo,
F., and Lattanzio, F. (2010). Frailty and muscle metabolism dysregulation in the
elderly. Biogerontology, 11, 527-536.
[177] Dardevet, D., Sornet, C., Attaix, D., Baracos, V. E., and Grizard, J. (1994). Insulin-like
growth factor-I and insulin resistance in skeletal muscles of adults. Endocrinology, 134,
1475-1484.
[178] Arvat, E., Broglio, F. and Ghigo, E. (2000). Insulin-like growth factor I: Implication in
aging. Drugs Aging, 16, 29-40.
117
[179] Wilkes, E. A., Selby, A. L., Atherton, P. J., Patel, R., Rankin, D., Smith, K., and
Rennie, M. J. (2009). Blunting of insulin inhibition of proteolysis in legs of older
subjects may contribute to age-related sarcopenia. Am. J. Clin. Nutr., 90, 1343-1350.
[180] Kojima, M. and Kangawa, K. (2005). Ghrelin: Structure and function. Physiol. Rev., 85,
495-522.
[181] Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., and Kangawa, K. (1999).
Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402,
656-660.
[182] Dixit, V. D., Schaffer, E. M., Pyle, R. S., Collins, G. D., Sakthivel, S. K., Palaniappan,
R., Lillard, J. W., Jr. and Taub, D. D. (2004). Ghrelin inhibits leptin- and activationinduced proinflammatory cytokine expression by human monocytes and T cells. J. Clin.
Invest., 114, 57-66.
[183] Akamizu, T. and Kangawa, K. (2010). Ghrelin for cachexia. J. Cachexia Sarcopenia
Muscle, 1, 169-176.
[184] Nagaya, N., Itoh, T., Murakami, S., Oya, H., Uematsu, M., Miyatake, K., and Kangawa,
K. (2005). Treatment of cachexia with ghrelin in patients with COPD. Chest, 128,
1187-1193.
[185] Nagaya, N., Moriya, J., Yasumura, Y., Uematsu, M., Ono, F., Shimizu, W., Ueno, K.,
Kitakaze, M., Miyatake, K., and Kangawa, K. (2004). Effects of ghrelin administration
on left ventricular function, exercise capacity, and muscle wasting in patients with
chronic heart failure. Circulation, 110, 3674-3679.
[186] Bach, M. A., Rockwood, K., Zetterberg, C., Thamsborg, G., Hbert, R., Devogelaer, J.
P., Christiansen, J. S., Rizzoli, R., Ochsner, J. L., Beisaw, N., Gluck, O., Yu, L.,
Schwab, T., Farrington, J., Taylor, A. M., Ng, J., and Fuh, V., MK 0677 Hip Fracture
Study Group. (2004). The effects of MK-0677, an oral growth hormone secretagogue,
in patients with hip fracture. J. Am. Geriatr. Soc., 52, 516-523.
[187] Nass, R., Gaylinn, B. D. and Thorner, M. O. (2011). The ghrelin axis in disease:
Potential therapeutic indications. Mol. Cell Endocrinol., 340, 106-110.
[188] McPherron, A. C., Lawler, A. M. and Lee, S. J. (1997). Regulation of skeletal muscle
mass in mice by a new member TGF-beta superfamily member. Nature, 387, 83-90.
[189] Lee, S. J. (2004). Regulation of muscle mass by myostatin. Annu. Rev. Cell Dev. Biol.,
20, 61-86.
[190] Lee, S. J. and McPherron, A. C. (2001). Regulation of myostatin activity and muscle
growth. Proc. Natl. Acad. Sci. U. S. A., 98, 9306-9311.
[191] Sakuma, K., Watanabe, K., Hotta, N., Koike, T., Ishida, K., Katayama, K., and Akima,
H. (2009). The adaptive responses in several mediators linked with hypertrophy and
atrophy of skeletal muscle after lower limb unloading in humans. Acta Physiol. (Oxf.),
197, 151-159.
[192] Wehling, M., Cai, B. and Tidball, J. G. (2000). Modulation of myostatin expression
during modified muscle use. FASEB J., 14, 103-110.
[193] Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K.,
Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., Nair, G., Arver, S., and Bhasin, S.
(1998). Organization of the human myostatin gene and expression in healthy men and
HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. U. S. A., 95, 1493814943.
118
[194] Sakuma, K. and Yamaguchi, A. (2012). Sarcopenia and cachexia: The adaptations of
negative regulators of skeletal muscle mass. J. Cachexia Sarcopenia Muscle, 3, 77-94.
[195] Carlson, M. E., Hsu, M. and Conboy, I. M. (2008). Imbalance between pSmad3 and
Notch induces CDK inhibitors is old muscle stem cells. Nature, 454, 528-532.
[196] Lger, B., Derave, W., De Bock, K., Hespel, P., and Russell, A. P. (2008). Human
sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of
Akt phosphorylation. Rejuvenat. Res., 11, 163-175.
[197] McKay, B. R., Ogborn, D. I., Bellamy, L. M., Tarnopolsky, M. A. and Parise, G.
(2012). Myostatin is associated with age-related human muscle stem cell dysfunction.
FASEB J., 25, 2509-2521.
[198] Siriett, V., Platt, L., Salerno, M. S., Ling, N., Kambadur, R., and Sharma, M. (2006).
Prolonged absence of myostatin reduces sarcopenia. J. Cell. Physiol., 209, 866-873.
[199] Lebrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P., and
Brown, T. A. (2009). Myostatin inhibition enhances the effects on performance and
metabolic outcomes in aged mice. J. Gerontol. A Biol. Sci. Med. Sci., 64, 940-948.
[200] Murphy, K. T., Koopman, R., Naim, T., Lger. B., Trieu, J., Ibebunjo, C., and Lynch,
G. S. (2010). Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel
roles for myostatin signaling in skeletal muscle structure and function. FASEB J., 24,
4433-4442.
[201] Welle, S., Burgess, K. and Mehta, S. (2009). Stimulation of skeletal muscle
myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6
phosphorylation by inhibition of myostatin in mature mice. Am. J. Physiol. Endocrinol.
Metab., 296, E567-E572.
[202] Amirouche, A., Durieux, A. C., Banzet, S., Koulmann, N., Bonnefoy, R., Mouret, C.,
Bigard, X., Peinnequin, A., and Freyssenet, D. (2009). Down-regulation of Akt/
mammalian target of rapamycin signaling pathway in response to myostatin
overexpression in skeletal muscle. Endocrinolgy, 150, 286-294.
[203] Mendias, C. L., Bakhurin, K. I. and Faulkner, J. A. (2008). Tendons of myostatindeficient mice are small, brittle, and hypocellular. Proc. Natl. Acad. Sci. U. S. A., 105,
288-293.
[204] De Cavanagh, E. M. V., Piotrkowski, B., Basso, N., Stella, I., Inserra, F., Ferder, L.,
and Fraga, C. G. (2003). Enalapril and losartan attenuate mitochondrial dysfunction in
aged rats. FASEB J., 17, 1096-1098.
[205] Maggio, M., Ceda, G. P., Lauretani, F., Pahor, M., Bandinelli, S., Najjar, S. S., Ling, S.
M., Basaria, S., Ruggiero, C., Valenti, G., and Ferrucci, L. (2006). Relation of
angiotensin converting enzyme inhibitor treatment to insulin-like growth factor-1 serum
levels in subjects > 65 years of age (the InCHIANTI study). Am. J. Cardiol., 97, 15251529.
[206] Onder, G., Penninx, B. W. J. H., Balkrishnan, R., Fried. L. P., Chaves, P. H.,
Williamson, J., Carter, C., Di Bari, M., Guralnik, J. M., and Pahor, M. (2002). Relation
between use of angiotensin-converting enzyme inhibitors and muscle strength and
physical function in older women: An observational study. Lancet, 359, 926-930.
[207] Dssegger, L., Aldor, E., Baird, M. G., Braun, S., Cleland, J. G. F., Donaldson, R.,
Jansen, L. J., Joy, M. D., Marin-Neto, J. A., Nogueira, E., Stahnke, P. L., and Storm, T.
(1993). Influence of angiotensin converting enzyme-inhibition on exercise performance
119
and clinical symptoms in chronic heart-failure - a multicenter, double-blind, placebocontrolled trial. Eur. Heart J., 14, 18-23.
[208] Schellenbaum, G. D., Smith, N. L., Heckbert, S. R., Lumley, T., Rea, T. D., Furberg, C.
D., Lyles, M. F., and Psaty, B. M. (2005). Weight loss, muscle strength, and
angiotensin-converting enzyme inhibitors in older adults with congestive heart failure
or hypertension. J. Am. Geriatr. Soc., 53, 1996-2000.
[209] Sumukadas, D., Witham, M. D., Struthers, A. D., and Mcmurdo, M. E. T. (2007).
Effect of perindopril on physical function in elderly people with functional impairment:
A randomized controlled trial. CMAJ, 177, 867-874.
[210] Bunout, D., Barrera, G., De La Maza, M. P., Leiva, L., Backhouse, C., and Hirsch, S.
(2009). Effects of enalapril or nifedipine on muscle strength or functional capacity in
elderly subjects. A double blind trial. J. Renin Angiotensin Aldosterone Syst., 10, 77-84.
[211] Cai, D., Frantz, J. D., Tawa, N. E. Jr., Melendez, P. A., Oh, B. C., Lidov, H. G.,
Hasselgren, P. O., Frontera, W. R., Lee, J., Glass, D. J., and Shoelson, S. E. (2004).
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119, 285289.
[212] Sandri, M., Sandri, C., Gilbert, A. Skurk, C., Calabria, E., Picard, A., Walsh, K.,
Schiaffino, S., Lecker, S. H., and Goldberg, A. L. (2004). Foxo transcription factors
induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Cell, 117, 399-412.
[213] Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O.,
Gonzalez, M., Yancopoulos, G. D., and Glass, D. J. (2004). The IGF-I/PI3K/Akt
pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting
FOXO transcription factors. Mol. Cell, 14, 395-403.
[214] Combaret, L., Dardevet, D., Bchet, D., Taillandier, D., Mosoni, L., and Attaix, D.
(2009). Skeletal muscle proteolysis in aging. Curr. Opin. Clin. Nutr. Metab. Care, 12,
37-41.
[215] Pattison, J. S., Folk, L. C., Madsen, R. W., Childs, T. E., and Booth, F. W. (2003).
Transcriptional profiling identifies extensive downregulation of extracellular matrix
gene expression in sarcopenic rat soleus muscle. Physiol. Genomics, 15, 34-43.
[216] DeRuisseau, K. C., Kavazis, A. N. and Powers, S. K. (2005). Selective downregulation
of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp.
Gerontol., 40, 526-531.
[217] Clavel, S., Coldefy, A. S., Kurkdjian, E., Salles, J., Margaritis, I., and Derijard, B.
(2006). Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in
aged rat tibialis anterior muscle. Mech. Ageing Dev., 127, 794-801.
[218] Edstrm, E., Altun, M., Hgglund, M., and Ulfhake, B. (2006). Atrogin-1/MAFbx and
MuRF1 are downregulated in ageing-related loss of skeletal muscle. J. Gerontol. A
Biol. Sci. Med. Sci., 61, 663-674.
[219] Welle, S., Brooks, A. L., Delehany, J. M., Needler, N., and Thornton, C. A. (2003).
Gene expression profile of aging in human muscle. Physiol. Genomics, 14, 149-159.
[220] Whitman, S. A., Wacker, M. J., Richmond, S. R., and Godard, M. P. (2005).
Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal
muscle wasting with age. Pflgers Arch., 450, 437-446.
120
[221] Attaix, D., Mosoni, L., Dardevet, D., Combaret, L., Mirand, P. P., and Grizard, J.
(2005). Altered responses in skeletal muscle protein turnover during aging in anabolic
and catabolic periods. Int. J. Biochem. Cell Biol., 37, 1962-1973.
[222] Lee, D. H. and Goldberg, A. L. (1998). Proteasome inhibitors: Valuable new tools for
cell biologists. Trends Cell Biol., 8, 397-403.
[223] Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D.,
Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. (1999). Proteasome inhibitors: A
novel class of potent and effective antitumor agents. Cancer Res., 59, 2615-2622.
[224] Orlowski, R. Z. (1997). Proteasome inhibitors in cancer therapy. Methods Mol. Biol.,
100, 197-203.
[225] Gazzerro, E., Assereto, S., Bonetto, A., Sotgia, F., Scarf, S., Pistorio, A., Bonuccelli,
G., Cilli, M., Bruno, C., Zara, F., Lisanti, M. P., and Minetti, C. (2010). Therapeutic
potential of proteasome inhibition in Duchenne and Becker muscular dystrophies. Am.
J. Pathol., 176, 1863-1877.
[226] Holick, M. F. (2007). Vitamin D deficiency. N Engl. J. Med., 357, 266-281.
[227] Gloth, F. M. 3rd, Gundberg, C. M., Hollis, B. W., Haddad, J. G. J., and Tobin, J. D.
(1995). Vitamin D deficiency in homebound elderly persons. JAMA, 274, 1683-1686.
[228] Goldray, D., Mizrahi-Sasson, E., Merdler, C., Edelstein-Singer, M., Algoetti, A.,
Eisenberg, Z., Jaccard, N., and Weisman, Y. (1989). Vitamin D deficiency in elderly
patients in a general hospital. J. Am. Geriatr. Soc., 37, 589-592.
[229] Wicherts, I. S., Van Schoor, N. M., Boeke, A. J., Visser, M., Deeg, D. J., Smit, J., Knol,
D. L., and Lips, P. (2007). Vitamin D status predicts physical performance and its
decline in older persons. J. Clin. Endocrinol. Metab., 92, 2058-2065.
[230] Sato, Y., Iwamoto, J., Kanoko, T., and Satoh, K. (2005). Low-dose vitamin D prevents
muscular atrophy and reduces falls and hip fractures in women after stroke: A
randomized controlled trial. Cerebrovasc. Dis., 20, 187-192.
[231] Montero-Odasso, M. and Duque, G. (2005). Vitamin D in the aging musculoskeletal
system: An authentic strength preserving hormone. Mol. Aspects Med., 26, 203-219.
[232] Yoshikawa, S., Nakamura, T., Tanabe, H., and Imamura, T. (1979). Osteomalacic
myopathy. Endocr. J., 26, 65-72.
[233] Faulkner, K. A., Cauley, J. A., Zmuda, J. M., Landsittel, D. P., Newman, A. B.,
Studenski, S. A., Redfern, M. S., Ensrud, K. E., Fink, H. A., Lane, N. E., and Nevitt, M.
C. (2006). Higher 1,25-dihydroxyvitamin D3 concentrations associated with lower fall
rates in older community-dwelling women. Osteoporosis Int., 17, 1318-1328.
[234] Flicker, L., Mead, K., MacInnis, R. J., Nowson, C., Scherer, S., Stein, M. S., Thomasx,
J., Hopper, J. L., and Wark, J. D. (2003). Serum vitamin D and falls in older women in
residential care in Australia. J. Am. Geriatr. Soc., 51, 1533-1538.
[235] Snijder, M. B., Van Schoor, N. M., Pluijm, S. M., Van Dam, R. M., Visser, M., and
Lips, P. (2006). Vitamin D status in relation to one-year risk of recurrent falling in older
men and women. J. Clin. Endocrinol. Metab., 91, 2980-2985.
[236] Annweiler, C., Schott, A. M., Berrut, G., Fantino, B., and Beauchet, O. (2009). Vitamin
D-related changes in physical performance: A systemic review. J. Nutr. Heatlth Aging,
13, 893-898.
[237] Bischoff-Ferrari, H. A., Dawson-Hughes, B., Staehelin, H. B., Orav, J. E., Stuck, A. E.,
Theiler, R., Wong, J. B., Egli, A., Kiel, D. P., and Henschkowski, J. (2009). Fall
121
122
[251] McKiernan, S. H., Colman, R. J., Lopez, M., Beasley, T. M., Aiken, J. M., Anderson,
R. M., and Weindruch, R. (2011). Caloric restriction delays aging-induced cellular
phenotypes in rhesus monkey skeletal muscle. Exp. Gerontol., 46, 23-29.
[252] Dirks, A. J. and Leeuwenburgh, C. (2006). Caloric restriction in humans: Potential
pitfalls and health concerns. Mech. Ageing Dev., 127, 1-7.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 5
Abstract
Reactive oxygen species (ROS) are produced via several sources in the skeletal
muscle. In particular, the mitochondrial electron transport chain in the muscle cells could
be a major source of ROS, with an elevation of oxygen consumption. Physical exercise, a
sedentary lifestyle, and the aging process can all generate oxidative stress. Such oxidative
stress can cause transcriptional and post-translational regulation of key proteins and
affect their functionality. Evidence has suggested that some muscle proteins (i.e.,
myofiber proteins, metabolic signaling proteins, and inflammatory factors) can be the
targets of oxidative stress. Continuous or excess elevation of ROS in muscle tissues
results in inflammation, loss of muscle mass, and metabolic dysfunction. In contrast,
growing evidence has suggested that moderate and transient elevations in ROS contribute
to the metabolic improvement and maintenance of muscle mass via modulating related
proteins, which mediate health benefits induced by moderate exercise. The oxidative
proteins may be also useful as potential biomarkers to examine the oxidative stress levels,
antioxidant compounds, and their possible benefits or dysfunction.
Introduction
Reactive oxygen species (ROS) are generated in various conditions in the living body. A
small percent of the oxygen utilized in the mitochondria is converted to superoxide during the
electron transport chain reaction.
Corresponding autor: Wataru Aoi. Laboratory of Health Science, Graduate School of Life and Environmental
Sciences, Kyoto Prefectural University, Kyoto 606-8522, Japan. Phone: +81-75-703-5417; Fax: +81-75-7035417; E-mail: waoi@kpu.ac.jp.
124
Wataru Aoi
Therefore, the skeletal muscle is a major source of ROS production since it is a major
metabolic organ. It is known that oxygen consumption during aerobic exercise is elevated 10
to 20-fold in the body as a whole and over 100-fold in the skeletal muscle alone (Figure 1).
In addition, endothelium and invaded phagocytes also produces ROS in muscle tissues
via reactions by such xanthine oxidase, NADPH oxidase, and myeroperoxidase. When ROS
are generated above the protective capacity of antioxidants during physical exercise, the aging
process, and pathogenesis, they induce oxidative stress in the muscle tissues.
Cell components such as lipids, proteins, and DNA, are easy targets for ROS, and
accumulated oxidative products of these components are observed in the conditions that
generate oxidative stress. Such oxidative damage is closely associated with the pathogenesis
of life-style diseases, age-related diseases, dystrophic diseases, and exercise-induced muscle
fatigue/damage.
Interestingly, a moderate level of oxidative stress mediates the maintenance of
physiological homeostasis and additional exercise-induced beneficial adaptations.
Figure 1. Generation of reactive oxygen species in skeletal muscle. ROS are continuously generated
from various sources with various physiological and pathological conditions. Consequently, muscles
are exposed to oxidative stress and cellular components such as DNA, lipids, and proteins are oxidized.
Such oxidative stress can also cause transcriptional and post-translational regulation of key proteins and
affect their functionality.
125
Growing evidence has shown that several oxidative-sensitive signaling pathways exist in
the muscle cells, and the regulation of the signaling activity is thought to be a major factor
contributing to the effect of ROS on muscular function. In particular, the post-translational
and transcriptional regulation of proteins induced by oxidative stress is closely associated
with the expression of those functions via regulating the activity of key proteins. In this
chapter, we review oxidative stress-induced signals associated with various phenotypic
functions in the skeletal muscle.
126
Wataru Aoi
from I-kappa B into nucleus. The translocated NF-B binds to the genetic region of DNA
encoding for proinflammatory cytokines, chemokines, and adhesion molecules.
Consequently, oxidative stress induces inflammation with the infiltration of phagocytes
through the expression of inflammatory mediators and NF-B activation. In addition to the
transcription factor, some transcriptional coactivators, which regulate gene expression by
interacting with transcription factors, are also shown to have redox sensitivity in the
regulation of its activity and contents.
Previously, it has been shown that several muscular proteins are also targets that can be
modified by ROS or nitrogen oxide species that are generated by physiological and
pathological conditions [7-17] (Table 1). ROS generated by high-intensity acute/chronic
exercise directly induce the oxidation of the thiol moiety on the side chain of the amino acid
cysteine residues in proteins and indirectly modify other amino acid residues of the proteins
by lipid peroxides. Such modifications could be a mechanism of delayed-onset muscle
damage and muscular fatigue [8, 10, 12, 16], as described later. In addition, oxidative protein
modifications can also be found in chronic pathological conditions (e.g., disuse atrophy and
insulin resistance) [9, 11, 13, 14] and is closely associated with these disorders via abnormal
signal transduction.
127
upstream kinases may also phosphorylate p65, the active subunit of NF-B. Free, activated
NF-B, in the form of the p65-p50 heterodimer, is translocated to the nucleus. There, it binds
to the B sequences located in the promoter of the target gene.
Alternatively, MAPKs can activate AP-1 components, c-Jun, and c-Fos, leading to the
binding of AP-1 (c-Jun-c-Fos heterodimer) to the cyclic AMP response element (CRE)
sequences of the target promoter gene [6].
Unaccustomed and strenuous exercise causes muscle damage that presents clinically as
muscular pain and involves protein degradation and ultrastructural changes. The release of
soluble muscle enzymes, most notably creatine kinase (CK), leads to the disruption of
sarcomere architecture [22, 23] and surface membrane damage [24, 25]. Muscle damage
usually occurs after some time after exercise (rather than during or immediately after
exercise), peaks at about 2448 h, and is called delayed-onset muscle damage [26]. Muscledamaging exercise leads to phagocytic infiltration into the muscle tissue and the inflammatory
response induces delayed-onset muscle damage [27]. Previous studies have shown that
delayed-onset muscle damage is mainly induced by mechanical stress, especially eccentric
muscle contraction [28-30]. In addition, we demonstrated that delayed-onset muscle damage
induced by prolonged exercise is partly associated with inflammation through phagocyte
infiltration caused by ROS [31]. In an in vitro study that used myotube cells from rats, the
addition of hydrogen peroxide (H2O2) induced the translocation of p65 (a component of NFB) into the nucleus and, subsequently, increased the expression of cytokine-induced
128
Wataru Aoi
129
can regulate the ubiquitin-proteasome proteolytic pathway through induction of MuRF1 and
proteasome expression [55-57].
Furthermore, it has been shown that the 20S proteasome can selectively degrade modified
proteins oxidatively without ubiquitination [58, 59].
Figure 3. Muscle loss signaling in response to chronic oxidative stress. Chronic oxidative stress
accelerates protein degradation via ubiquitin-proteasome- and calpain- systems, as well as an activation
of apoptotic signaling. The protein degradation and apoptosis leads to muscle atrophy with aging,
inactivity, and diseases.
These observations suggest that protein degradation could be the link between oxidative
stress and muscle atrophy. In fact, the hyperactivity of NF-B and the ubiquitin-proteasome
pathway have been identified as a major cause of aging-related muscle atrophy [60, 61]. TNF, an inflammatory cytokine, led to ROS-mediated NF-B activation, which resulted in the
reduction of total protein and a specific loss in the myosin heavy chain in C2C12 myotubes
and muscle tissues from mice [62]. Another in vivo study [63] has also shown that circulating
TNF- causes ROS-mediated NF-B activation along with contractile dysfunction in
respiratory muscles. In contrast, we found that the inhibition of NF-B reduced oxidative
stress-induced protein degradation [51]. Some antioxidants can also prevent muscle atrophy
in atrophy models.
130
Wataru Aoi
These observations demonstrate a close relationship between oxidative stress and protein
degradation during muscle atrophy. As another pathway, it is also possible that the
intracellular production of ROS could play a key role in the observed disturbances in calcium
homeostasis. Oxidative stress-induced decreases in Ca2+-ATPase activity in the sarcoplasmic
reticulum (SR) would reduce Ca2+ removal from the cytoplasm and promote intracellular Ca2+
accumulation, which leads to an increase in proteolysis through the activation of the calciumdependent protease calpain [64-66].
In addition to muscle fiber atrophy, a complete loss of muscle fibers also contributes to a
loss in muscle mass. A decrease in the number of muscle fiber is caused by the apoptosis,
which results from mitochondrial dysfunction and the activation of apoptotic signaling
pathways. In fact, accelerated apoptosis of muscle fibers has been documented to occur with
age [67, 68]. Apoptosis and the amount of cleaved caspase-3, an effector protease in the
apoptosis cascade, are elevated in the gastrocnemius muscles of old Fischer 344 rats
compared to that in young animal [69]. Oxidative stress induced by H2O2 leads to the
elevation of apoptotic DNA fragmentation and an increase in pro-apoptotic factors such as
Bcl2-associated X protein (Bax), caspase-3, and caspase-9 in C2C12 myotubes [70, 71]. It is
suggested that receptor signaling via TNF may contribute to the activation of caspasedependent apoptotic signaling in aged muscles. The activation of caspase-3 via caspase-8
occurs after the binding of TNF- to TNF receptor 1 and leads to nuclear DNA fragmentation
[72]. Elevations in TNF- are observed in aged muscles, suggesting that elevated oxidative
stress can lead to the apoptosis of myocytes via TNF. In addition, it was reported that
oxidative stress activates not only the caspase-dependent apoptotic pathway but also the
caspase-independent pathway via an apoptosis-inducing factor, which is released from the
mitochondria and is translocated to the nucleus where it plays a role in DNA fragmentation
[70]. Conversely, muscle apoptosis induced by menadione, a compound that instigates
oxidative stress, is attenuated along with the inhibition of lipid peroxide [73], thus supporting
the relationship between ROS and apoptosis. Such apoptosis can also cause a reduction in
fiber size [74].
131
132
Wataru Aoi
A possible factor influencing the utilized ratio of these energy substrates is the
colocalization of CPT I with FAT/CD36. Exercise-induced ROS may partly limit the
utilization of fatty acids by diminishing the CPT I activity caused by HEL modification.
Indeed, we and another group found that the inhibition of this modification by dietary
astaxanthin increased fat utilization during exercise and prolonged the running time to
exhaustion, when compared with mice on a normal diet [7, 95].
Therefore, HEL-modification of CPT I can partly suppress lipid metabolism during
exercise, which would affect the endurance performance and efficiency of adipose tissue
reduction with training.
Under the condition of exercise-induced muscle damage, oxidative stress can also
transiently decrease insulin-stimulated glucose uptake in skeletal muscle. In a euglycemichyperinsulinemic clamp study, Kirwan et al. first reported that, in human subjects, systemic
insulin resistance and elevated circulating CK levels persist 48 h after eccentric exercise. This
effect was not observed after concentric exercise or in the resting state [96]. We recently
reported that the insulin-stimulated uptake of 2-deoxy-[3H] glucose in damaged muscle was
significantly lower after downhill running when compared to the uptake that was found to
occur in sedentary mice [8].
Furthermore, Del Aguila et al. [97] reported that muscle-damaging exercise impairs the
insulin-stimulated activity of insulin receptor substrate-1 (IRS-1), PI3-K, and Akt in the
muscle tissues. In addition to proinflammatory cytokines such as TNF-, intereukin-1, and
interleukn-6, we observed the elevation of 4-HNE, a lipid peroxidation product that
covalently modifies the proteins on cysteine, histidine, and lysine residues, in the damaged
muscle obtained from mice on the next day after acute running [8]. Liu et al. [98] reported a
positive correlation between 4-HNE and CK activity in the blood, following strenuous
exercise in humans. Recently, insulin receptor substrate-1 (IRS-1) was detected as a 4-HNEtargeted protein in the damaged muscle [8]. IRS-1 is upstream in the PI3K/Akt-dependent
insulin-signaling pathway in muscle cells and regulates glucose uptake via GLUT4. In the
damaged muscle after strenuous exercise, insulin-stimulated glucose uptake is decreased
along with a reduction of insulin signal transduction, which suggests that 4-HNE modification
of IRS-1 is involved in the transient impairment of insulin sensitivity. In addition, Sahlin et
al. [15] showed a marked elevation in the 4-HNE modification of mitochondrial protein after
acute endurance exercise, which would also be associated with metabolic dysfunction in
damaged muscle.
133
Studies using excised muscle fiber bundles also revealed that force production during
submaximal tetanic contractions is decreased with nitric oxide (NO) donors [107, 108] and
increased with nitric oxide synthetase (NOS) inhibitors and NO scavengers [109, 110].
The influence of oxidative stress on the SR, a subcellular organelle that controls the
contractile state of the muscle by regulating the calcium concentration in the cytosol, has been
studied extensively in the skeletal muscle, and is associated with the oxidative modification of
membrane proteins [111-113]. Muscle contraction is performed by increasing intracellular
calcium concentrations, which are released from the SR via the ryanodine receptor (RyR)
calcium-release channel following active potentials during the excitation-contraction coupling
process. Afterwards, calcium is immediately taken into the SR via SR calcium-dependent
ATPase (SERCA), which relaxes the muscle. It has been known that the responsive proteins
in the SR are sensitive to redox modulation [114, 115]. The RyR appears to be in close
association with the NADP(H) oxidase(s) found in the SR, and locally generated superoxide
appears to be the major ROS capable of influencing this channel [113]. Each subunit of this
large tetrameric protein contains a small number of regulatory cysteines. ROS and NO
oxidize thiol residues on neighboring cysteines to form disulfide bonds, which induce channel
opening. Disulfide formation is reversed by reducing agents, and it provides a mechanism for
the direct redox modulation of channel activity. The SERCA, another potential target,
contains a small number of critical sulfhydryls near the SERCA active site, which has been
shown to slow the reuptake of calcium into the SR [116-118]. Exposure to elevated NO also
inhibits SERCA activity via thiol oxidation and nitration of tyrosine residues [119, 120].
Consequently, oxidation of SR proteins tends to increase cytosolic calcium levels, which
prevents of muscle relaxation. Therefore, the modification of calcium transport proteins in the
SR can causes excess or chronic muscle contraction by increasing intracellular calcium levels,
which leads to muscle fatigue.
Muscle myofilaments are also sensitive to direct redox modification [121]. Myosin heavy
chains contain several sulfhydryl residues, which are useful sites for protein labeling.
However, thiol modification generally does not dramatically alter myosin function [122]. On
the other hand, Yamada et al. [17] reported that a force reduction in the soleus muscle of
hyperthyroid rat is associated with carbonylation of the myosin heavy chain. In addition, it
has been suggested that the myosin heavy chain is easily glycosylated, which changes the
structural and functional properties of the protein [123]. However, the involvement of these
modifications on exercise-induced fatigue is unclear. In contrast, myosin light chains, actin,
and tropomyosin appear less sensitive to redox modulation [124, 125].
134
Wataru Aoi
Figure 4. Beneficial effects mediated by moderate exercise-induced oxidative stress. Moderate exercise
induces transient and mild oxidative stress which plays an important role in improving beneficial
adaptations (e.g. metabolic improvement, antioxidant, and antiinflammation) through exercise.
Previously, it has been suggested that a moderate level of oxidative stress caused by lowto-moderate intensity exercise (which does not cause muscle damage) is important for signal
transduction in the cell.
135
Regular exercise adaptively improves glucose and lipid metabolism, and the expression/
activity of several key proteins in the skeletal muscle is involved in the development of this
adaptation. Specifically, peroxisome proliferator-activated receptor gamma coactivator-1
alpha (PGC-1), a family of transcriptional co-activators, plays an important role as a
modulator and in improving the metabolic rate through regular exercise [127].
The activation of PGC-1 alters the metabolic phenotype through interaction with the
nuclear respiratory factor and peroxisome proliferator-activated receptor (PPAR) [127,
128], which improves lipid metabolism, elevates mitochondrial biogenesis, and facilitates a
fast-to-slow fiber type switch. Therefore, an improved understanding of the activation of the
PGC-1 protein with exercise has implications beyond better athletic performance [129, 130],
including the possibility of providing targets for the treatment of muscle weakness in the
elderly, obese, and sick (e.g., mitochondrial myopathies and diabetes) [131-133]. The
expression/activity of PGC-1 could partly be caused by ROS and the activation of other
upstream signal molecules including AMP activated protein kinase, calcineurin, CaMKs, and
p38 MAPK [134-137], which are induced by exercise. Cellular ROS levels are regulated by
the inducible defense system including antioxidant enzymes and thiol reductants. These are
predominantly regulated by the transcription factor Nrf2 (nuclear erythroid 2-related factor 2)
and its cytosolic repressor protein, Keap1 [138]. The S-thiolation of Keap1, the cytoplasmic
inhibitor of Nrf2, by ROS or electrophiles results in the dissociation of the Keap1-Nrf2
complex. Once freed from inhibition by Keap1, Nrf2 translocates to the nucleus and binds to
the antioxidant-responsive element (ARE)-containing gene. Exercise induces expression of
various antioxidant enzymes via activation of Nrf2 in human muscles, which presumably
resulted from moderate oxidative stress in response to exercise [139]. In contrast, abnormal
Nrf2/ARE signaling is found in aged skeletal muscles, and this impairs the antioxidant system
[139]. NF-B and MAPK pathways in the skeletal muscle have also been shown to enhance
the gene expression of several antioxidant enzymes, such as mitochondrial superoxide
dismutase (MnSOD) [126]. Although there is still some controversy, moderate exercise can
lead to the mild activation of NF-B and MAPK (without inflammation and with phagocyte
infiltration) via moderate oxidative stress, which contributes to the up-regulation of
antioxidant capacity. In contrast, a high-dose of dietary antioxidants combined with a dietaryexercise regimen can counteract the oxidative stress that induces beneficial effects brought
about by moderate exercise. Therefore, there is some debate about the intake of dietary
antioxidants during exercise. Gomez-Cabrera et al. [140] demonstrated, in a human doubleblind study, that oral administration of vitamin C (1 g/d) suppresses the adaptation of
endurance capacity with exercise training for 8 weeks. In this case, the suppression of PGC1 expression, a key modulator of mitochondria biogenesis, was found. Ristow et al. [141]
also reported that administration of vitamin C (1000 mg/d) and vitamin E (400 IU/d) with a 4week intervention of exercise training significantly ameliorated improvements in glucose
infusion rates (GIR) during a hyperinsulinemic, euglycemic clamp along with the downregulation of PGC-1 and Mn-SOD. Therefore, the negative effects of antioxidant vitamin
would result from its capacity to reduce the exercise-induced expression of key transcription
factors involved in nutrient metabolism and antioxidation. However, some antioxidants
accelerate energy metabolism and insulin sensitivity induced by exercise through the
elevation in the level and activity of key modulators [140-143]. This may be responsible for
the specific actions of each compound in addition to antioxidant properties. Therefore, the
136
Wataru Aoi
Conclusion
The effect of oxidative stress on cellular signal transduction has been elucidated. We
found that oxidative stress is closely associated with pathogenesis, including muscle
dystrophy, insulin resistance, and disuse muscle atrophy. In addition, phenotypic changes that
occur after acute and chronic exercise are partly mediated by oxidative stress. However, there
are many proteins modified by oxidation, which have not been yet identified. Therefore, the
effect of oxidative stress on signal transduction via the post-translational modification of
proteins remains unclear, in contrast to the phosphorylated modification of proteins. Further
studies are needed to elucidate the physiological and pathological significance of the effect of
oxidative stress on skeletal muscles.
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
137
Feng, J., Xie, H., Meany, D. L. Thompson, L. V., Arriaga, E. A., and Griffin, T. J.
(2008). Quantitative proteomic profiling of muscle type-dependent and age-dependent
protein carbonylation in rat skeletal muscle mitochondria. J. Gerontol. A Biol. Sci. Med.
Sci., 63, 1137-1152.
Kato, Y., Miyake, K., Yamamoto, Y., Shimomura, H., Ochi, Y., Mori, T., and Osawa,
T. (2000). Preparation of a monoclonal antibody to N(epsilon)-(Hexanonyl)lysine:
application to the evaluation of protective effects of flavonoid supplementation against
exercise-induced oxidative stress in rat skeletal muscle. Biochem. Biophys. Res.
Commun., 274, 389-393.
Meany, D. L., Xie, H., Thompson, L. V., Arriaga, E. A., and Griffin, T. J. (2007).
Identification of carbonylated proteins from enriched rat skeletal muscle mitochondria
using affinity chromatography-stable isotope labeling and tandem mass spectrometry.
Proteomics, 7, 1150-1163.
Magherini, F., Abruzzo, P. M., Puglia, M., Bini, L., Gamberi, T., Esposito, F.,
Veicsteinas, A., Marini, M., Fiorillo, C., Gulisano, M., and Modesti, A. (2012).
Proteomic analysis and protein carbonylation profile in trained and untrained rat
muscles. J. Proteomics, 75, 978-992
Oh-Ishi, M., Ueno, T. and Maeda, T. (2003). Proteomic method detects oxidatively
induced protein carbonyls in muscles of a diabetes model Otsuka Long-Evans
Tokushima Fatty (OLETF) rat. Free Radic. Biol. Med., 34, 11-22.
Safdar, A., Hamadeh, M. J., Kaczor, J. J., Raha, S., Debeer, J., and Tarnopolsky, M. A.
(2010). Aberrant mitochondrial homeostasis in the skeletal muscle of sedentary older
adults. PLoS One, 5, e10778.
Sahlin, K., Shabalina, I. G., Mattsson, C. M., Bakkman, L., Fernstrm, M.,
Rozhdestvenskaya, Z., Enqvist, J. K., Nedergaard, J., Ekblom, B., and Tonkonogi, M.
(2010). Ultraendurance exercise increases the production of reactive oxygen species in
isolated mitochondria from human skeletal muscle. J. Appl. Physiol., 108, 780-787.
Viner, R. I., Hhmer, A. F., Bigelow, D. J., and Schneich, C. (1996). The oxidative
inactivation of sarcoplasmic reticulum Ca(2+)-ATPase by peroxynitrite. Free Radic.
Res., 24, 243-259.
Yamada, T., Mishima, T., Sakamoto, M., Sugiyama, M., Matsunaga, S., and Wada, M.
(2007). Myofibrillar protein oxidation and contractile dysfunction in hyperthyroid rat
diaphragm. J. Appl. Physiol., 102, 1850-1855.
Ji, L. L., Gomez-Cabrera, M. C. and Vina, J. (2007). Role of nuclear factor kappaB and
mitogen-activated protein kinase signaling in exercise-induced antioxidant enzyme
adaptation. Appl. Physiol. Nutr. Metab., 32, 930-935
Kabe, Y., Ando, K., Hirao, S., Yoshida, M., and Handa, H. (2005). Redox regulation of
NF-B activation: distinct redox regulation between the cytoplasm and the nucleus.
Antioxid. Redox. Signal, 7, 395403
Smith, H. J., Wyke, S. M. and Tisdale, M. J. (2004). Role of protein kinase C and NFkappaB in proteolysis-inducing factor-induced proteasome expression in C2C12
myotubes. Br. J. Cancer, 90, 1850-1857.
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J. and Sonenshein, G. E.
(2001). Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway
involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the
tumor suppressor PTEN. Oncogene, 20, 1287-1299.
138
Wataru Aoi
[22] Fridn, J., Sjstrm, M. and Ekblom, B. (1981). A morphological study of delayed
muscle soreness. Experientia, 37, 506-507.
[23] Fridn, J., Sjstrm, M. and Ekblom, B. (1983). Myofibrillar damage following intense
eccentric exercise in man. Int. J. Sports Med., 4, 170-176.
[24] Schwane, J. A., Johnson, S. R., Vandenakker, C. B. and Armstrong, R. B. (1983).
Delayed-onset muscular soreness and plasma CPK and LDH activities after downhill
running. Med. Sci. Sports Exerc., 15, 51-56.
[25] Newham, D. J., Jones, D. A. and Edwards, R. H. (1983). Large delayed plasma creatine
kinase changes after stepping exercise. Muscle Nerve, 6, 380-385.
[26] Maughan, R. J., Donnelly, A. E., Gleeson, M., Whiting, P. H., Walker, K. A., and
Clough, P. J. (1989). Delayed-onset muscle damage and lipid peroxidation in man after
a downhill run. Muscle Nerve, 12, 332-336.
[27] Tidball, J. G. (1995). Inflammatory cell response to acute muscle injury. Med. Sci.
Sports Exerc., 27, 1022-1032.
[28] Proske, U. and Morgan, D. L. (2001). Muscle damage from eccentric exercise:
mechanism, mechanical signs, adaptation and clinical applications. J. Physiol., 537,
333-345.
[29] Kyrlinen, H., Takala, T. E. and Komi, P. V. (1998). Muscle damage induced by
stretch-shortening cycle exercise. Med. Sci. Sports Exerc., 30, 415-420.
[30] Newham, D. J., McPhail, G., Mills, K. R. and Edwards, R. H. (1983). Ultrastructural
changes after concentric and eccentric contractions of human muscle. J. Neurol. Sci.,
61, 109-122.
[31] Aoi, W., Naito, Y., Takanami, Y., Kawai, Y., Sakuma, K., Ichikawa, H., Yoshida, N.
and Yoshikawa, T. (2004). Oxidative stress and delayed-onset muscle damage after
exercise. Free Radic. Biol. Med., 37, 480-487.
[32] Hollander, J., Fiebig, R., Gore, M., Ookawara, T., Ohno, H., and Ji, L. L. (2001).
Superoxide dismutase gene expression is activated by a single bout of exercise in rat
skeletal muscle. Pflgers Arch., 442, 426-434.
[33] Bloch-Damti, A. and Bashan, N. (2005). Proposed mechanisms for the induction of
insulin resistance by oxidative stress. Antioxid. Redox Signal, 7, 1553-1567.
[34] Paolisso, G., DAmore, A., Volpe, C., Balbi, V., Saccomanno, F., Galzerano, D.,
Giugliano, D., Varricchio, M., and D'onofrio, F. (1994). Evidence for a relationship
between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic
patients. Metabolism, 43, 1426-1429.
[35] Reid, M. B. and Li, Y. P. (2001). Cytokines and oxidative signalling in skeletal muscle.
Acta Physiol. Scand., 171, 225-232.
[36] Kadoglou, N. P., Perrea, D., Iliadis, F., Angelopoulou, N., Liapis, C., and Alevizos, M.
(2007). Exercise reduces resistin and inflammatory cytokines in patients with type 2
diabetes. Diabetes Care, 30, 719-721.
[37] Haus, J. M., Solomon, T. P., Marchetti, C. M., O'Leary, V. B., Brooks, L. M, Gonzalez,
F., and Kirwan, J. P. (2009). Decreased visfatin after exercise training correlates with
improved glucose tolerance. Med. Sci. Sports Exerc., 41, 12551260.
[38] Choi, K. M., Kim, T. N., Yoo, H. J., Lee, K. W., Cho, G. J., Hwang, T. G., Baik, S. H.,
Choi, D. S., Kim, S. M. (2009). Effect of exercise training on A-FABP, lipocalin-2 and
RBP4 levels in obese women. Clin. Endocrinol. (Oxf.), 70, 569574.
139
[39] Fruebis, J., Tsao, T. S., Javorschi, S., Ebbets-Reed, D., Erickson, M. R., Yen, F. T.,
Bihain, B. E., and Lodish, H. F. (2001). Proteolytic cleavage product of 30-kDa
adipocyte complement-related protein increases fatty acid oxidation in muscle and
causes weight loss in mice. Proc. Natl. Acad. Sci. US, 98, 2005-2010.
[40] Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide,
T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O.,
Vinson, C., Reitman, M. L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe,
K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T. (2001). The fatderived hormone adiponectin reverses insulin resistance associated with both
lipoatrophy and obesity. Nat. Med., 7, 941-946.
[41] Lexell, J., Taylor, C. C. and Sjstrm, M. (1988). What is the cause of the ageing
atrophy? Total number, size and proportion of different fiber types studied in whole
vastus lateralis muscle from 15- to 83-year-old men. J. Neurol. Sci., 84, 275-294.
[42] Larsson, L. and Ansved, T. (1995). Effects of ageing on the motor unit. Prog.
Neurobiol., 45, 397-458.
[43] Sakuma, K. and Yamaguchi, A. (2010). Molecular mechanisms in aging and current
strategies to counteract sarcopenia. Curr. Aging Sci., 3, 90-101.
[44] Conboy, I. M. and Rando, T. A. (2005). Aging, stem cells and tissue regeneration:
lessons from muscle. Cell Cycle, 4, 407-410.
[45] Combaret, L., Dardevet, D., Bchet, D., Taillandier, D., Mosoni, L., and Attaix, D.
(2009). Skeletal muscle proteolysis in aging. Curr. Opin. Clin. Nutr. Metab. Care, 12,
37-41.
[46] Ikemoto, M., Nikawa, T., Takeda, S., Watanabe, C., Kitano, T., Baldwin, K. M., Izumi,
R., Nonaka, I., Towatari, T., Teshima, S., Rokutan, K., and Kishi, K. (2001). Space
shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association
with activation of ubiquitin-proteasome pathway. FASEB J., 15, 1279-1281.
[47] Wing, S. S., Haas, A. L. and Goldberg, A. L. (1995). Increase in ubiquitin-protein
conjugates concomitant with the increase in proteolysis in rat skeletal muscle during
starvation and atrophy denervation. Biochem. J., 307, 639-645.
[48] DeMartino, G. N. and Ordway, G. A. (1998). Ubiquitin-proteasome pathway of
intracellular protein degradation: implications for muscle atrophy during unloading.
Exerc. Sport Sci. Rev., 26, 219-252.
[49] Tawa, N. E. Jr., Odessey, R. and Goldberg, A. L. (1997). Inhibitors of the proteasome
reduce the accelerated proteolysis in atrophying rat skeletal muscles. J. Clin. Invest.,
100, 197-203.
[50] Gomes-Marcondes, M. C. and Tisdale, M. J. (2002). Induction of protein catabolism
and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett., 180, 6974.
[51] Aoi, W., Takanami, Y., Kawai, Y., Naito, Y., and Yoshikawa, T. (2007). Contribution
of oxidative stress to protein catabolism in skeletal muscle. Med. Sci. Sports Exerc., 39,
S313.
[52] Onishi, Y., Hirasaka, K., Ishihara, I., Oarada, M., Goto, J., Ogawa, T., Suzue, N.,
Nakano, S., Furochi, H., Ishidoh, K., Kishi, K., and Nikawa, T. (2005). Identification of
mono-ubiquitinated LDH-A in skeletal muscle cells exposed to oxidative stress.
Biochem. Biophys. Res. Commun., 336, 799-806.
140
Wataru Aoi
[53] Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A.,
Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., Valenzuela, D.
M., DeChiara, T. M., Stitt, T. N., Yancopoulos, G. D., and Glass, D. J. (2001).
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294,
1704-1708.
[54] Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A., and Goldberg, A. L. (2001).
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.
Proc. Natl. Acad. Sci. US, 98, 14440-14445.
[55] Cai, D. S., Frantz, J. D., Tawa, N. E., Melendez, P. A., Oh, B. C., Lidov, H. G. W.,
Hasselgren, P. O., Frontera, W. R., Lee, J., Glass, D. J., and Shoelson, S. E. (2004).
IKK beta/NF-kappa B activation causes severe muscle wasting in mice. Cell, 119, 285298.
[56] Bar-Shai, M., Carmeli, E. and Reznick, A. Z. (2005). The role of NF-kappaB in protein
breakdown in immobilization, aging, and exercise: from basic processes to promotion
of health. Ann. N Y Acad. Sci., 1057, 431-447.
[57] Wyke, S. M. and Tisdale, M. J. (2005). NF-kappaB mediates proteolysis-inducing
factor induced protein degradation and expression of the ubiquitin-proteasome system
in skeletal muscle. Br. J. Cancer, 92, 711-721.
[58] Grune, T. and Davies, K. J. (2003). The proteasomal system and HNE-modified
proteins. Mol. Aspects Med., 24, 195-204.
[59] Grune, T., Merker, K., Sandig, G., and Davies, K. J. (2003). Selective degradation of
oxidatively modified protein substrates by the proteasome. Biochem. Biophys. Res.
Commun., 305, 709-718.
[60] Bar-Shai, M., Carmeli, E., Ljubuncic, P., and Reznick, A. Z. (2008). Exercise and
immobilization in aging animals: The involvement of oxidative stress and NF-B
activation. Free Radic. Biol. Med., 44, 202-214.
[61] Clavel, S., Coldefy, A. S., Kurkdjian, E., Salles, J., Margaritis, I., and Derijard, B.
(2006). Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in
aged rat Tibialis Anterior muscle. Mech. Ageing Dev., 127, 794-801.
[62] Li, Y. P., Schwartz, R. J., Waddell, I. D., Holloway, B. R., and Reid, M. B. (1998).
Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NFkappaB activation in response to tumor necrosis factor alpha. FASEB J., 12, 871-880.
[63] Li, X., Moody, M. R., Engel, D., Walker, S., Clubb, F. J. Jr., Sivasubramanian, N.,
Mann, D. L., and Reid, M. B. (2000). Cardiac-specific overexpression of tumor
necrosis factor-alpha causes oxidative stress and contractile dysfunction in mouse
diaphragm. Circulation, 102, 1690-1696.
[64] Scherer, N. M. and Deamer, D. W. (1986). Oxidative stress impairs the function of
sarcoplasmic reticulum by oxidation of sulfhydryl groups in the Ca2+-ATPase. Arch.
Biochem. Biophys., 246, 589-601.
[65] Gutierrez-Martin, Y., Martin-Romero, F. J., Inesta-Vaquera, F. A., Gutierrez-Merino,
C., and Henao, F. (2004). Modulation of sarcoplasmic reticulum Ca2+-ATPase by
chronic and acute exposure to peroxynitrite. Eur. J. Biochem., 271, 2647-2657.
[66] Dargelos, E., Brul, C., Stuelsatz, P., Mouly, V., Veschambre, P., Cottin, P., and
Poussard, S. (2010). Up-regulation of calcium-dependent proteolysis in human
myoblasts under acute oxidative stress. Exp. Cell Res., 316, 115-125.
141
[67] Whitman, S. A., Wacker, M. J., Richmond, S. R., and Godard, M. P. (2005).
Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal
muscle wasting with age. Pflgers Arch., 450, 437-446.
[68] Marzetti, E. and Leeuwenburgh, C. (2006). Skeletal muscle apoptosis, sarcopenia and
frailty at old age. Exp. Gerontol., 41, 1234-1238.
[69] Dirks, A. J. and Leeuwenburgh, C. (2004). Aging and lifelong calorie restriction result
in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, Xlinked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic. Biol. Med., 36, 2739.
[70] Siu, P. M., Wang, Y. and Always, S. E. (2009). Apoptotic signaling induced by H2O2mediated oxidative stress in differentiated C2C12 myotubes. Life Sci., 84, 468-481.
[71] D'Emilio, A., Biagiotti, L., Burattini, S., Battistelli, M., Canonico, B., Evangelisti, C.,
Ferri, P., Papa, S., Martelli, A. M., and Falcieri, E. (2010). Morphological and
biochemical patterns in skeletal muscle apoptosis. Histol. Histopathol., 25, 21-32.
[72] Sun, X. M., MacFarlane, M., Zhuang, J., Wolf, B. B., Green, D. R., and Cohen, G. M.
(1999). Distinct caspase cascades are initiated in receptor-mediated and chemicalinduced apoptosis. J. Biol. Chem., 274, 5053-5060.
[73] Chiou, T. J., Chu, S. T. and Tzeng, W. F. (2003). Protection of cells from menadioneinduced apoptosis by inhibition of lipid peroxidation. Toxicology, 191, 77-88.
[74] Always, S. E. and Siu, P. M. (2008). Nuclear apoptosis contributes to sarcopenia.
Exerc. Sport Sci. Rev., 36, 51-57.
[75] Zurlo, F., Larson, K., Bogardus, C., and Ravussin, E. (1990). Skeletal muscle
metabolism is a major determinant of resting energy expenditure. J. Clin. Invest., 86,
1423-1427.
[76] Bosy-Westphal, A., Eichhorn, C., Kutzner, D., Illner, K., Heller, M., and Mller, M. J.
(2003). The age-related decline in resting energy expenditure in humans is due to the
loss of fat-free mass and to alterations in its metabolically active components. J. Nutr.,
133, 2356-2362.
[77] Rooyackers, O. E., Adey, D. B., Ades, P. A., and Nair, K. S. (1996). Effect of age in
vivo rates of mitochondrial protein synthesis in human skeletal muscle. Proc. Natl.
Acad. Sci. US, 93, 15364-15369.
[78] Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro,
L., Cline, G. W., and Shulman, G. I. (2003). Mitochondrial dysfunction in the elderly:
possible role in insulin resistance. Science, 300, 1140-1142.
[79] Conley, K. E., Jubrias, S. A. and Esselman, P. C. (2000). Oxidative capacity and ageing
in human muscle. J. Physiol., 526, 203-210.
[80] Wei, Y., Chen, K., Whaley-Connell, A. T., Stump, C. S., Ibdah, J. A., and Sowers, J. R.
(2008). Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive
oxygen species. Am. J. Physiol. Regul. Integr. Comp. Physiol., 294, R673-R680.
[81] Paolisso, G., DAmore, A., Volpe, C., Balbi, V., Saccomanno, F., Galzerano, D.,
Giugliano, D., Varricchio, M., and D'Onofrio, F. (1994). Evidence for a relationship
between oxidative stress and insulin action in non-insulin-dependent (type II) diabetic
patients. Metabolism, 43, 1426-1429.
[82] Irrcher, I., Ljubicic, V. and Hood, D. A. (2009). Interactions between ROS and AMP
kinase activity in the regulation of PGC-1 transcription in skeletal muscle cells Am. J.
Physiol. Cell Physiol., 296, C116-C123.
142
Wataru Aoi
[83] Singh, I., Carey, A. L., Watson, N., Febbraio, M. A., and Hawley, J. A. (2008).
Oxidative stress-induced insulin resistance in skeletal muscle cells is ameliorated by
gamma-tocopherol treatment. Eur. J. Nutr., 47, 387-392.
[84] Maddux, B. A., See, W., Lawrence, J. C. Jr., Goldfine, A. L., Goldfine, I. D., and
Evans, J. L. (2001). Protection against oxidative stress-induced insulin resistance in rat
L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes, 50, 404410.
[85] Wei, Y., Chen, K., Whaley-Connell, A. T., Stump, C. S., Ibdah, J. A., and Sowers, Jr.
(2008). Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive
oxygen species. Am. J. Physiol. Regul. Integr. Comp. Physiol., 294, R673-R680.
[86] Scheede-Bergdahl, C., Penkowa, M., Hidalgo, J., Olsen, D. B., Schjerling, P., Prats, C.,
Boushel, R., and Dela, F. (2005). Metallothionein-mediated antioxidant defense system
and its response to exercise training are impaired in human type 2 diabetes. Diabetes,
54, 3089-3094.
[87] Schrauwen, P. and Hesselink, M. K. (2004). Oxidative capacity, lipotoxicity, and
mitochondrial damage in type 2 diabetes. Diabetes, 53, 1412-1417.
[88] Bonnard, C., Durand, A., Peyrol, S., Chanseaume, E., Chauvin, M. A., Morio, B.,
Vidal, H., and Rieusset, J. (2008). Mitochondrial dysfunction results from oxidative
stress in the skeletal muscle of diet-induced insulin-resistant mice. Clin. Invest., 118,
789-800.
[89] Henriksen, E. J. (2006). Exercise training and the antioxidant [alpha]-lipoic acid in the
treatment of insulin resistance and type 2 diabetes. Free Radic. Biol. Med., 40, 3-12.
[90] Kato, Y., Mori, Y., Makino, Y., Morimitsu, Y., Hiroi, S., Ishikawa, T., and Osawa, T.
(1999). Formation of Nepsilon-(hexanonyl)lysine in protein exposed to lipid
hydroperoxide. A plausible marker for lipid hydroperoxide-derived protein
modification. J. Biol. Chem., 274, 20406-20414.
[91] Osawa, T. and Kato, Y. (2005). Protective role of antioxidative food factors in
oxidative stress caused by hyperglycemia. Ann. N Y Acad. Sci., 1043, 440-451.
[92] McGarry, J. D. and Brown, N. F. (1997). The mitochondrial carnitine
palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem.,
244, 1-14.
[93] Campbell, S. E., Tandon, N. N., Woldegiorgis, G., Luiken, J. J., Glatz, J. F., and Bonen,
A. (2004). A novel function for fatty acid translocase (FAT)/CD36: involvement in
long chain fatty acid transfer into the mitochondria. J. Biol. Chem., 279, 36235-36241.
[94] Holloway, G. P., Bezaire, V., Heigenhauser, G. J., Tandon, N. N., Glatz, J. F., Luiken,
J. J., Bonen, A., and Spriet, L. L. (2006). Mitochondrial long chain fatty acid oxidation,
fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in
human skeletal muscle during aerobic exercise. J. Physiol., 571, 201-210.
[95] Ikeuchi, M., Koyama, T., Takahashi, J., and Yazawa, K. (2006). Effects of astaxanthin
supplementation on exercise-induced fatigue in mice. Biol. Pharm. Bull., 29, 21062110.
[96] Kirwan, J. P., Hickner, R. C., Yarasheski, K. E., Kohrt, W. M., Wiethop, B. V., and
Holloszy, J. O. (1992). Eccentric exercise induces transient insulin resistance in healthy
individuals. J. Appl. Physiol., 72, 2197-2202.
[97] Del Aguila, L. F., Krishnan, R. K., Ulbrecht, J. S., Farrell, P. A., Correll, P. H., Lang,
C. H., Zierath, J. R., and Kirwan, J. P. (2000). Muscle damage impairs insulin
143
144
Wataru Aoi
[113] Xia, R., Webb, J. A., Gnall, L. L., Cutler, K., and Abramson, J. J. (2003). Skeletal
muscle sarcoplasmic reticulum contains a NADH-dependent oxidase that generates
superoxide. Am. J. Physiol. Cell Physiol., 285, C215-C221.
[114] Sun, J., Xu, L., Eu, J. P., Stamler, J. S., and Meissner, G. (2001). Classes of thiols that
influence the activity of the skeletal muscle calcium release channel. J. Biol. Chem.,
276, 15625-15630.
[115] Zhang, J. Z., Wu, Y., Williams, B. Y., Rodney, G., Mandel, F., Strasburg, G. M., and
Hamilton, S. L. (1999). Oxidation of the skeletal muscle Ca2+ release channel alters
calmodulin binding. Am. J. Physiol. Cell Physiol., 276, C46-C53.
[116] Daiho, T. and Kanazawa, T. (1994). Reduction of disulfide bonds in sarcoplasmic
reticulum Ca2+-ATPase by dithiothreitol causes inhibition of phosphoenzyme
isomerization in catalytic cycle. This reduction requires binding of both purine
nucleotide and Ca2+ to enzyme. J. Biol. Chem., 269, 11060-11064.
[117] Gutierrez-Martin, Y., Martin-Romero, F. J., Inesta-Vaquera, F. A., Gutierrez-Merino,
C., and Henao, F. (2004). Modulation of sarcoplasmic reticulum Ca2+-ATPase by
chronic and acute exposure to peroxynitrite. Eur. J. Biochem., 271, 2647-2657.
[118] Xu, K. Y., Zweier, J. L. and Becker, L. C. (1997). Hydroxyl radical inhibits
sarcoplasmic reticulum Ca2+-ATPase function by direct attack on the ATP binding site.
Circ. Res., 80, 76-81.
[119] Viner, R. I., Krainev, A. G., Williams, T. D., Schoneich, C., and Bigelow, D. J. (1997).
Identification of oxidation-sensitive peptides within the cytoplasmic domain of the
sarcoplasmic reticulum Ca2+-ATPase. Biochemistry, 36, 7706-7716.
[120] Viner, R. I., Williams, T. D. and Schoneich, C. (2000). Nitric oxide-dependent
modification of the sarcoplasmic reticulum Ca-ATPase: localization of cysteine target
sites. Free Radic. Biol. Med., 29, 489-496.
[121] Fedorova, M., Kuleva, N. and Hoffmann, R. (2009). Reversible and irreversible
modifications of skeletal muscle proteins in a rat model of acute oxidative stress.
Biochim. Biophys. Acta, 1792, 1185-1193.
[122] Crowder, M. S. and Cooke, R. (1984). The effect of myosin sulphydryl modification on
the mechanics of fibre contraction. J. Muscle Res. Cell Motil., 5, 131-146.
[123] Haus, J. M., Carrithers, J. A., Trappe, S. W., and Trappe, T. A. (2007). Collagen, crosslinking, and advanced glycation end products in aging human skeletal muscle. J. Appl.
Physiol., 103, 2068-2076.
[124] Liu, D. F., Wang, D. and Stracher, A. (1990). The accessibility of the thiol groups on
G- and F-actin of rabbit muscle. Biochem. J., 266, 453-459.
[125] Williams, D. L. Jr. and Swenson, C. A. (1982). Disulfide bridges in tropomyosin Effect
on ATPase activity of actomyosin. Eur. J. Biochem., 127, 495-499.
[126] Ji, L. L., Gomez-Cabrera, M. C. and Vina, J. (2006). Exercise and hormesis: activation
of cellular antioxidant signaling pathway. Ann. N Y Acad. Sci., 1067, 425-435.
[127] Baar, K. (2004). Involvement of PPAR gamma co-activator-1, nuclear respiratory
factors 1 and 2, and PPAR alpha in the adaptive response to endurance exercise. Proc.
Nutr. Soc., 63, 269-273.
[128] Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y.,
Kohane, I., Costello, M., Saccone, R., Landaker, E. J., Goldfine, A. B., Mun, E.,
DeFronzo, R., Finlayson, J., Kahn, C. R., and Mandarino, L. J. (2003). Coordinated
145
146
Wataru Aoi
[142] Radk, Z., Pucsok, J., Mecseki, S., Csont, T., and Ferdinandy, P. (1999). Muscle
soreness-induced reduction in force generation is accompanied by increased nitric oxide
content and DNA damage in human skeletal muscle. Free Radic. Biol. Med., 26, 10591063.
[143] Gomez-Cabrera, M. C., Domenech, E. and Via, J. (2008). Moderate exercise is an
antioxidant: upregulation of antioxidant genes by training. Free Radic. Biol. Med., 44,
126-131.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 6
Abstract
Heat shock proteins (HSPs) are known as highly conserved prosurvival molecules.
HSPs have been demonstrated to contribute to improving several pathological alterations
in skeletal muscle. It has been reported that several HSPs attenuate contraction-induced
and age-related muscle damage in overexpression models. Activation of the ubiquitin
proteasome pathway induces skeletal muscle atrophy during immobilization, but
overexpression of HSPs can block the activity. In muscular dystrophy, enhanced HSP72
preserves muscle function and slows progression of muscle atrophy. Furthermore, the
enhancements of HSP72 in skeletal muscle potentially contribute to preventing obesityand hyperlipidemia-induced insulin resistance through regulation of inflammatory
factors, thereby preventing diabetes. This review focuses on recent progress in the
understanding of HSP functions in skeletal muscle.
Introduction
Metabolic disorders including hyperglycemia, hyperlipidemia, and hypertension are
attributed to individual genetic factors, aging, and lifestyle. Many people try to improve their
metabolic disorders through exercise or sports. It is well known that moderate exercise
contributes to health by preventing disease or improving the negative consequences of
conditions related to obesity, diabetes, or chronic inflammatory conditions. On the other hand,
intense exercise causes muscle fiber damage induced by excessive reactive oxygen species
(ROS), heat stress, and mechanical stretch. A multitude of physiologic stresses result in
148
Tomonori Ogata
protein damage and misfolded protein structure, leading to cellular injury and death in
skeletal muscle [1-3].
The cell has a number of protective measures to promote survival during periods of
environmental stress. One of the most highly conserved mechanisms of cellular protection
involves the expression of a polypeptide family known as heat shock proteins (HSPs). HSPs
ubiquitously express in multiple cells and act as molecular chaperones that have
cytoprotective functions: 1) to help protein folding in various intracellular compartments, 2)
to maintain structural proteins, 3) to translocate proteins across membranes into cellular
compartments, 4) to prevent protein aggregation, and 5) to degrade unstable proteins [4-6].
Their expression is increased when cells are exposed to elevated temperatures or other
stressors inducing protein damage. In addition, HSPs are involved in many signaling
pathways and regulate cell death [7, 8], ubiquitin proteasome [9, 10], inflammation [10, 11],
and insulin sensitivity [12] in skeletal muscle, indicating they play essential roles in muscle
function and several pathologies. In fact, the ability of muscular cells to induce HSPs
following stress is significantly decreased with aging [13, 14] and pathological conditions
such as diabetes [15].
Multiple HSPs are expressed in skeletal muscle. HSPs have normally been classified
according to molecular mass. The most prominent are small HSP (A- and B- crystallin and
HSP27), HSP40, HSP60, HSP70, HSP90, and HSP110 families. HSPs are expressed either
constitutively or can be induced by stress stimulation in skeletal muscle [4, 16]. This review
focuses mainly on HSP72, which has been well characterized in skeletal muscle and which
recent evidence suggests is functionally important to skeletal muscle.
149
HSP72 may play important roles in protection and repair of skeletal muscle from exerciseinduced stresses.
The level of HSP72 expression is associated with the features of fiber type in skeletal
muscle. Oxidative muscle, predominantly composed of slow-twitch fibers, tends to exhibit a
higher constitutive level of HSP72 than non-oxidative muscle, predominantly composed of
fast-twitch fibers. HSP72 protein content positively correlates with type I myosin heavy chain
(MyHC) content in skeletal muscle [20, 30, 31], which is found in greater abundance in
muscle with slow twitch fibers. For example, the content of HSP72 in soleus muscle,
predominately type I MyHC, is ~2 to 5 folds greater than in plantaris and tibialis anterior
muscles, predominately type II MyHC [20]. Histochemical studies have reported that HSP72
is constitutively expressed in slow-twitch fibers, but onl`y slightly expressed in fast-twitch
fibers (Figure 1).
Slow-twitch fibers are frequently recruited in muscle contraction accompanied by
mechanical, oxidative, or heat stress, suggesting that HSP72 expression is strongly influenced
by exogenous stresses. On the other hand, endogenous factors also seem to contribute to
HSP72 expression.
During the embryonic and early neonatal periods, muscle fibers receive polyinnervation
and most muscles have similar metabolic and contractile properties [32, 33]. Exogenous stress
levels in slow-twitch and fast-twitch fibers seem to be similar in embryonic muscle, but
HSP72 already is more highly expressed in slow-twitch fibers during the embryonic period
(Figure 1). In addition, expression of HSP72 is diminished when type I MyHC content is
reduced by treatment with thyroid hormone and clenbuterol [34, 35]. These findings indicate
that the expression of HSP72 is influenced not only by exogenous stresses, but also by
endogenous factors in muscles with slow twitch fibers, suggesting that it has functions other
than cellular protection.
In response to stress stimulation, several HSPs appear to show different localized
accumulation in skeletal muscle fiber. Paulsen et al. (2007 and 2009) observed that small
HSPs (B-crystallin and HSP27) are enhanced and rapidly translocate from the cytosolic
compartment to cytoskeletal/myofibrillar structures during and/or after exercise in human
skeletal muscle.
Similarly, HSP72 was enhanced and translocated in cytoskeletal/myofibrillar structures
after exercise, but the enhancement and translocation of HSP72 required a longer time than
both small HSPs [36, 37]. Larkins et al. (2012) reported that B-crystallin and HSP27 can
tightly bind to nonmembranous myofibrillar sites at a lower temperature than HSP72 when
skinned (sarcolemma removed ) fibers were exposed to heat stress (HSP27 and B-crystallin
at ~40 vs. HSP72 at 44) [38].
These findings indicate that there are differences in the processes controlling the binding
of two small HSPs and HSP72. Thus, enhancement level and time required for translocation
of HSPs appear to differ dependent on type of HSPs and stress condition, suggesting
differential roles of each HSP according to the physiological situation.
150
Tomonori Ogata
F, fibula; S, soleus; GS, superficial region of the gastrocnemius; GD, deep region of the gastrocnemius;
PS, superficial region of the plantaris; PD, deep region of the plantaris. Scale bars in the right panel
of each age indicate 50m, respectively.
Figure 1. Differential expression intensities of HSP72 in the skeletal muscle fibers. Immunohistochemical staining of plantaris muscles by anti-HSP72 and anti-type I MyHC antibodies was performed
on embryonic day 22 and postnatal day 56. The arrows indicate the same fibers in the serial sections at
each age.
151
of downhill running as well as an attenuation of the induced increment of glucose-6phosphate dehydrogenase in muscle and creatine phosphokinase activity in plasma [41].
The acquisition of muscle tolerance to contraction-induced muscle damage through
exercise training appears to be partially associated with molecular mechanisms that include
chaperone functions of HSPs as well as neuromuscular and morphological adaptations.
Several studies have reported that prolonged exercise training increases several molecular
chaperone proteins in skeletal muscle, including HSP27, HSP72 and GRP78 [16, 42].
Interestingly, prolonged exercise training notably increases HSP72 expression compared with
a single bout of acute exercise and the enhancement persists for more than 2 weeks after the
last training session (Figure 2).
The enhancement by acute exercise, however, returns to pre-exercise levels within 2
days. This long-term enhancement of HSP72 may be one of the adaptive cellular protective
responses to repeated daily exercise in skeletal muscle.
Cont, control; PE, post-acute exercise; DT, detraining; d, days. *P<0.05 compared with control; P<0.05
compared with PE-4d; #P 0.05 compared with DT-28d. Values are means SEM. Reproduced
from Ogata et al. (2009).
Figure 2. Prolonged exercise training but not a single bout of acute exercise induces long-term
enhancement of HSP72 expression in rat skeletal muscle. Changes of HSP72 levels after acute exercise
(left) and prolonged training (right). Protein expression in plantaris muscle was analyzed by western
blotting during periods after a single bout of acute treadmill running, or treadmill running training for 8
weeks.
In addition, HSP72 protein content positively correlated with muscle weight during
detraining in that study, suggesting contribution to maintaining muscle mass after exercise
training [42].
The enhancements of HSPs in response to acute stress in eukaryotic cells are primarily
induced by transcription and translation of HSPs mRNA accompanied by the activation of
heat shock transcription factors (HSFs) [27, 43, 44]. HSF-1 is known to be activated by
several stressors such as heat, oxidative stress, and denatured proteins, and increases HSP72
mRNA via interaction with the nuclear heat shock element in the promoter region of HSP72.
152
Tomonori Ogata
a
Figure 3. (Continued).
153
c
Cont, control; DT, detraining; d, days. Values are means SEM. There are no statistically significant
differences among all groups. Reproduced from Ogata et al. (2009).
Figure 3. The expression of HSF-1 (A) and HSF-2 (B) proteins and HSP72 mRNA (C) during
detraining. Protein expression determined by western blotting and mRNA by real-time PCR were
analyzed in plantaris muscle during detraining after treadmill running training for 8 weeks.
A second possible reason for the disconnect between HSP72 protein and mRNA is a
decline in the degradation rate of HSP72 that prolongs the half-life. Protein degradation rate
is strongly affected by changes in cellular stress and the half-life of HSP72 will likely be as
well. The duration of the HSP72 increase caused by transient stress stimulation is short in
mammalian cells [21, 49]. Mizzen et al. (1988) indicated that the half-life of HSP72 induced
by elevated temperature using rat embryo fibroblast cells was around 48 hours [49].
In fact, HSP72 content after an acute single bout of exercise returned to control levels
within 48 hours in rat skeletal muscle. If the half-life of HSP72 is extended by prolonged
exercise training, the notable increase of HSP72 during detraining periods might result from
the accumulation of HSP72 in the muscle. Several studies suggest that exercise training
attenuates the activation of the ubiquitin-proteasome pathway [53]. Prolonged exercise
training may affect the half-life of HSP72 because degradation of HSP72 is mediated by
154
Tomonori Ogata
ubiquitination [54]. However, there is no direct evidence regarding whether repeated stress
stimulation prolongs the half-life of HSP72.
Future studies are needed to determine the relation between the half-life of HSP72 and
exercise stimulation. Together, HSP72 content may be regulated not only by transcription, but
also by translational efficiency and protein half-life, depending upon changes in physiological
status within skeletal muscle.
155
156
Tomonori Ogata
display sectional atrophy, splitting, and increased steady-state levels of oxidative nucleic
damage [69, 70].
Thus, age-related mitochondrial DNA mutation is one of the leading candidates to induce
muscle fiber disruption and atrophy through ROS generation. To determine whether the
benefit from overexpression of mitochondrial HSP10 is related to the maintenance of
mitochondrial DNA and proteins in skeletal muscle, an examination of the relationship
between mitochondrial dysfunction and mitochondrial HSPs would provide major progress in
the prevention of age-related muscle atrophy, or sarcopenia.
Together, attenuated heat shock responses result from aging and cause chronic
inflammatory reactions and ROS production via organelle dysfunction, leading to age-related
muscle weakness [13]. As countermeasures, increasing HSPs can prevent or delay cellular
damage and protein degradation in aged skeletal muscle [59, 60].
These data demonstrate that the development of age-related muscle weakness and
atrophy is not inevitable. However, because specific triggers for impaired induction of HSPs
during aging remains unknown at the present time, further studies are required to elucidate
the underlying mechanisms.
157
following denervation [76]. These E3 ligases are known as representative marker proteins in
the ubiquitin proteasome pathway. Both MAFbx and MuRF1 are controlled directly or
indirectly by forkhead box O (FOXO) and nuclear factor-B (NF-B) [77, 78]. FOXO
signaling is able to account for ~40% of disuse muscle fiber atrophy [9]. Therefore, regulation
of FOXO and NF-B transcriptional activity plays an important role for protein degradation
via the ubiquitin proteasome pathway in muscle atrophy [9, 77].
HSP72 expression is downregulated in atrophying muscle during hindlimb
immobilization in mice [71]. On the other hand, HSP72 overexpression restrains progression
of disuse-related muscle fiber atrophy [9, 10, 79]. Senf et al. (2008) demonstrated that HSP72
overexpression by injection of an HSP72 expression plasmid abolished any increase of total
ubiquitinated proteins in muscle after seven days of immobilization [10]. In addition, they
reported that FOXO3a transcriptional activity was increased by 7-fold following seven days
of hindlimb immobilization, but was completely abolished in muscle injected with HSP72.
This interaction between HSP72 and FOXO3a is also demonstrated by the inhibition of
FOXO3a-dependent transcription of MAFbx by HSP72 [9, 10]. Similar to FOXO3a,
enhancement of NF-B transcriptional activity during muscle disuse is completely abolished
by HSP72 overexpression [10].
Pharmacological enhancement of HSP72 by 17-demethoxygeldanamycin can also
attenuate disuse-induced muscle atrophy and increasing -calpain and conjugated ubiquitin
levels [79].
Disuse-induced muscle atrophy in senescence can also be attenuated by enhancement of
HSP72 [80]. Dodd et al. (2009) reported that HSP72 overexpression by plasmid injection
prevented decreasing muscle fiber cross sectional area in soleus muscle in both young and
senescent rats following immobilization for 6 days.
In addition, HSP72 overexpression prevented the increase in NF-B and the decrease in
inhibitor of B (I-B) expression in senescent animals after immobilization [80]. Because
aging and reduced physical activity appear to have a synergistic effect on muscle wasting,
HSP72 might contribute to slower progression of age-related muscle deterioration.
HSP27 is also associated with the ubiquitin proteasome pathway during disuse-induced
muscle atrophy. Dodd et al. (2009) showed that hindlimb immobilization caused a 35%
decrease in the mean fiber cross sectional area of nontransfected muscle and an 18% decrease
in muscle transfected with an HSP27 expression plasmid, indicating attenuation of disuse
atrophy by HSP27 [11].
In this model, NF-B transcriptional activity increased ~4.5-fold following seven days of
immobilization, but HSP27 overexpression abolished this increase. In addition, HSP27
inhibited the disuse-induced increase in MuRF1 and atrogin-1 transcription. Unlike HSP72,
HSP27 had no effect on FOXO transactivation; HSP27 overexpression does not inhibit
disuse-induced FOXO-dependent reporter activity [11]. HSP27 seems to be a negative
regulator of NF-B in skeletal muscle in vivo, and inhibits MuRF1 and atrogin-1, and
attenuates skeletal muscle disuse atrophy. Therefore, HSP72 regulates the ubiquitin
proteasome pathway through both FOXO and NF-B, and HSP27 regulates it through NF-B
to attenuate disuse-related muscle atrophy.
These findings partly explain why heat stress treatment inhibits progression of disuseinduced muscle atrophy.
A common event in atrophying muscle is the loss of myonuclei or satellite cells via
apoptosis [81]. The change of physiological conditions related to muscle atrophy, such as
158
Tomonori Ogata
hindlimb unloading, denervation, and spinal cord transection, results in a decrease in the
number of myonuclei and an increase in apoptotic myonuclei in rat skeletal muscle [82-84].
Based on the concept that the nuclear domain, which represents the amount of cytosol per one
myonucleus, is unchanged following the alteration of muscle size, a decrease in myonucleus
number by apoptosis may cause muscle atrophy.
It is indicated that HSP72 is involved in suppression of the apoptotic cell death cascade at
different levels. It can inhibit cytochrome C release from mitochondria and activation of
various caspases [85, 86]. For example, overexpression of HSP72 appears to inhibit apoptosis
by blocking caspase activation and activity in lymphoid tumor cell lines [87]. In C2C12
muscle cells, the increase of HSP27 and HSP72 by heat treatment attenuates apoptotic cell
death in response to H2O2 [88]. Because HSP72 is downregulated in atrophying muscle, the
reduced anti-apoptotic effect of HSPs may accelerate disuse-induced atrophy.
Together, disuse-related muscle atrophy is associated with protein degradation by the
ubiquitin proteasome pathway and with nuclear elimination by apoptosis induction.
Increasing HSPs presumably can attenuate muscle atrophy by regulation of signal
transduction on ubiquitin and apoptosis pathways, and by helping protein folding as a
molecular chaperone.
159
of HSP72 by BGP-15 treatment not only ameliorates muscle wasting, but also can prolong
lifespan in severely dystrophic dko mice. These findings provide evidence that increasing
HSP72 in skeletal muscle can become a significant therapeutic target for ameliorating DMD
via interaction with SERCA.
In skeletal muscle from DMD mice, IB kinase (IKK)/ NF-B signaling is persistently
enhanced in immune cells and in regenerating muscle fibers, contributing to chronic
inflammation [93]. Heterozygous deletion of the p65 subunit of NF-B in the mdx mice
resulted in amelioration in muscle pathogenesis and enhanced regeneration of myofibers.
Similarly, genetic deletion and pharmacological inhibition of IKK attenuated muscle
pathology and augmented skeletal muscle regeneration in the mdx mice [93]. Thus,
depression of the IKK/ NF-B-related inflammatory response seems to be one of the
therapeutic targets for DMD. On the other hand, overexpression of HSP72 by transfection in
skeletal muscle can inhibit NF-B reporter activity and progression of muscle atrophy [10]. In
addition, pharmacological activation of HSP72 can depress phosphorylation of JNK in a
mouse obesity model [12].
Together, HSP72 seems to play a role in ameliorating muscular dystrophies by stabilizing
SERCA function and attenuating inflammatory responses. The anti-apoptotic effect of HSP72
[85, 88] and its role in protein folding and refolding [17] also might ameliorate progressive
DMD. Further studies are required to confirm the biological roles of HSP72 and other HSPs
on muscular dystrophies, because there is little information at this time.
160
Tomonori Ogata
treatment upregulates HSP72, the increase is attenuated by a high-fat diet [12]. In addition,
the level of HSP72 enhancement by exercise training is less pronounced in diabetic animals
than in non-diabetic animals. Endurance training induces the activation and expression of
HSF-1 which is a transcriptional regulator of HSPs, in skeletal muscle from non-diabetic
animals, but not in diabetic animals [102].
It is well known that HSP72 is downregulated in aged skeletal muscle [13, 64]. However,
in a recent study using vervet monkeys, it was observed that HSP72 was not decreased with
aging when animals consumed a low-fat diet and did not have chronic insulin resistance,
which indicated that aging did not reduce HSP72 in the absence of insulin resistance [103].
Therefore, inhibition at the transcriptional level with insulin resistance may be related to
downregulation of HSP72 in skeletal muscle, but the mechanism for the reduced HSP72
expression in diabetes still remains unclear.
The interaction between HSP72 and insulin resistance has been shown in animal models
that overexpress HSP72 [12]. Chung et al. (2008) reported that transgenic mice with musclespecific overexpression of HSP72 have lower levels of fasting glucose and insulin than wildtype mice after 16 weeks on a high-fat diet. In addition, mice with HSP72 overexpression
display notably improved glucose and insulin tolerance compared with wild-type mice when
placed on a high-fat diet [12]. Upregulation of HSP72 by BGP-15 treatment also shows the
same effects as the transgenic model on insulin resistance [12]. These findings indicate that
HSP72 counteracts the high-fat diet-induced development of insulin resistance and provide
supportive evidence for the beneficial effects of heat therapy.
Obesity- and hyperlipidemia-induced insulin resistance is characterized by increased
oxidative stress and inflammation. Increased ROS and peroxidation in lipid and protein are
common features observed in aging and obesity. Oxidative stress promotes activation of
inflammatory kinases, such as JNK and IKK-, and induces insulin resistance. The effect of
HSP72 on insulin resistance may be associated with its anti-inflammatory action. Activation
of the inflammatory factors JNK and IKK is commonly observed in diabetic patients, and
can cause phosphorylation of insulin receptor substrate (IRS)-1 on serine 307, leading to
insulin resistance [104, 105]. A high-fat diet leads to increased JNK phosphorylation, but this
increase is suppressed by overexpression of HSP72 [12] and heat treatment [98], supporting
other studies that show HSP72 to be a negative regulator of JNK. HSP72 antisense
oligonucleotides block HSP72 expression in NIH 3T3 cells and concomitantly abolish the
suppressive effect of JNK activation and apoptosis [106]. Increased HSP72 by antioxidant
lipoic acid in skeletal muscle also prevents diet-induced insulin resistance through JNK
inhibition [107]. It seems that HSP72 can modulate stress-activated signaling by directly
inhibiting JNK. To support the interaction between HSP72 and JNK, phosphorylation of JNK
in response to a high-fat diet is lower in slow-twitch muscle, which has constitutively higher
HSP72 content, than in fast-twitch muscle, which has lower HSP72 content [98].
In addition to the inhibition of inflammatory kinases, HSP72 may contribute to reduced
ROS generation through the mitochondrial respiratory function and concomitantly attenuate
the development of insulin resistance [108, 109]. In human skeletal muscle, HSP72 mRNA
expression positively correlates with the activity of mitochondrial enzymes such as citrate
synthase (CS) and -hydroxyacyl-CoA dehydrogenase (-HAD) [110]. Transgenic mice that
overexpress HSP72 show higher enzyme activities of CS and -HAD in skeletal muscle than
wild-type mice [12]. HSP72 overexpression in astrocytes actually reduces the induction of
161
ROS [108]. Thus, decreasing ROS generation by HSP72 may also account for reduced insulin
resistance following heat therapy.
These findings provide strong evidence that HSP72 induction in skeletal muscle can be a
therapeutic target for insulin resistance. Because HSP72 can be easily increased by heat
treatment (e.g. sauna, hot pack, and infrared radiation) and/or exercise, it potentially has wide
clinical application for diabetic patients.
Although there is little information about the relationship between other HSPs and
diabetes, a recent study by Marker et al. (2012) indicates that HSP60 released by adipocytes
contributes to the development of insulin resistance in skeletal muscle cells [111]. They
observed that plasma HSP60 levels were higher in obese than in non-obese men, and were
positively correlated with BMI and insulin resistance. HSP60 treatment impaired insulin
signal transduction, which decreased phosphorylation of AKT and GSK3, and decreased
insulin-stimulated glucose uptake in skeletal muscle cells. In addition, treatment of HSP60
activates ERK1/2, JNK, and NF-B and increases phosphorylation of IRS-1 [111]. Therefore,
contrary to the function of HSP72, HSP60 may function as a negative regulator of insulin
signaling via an inflammatory effect, and impair insulin sensitivity in skeletal muscle,
although there is no direct evidence in vivo at this time.
Endoplasmic reticulum (ER) stress has been assumed as one of the central mechanisms of
impaired insulin sensitivity in several cell types [112, 113]. ER stress is defined as an
accumulation of unfolded proteins in the ER, and the activation of ER stress signaling
(describe as unfolded protein response) is associated with apoptotic death of -cells in the
pancreas and impaired insulin signaling [112].
Heat stress
Exercise
Inactivity
HSP72
ROS
Myofiber
damage
Ubiquitin
proteasome
Sarcopenia
Inflammation
Protein
folding
Apoptosis
Disuse
atrophy
Muscle
dystrophies
Insulin
resistance
Figure 4. Functional roles of HSP72 in skeletal muscle. The schema summarizes the functions and
contributions of HSP72 in skeletal muscle described in this chapter.
162
Tomonori Ogata
Conclusion
In summary, several HSPs are expressed in skeletal muscle and the expression is altered
in accordance with physiological conditions. In particular, HSP72 appears to play multiple
roles in maintaining physiological function and ameliorating pathological conditions by: 1)
protecting muscle damage by several stressors including exercise, 2) ameliorating muscle
atrophies induced by aging, disuse, and pathological dystrophin deficiency, and 3)
ameliorating the development of insulin resistance in skeletal muscle (Figure 4). Accumulated
recent studies provide evidence that HSP72 is associated with the life cycle of multiple
proteins and cells through signal transduction pathways involving inflammation, the ubiquitin
proteasome, and apoptosis. Therefore, some health benefits acquired by exercise can be
accounted for in term of expression and functions of HSP72. A better understanding of the
role of HSPs in skeletal muscle promises to lead to clinical applications for multiple
physiological conditions.
References
[1]
[2]
[3]
[4]
[5]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
163
164
Tomonori Ogata
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
165
rapid accumulation of small heat shock proteins on myofibrils and a delayed HSP70
response in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol., 293, R844-R853.
Larkins, N. T., Murphy, R. M. and Lamb, G. D. (2012). Influences of temperature,
oxidative stress, and phosphorylation on binding of heat shock proteins in skeletal
muscle fibers. Am. J. Physiol. Cell Physiol., 303, C654-C665.
Belcastro, A. N. (1993). Skeletal muscle calcium-activated neutral protease (calpain)
with exercise. J. Appl. Physiol., 74, 1381-1386.
Niess, A. M. and Simon, P. (2007). Response and adaptation of skeletal muscle to
exercise--the role of reactive oxygen species. Front Biosci., 12, 4826-4838.
Schwane, J. A. and Armstrong, R. B. (1983). Effect of training on skeletal muscle
injury from downhill running in rats. J. Appl. Physiol., 55, 969-975.
Ogata, T., Oishi, Y., Higashida, K., Higuchi, M., and Muraoka, I. (2009). Prolonged
exercise training induces long-term enhancement of HSP70 expression in rat plantaris
muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol., 296, R1557-R1563.
Cotto, J. J., Kline, M. and Morimoto, R. I. (1996). Activation of heat shock factor 1
DNA binding precedes stress-induced serine phosphorylation. Evidence for a multistep
pathway of regulation. J. Biol. Chem., 271, 3355-3358.
Cotto, J. J. and Morimoto, R. I. (1999). Stress-induced activation of the heat-shock
response: cell and molecular biology of heat-shock factors. Biochem. Soc. Symp., 64,
105-118.
Kayani, A. C., Close, G. L., Jackson, M. J., and McArdle, A. (2008). Prolonged
treadmill training increases HSP70 in skeletal muscle but does not affect age-related
functional deficits. Am. J. Physiol. Regul. Integr. Comp. Physiol., 294, R568-R576.
Maloyan, A., Palmon, A. and Horowitz, M. (1999). Heat acclimation increases the
basal HSP72 level and alters its production dynamics during heat stress. Am. J.
Physiol., 276, R1506-R1515.
Moseley, P. L., Wallen, E. S., McCafferty, J. D., Flanagan, S., and Kern, J. A. (1993).
Heat stress regulates the human 70-kDa heat-shock gene through the 3'-untranslated
region. Am. J. Physiol., 264, L533-L537.
Petersen, R. B. and Lindquist, S. (1989). Regulation of HSP70 synthesis by messenger
RNA degradation. Cell Regul., 1, 135-149.
Mizzen, L. A. and Welch, W. J. (1988). Characterization of the thermotolerant cell. I.
Effects on protein synthesis activity and the regulation of heat-shock protein 70
expression. J. Cell Biol., 106, 1105-1116.
Xu, C., Lu, Y., Pan, Z., Chu, W., Luo, X., Lin, H., Xiao, J., Shan, H., Wang, Z., and
Yang, B. (2007). The muscle-specific microRNAs miR-1 and miR-133 produce
opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in
cardiomyocytes. J. Cell Sci., 120, 3045-3052.
Rao, P. K., Kumar, R. M., Farkhondeh, M., Baskerville, S., and Lodish, H. F. (2006).
Myogenic factors that regulate expression of muscle-specific microRNAs. Proc. Natl.
Acad. Sci. US, 103, 8721-8726.
McCarthy, J. J. and Esser, K. A. (2007). MicroRNA-1 and microRNA-133a expression
are decreased during skeletal muscle hypertrophy. J. Appl. Physiol., 102, 306-313.
Reid, M. B. (2005). Response of the ubiquitin-proteasome pathway to changes in
muscle activity. Am. J. Physiol. Regul. Integr. Comp. Physiol., 288, R1423-R1431.
166
Tomonori Ogata
[54] Kim, S. A., Chang, S., Yoon, J. H., and Ahn, S. G. (2008). TAT-Hsp40 inhibits
oxidative stress-mediated cytotoxicity via the inhibition of Hsp70 ubiquitination. FEBS
Lett., 582, 734-740.
[55] Touchberry, C. D., Gupte, A. A., Bomhoff, G. L., Graham, Z. A., Geiger, P. C., and
Gallagher, P. M. (2012). Acute heat stress prior to downhill running may enhance
skeletal muscle remodeling. Cell Stress Chaperones, 17, 693-705.
[56] Liu, C. C., Lin, C. H., Lin, C. Y., Lee, C. C., Lin, M. T., and Wen, H. C. (2013).
Transgenic overexpression of heat shock protein 72 in mouse muscle protects against
exhaustive exercise-induced skeletal muscle damage. J. Formos Med. Assoc., 112, 2430.
[57] Miyabara, E. H., Nascimento, T. L., Rodrigues, D. C., Moriscot, A. S., Davila, W. F.,
AitMou, Y., deTombe, P. P., and Mestril, R. (2012). Overexpression of inducible 70kDa heat shock protein in mouse improves structural and functional recovery of skeletal
muscles from atrophy. Pflgers Arch., 463, 733-741.
[58] Miyabara, E. H., Martin, J. L., Griffin, T. M., Moriscot, A. S., and Mestril, R. (2006).
Overexpression of inducible 70-kDa heat shock protein in mouse attenuates skeletal
muscle damage induced by cryolesioning. Am. J. Physiol. Cell Physiol., 290, C1128C1138.
[59] Broome, C. S., Kayani, A. C., Palomero, J., Dillmann, W. H., Mestril, R., Jackson, M.
J., and McArdle, A. (2006). Effect of lifelong overexpression of HSP70 in skeletal
muscle on age-related oxidative stress and adaptation after nondamaging contractile
activity. FASEB J., 20, 1549-1551.
[60] Kayani, A. C., Close, G. L., Broome, C. S., Jackson, M. J., and McArdle, A. (2008).
Enhanced recovery from contraction-induced damage in skeletal muscles of old mice
following treatment with the heat shock protein inducer 17-(allylamino)-17demethoxygeldanamycin. Rejuvenation Res., 11, 1021-1030.
[61] Kayani, A. C., Close, G. L., Dillmann, W. H., Mestril, R., Jackson, M. J., and McArdle,
A. (2010). Overexpression of HSP10 in skeletal muscle of transgenic mice prevents the
age-related fall in maximum tetanic force generation and muscle Cross-Sectional Area.
Am. J. Physiol. Regul. Integr. Comp. Physiol., 299, R268-R276.
[62] Koh, T. J. and Escobedo, J. (2004). Cytoskeletal disruption and small heat shock
protein translocation immediately after lengthening contractions. Am. J. Physiol. Cell
Physiol., 286, C713-C722.
[63] Lexell, J., Taylor, C. C. and Sjostrom, M. (1988). What is the cause of the ageing
atrophy? Total number, size and proportion of different fiber types studied in whole
vastus lateralis muscle from 15- to 83-year-old men. J. Neurol. Sci., 84, 275-294.
[64] Ogata, T., Machida, S., Oishi, Y., Higuchi, M., and Muraoka, I. (2009). Differential cell
death regulation between adult-unloaded and aged rat soleus muscle. Mech. Ageing
Dev., 130, 328-336.
[65] Snow, L. M., McLoon, L. K. and Thompson, L. V. (2005). Adult and developmental
myosin heavy chain isoforms in soleus muscle of aging Fischer Brown Norway rat.
Anat. Rec. A Discov. Mol. Cell Evol. Biol., 286, 866-873.
[66] Fu, M. H. and Tupling, A. R. (2009). Protective effects of Hsp70 on the structure and
function of SERCA2a expressed in HEK-293 cells during heat stress. Am. J. Physiol.
Heart Circ. Physiol., 296, H1175-H1183.
167
[67] Deocaris, C. C., Kaul, S. C. and Wadhwa, R. (2006). On the brotherhood of the
mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chaperones,
11, 116-128.
[68] Harman, D. (1972). The biologic clock: the mitochondria? J. Am. Geriatr. Soc., 20,
145-147.
[69] Wanagat, J., Cao, Z., Pathare, P., and Aiken, J. M. (2001). Mitochondrial DNA deletion
mutations colocalize with segmental electron transport system abnormalities, muscle
fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. FASEB J., 15, 322332.
[70] Bua, E. A., McKiernan, S. H., Wanagat, J., McKenzie, D., and Aiken, J. M. (2002).
Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J.
Appl. Physiol., 92, 2617-2624.
[71] Naito, H., Powers, S. K., Demirel, H. A., Sugiura, T., Dodd, S. L., and Aoki, J. (2000).
Heat stress attenuates skeletal muscle atrophy in hindlimb-unweighted rats. J. Appl.
Physiol., 88, 359-363.
[72] Takeda, I., Fujino, H., Murakami, S., Kondo, H., Nagatomo, F., and Ishihara, A. (2009).
Thermal preconditioning prevents fiber type transformation of the unloading inducedatrophied muscle in rats. J. Muscle Res. Cell Motil., 30, 145-152.
[73] Yamaguchi, T., Suzuki, T., Arai, H., Tanabe, S., and Atomi, Y. (2010). Continuous
mild heat stress induces differentiation of mammalian myoblasts, shifting fiber type
from fast to slow. Am. J. Physiol. Cell Physiol., 298, C140-C148.
[74] Costelli, P. and Baccino, F. M. (2003). Mechanisms of skeletal muscle depletion in
wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr. Opin. Clin.
Nutr. Metab. Care, 6, 407-412.
[75] Cao, P. R., Kim, H. J. and Lecker, S. H. (2005). Ubiquitin-protein ligases in muscle
wasting. Int. J. Biochem. Cell Biol., 37, 2088-2097.
[76] Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A.,
Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., Valenzuela, D.
M., DeChiara, T. M., Stitt, T. N., Yancopoulos, G. D., and Glass, D. J. (2001).
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294,
1704-1708.
[77] Cai, D., Frantz, J. D., Tawa, N. E., Jr., Melendez, P. A., Oh, B. C., Lidov, H. G.,
Hasselgren, P. O., Frontera, W. R., Lee, J., Glass, D. J., and Shoelson, S. E. (2004).
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell, 119, 285298.
[78] Sandri, M., Sandri, C., Gilbert, A., Skurk, C., Calabria, E., Picard, A., Walsh, K.,
Schiaffino, S., Lecker, S. H., and Goldberg, A. L. (2004). Foxo transcription factors
induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Cell, 117, 399-412.
[79] Lomonosova, Y. N., Shenkman, B. S. and Nemirovskaya, T. L. (2012). Attenuation of
unloading-induced rat soleus atrophy with the heat-shock protein inducer 17(allylamino)-17-demethoxygeldanamycin. FASEB J., 26, 4295-4301.
[80] Dodd, S., Hain, B. and Judge, A. (2009). Hsp70 prevents disuse muscle atrophy in
senescent rats. Biogerontology, 10, 605-611.
168
Tomonori Ogata
[81] Bruusgaard, J. C., Liestol, K. and Gundersen, K. (2006). Distribution of myonuclei and
microtubules in live muscle fibers of young, middle-aged, and old mice. J. Appl.
Physiol., 100, 2024-2030.
[82] Dupont-Versteegden, E. E., Murphy, R. J., Houle, J. D., Gurley, C. M., and Peterson, C.
A. (2000). Mechanisms leading to restoration of muscle size with exercise and
transplantation after spinal cord injury. Am. J. Physiol. Cell Physiol., 279, C1677C1684.
[83] Leeuwenburgh, C., Gurley, C. M., Strotman, B. A., and Dupont-Versteegden, E. E.
(2005). Age-related differences in apoptosis with disuse atrophy in soleus muscle. Am.
J. Physiol. Regul. Integr. Comp. Physiol., 288, R1288-R1296.
[84] Siu, P. M. and Alway, S. E. (2005). Mitochondria-associated apoptotic signalling in
denervated rat skeletal muscle. J. Physiol., 565, 309-323.
[85] Saleh, A., Srinivasula, S. M., Balkir, L., Robbins, P. D., and Alnemri, E. S. (2000).
Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol., 2, 476-483.
[86] Kelly, S., Zhang, Z. J., Zhao, H., Xu, L., Giffard, R. G., Sapolsky, R. M., Yenari, M.
A., and Steinberg, G. K. (2002). Gene transfer of HSP72 protects cornu ammonis 1
region of the hippocampus neurons from global ischemia: influence of Bcl-2. Ann.
Neurol., 52, 160-167.
[87] Mosser, D. D., Caron, A. W., Bourget, L., Denis-Larose, C., and Massie, B. (1997).
Role of the human heat shock protein hsp70 in protection against stress-induced
apoptosis. Mol. Cell Biol., 17, 5317-5327.
[88] Xiao, R., Ferry, A. L. and Dupont-Versteegden, E. E. (2011). Cell death-resistance of
differentiated myotubes is associated with enhanced anti-apoptotic mechanisms
compared to myoblasts. Apoptosis, 16, 221-234.
[89] Gehrig, S. M., van der Poel, C., Sayer, T. A., Schertzer, J. D., Henstridge, D. C.,
Church, J. E., Lamon, S., Russell, A. P., Davies, K. E., Febbraio, M. A., and Lynch, G.
S. (2012). Hsp72 preserves muscle function and slows progression of severe muscular
dystrophy. Nature, 484, 394-398.
[90] Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. (2002). Function and genetics of
dystrophin and dystrophin-related proteins in muscle. Physiol. Rev., 82, 291-329.
[91] Nicolas-Metral, V., Raddatz, E., Kucera, P., and Ruegg, U. T. (2001). Mdx myotubes
have normal excitability but show reduced contraction-relaxation dynamics. J. Muscle
Res. Cell Motil., 22, 69-75.
[92] Goonasekera, S. A., Lam, C. K., Millay, D. P., Sargent, M. A., Hajjar, R. J., Kranias, E.
G., and Molkentin, J. D. (2011). Mitigation of muscular dystrophy in mice by SERCA
overexpression in skeletal muscle. J. Clin. Invest., 121, 1044-1052.
[93] Acharyya, S., Villalta, S. A., Bakkar, N., Bupha-Intr, T., Janssen, P. M., Carathers, M.,
Li, Z. W., Beg, A. A., Ghosh, S., Sahenk, Z., Weinstein, M., Gardner, K. L., RafaelFortney, J. A., Karin, M., Tidball, J. G., Baldwin, A. S., and Guttridge, D. C. (2007).
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle
degeneration in Duchenne muscular dystrophy. J. Clin. Invest., 117, 889-901.
[94] Song, X. M., Ryder, J. W., Kawano, Y., Chibalin, A. V., Krook, A., and Zierath, J. R.
(1999). Muscle fiber type specificity in insulin signal transduction. Am. J. Physiol., 277,
R1690-R1696.
169
[95] DeFronzo, R. A., Gunnarsson, R., Bjorkman, O., Olsson, M., and Wahren, J. (1985).
Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulindependent (type II) diabetes mellitus. J. Clin. Invest., 76, 149-155.
[96] Knowler, W. C., Barrett-Connor, E., Fowler, S. E., Hamman, R. F., Lachin, J. M.,
Walker, E. A., and Nathan, D. M. (2002). Reduction in the incidence of type 2 diabetes
with lifestyle intervention or metformin. N Engl. J. Med., 346, 393-403.
[97] Hooper, P. L. (1999). Hot-tub therapy for type 2 diabetes mellitus. N Engl. J. Med.,
341, 924-925.
[98] Gupte, A. A., Bomhoff, G. L., Swerdlow, R. H., and Geiger, P. C. (2009). Heat
treatment improves glucose tolerance and prevents skeletal muscle insulin resistance in
rats fed a high-fat diet. Diabetes, 58, 567-578.
[99] Geiger, P. C. and Gupte, A. A. (2011). Heat shock proteins are important mediators of
skeletal muscle insulin sensitivity. Exerc. Sport Sci. Rev., 39, 34-42.
[100] Gupte, A. A., Bomhoff, G. L., Touchberry, C. D., and Geiger, P. C. (2011). Acute heat
treatment improves insulin-stimulated glucose uptake in aged skeletal muscle. J. Appl.
Physiol., 110, 451-457.
[101] Henstridge, D. C., Forbes, J. M., Penfold, S. A., Formosa, M. F., Dougherty, S., Gasser,
A., de Courten, M. P., Cooper, M. E., Kingwell, B. A., and de Courten, B. (2010). The
relationship between heat shock protein 72 expression in skeletal muscle and insulin
sensitivity is dependent on adiposity. Metabolism, 59, 1556-1561.
[102] Atalay, M., Oksala, N. K., Laaksonen, D. E., Khanna, S., Nakao, C., Lappalainen, J.,
Roy, S., Hanninen, O., and Sen, C. K. (2004). Exercise training modulates heat shock
protein response in diabetic rats. J. Appl. Physiol., 97, 605-611.
[103] Kavanagh, K., Wylie, A. T., Chavanne, T. J., Jorgensen, M. J., Voruganti, V. S.,
Comuzzie, A. G., Kaplan, J. R., McCall, C. E., and Kritchevsky, S. B. (2012). Aging
does not reduce heat shock protein 70 in the absence of chronic insulin resistance. J.
Gerontol. A Biol. Sci. Med. Sci., 67, 1014-1021.
[104] Vinayagamoorthi, R., Bobby, Z. and Sridhar, M. G. (2008). Antioxidants preserve
redox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin
signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine
phosphorylation and insulin resistance. J. Endocrinol., 197, 287-296.
[105] Wellen, K. E. and Hotamisligil, G. S. (2005). Inflammation, stress, and diabetes. J.
Clin. Invest., 115, 1111-1119.
[106] Park, H. S., Lee, J. S., Huh, S. H., Seo, J. S., and Choi, E. J. (2001). Hsp72 functions as
a natural inhibitory protein of c-Jun N-terminal kinase. EMBO J., 20, 446-456.
[107] Gupte, A. A., Bomhoff, G. L., Morris, J. K., Gorres, B. K., and Geiger, P. C. (2009).
Lipoic acid increases heat shock protein expression and inhibits stress kinase activation
to improve insulin signaling in skeletal muscle from high-fat-fed rats. J. Appl. Physiol.,
106, 1425-1434.
[108] Ouyang, Y. B., Xu, L. J., Sun, Y. J., and Giffard, R. G. (2006). Overexpression of
inducible heat shock protein 70 and its mutants in astrocytes is associated with
maintenance of mitochondrial physiology during glucose deprivation stress. Cell Stress
Chaperones, 11, 180-186.
[109] Houstis, N., Rosen, E. D. and Lander, E. S. (2006). Reactive oxygen species have a
causal role in multiple forms of insulin resistance. Nature, 440, 944-948.
170
Tomonori Ogata
[110] Bruce, C. R., Carey, A. L., Hawley, J. A., and Febbraio, M. A. (2003). Intramuscular
heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2
diabetes: evidence that insulin resistance is associated with a disturbed antioxidant
defense mechanism. Diabetes, 52, 2338-2345.
[111] Marker, T., Sell, H., Zillessen, P., Glode, A., Kriebel, J., Ouwens, D. M., Pattyn, P.,
Ruige, J., Famulla, S., Roden, M., Eckel, J., and Habich, C. (2012). Heat shock protein
60 as a mediator of adipose tissue inflammation and insulin resistance. Diabetes, 61,
615-625.
[112] Eizirik, D. L., Cardozo, A. K. and Cnop, M. (2008). The role for endoplasmic reticulum
stress in diabetes mellitus. Endocr. Rev., 29, 42-61.
[113] Rieusset, J., Chauvin, M. A., Durand, A., Bravard, A., Laugerette, F., Michalski, M. C.,
and Vidal, H. (2012). Reduction of endoplasmic reticulum stress using chemical
chaperones or Grp78 overexpression does not protect muscle cells from palmitateinduced insulin resistance. Biochem. Biophys. Res. Commun., 417, 439-445.
[114] Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O.,
Gorgun, C. Z., and Hotamisligil, G. S. (2006). Chemical chaperones reduce ER stress
and restore glucose homeostasis in a mouse model of type 2 diabetes. Science, 313,
1137-1140.
[115] Kammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferre,
P., and Foufelle, F. (2009). GRP78 expression inhibits insulin and ER stress-induced
SREBP-1c activation and reduces hepatic steatosis in mice. J. Clin. Invest., 119, 12011215.
[116] Rao, R. V., Peel, A., Logvinova, A., del Rio, G., Hermel, E., Yokota, T., Goldsmith, P.
C., Ellerby, L. M., Ellerby, H. M., and Bredesen, D. E. (2002). Coupling endoplasmic
reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS
Lett., 514, 122-128.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 7
Abstract
Myofibrils are the contractile components of the skeletal muscle fibers. However, the
myofibril does not simply work as a contractile apparatus, but also plays a crucial role in
the sensing of mechanical stress and capture of the signaling molecules. The giant
sarcomeric protein, titin, spans from the Z-disc to the M-band, and acts as a mechanical
sensor. Muscle-specific RING finger 1, E3 ubiquitin ligase, and calpain-3 bind to titin
and contribute to the stress response of myofibrils following the structural change of titin.
Lack of these proteins causes a severe myopathic disease. The Z-disc mediates the
important signalings related to the muscle characteristics via various proteins, including
calcineurin, the protein phosphatase that activates the slow-twitch muscle-specific gene
transcription in a Ca2+ concentration-dependent manner, and the muscle LIM protein, the
transcriptional co-regulator of the basic helix-loop-helix responsible consequence such as
MyoD and myogenin. Furthermore, some differences are found in the core structure of
sarcomere, including a thicker Z-disc, a longer thin actin filament, and longer titin, in
slow-twitch compared to fast-twitch muscle fibers. These properties potentially affect the
mechanical strength and the signal transduction. The adaptive transformation is
postulated on the structural organization as well as its components, in accordance with
the level and the pattern of the muscle activity.
Corresponding author: Department of Health and Sport Sciences, Graduate School of Medicine, Osaka University,
1-17 Machikaneyama-cho, Toyonaka City, Osaka 560-0043, Japan, E-mail: kawaco@space.hss.osaka-u.ac.jp;
Phone: +81-6-6850-6018; Fax: +81-6-6850-6030.
172
Fuminori Kawano
Introduction
Skeletal muscle fibers undergo hypertrophy in response to enhanced mechanical stress
[1-6], a key physiological stimulus resulting from muscle activities such as exercise and
resistance training. It is well known that the level of the protein synthesis is critical for the
production of the muscle-specific proteins and contractile cytoskeletons, leading to
hypertrophy or atrophy, if the workload is altered from the sedentary level [7-9]. In addition
to the influences in the muscle mass, metabolic properties are improved by the repeated use of
muscles. In animal studies, chronic voluntary running up-regulates the mitochondrial
function, enabling it to prevent the age-related accumulation of body fat [10-12]. These facts
highlight the importance of muscle activity for the regulation of muscle characteristics.
However, it has not been fully understood how muscle fibers sense the mechanical stress
produced by the contraction and force development, and transmit the signals to the pathways
providing the muscular characteristics. To date, many studies have been carried out to
investigate the precise structure of myofibrils of skeletal muscle fibers, which form an
essential cytoskeleton generating the muscle force. In addition, it has recently been
demonstrated that myofibril does not simply function as a contractile apparatus, but it also
plays a crucial role in sensing of the mechanical stress and capture of the signaling molecules.
Skeletal muscles can be classified into mainly two types: those exhibiting a slow-twitch
contractile property with oxidative metabolism and those with a fast-twitch contractile
property with anaerobic metabolism [13-15]. In mammals, slow-twitch muscles generally
exhibit tonic activity in order to maintain the posture of an individual against the force of
gravity. In contrast, fast-twitch muscles are activated during locomotion and generate great
force. The level and the pattern of the applied mechanical stress, as well as the required
strength of myofibrils, appear to be different between slow- and fast-twitch muscles, which
may lead to the different potential to respond of the signaling pathways to the physiological
stimuli due to their unique components. This chapter reviews the current information on
myofibrillar structure, protein components and their roles in the regulation of slow- and fasttwitch skeletal muscle fibers
173
Figure 1. Main structure of sarcomere. Typical differences in sarcomeres between fast- (upper) and
slow- (lower) twitch muscle fibers are shown. Note that thicker Z-disc [67], longer thin filament [31,
36], longer titin [21] and differential pattern of M-lines [61-63] are marked in the sarcomere of slowtwitch fibers.
The giant protein titin, also known as connectin, is the main source of elasticity in the
sarcomeres [16, 17]. The titin filament are inserted, along with the N-terminus, in the Z-disc
and reach all way to the center of the sarcomere, the M-band. This length corresponds to half
of a sarcomere, ~1.0 m or more depending on the stretch of the sarcomeres. Titin is
expressed in potentially millions of different isoforms generated by alternative splicing from
the transcript of a single titin gene [18, 19]. The size of the human titin isoforms sequenced so
far ranges from 625 kDa for the low-abundance novex-3 isoform up to 3,700 kDa for the
human soleus titin [20], which is the so-called N2A isoform characteristic of skeletal muscles.
In a set of ~40 different rabbit skeletal muscles, the size range of N2A isoforms was found to
be ~3,300 to 3,700 kDa [21]. The extensible segment of titin begins ~100 nm from the Z-disc
center and bridges the remaining I-band portion of the sarcomere as an elastic spring until it
enters the thick filament (A-band) portion. The PEVK domain, a part of the I-band region,
plays a key role for the elasticity of sarcomeres [17]. The static tension is not developed by
sarcomeres while the PEVK domain is kept at the slack position, even though the myofibrils
are stretched up to approximately 2.5 m of the sarcomere length [17, 22]. Beyond this
length, a linear extension of the titin PEVK domain generates an exponential increase in the
static tension. The N2A domain locates at a neighbor in the N-terminal end of the PEVK
domain in the I-band [16, 17]. This elastic property of titin is the main route of mechanical
continuity through relaxed sarcomeres and is also important for the elastic recovery of resting
sarcomere length after active shortening or passive stretch of the muscle. The tension
developed by such connection centers the A-band in the sarcomere.
174
Fuminori Kawano
Degradation of titin and/or nebulin induces the thick filament misalignment on stretch or
activation, leading to a failure in the effective force production [23].
Thin Filament
The major component of the thin filament is F-actin. The three-component complex
consists of troponin I, troponin C and troponin T localized on the actin filament and interferes
with the mediation of muscle contraction [24, 25] (Figure 2). By shifting the position along
thin filaments in response to Ca2+ binding to troponin C, tropomyosin exposes the myosinbinding site on actin, starting the formation of cross-bridge cycling and contractile action [2630]. The length of the thin filament ranges from ~0.95 to ~1.30 m from the Z-disc in skeletal
muscles [31-33]. Slow-twitch muscle has a longer thin filament than fast-twitch muscle
(Figure 1).
Nebulin is a giant protein spanning most of the length of the thin filament with the Cterminus anchored at the Z-disc to N-terminal region, the M1M2M3 domain, directed toward
the pointed-end [34] (Figure 2). The number of its modular nebulin motifs closely correlates
with the I-band length [35]. Some recent studies in nebulin-deficient mouse models [36, 37]
and human myopathy patients [38] have shown an important contribution of nebulin to the
regulation of the thin filament length. Witt et al. [37] reported that shorter thin filaments with
an average length of ~0.8 m were noted in nebulin-deficient muscle, compared with the
length in wild type muscle, which was a constant 1.2 m. Such reduction in the thin filament
length caused the severe effects in the Ca2+ sensitivity and force production of myofibrils
[38].
Stabilization of the thin filament is also regulated by actin capping proteins (Figure 2).
CapZ is a barbed-end capping protein at the Z-disc, and organizes the correct assembly of the
filaments at the Z-disc [39]. Tropomodulin (Tmod), a pointed-end capping protein, binds
strongly to actin in the presence of tropomyosin [40]. Four isoforms of Tmod are present
within mammals (Tmod1-4). Tmod1 is expressed in terminally differentiated cells, such as
striated muscles, Tmod2 is expressed in neuronal tissues, Tmod3 is expressed ubiquitously,
and Tmod4 is restricted to skeletal muscles in mammals [41-47]. Tmod1, -3 and -4 potentially
regulate the length of the thin filaments in skeletal muscle sarcomeres. Nebulin does not
extend all the way to the pointed-end of the thin filament from the Z-disc, because the actinbinding site, the M1M2M3 domain, of nebulin is localized at a relatively fixed distance ~0.9
m from the Z-disc [31, 32]. Previous studies [31-33, 48-50] have indicated that Tmod
regulates the length of a relatively more dynamic, nebulin-free, pointed-end extension,
whereas nebulin mechanically and chemically stabilizes an ~0.9- to ~1.0-m-long core region
of the thin filament. The localization site of Tmod from the Z-disc ranges from 1.11 m in the
extensor digitorum longus muscle, to 1.22 m in the soleus muscle, to 1.26 m in the
embryonic flank, which is consistent with the lengths of the thin filaments found in rabbit and
mouse muscles [31, 36]. Furthermore, the length of the thin filament is inversely correlated
with the composition of the type IIx myosin heavy chain in human skeletal muscles, also
suggesting a shorter thin filament in fast-twitch muscles [51]. The sarcomere with a shorter
thin filament can generate the maximum force when it is lengthened to approximately 2.5 m
(the optimal sarcomere length) and thereafter the force production decreases as the sarcomere
length is stretched more [51].
175
Figure 2. Thin filament organization. Thin filament, formed by the polymerization of actin molecules,
are capped with CapZ at the barbed-end in the Z-disc [39], and with Tmod at the pointed-end [40].
Nebulin binds to the thin filament, spans through most of the thin filament length, and stabilizes the
filament. The length of nebulin-free region observed in the pointed-end is regulated by Tmod, resulting
in the differential mechanical property (see the main text for precise details). Tropomyosin is also
known as actin binding protein, interfering the interaction of actin and myosin heavy chain. Binding of
Ca2+ to TnC triggers the formation of cross-bridges and contraction subsequently start [26-30]. Tmod,
tropomodulin; TnI, troponin I; TnC, troponin C; TnT, troponin T.
However, the optimal sarcomere length becomes slightly longer in the sarcomere with a
longer thin filament. Therefore, slow-twitch muscles enable the development of tension rather
at the stretched position.
Tmod1 null cardiac myocytes in the embryonic mouse heart completely fail to assemble
myofibrils and do not beat, resulting in the failure of cardiac looping and aborted
development [52, 53]. In contrast, Tmod1 is not necessary for the assembly of myofibrils or
for the development of the skeletal muscles, since Tmod3 and -4 compensate for the absence
of Tmod1 structurally [32]. However, the absence of Tmod1 results in depressed isometric
force production and systemic locomotor deficits in the skeletal muscles of Tmod1 null mice
[32].
Thick Filament
The thick filament is composed of myosin heavy chain and light chain. These myosins
form hexamers characterized by a two-headed structure, a flexible neck region containing the
myosin light chains and a long coiled-coil tail domain. The catalytic domain of the myosin
heavy chain contains the ATPase and actin-binding activities [54].
Myosin-binding protein C (MyBPC), an accessory protein of the thick filament, directly
interacts with both thin and thick filaments [55, 56]. To date, three isoforms have been
identified in skeletal muscles and cardiac myocytes. MyBPC1 and -2 are restricted to skeletal
muscles, whereas MyBPC3 is expressed exclusively in cardiac myocytes [57, 58]. MyBPC3
modulates the formation of cross-bridges in cardiac myocytes and directly affect the Ca2+
sensitivity in the myofibril [56]. An increase in Ca2+ sensitivity has been shown in the
MyBPC3-deficient myocardium [59]. In skeletal muscles, the mutations in the skeletal
muscle isoforms of MyBPC were also identified in patients suffering from a disorder
characterized by congenital contractures of the hands and feet [60].
176
Fuminori Kawano
Z-disc
The Z-disc is the essential structure for the production of tension in muscle fibers [65].
The major component of many of proteins of the Z-disc is -actinin, which plays a key role in
mediating, integrating and preserving the Z-disc [66]. The thin actin filaments, titin and
nebulin directly attach to the Z-disc. Z-discs can be observed in the longitudinal view, across
the sarcomere, of electron micrographs as dense bands with a width ranging between 30 and
50 nm in fast-twitch muscles, and 100 and 140 nm in slow-twitch and cardiac muscles [67]
(Figure 1). Z-disc widths are determined by the number of layers of -actinin, which can
range from two to six or more. Interestingly, the thinner Z-discs in fast-twitch muscles
produce the higher shortening velocities of sarcomeres. Many proteins have recently been
shown to associate with the Z-discs, and to be capable of sensitizing a mechanical stress and
subsequently mediating a signal transduction (see the sections below). The fiber type-related
differences in the thickness of Z-discs may result from the adaptation to specific activities and
stimuli.
The -actinin family comprises four members, with -actinin-1 and -4 being expressed in
non-muscle tissues and -actinin-2 and -3 being striated muscle-specific isoforms [68]. Slowtwitch skeletal muscle fibers express predominantly -actinin-2, whereas the expression of actinin-3 is restricted to fast-twitch fibers [69]. Mutant mice lacking -actinin-3 show the
compensatory replacement of missing actinin with -actinin-2, suggesting that -actinin-3 is
not a critical component for myofibril formation in fast-twitch fibers [70, 71]. In practical
terms, -actinin-3 appears to be a functionally dispensable isoform, since 16% of the world
population have a congenital deficiency of -actinin-3 [72]. In addition, it has been reported
that -actinin-3 polymorphism is closely related to the work performance in athletes [73],
although some studies have reported that the presence of -actinin-3 does not influence the
characteristics of muscle contraction [74, 75]. Nevertheless, it is the current consensus that
exercise stimulates the shift of the isoform from -actinin-3 to -2, in association with an
elevated aerobic capacity and fiber phenotype transition of fast-to-slow in fast-twitch skeletal
muscles [76, 77]. These phenomena are strongly supported by the results obtained by
MacArthur et al. [71], who demonstrated that loss of -actinin-3 triggers a shift in the muscle
metabolism toward the more efficient aerobic pathway and an increase in the intrinsic
endurance performance.
177
-actinin is not only a constitutive Z-disc component but also a mediator of the particular
signaling which stimulates the slow-twitch-specific oxidative function in skeletal muscles.
Desmin, the most abundant intermediate filament protein in muscle, surrounds Z-discs
and supports their integration [78]. It is also known that expression of desmin precedes that of
other muscle-specific structural genes and some transcriptional factors, such as MyoD,
myogenin and MRF4, during muscular development [78-80]. However, it has been
demonstrated that desmin is not essential for the myogenic commitment in the early stage of
myogenesis and myofibrillogenesis, because somites and myotomes form normally and
mononucleated muscle precursor cells migrate during embryogenesis in the absence of
desmin [81]. After migration, primary and secondary myotube formation occurs in an
identical manner in desmin null and wild type mice. The Z-discs are formed normally, and the
subsequent assembly of the associated proteins is sufficient in desmin null mice [81, 82]. The
first discernable effects of the lack of desmin are seen on the muscle fiber phenotype after
birth [81]. These effects are mainly observed in the slow-twitch muscles, soleus and
diaphragm, where this modification is accompanied by morphological and biochemical
changes. These include a variability in fiber diameter, the presence of central nuclei, the
presence of crescent-shaped sarcolemmal masses, and a decrease in the amount of type II
myosin heavy chain. Despite the normal myogenesis and myofibrogenesis, skeletal muscles
of desmin null mice exhibit less strength and less fatigue resistance compared with either
heterozygous or control littermates [81]. Moreover, it is noted that muscle fibers with centralnucleation, a marker of regeneration and degeneration, are observed more frequently in
association with increases in age or mechanical loading by exercise [81, 83]. These
pathological changes are more massive in the slow-twitch skeletal muscle.
Desmin intermediate filaments connect parallel myofibrils transversely and have been
implicated in the correction for the direction of the tension transmission within the muscle
fiber. A recent study [83] has further found that muscles lacking desmin become
progressively stiffer, accumulate increased collagen, and exhibit an increased expression of
genes involved in extracellular matrix turnover. It has also been reported that cell populations
identified by the muscle progenitor marker, 7-integrin, are reduced, while cell populations
identified by the fibroadipogenic marker, Sca-1, are elevated in the skeletal muscle of desmin
null mice. In addition, the increase in macrophage infiltration is also pronounced in desmin
null mice. Most myopathies are complicated with fibrosis during an insufficient regeneration
followed by degeneration usually triggered by mechanical stress. Fibrosis is one of the
debilitating factors which interfere with muscle regeneration and the normalization of muscle
function. Desmin plays a key role in developing the integrity of myofibrils and providing
resistance against cytoskeletal ruptures.
178
Fuminori Kawano
The stimulation of proteolysis observed during atrophy is shown to occur at least in part
due to an activation of the ubiquitin-proteasome pathway [84]. The addition of ubiquitin to a
protein substrate acts a signal to mediate the degradation of a specific target. Three distinct
enzymatic components are required, an E1 ubiquitin-activating enzyme, an E2 ubiquitinconjugating enzyme, and an E3 ubiquitin-ligating enzyme. The E3 ubiquitin ligases are the
components which confer substrate specificity. Many different E3 enzymes have been
identified, and each molecule modulates the ubiquitination of a distinct set of substrates [85].
The E3 ubiquitin ligases, MuRF1 and atrogin-1, also known as muscle atrophy F box
protein (MAFbx), were first identified as key factors up-regulated in several atrophy models
by Bodine et al. [7]. Numerous studies [86-90] have since demonstrated the increased
expression of MuRF1 and atrogin-1 in the atrophied skeletal muscles following the
experimental models. Mice lacking MuRF1 (MuRF1/) or MAFbx (MAFbx/) appear
phenotypically normal. However, under atrophying conditions, significantly less muscle mass
is lost in either MuRF1/ or MAFbx/ animals in comparison to their control littermates
[7].
Three MuRFs (MuRF1, -2 and -3) were characterized by Centner et al. [91]. MuRF1
associates with M-lines via binding to the Ig-domains of titin (Figure 3). Overexpression of
MuRF1 results in disruption of the MuRF1-binding domain of titin, suggesting that MuRF1
plays a role in titin turnover [92]. MuRF3, which is a microtubule-associated and stabilizing
protein exclusively expressed in cardiac and skeletal muscles, localizes at Z-discs in skeletal
muscles [93]. It has also been shown that MuRF1 binds to a multitude of sarcomere proteins,
such as telethonin and myotilin, implying that MuRF1 may participate in a pathway for the
degradation of these proteins [94]. MuRF2 co-localizes with MuRF1 at the M-line and with
the microtubule-associated MuRF3 [95, 96]. However, a Z-disc localization has not been
shown yet.
Atrogin-1 interacts strongly and specifically with the Z-disc protein, -actinin-2, in
cardiac myocytes [97], although the localization and the interaction in skeletal muscles are
still unknown. Recently, MyoD [98] and calcineurin [97] have been identified as the
substrates of atrogin-1 in myoblasts and cardiac myocytes.
Calpain
Calpain is a member of the non-lysosomal Ca2+-dependent cysteine proteases, which are
involved in many cellular processes mediating the selective proteolysis of target proteins [99].
Calpain-1, -2 and -3 are predominantly expressed in skeletal muscles [100]. Calpain-1 colocalizes with -actinin at the Z-discs, and an interaction is further detected with titin at two
positions within the I-band and the lateral edge of the Z-disc [101]. This association of
calpain with sarcomeric proteins might serve a role in the signaling and the mechanical
transmission.
Calpain-3 is a skeletal muscle-specific isoform that is distinct from other calpains in
terms of its Ca2+ dependence and rapid autolysis [102]. In addition to the four universal
domains of the ubiquitous calpains, calpain-3 has three additional unique insertion sequences
called NS, IS1, and IS2 [103]. IS1 includes three autolytic sites that are involved in the
regulation of its activity [104]. The IS2 domain contains a nuclear translocation signal and a
binding site for titin [105].
179
Figure 3. Titin binding proteins. MuRF1 [91] and capain-3 [108] localize at M-band by binding to titin.
MuRF1 plays a role for the titin turnover [92], whereas capain-3 shows its proteolytic activity in many
cytoskeletal proteins following autolysis [108]. MARPs bind to the N2A domain of titin in I-band,
mechanically flexible region sensitizing a force [113, 114]. In accordance with mechanical stress
applied by contraction, the I-band region of titin, including the PEVK domain, transforms and releases
MARPs, which are replaced with a competitive binding of capain-3 to this region [115]. MARPs
translocate to a nucleus and contribute to stress response-related transcription. MuRF1, muscle-specific
RING finger 1; Capn3, calpain-3; MARP, muscle ankyrin repeat protein.
180
Fuminori Kawano
Ojima et al. [115] demonstrated that calpain-3 shifts its location from the M-line to the
N2A region of titin when the sarcomere is extended, suggesting that calpain-3 functions as a
sarcomere-length sensor in co-operation with titin. They also generated calpain-3-knockin
mice in which caplpain-3 is proteolytically inactive but structurally intact. The enlargement in
the proportion of central-nucleated muscle fibers was noted within the skeletal muscles of the
knockin mice, in accordance with the progression of age [116]. Exercise further promoted the
damage in the single muscle fibers. Translocation of MARP from the N2A region of titin is
thought to contribute to the adaptive response to physical stress, although the accumulation of
mutated calpain-3 in the N2A region was very slow and the level of induction of MARP was
lower than that in wild type mice. The mislocalization of calpain-3 has also been observed in
LGMD2A patients.
181
ALP enhances the ability of -actinin to crosslink actin filaments, indicating that ALP
stabilizes actin filament anchorage at Z-discs [127] (Figure 4B).
Knock-down of ALP expression affects the expression of MyoD and myogenin, resulting
in the inhibition of muscle differentiation [128]. Therefore, ALP is thought to play a crucial
role in the formation of myofibrils and transcriptional regulation in muscle differentiation.
182
Fuminori Kawano
specific genes such as myoglobin and troponin I slow [133, 134]. Together with the gene
transcription, activation of the calcineurin-NFATc mechanism specifically induces a muscle
fiber property switch toward a slow-twitch phenotype and oxidative metabolism, further
resulting in an enhancement of fatigue resistance. An increase in the number of slow-twitch
muscle fibers has been noted in mutant mice with forced overexpression of calcineurin [135].
On the other hand, lack of calcineurin A leads to a significant decrease in slow-twitch and
oxidative fibers. It has also been reported that slow-twitch fibers fail to respond to the
increased workload in skeletal muscle-specific calcineurin B1-null mice [136].
Motor nerve-driven tonic activity (10-15 Hz) in slow-twitch muscle fibers results in the
sustained elevation of intracellular Ca2+ concentration in a range between 100 and 300 nM,
and such sustained increase in intracellular Ca2+ has been predicted to activate calcineurin
[137]. In fast-twitch muscle fibers, the resting intracellular Ca2+ concentration is maintained
at ~50 nM. High amplitude (~1 M) Ca2+ transients induced by motor nerve activity are
predicted to be of insufficient duration to evoke the calcineurin signaling [138]. Chronic
stimulation of motor nerves innervating the fast-twitch muscle fibers results in a sustained
elevation of intracellular Ca2+ concentration and fast-to-slow fiber transformation [139, 140].
Chin et al. [133] further demonstrated that the inhibition of calcineurin activity by
administration of cyclosporin A induced a slow-to-fast fiber transformation with a
dependence on switching of the combinational transcription activity of NFATc and MEF2.
These previous findings clearly indicate the critical roles of calcineurin-NFATc mechanisms
in slow-twitch muscle-specific gene transcription.
Liu et al. [141] demonstrated the localization of NFATc in a resting state and in response
to stimulation by techniques using green fluorescent protein-fused or constitutively active
mutant NFATc. Interestingly, in resting skeletal muscle fibers, NFATc was localized at the
sarcomeric Z-discs and absent from nuclei (Figure 4C). They also simulated the activity
patterns typical of slow-twitch muscle by electrical stimulation with a continuous or trained
pulse at 10 Hz, resulting in the nuclear appearance of fluorescent foci of green fluorescent
protein-fused NFATc. However, nuclear translocation of NFATc did not occur with either
continuous 1 Hz stimulation or with the fast-twitch fiber activity pattern of short-duration
trains at 50 Hz.
Recently, Frey et al. [142] discovered a family of striated muscle-specific calcineurinbinding proteins, the calsarcins, which localize to the Z-disc of the sarcomere [143] (Figure
4C). The calsarcin family consists of 3 members. Calsarcin-1 is expressed in the adult heart
and in slow-twitch fibers of skeletal muscles. Calsarcin-2, also known as myozenin 1 [144]
or FATZ-1 [145], and calsarcin-3 are exclusively expressed in fast-twitch fibers of skeletal
muscles [142, 146]. Calsarcins also bind to -actinin, cypher, telethonin, -filament [142,
146] and myotilin [147] to localize to the Z-disc. Myozenin 1 and calsarcin-1 suppress the
NFATc-related transcription via the inhibition of calcineurin activity [148]. Thus, myozenin
1-knockout mice display a switching of fiber phenotype to the slow-twitch type as well as a
drastic improvement in the oxidative function in skeletal muscle fibers. Physical performance
as measured by the voluntary running distances is enhanced in the knockout mice. The lack of
calsarcin-1 also leads to an increase in the calcineurin activity, which in turn is associated
with an expansion of slow-twitch skeletal muscle fibers [149]. Together, these observations
strongly suggest a model in which the Z-disc-associated proteins modulate the intracellular
signal transduction due to the muscle activities.
183
184
Fuminori Kawano
muscle-specific gene transcription [130, 133, 134], it is predicted that MLP plays a crucial
role in the transcription of key genes related to the response and adaption of skeletal muscle
fibers to physiological stimuli.
Remodeling of Myofibrils
Mechanical stress on muscle fibers produced by the contraction and force development
causes myofibrillar disorganization, in which Z-disc streaming, Z-disc smearing and Z-disc
disruption occur as morphological hallmarks of delayed onset muscle soreness [166].
According to the results of previous studies using animal models simulating enhanced
mechanical stress, the desmin intermediate filaments are affected shortly after the contractile
stimulation [167-169], indicating that the morphology of desmin is a possible marker of
myofibrillar damage. For example, a focal initial loss of immunohistochemical staining for actinin, titin and nebulin is correlated with the strong expression of desmin, particularly in the
disorganized region after eccentric exercise [170]. However, an addition of new sarcomeres to
the pre-existing sarcomeres is also observed following contractile stimulation. These
observations suggest a model in which an adaptive remodeling of myofibrils is induced after
the damage. These processes lead to sarcomerogenesis and lengthening of the myofibrils
[170-173], and subsequently prevent soreness through an additional loading. A novel
contribution of two related proteins in the myofibrillar remodeling is reviewed below.
Myotilin
Myotilin, which is highly expressed in skeletal muscles and moderately expressed in the
heart [174], is localized at the Z-discs by binding to -actinin [175], actin [176], -filament
[177] and myozenin 1 [147].
Carlsson et al. [178] reported that the intensity of myotilin staining was markedly
increased in areas with myofibrillar alterations induced by eccentric exercise. Myotilin was
strongly detected in sites ranging from a single broadened Z-disc up to large lesions involving
several consecutive sarcomeres. The staining also co-existed with the areas showing increased
phalloidin staining, in which a temporary lack of -actinin, titin and nebulin was noted [170,
173]. The addition of new sarcomeres was postulated to occur either by the splitting of an
existing Z-disc or by the reintegration of -actinin and related Z-disc proteins (titin and
nebulin) in a single broadened sarcomere. They further found that the staining of myotilin
was more abundant in the Z-discs of slow- than fast-twitch skeletal muscle fibers. The
difference in the width of Z-discs may cause the alteration in the amount of myotilin captured
within the Z-discs, because the thickness of Z-discs in slow-twitch fibers is broader than that
in fast-twitch fibers [67]. It is predicted that the different fiber types will show at least some
differences in their ability to respond to the mechanical stress produced by contractile
activity.
Pathogenic mutations in the myotilin gene cause a subset of myofibrillar myopathies and
LGMD type 1A (LGMD1A) that are characterized by streaming of Z-discs and degeneration
of muscle fibers [179-181]. Typically, the skeletal muscle of LGMD1A patients exhibits
185
multiple myopathic features, variant fiber size, fiber splitting, central nuclei, fibrosis, rimmed
autophagic vesicles and Z-disc streaming. Myotilin binds to -actinin via its N-terminus,
whereas the sites for the -filament binding and for dimerization locate at the C-terminus
[175, 177, 180]. This dimerization is necessary for the actin binding activity. Myotilin
protects the thin filament from pharmacologically induced disassembly by cross-linking the
actin filaments alone or in concert with -actinin [176]. Further, the expression of terminally
truncated myotilin fragments in differentiating muscle cells leads to myofibril disarray,
indicating an indispensable role for the full length myotilin in stabilization and anchorage of
thin filaments. In LGMD1A patients of the first-identified pedigree, one allele exhibits a
cytosine-to-thymidine mutation at position 450 of the myotilin gene, resulting in a Thr57Ile
substitution in exon 2 [180]. Since the -actinin binding activity of mutated myotilin is still
present, the mutation may interfere with the thin filament organization and lead to the failure
in the correct Z-disc integration. A recent study [182] has identified a novel mutation on exon
9 of the myotilin gene, in which the amount of myotilin monomer is increased in the patient
muscle, but the homodimer of myotilin is decreased, resulting in a clinically typical
LGMD1A pathology. Mutant myotilin in this patient further exhibits decreased binding
activity to -actinin. These observations indicate that the pathologic mutation of myotilin
loosens the complex formed by actin bundlers at the Z-discs, leading to a decrease in the
strength and the ability of the Z-discs to resist mechanical stress during muscle contraction.
In contrast to the abnormalities of myotilin function seen in LGMD1A patients, the lack
of myotilin does not influence muscle mass, fiber size or force development [66]. Myotilin is
part of a small subfamily that includes palladin and myopalladin [174]. These functionally
redundant proteins exist in all striated muscles, and their expression may be sufficient to
overcome the lack of myotilin. Myopalladin, the Z-disc protein, indirectly coordinates the
assembly of an intra-Z-disc meshwork by tethering the thin filaments via -actinin [183].
Similarly to the LGMD1A patients, the transgenic mice expressing human myotilin with a
Thr57Ile mutation also exhibit severe myopathies, Z-disc streaming, excess myofibrillar
vacuolization and plaque-like myofibrillar aggregation [184]. Surprisingly, the degree of
myofibrillar aggregation is different in various muscles.
Gastrocnemius and extensor digitorum longus muscles, composed predominantly of fasttwitch fibers, are heavily populated with the aggregation in the transgenic mice, whereas
slow-twitch muscles such as the soleus and diaphragm are completely spared of any abnormal
myopathology [184]. Furthermore, a physiological deficit in muscle stiffness, as determined
by the level of force reduction after lengthening contraction, is also noted in the fast-twitch
extensor digitorum longus muscle, while no reduction is induced in the slow-twitch soleus
muscle. These data again suggest an abundance of compensatory proteins or protective
signaling based on the thicker Z-discs of slow-twitch fibers.
186
Fuminori Kawano
association with the severe atrophy of slow-twitch soleus muscle [187, 192]. The level of
HSP25 expression, in contrast, is elevated in response to the ablation of synergists, leading to
mechanical overload and muscular hypertrophy [186]. Forced expression of HSP25 can
attenuate the disuse-induced atrophy in the slow-twitch muscle due to the inhibition of
MuRF1 and atrogin-1 transcription, as well as NF-B activation [193]. These studies clearly
indicate the importance of HSP25 in the regulation of skeletal muscle mass, although some
studies [190, 194] have documented that several HSPs are not affected by unloading.
Molecular chaperoning is a common function of HSPs. Particularly in HSP25, the
phosphorylation triggers the formation of an oligomeric complex, which is necessary for the
chaperone action and resistance against cellular stress [195]. Serine 15 and 86 (Ser15 and
Ser86, respectively) are the major phosphorylated sites of HSP25 [195-197]. In rodents, three
kinds of phosphorylated HSP25, i.e., the non-, single- (at either Ser15 or 86 site) and dual- (at
both Ser15 and 86 sites) phosphorylated forms, have been identified [186, 197-201]. The
lengthening contraction causes an immediate increase of the dual phosphorylation of HSP25
and translocation from the soluble to the insoluble fraction [200]. In humans, the eccentric
exercise stimulates the accumulation of HSP27 in the Z-discs and the disrupted sarcomeres
[202]. Non- and single-phosphorylated HSP25s are generally expressed in the cytoplasm of
normal skeletal muscles. Ser86 is thought to be a constantly phosphorylated site of HSP25
[203]. Mechanical stress applied to the skeletal muscle promotes the phosphorylation
selectively at Ser15, leading to the production of a dual-phosphorylated form and
translocation from the cytoplasm to myofibrils. Under normal conditions, HSP25 forms a
large molecular complex, likely a homo- or hetero-oligomer, with a size ranging from 600800 kDa. However, the mechanical stress stimulates the dissociation of a free single HSP25
from the complex, and an interaction directly or indirectly with desmin, not actin or actinin, in
the disorganized region of the myofibrils. Interestingly, in these lesions, desmin forms a Zdisc-like striated structure, but the interval distance is longer than in normal sarcomeres,
suggesting that the onset of sarcomerogenesis follows the disruption of myofibrillar protein
organization. Progression of phosphorylation might alter the HSP25 function toward
myofibrillar protection.
187
188
Fuminori Kawano
length, as stated above. Even though the tension development is still very low when the ankle
joint angle is 160o, it becomes capable of generating force when the ankle joint is 140o within
2 weeks of tail suspension [3].
It is clear that the number of sarcomeres is decreased in response to chronic shortening of
the muscle length and the sarcomere length at a given angle of the ankle joint is increased [3].
Therefore, the soleus muscle fibers are slightly stretched even though the ankle joints are still
plantarflexed during tail suspension. The mean sarcomere lengths at ~60o on the floor before
tail suspension and at ~90o on the 14th day during tail suspension are similar, suggesting that
the static force can be produced by the remodeling of sarcomeres even without an external
load.
Shah et al. [217] tested the roles of desmin in regulating the lengthening- or shorteninginduced remodeling of sarcomeres in the hindlimb muscles of mice. The immobilization of
ankle joints by plaster casting at the plantarflexed position caused an increase in the serial
sarcomere number of the tibialis anterior and extensor digitorum longus, due to the
lengthening of the muscles.
A consistent result was observed in the shortened soleus. Surprisingly, the muscles in
desmin null mice showed similar remodeling of sarcomeres, with an increase in the serial
sarcomere number in dorsiflexors, and inversely in the soleus. This fact indicates that desmin
is not essential for sarcomerogenesis in terms of the adaptation of muscle length in mature
skeletal muscles. However, it cannot be excluded that a defect in desmin may enhance the
myofibrillar damage and activates a regeneration/degeneration cycle [81-83, 217].
Elastic Properties
Discharges of Ia and II afferent nerve fibers in response to a given stretch of rat soleus
muscle fibers are increased after 14 days of tail suspension, suggesting that increased
connective tissues could contribute to a better transmission of passive mechanical stretch to
the muscle spindles [218]. Further, the relative proportion of type III collagen, which is more
elastic than type I, increases in response to 14 and 28 days of tail suspension in rats [219].
Passive tension of soleus fibers, atrophied after 14 days of tail suspension, increases less
steeply in response to stretching than that of normal fibers [220].
Elasticity of the I-band region of titin filaments in atrophied soleus muscle fibers is also
reduced following tail suspension, whereas that in fast-twitch extensor digitorum longus
muscle fibers is not affected [204]. Splicing variation of the titin gene results in the
production of variant proteins with different molecular sizes [18, 19]. The titin expressed in
slow-twitch muscles is larger than that in fast-twitch muscles. It is indicated that titin-borne
tension is inversely related to the molecular size of titin [21]. Titin size is also correlated with
the expression of type I myosin heavy chain or the percentage of slow-twitch fibers in the
muscle. Slow-twitch muscles usually express long titin, resulting in the low titin-based
stiffness [21, 22]. However, total passive stiffness, provided under lack of titin, is high in the
rabbit soleus, in which abundant collagen fibers in the extra-myofibrillar space are noted.
These structural features may help to protect myofibrils from the tonic mechanical stress in
slow-twitch muscles.
189
Conclusion
Skeletal muscle fibers can adapt in various directions, e.g., hypertrophic, atrophic,
oxidative, or stress-resistive, in response to a given environment and physiological stimuli.
This adaptation results in slow- or fast-twitch characteristics, which are not only for the
differential contractile apparatus and metabolism but also for changing the capacity of
molecular responses to the muscle activity. Titin is a novel mechanical sensor that is
transformed in response to mechanical stress, and releases MARPs. Together with the
association of MuRF1 and calpain-3 with titin, these results suggest that titin plays a crucial
role in the biological process of myofibrillar kinetics. Interestingly, numerous molecules that
induce important signals are localized to the Z-disc in the sarcomere. Some of these
molecules also contribute to the myofibrillar organization, construction and repair. Again,
these structural components vary between slow- and fast-twitch muscle fibers.
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
Huey, K. A., Burdette, S., Zhong, H., and Roy, R. R. (2010). Early response of heat
shock proteins to functional overload of the soleus and plantaris in rats and mice. Exp.
Physiol., 95, 1145-1155.
Huey, K. A., McCall, G. E., Zhong, H., and Roy, R. R. (2007). Modulation of HSP25
and TNF-alpha during the early stages of functional overload of a rat slow and fast
muscle. J. Appl. Physiol., 102, 2307-2314.
Kawano, F., Ishihara, A., Stevems, J. L., Wang, X. D., Ohshima, S., Horisaka, M.,
Maeda, Y., Nonaka, I., and Ohira, Y. (2004). Tension- and afferent-input-associated
responses of neuromuscular system of rats to hindlimb suspension and/or tenotomy.
Am. J. Physiol. Regul. Integr. Comp. Physiol., 287, R76-R86.
Kawano, F., Matsuoka, Y., Oke, Y., Higo, Y., Terada, M., Wang, X. D., Nakai, N.,
Fukuda, H., Imajoh-Ohmi, S., and Ohira, Y. (2007). Role(s) of nucleoli,
phosphorylation of ribosomal protein S6 and/or HSP27 in the regulation of muscle
mass. Am. J. Physiol. Cell Physiol., 293, C35-C44.
McCarthy, J. J., Mula, J., Miyazaki, M., Erfani, R., Garrison, K., Farooqui, A. B.,
Srikuea, R., Lawson, B. A., Grimes, B., Keller, C., Van Zant, G., Campbell, K. S.,
Esser, K. A., Dupont-Versteegden, E. E., and Peterson, C. A. (2011). Effective fiber
hypertrophy in satellite cell-depleted skeletal muscle. Development, 138, 3657-3666.
Roy, R. R., Monke, S. R., Allen, D. L., and Edgerton, V. R. (1999). Modulation of
myonuclear number in functionally overloaded and exercised rat plantaris fibers. J.
Appl. Physiol., 87, 634-642.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A.,
Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., Valenzuela, D.
M., DeChiara, T. M., Stitt, T. N., Yancopoulos, G. D., and Glass, D. J. (2001).
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294,
1704-1708.
190
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
Fuminori Kawano
Kimball, S. R., Farrell, P. A. and Jefferson, L. S. (2002). Invited Review: Role of
insulin in translational control of protein synthesis in skeletal muscle by amino acids or
exercise. J. Appl. Physiol., 93, 1168-1180.
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N.,
Yancopoulos, G. D., and Glass, D. J. (2001). Mediation of IGF-1-induced skeletal
myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell
Biol., 3, 1009-1013.
Matiello, R., Fukui, R. T., Silva, M. E. R., Rocha, D. M., Wajchenberg, B. L., Azhar,
S., and Santos, R. (2010). Differential regulation of PGC-1 expression in rat liver and
skeletal muscle in response to voluntary running. Nutr. Metab., 7, 36.
Rck, K. S. C., Hirshman, M. F., Brandauer, J., Fujii, N., Witters, L. A., and Goodyear,
L. J. (2007). Skeletal muscle adaptation to exercise training: AMP-activated protein
kinase mediates muscle fiber type shift. Diabetes, 56, 2062-2069.
Rowe, G. C., El-Khoury, R., Patten, I. S., Rustin, P., and Arany, Z. (2012). PGC-1 is
dispensable for exercise-induced mitochondrial biogenesis in skeletal muscle. PLoS
One, 7, e41817.
Armstrong, R. B. and Phelps, R. O. (1984). Muscle fiber type composition of the rat
hindlimb. Am. J. Anat., 171, 259-272.
Baldwin, K. M., Roy, R. R., Sacks, R. D., Blanco, C., and Edgerton, V. R. (1984).
Relative independence of metabolic enzymes and neuromuscular activity. J. Appl.
Physiol., 56, 1602-1607.
Ishihara, A. and Taguchi, S. (1991). Histochemical differentiation of fibers in the rat
slow and fast twitch muscles. Jpn. J. Physiol., 41, 251-258.
Krger, M. and Linke, W. A. (2011). The giant protein titin: a regulatory node that
integrates myocyte signaling pathways. J. Biol. Chem., 286, 9905-9912.
Linke, W. A., Ivemeyer, M., Mundel, P., Stockmeier, M. R., and Kolmerer, B. (1998).
Nature of PEVK-titin elasticity in skeletal muscle. Proc. Natl. Acad. Sci. US, 95, 80528057.
Guo, W., Bharmal, S. J., Esbona, K., and Greaser, M. L. (2010). Titin diversity-alternative splicing gone wild. J. Biomed. Biotechnol., 2010, 753675.
Labeit, S. and Kolmerer, B. (1995). Titins: giant proteins in charge of muscle
ultrastructure and elasticity. Science, 270, 293-296.
Bang, M. L., Centner, T., Fornoff, F., Geach, A. J., Gotthardt, M., McNabb, M., Witt,
C. C., Labeit, D., Gregorio, C. C., Granzier, H., and Labeit, S. (2001). The complete
gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform,
and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ.
Res., 89, 1065-1072.
Prado, L. G., Makarenko, I., Andresen, C., Krger, M., Opitz, C. A., and Linke, W. A.
(2005). Isoform diversity of giant proteins in relation to passive and active contractile
properties of rabbit skeletal muscles. J. Gen. Physiol., 126, 461-480.
Wang, K., McCarter, R., Wright, J., Beverly, J., and Ramirez-Mitchell, R. (1991).
Regulation of skeletal muscle stiffness and elasticity by titin isoforms: A test of the
segmental extension model of resting tension. Proc. Natl. Acad. Sci. US, 88, 71017105.
Horowits, R., Kempner, E. S., Bisher, M. E., and Podolsky, R. J. (1986). A
physiological role for titin and nebulin in skeletal muscle. Nature, 323, 160-164.
191
[24] Greaser, M. and Gergely, J. (1971). Reconstitution of troponin activity from three
protein components. J. Biol. Chem., 246, 4226-4233.
[25] Gordon, A. M., Homsher, E. and Regnier, M. (2000). Regulation of contraction in
striated muscle. Physiol. Rev., 80, 853-924.
[26] Haselgrove, J. C. (1972). X-ray evidence for a conformational change in actincontaining filaments of vertebrate striated muscle. Cold Spring Harbor Symp. Quant.
Biol., 37, 341-352.
[27] Huxley, H. E. (1972). Structural changes in actin- and myosin-containing filaments
during contraction. Cold Spring Harbor Symp. Quant. Biol., 37, 361-376.
[28] Lehman, W., Craig, R. and Vibert, P. (1994). Ca2+-induced tropomyosin movement in
Limulus thin filaments revealed by three dimensional reconstruction. Nature, 368, 6567.
[29] Parry, D. A. D. and Squire, J. M. (1973). Structural role of tropomyosin in muscle
regulation: analysis of the Xray patterns from relaxed and contracting muscles. J. Mol.
Biol., 75, 33-55.
[30] Vibert, P., Craig, R. and Lehman,W. (1997). Steric-model for activation of muscle thin
filaments. J. Mol. Biol., 266, 8-14.
[31] Castillo, A., Nowak, R., Littlefield, K. P., Fowler, V. M., and Littlefield, R. S. (2009).
A nebulin ruler does not dictate thin filament lengths. Biophys, J., 96, 1856-1865.
[32] Gokhin, D. S., Lewis, R. A., McKeown, C. R., Nowak, R. B., Kim, N. E., Littlefield, R.
S., Lieber, R. L., and Fowler, V. M. (2010). Tropomodulin isoforms regulate thin
filament pointed-end capping and skeletal muscle physiology. J. Cell Biol., 189, 95109.
[33] Granzier, H. L., Akster, H. A. and Ter Keurs, H. E. (1991). Effect of thin filament
length on the force-sarcomere length relation of skeletal muscle. Am. J. Physiol. Cell
Physiol., 260, C1060-C1070.
[34] Wang, K. and Wright, J. (1988). Architecture of the sarcomere matrix of skeletal
muscle: immunoelectron microscopic evidence that suggests a set of parallel
inextensible nebulin filaments anchored at the Z line. J. Cell Biol., 107, 2199-2212.
[35] Kruger, M., Wright, J. and Wang, K. (1991). Nebulin as a length regulator of thin
filaments of vertebrate skeletal muscles: correlation of thin filament length, nebulin
size, and epitope profile. J. Cell Biol., 115, 97-107
[36] Bang, M. L., Li, X., Littlefield, R., Bremner, S., Thor, A., Knowlton, K. U., Lieber, R.
L., and Chen, J. (2006). Nebulin-deficient mice exhibit shorter thin filament lengths and
reduced contractile function in skeletal muscle. J. Cell Biol., 173, 905-916.
[37] Witt, C. C., Burkart, C., Labeit, D., McNabb, M., Wu, Y., Granzier, H., and Labeit, S.
(2006). Nebulin regulates thin filament length, contractility, and Z-disk structure in
vivo. EMBO J., 25, 3843-3855.
[38] Ottenheijm, C. A., Witt, C. C., Stienen, G. J., Labeit, S., Beggs, A. H., and Granzier, H.
(2009). Thin filament length dysregulation contributes to muscle weakness in nemaline
myopathy patients with nebulin deficiency. Hum. Mol. Genet., 18, 2359-2369.
[39] Schafer, D. A. and Cooper, J. A. (1995). Control of actin assembly at filament ends.
Annu. Rev. Cell Dev. Biol., 11, 497518.
[40] Weber, A., Pennise, C. R., Babcock, G. G., and Fowler, V. M. (1994). Tropomodulin
caps the pointed ends of actin filaments. J. Cell Biol., 127, 1627-1635.
192
Fuminori Kawano
[41] Almenar-Queralt, A., Lee, A., Conley, C. A., Ribas de Pouplana, L., and Fowler, V. M.
(1999). Identification of a novel tropomodulin isoform, skeletal tropomodulin, that caps
actin filament pointed ends in fast skeletal muscle. J. Biol. Chem., 274, 28466-28475.
[42] Conley, C. A., Fritz-Six, K. L., Almenar-Queralt, A., and Fowler, V. M. (2001).
Leiomodins: larger members of the tropomodulin (Tmod) gene family. Genomics, 73,
127-139.
[43] Cox, P. R. and Zoghbi, H. Y. (2000). Sequencing, expression analysis, and mapping of
three unique human tropomodulin genes and their mouse orthologs. Genomics, 63, 97107.
[44] Fowler, V. M. (1990). Tropomodulin: a cytoskeletal protein that binds to the end of
erythrocyte tropomyosin and inhibits tropomyosin binding to actin. J. Cell Biol., 111,
471-481.
[45] Fowler, V. M. (1987). Identification and purification of a novel Mr 43,000
tropomyosin-binding protein from human erythrocyte membranes. J. Biol. Chem., 262,
12792-12800.
[46] Sung, L. A., Fowler, V. M., Lambert, K., Sussman, M. A., Karr, D., and Chien, S.
(1992). Molecular cloning and characterization of human fetal liver tropomodulin. A
tropomyosin-binding protein. J. Biol. Chem., 267, 2616-2621.
[47] Watakabe, A., Kobayashi, R. and Helfman, D. M. (1996). N-tropomodulin: a novel
isoform of tropomodulin identified as the major binding protein to brain tropomyosin.
J. Cell Sci., 109, 2299-2310.
[48] Littlefield, R., Almenar-Queralt, A. and Fowler, V. M. (2001). Actin dynamics at
pointed ends regulates thin filament length in striated muscle. Nat. Cell Biol., 3, 544551.
[49] Littlefield, R. S. and Fowler, V. M. (2008). Thin filament length regulation in striated
muscle sarcomeres: pointed-end dynamics go beyond a nebulin ruler. Semin. Cell Dev.
Biol., 19, 511-519.
[50] Pappas, C. T., Krieg, P. A. and Gregorio, C. C. (2010). Nebulin regulates actin filament
lengths by a stabilization mechanism. J. Cell Biol., 189, 859870.
[51] Gokhin, D. S, Kim, N. E., Lewis, S. A., Hoeneche, H. R., D'Lima, D. D., and Fowler,
V. M. (2012). Thin-filament length correlates with fiber type in human skeletal muscle.
Am. J. Physiol. Cell Physiol., 302, C555-C565.
[52] Fritz-Six, K. L., Cox, P. R., Fischer, R. S., Xu, B., Gregorio, C. C., Zoghbi, H. Y., and
Fowler, V. M. (2003). Aberrant myofibril assembly in tropomodulin1 null mice leads to
aborted heart development and embryonic lethality. J. Cell Biol., 163, 1033-1044.
[53] McKeown, C. R., Nowak, R. B., Moyer, J., Sussman, M. A., and Fowler, V. M. (2008).
Tropomodulin1 is required in the heart but not the yolk sac for mouse embryonic
development. Circ. Res., 103, 1241-1248.
[54] Kachur, T. M. and Pilgrim, D. B. (2008). Myosin assembly, maintenance and
degradation in muscle: Role of the chaperone UNC-45 in myosin thick filament
dynamics. Int. J. Mol. Sci., 9, 1863-1875.
[55] Offer, G., Moos, C. and Starr, R. (1973). A new protein of the thick filaments of
vertebrate skeletal myofibrils. Extraction, purification and characterization. J. Mol.
Biol., 74, 653-676.
[56] Knll, R. (2012). Myosin binding protein C: implications for signal-transduction. J.
Muscle Res. Cell Motil., 33, 31-42.
193
[57] Gautel, M., Zuffardi, O., Freiburg, A., and Labeit, S. (1995). Phosphorylation switches
specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac
contraction? EMBO J., 14, 1952-1960
[58] Weber, F. E., Vaughan, K. T., Reinach, F. C., and Fischman, D. A. (1993). Complete
sequence of human fast-type and slow-type muscle myosinbinding-protein C (MyBPC). Differential expression, conserved domain structure and chromosome assignment.
Eur. J. Biochem., 216, 661-669.
[59] Rybakova, I. N., Greaser, M. L. and Moss, R. L. (2011). Myosin binding protein C
interaction with actin: characterization and mapping of the binding site. J. Biol. Chem.,
286, 2008-2016.
[60] Gurnett, C. A., Desruisseau, D. M., McCall, K., Choi, R., Meyer, Z. I., Talerico, M.,
Miller, S. E., Ju, J. S., Pestronk, A., Connolly, A. M., Druley, T. E., Weihl, C. C., and
Dobbs, M. B. (2010). Myosin binding protein C1: a novel gene for autosomal dominant
distal arthrogryposis type 1. Hum. Mol. Genet., 19, 1165-1173.
[61] Carlsson, E. and Thornell, L. E. (1987). Diversification of the myofibrillar M-band in
rat skeletal muscle during postnatal development. Cell Tissue Res., 248, 169-180.
[62] Edman, A. C., Squire, J. M. and Sjstrm, M. (1988). Fine structure of the A-band in
cryo-sections. Diversity of M-band structure in chicken breast muscle. J. Ultrastruct.
Mol. Struct. Res., 100, 112.
[63] Sjstrm, M. and Squire, J. M. (1977). Fine structure of the A-band in cryo-sections.
The structure of the A-band of human skeletal muscle fibres from ultra-thin cryosections negatively stained. J. Mol. Biol, 109, 49-68.
[64] Agarkova, I. and Perriard, J. C. (2005). The M-band: an elastic web that crosslinks
thick filaments in the center of the sarcomere. Trend Cell Biol., 15, 477-485.
[65] Beqqali, A., Monshouwer-Kloots, J., Monteiro, R., Welling, M., Bakkers, J., Ehler, E.,
Verkleij, A., Mummery, C., and Passier, R. (2010). CHAP is a newly identified Z-disc
protein essential for heart and skeletal muscle function. J. Cell Sci., 123, 1141-1150.
[66] Ochala, J., Carpn, O. and Larsson, L. (2009). Maintenance of muscle mass, fiber size,
and contractile function in mice lacking the Z-disc protein myotilin. Ups. J. Med. Sci.,
114, 235-241.
[67] Knll, R., Buyandelger, B. and Lab, M. (2011). The sarcomere Z-disc and Zdiscopathies. J. Biomed. Biotech., 2011, 569628.
[68] Otey, C. A. and Carpen, O. (2004). Alpha-actinin revisited: a fresh look at an old
player. Cell Motil. Cytoskeleton, 58, 104-111.
[69] Mills, M., Yang, N., Weinberger, R., Vander Woude, D. L., Beggs, A. H., Easteal, S.,
and North, K. (2001). Differential expression of the actin-binding proteins, alphaactinin-2 and -3, in different species: implications for the evolution of functional
redundancy. Hum. Mol. Genet., 10, 1335-1346.
[70] MacArthur, D. G., Seto, J. T., Chan, S., Quinlan, K. G., Raftery, J. M., Turner, N.,
Nicholson, M. D., Kee, A. J., Hardeman, E. C., Gunning, P. W., Cooney, G. J., Head, S.
I., Yang, N., and North, K. N. (2008). An Actn3 knockout mouse provides mechanistic
insights into the association between alpha-actinin-3 deficiency and human athletic
performance. Hum. Mol. Genet., 17, 1076-1086.
[71] MacArthur, D. G., Seto, J. T., Raftery, J. M., Quinlan, K. G., Huttley, G. A., Hook, J.
W., Lemckert, F. A., Kee, A. J., Edwards, M. R., Berman, Y., Hardeman, E. C.,
Gunning, P. W., Easteal, S., Yang, N., and North, K. N. (2007). Loss of ACTN3 gene
194
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
Fuminori Kawano
function alters mouse muscle metabolism and shows evidence of positive selection in
humans. Nat. Genet., 39, 1261-1265.
North, K. N., Yang, N., Wattanasirichaigoon, D., Mills, M., Easteal, S., and Beggs, A.
H. (1999). A common nonsense mutation results in alpha-actinin-3 deficiency in the
general population. Nat. Genet., 21, 353-354.
MacArthur, D. G. and North, K. N. (2007). ACTN3: a genetic influence on muscle
function and athletic performance. Exerc. Sport Sci. Rev., 35, 30-34.
Ruiz, J. R., Fernndez del Valle, M., Verde, Z., Dez-Vega, I., Santiago, C., Yvert, T.,
Rodrguez-Romo, G., Gmez-Gallego, F., Molina, J. J., and Lucia, A. (2011). ACTN3
R577X polymorphism does not influence explosive leg muscle power in elite volleyball
players. Scand. J. Med. Sci. Sports, 21, e34-e41.
Hanson, E. D., Ludlow, A. T., Sheaff, A. K., Park, J., and Roth, S. M. (2010). ACTN3
genotype does not influence muscle power. Int. J. Sports Med., 31, 834-838.
Ogura, Y., Naito, H., Kakigi, R., Ichinoseki-Sekine, N., Kurosaka, M., Yoshihara, T.,
and Akema, T. (2011). Effects of ageing and endurance exercise training on alphaactinin isoforms in rat plantaris muscle. Acta Physiol., 202, 683-690.
Ogura, Y., Naito, H., Kakigi, R., Akema, T., Sugiura, T., Katamoto, S., and Aoki, J.
(2009). Different adaptations of alpha-actinin isoforms to exercise training in rat
skeletal muscles. Acta Physiol., 196, 341-349.
Capetanaki, Y., Bloch, R. J., Kouloumenta, A., Mavroidis, M., and Psarras, S. (2007).
Muscle intermediate filaments and their links to membranes and membranous
organelles. Exp. Cell Res., 313, 2063-2076.
Li, H. and Capetanaki, Y. (1993). Regulation of the mouse desmin gene: transactivated
by Myod, myogenin, Mrf4 anf Myf5. Nucleic Acids Res., 21, 335-343.
Olsen, E. N. (1990). Myod family: a paradigm for development? Genes Dev., 4, 14541461.
Li, Z., Mericskay, M., Agbulut, O., Butler-Browne, G., Carlsson, L., Thornell, L. E.,
Babinet, C., and Paulin, D. (1997). Desmin is essential for the tensile strength and
integrity of myofibrils but not for myogenic commitment, differentiation and fusion of
skeletal muscle. J. Cell Biol., 139, 129-144.
Carlsson, L., Li, Z. L., Paulin, D., Price, M. G., Breckler, J., Robson, R. M., Wiche, G.,
and Thornell, L. E. (2000). Differences in the distribution of synemin, paranemin, and
plectin in skeletal muscles of wild-type and desmin knock-out mice. Histochem. Cell
Biol., 114, 39-47.
Meyer, G. A. and Lieber, R. L. (2012). Skeletal muscle fibrosis develops in response to
desmin deletion. Am. J. Physiol. Cell Physiol., 302, C1609-C1620.
Jagoe, R. T., Lecker, S. H., Gomes, M., and Goldberg, A. L. (2002). Patterns of gene
expression in atrophying skeletal muscles: Response to food deprivation. FASEB J., 16,
1697-1712.
Glass, D. J. (2005). Skeletal muscle hypertrophy and atrophy signaling pathways. Int. J.
Biochem. Cell Biol., 37, 1974-1984.
Dehoux, M. J. M., van Beneden, R. P., Fernandez-Celemin, L., Lause, P. L., and
Thissen, J. -P. M. (2003). Induction of MafBx and Murf ubiquitin ligasemRNAs in rat
skeletal muscle after LPS injection. FEBS Lett., 544, 214-217.
DeRuisseau, K. C., Kavazis, A. N., Deering, M. A., Falk, D. J., Van Gammeren, D.,
Yimlamai, T., Ordway, G. A., and Powers, S. K. (2005). Mechanical ventilation
195
196
Fuminori Kawano
calpain 1 in the Z-band edges and in the N2-line region within the skeletal myofibril.
FEBS J., 272, 2578-2590.
[102] Sorimachi, H., Imajoh-Ohmi, S., Emori, Y., Kawasaki, H., Ohno, S., Minami, Y., and
Suzuki, K. (1989). Molecular cloning of a novel mammalian calcium-dependent
protease distinct from both m- and mu-types. Specific expression of the mRNA in
skeletal muscle. J. Biol. Chem., 264 20106-20111.
[103] Herasse, M., Ono, Y., Fougerousse, F., Kimura, E., Stockholm, D., Beley, C.,
Montarras, D., Pinset, C., Sorimachi, H., Suzuki, K., Beckmann, J. S., and Richard, I.
(1999). Expression and functional characteristics of calpain 3 isoforms generated
through tissue-specific transcriptional and posttranscriptional events. Mol. Cell Biol.,
19, 4047-4055.
[104] Diaz, B. G., Moldoveanu, T., Kuiper, M. J., Campbell, R. L., and Davies, P. L. (2004).
Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide. J.
Biol. Chem., 279, 27656-27666.
[105] Sorimachi, H., Kinbara, K., Kimura, S., Takahashi, M., Ishiura, S., Sasagawa, N.,
Sorimachi, N., Shimada, H., Tagawa, K., Maruyama, K., and Suzuki, K. (1995).
Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A,
associates with connectin through IS2, a p94-specific sequence. J. Biol. Chem., 270,
31158-31162.
[106] Sorimachi, H., Toyama-Sorimachi, N., Saido, T. C., Kawasaki, H., Sugita, H.,
Miyasaka, M., Arahata, K., Ishiura, S., and Suzuki, K. (1993). Muscle-specific calpain,
p94, is degraded by autolysis immediately after translation, resulting in disappearance
from muscle. J. Biol. Chem., 268, 10593-10605.
[107] Kinbara, K., Sorimachi, H., Ishiura, S., and Suzuki, K. (1997). Muscle-specific calpain,
p94, interacts with the extreme C-terminal region of connectin, a unique region flanked
by two immunoglobulin C2 motifs. Arch. Biochem. Biophys., 342, 99-107.
[108] Taveau, M., Bourg, N., Sillon, G., Roudaut, C., Bartoli, M., and Richard, I. (2003).
Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and
sarcolemmal components. Mol. Cell Biol., 23, 9127-9135.
[109] Richard, I., Broux, O., Allamand, V., Fougerousse, F., Chiannilkulchai, N., Bourg, N.,
Brenguier, L., Devaud, C., Pasturaud, P., Roudaut, C., Hillaire, D., Passos-Bueno, M.,
Zatz, M., Tischfield, J. A., Fardeau, M., Jackson, C. E., Cohen, D., and Beckmann, J. S.
(1995). Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular
dystrophy type 2A. Cell, 81, 27-40.
[110] Baghdiguian, S., Martin, M., Richard, I., Pons, F., Astier, C., Bourg, N., Hay, R. T.,
Chemaly, R., Halaby, G., Loiselet, J., Anderson, L. V., Lopez de Munain, A., Fardeau,
M., Mangeat, P., Beckmann, J. S., and Lefranc, G. (1999). Calpain 3 deficiency is
associated with myonuclear apoptosis and profound perturbation of the IkappaB
alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat. Med., 5,
503-511.
[111] Kramerova, I., Kudryashova, E., Tidball, J. G., and Spencer, M. J. (2004). Null
mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and
in vitro. Hum. Mol. Genet., 13, 1373-1388.
[112] Baghdiguian, S., Martin, M., Richard, I., Pons, F., Astier, C., Bourg, N., Hay, R. T.,
Chemaly, R., Halaby, G., Loiselet, J., Anderson, L. V., Lopez de Munain, A., Fardeau,
M., Mangeat, P., Beckmann, J. S., and Lefranc, G. (1999). Calpain 3 deficiency is
197
198
Fuminori Kawano
[126] Xia, H., Winokur, S. T., Kuo, W. L., Altherr, M. R., and Bredt, D. S. (1997). Actininassociated LIM protein: identification of a domain interaction between PDZ and
spectrin-like repeat motifs. J. Cell Biol., 139, 507-515.
[127] Pashmforoush, M., Pomis, P., Peterson, K. L., Kubalak, S., Ross, J. Jr., Hefti, A.,
Aebi, U., Beckerle, M. C., and Chien, K. R. (2001). Adult mice deficient in actininassociated LIM-domain protein reveal a developmental pathway for right ventricular
cardiomyopathy. Nat. Med., 7, 591-597.
[128] Pomies, P., Pashmforoush, M., Vegezzi, C., Chien, K. R., Auffray, C., and Beckerle, M.
C. (2007). The cytoskeleton-associated PDZLIM protein, ALP, acts on serum
response factor activity to regulate muscle differentiation. Mol. Biol. Cell, 18, 17231733.
[129] Rao, A., Luo, C. and Hogan, P. G. (1997). Transcription factors of the NFAT family:
Regulation and function. Annu. Rev. Immunol., 15, 707-747.
[130] Dolmetsch, R. E., Lewis, R. S., Goodnow, C. C., and Healy, J. I. (1997). Differential
activation of transcription factors induced by Ca2+ response amplitude and duration.
Nature, 386, 855-858.
[131] Crabtree, G. R. (1999). Generic signals and specific outcomes: signaling through Ca2+,
calcineurin, and NF-AT. Cell, 96, 611-614.
[132] Lopez-Rodriguez, C., Aramburu, J., Rakeman, A. S., and Rao, A. (1999). NFAT5, a
constitutively nuclear NFAT protein that does not cooperate with Fos and Jun. Proc.
Natl. Acad. Sci. US, 96, 7214-7219.
[133] Chin, E. R., Olson, E. N., Richardson, J. A., Yang, Q., Humphries, C., Shelton, J. M.,
Wu, H., Zhu, W., Bassel-Duby, R., and Williams, R. S. (1998). A calcineurindependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev., 12,
2499-2509.
[134] Delling, U., Tureckova J, Lim, H. W., De Windt, L. J., Rotwein, P., and Molkentin, J.
D. (2000). A calcineurin-NFATc3- dependent pathway regulates skeletal muscle
differentiation and slow myosin heavy-chain expression. Mol. Cell Biol., 20, 66006611.
[135] Naya, F. J., Mercer, B., Shelton, J., Richardson, J. A., Williams, R. S., and Olson, E. N.
(2000). Stimulation of slow skeletal muscle fiber gene expression by calcineurin in
vivo. J. Biol. Chem., 275, 4545-4548.
[136] Parsons, S. A., Millay, D. P., Wilkins, B. J., Bueno, O. F., Tsika, G. L., Neilson, J. R.,
Liberatore, C. M., Yutzey, K. E., Crabtree, G. R., Tsika, R. W., and Molkentin, J. D.
(2004). Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle
fiber type switching but not hypertrophy. J. Biol. Chem., 279, 26192-26200.
[137] Chin, E. R. and Allen, D. G. (1996). Changes in intracellular free Ca2+ concentration
during constant 10 Hz stimulation of mouse single skeletal muscle fibres. Physiologist,
39, A-75.
[138] Westerblad, H. and Allen, D. G. (1991). Changes in myoplasmic calcium concentration
during fatigue in single mouse muscle fibers. J. Gen. Physiol., 98, 615-635.
[139] Sreter, F. A., Lopez, J. R., Alamo, L., Mabuchi, K., and Gergely, J. (1987). Changes in
intracellular ionized Ca concentration associated with muscle fiber type transformation.
Am. J. Physiol., 253, C296-C300.
199
[140] Williams, R. S., Salmons, S., Newsholme, E. A., Kaufman, R. E., and Mellor, J. (1986).
Regulation of nuclear and mitochondrial gene expression by contractile activity in
skeletal muscle. J. Biol. Chem., 261, 376-380.
[141] Liu, Y., Cseresnys, Z., Randall, W. R., and Schneider, M. F. (2001). Activitydependent nuclear translocation and intranuclear distribution of NFATc in adult skeletal
muscle fibers. J. Cell Biol., 155, 27-39.
[142] Frey, N., Richardson, J. A. and Olson, E. N. (2000). Calsarcins, a novel family of
sarcomeric calcineurin- binding proteins. Proc. Natl. Acad. Sci. US, 97, 14632-14637.
[143] Frank, D., Kuhn, C., Katus, H. A., and Frey, N. (2006). The sarcomeric Z-disc: a nodal
point in signalling and disease. J. Mol. Med., 84, 446-468.
[144] Takada, F., Vander Woude, D. L., Tong, H. Q., Thompson, T. G., Watkins, S. C.,
Kunkel, L. M., and Beggs, A. H. (2001). Myozenin: an alpha-actininand gammafilamin-binding protein of skeletal muscle Z lines. Proc. Natl. Acad. Sci. US, 98, 15951600.
[145] Faulkner, G., Pallavicini, A., Comelli, A., Salamon, M., Bortoletto, G., Ievolella, C.,
Trevisan, S., Kojic', S., Dalla Vecchia, F., Laveder, P., Valle, G., and Lanfranchi, G.
(2000). FATZ, a filamin-, actinin-, and telethonin-binding protein of the Z-disc of
skeletal muscle. J. Biol. Chem., 275, 41234-41242.
[146] Frey, N. and Olson, E. N. (2002). Calsarcin-3, a novel skeletal muscle-specific member
of the calsarcin family, interacts with multiple Z-disc proteins. J. Biol. Chem., 277,
13998-14004.
[147] Gontier, Y., Taivainen, A., Fontao, L., Sonnenberg, A., van der Flier, A., Carpen, O.,
Faulkner, G., and Borradori, L. (2005). The Z-disc proteins myotilin and FATZ-1
interact with each other and are connected to the sarcolemma via muscle-specific
filamins. J. Cell Sci., 118, 3739-3749.
[148] Frey, N., Frank, D., Lippl, S., Kuhn, C., Kgler, H., Barrientos, T., Rohr, C., Will, R.,
Mller, O. J., Weiler, H., Bassel-Duby, R., Katus, H. A., and Olson, E. N. (2008).
Calsarcin-2 deficiency increases exercise capacity in mice through calcineurin/NFAT
activation. J. Clin. Invest., 118, 3598-3608.
[149] Frey, N., Barrientos, T., Shelton, J. M., Frank, D., Rtten, H., Gehring, D., Kuhn, C.,
Lutz, M., Rothermel, B, Bassel-Duby, R., Richardson, J. A., Katus, H. A., Hill, J. A.,
and Olson, E. N. (2004). Mice lacking calsarcin-1 are sensitized to calcineurin signaling
and show accelerated cardiomyopathy in response to pathological biomechanical stress.
Nat. Med., 10, 1336-1343.
[150] Arber, S., Halder, G. and Caroni, P. (1994). Muscle LIM protein, a novel essential
regulator of myogenesis, promotes myogenic differentiation. Cell, 79, 221-231.
[151] Heineke, J., Ruetten, H., Willenbockel, C., Gross, S. C., Naguib, M., Schaefer, A.,
Kempf, T., Hilfiker-Kleiner, D., Caroni, P., Kraft, T., Kaiser, R. A., Molkentin, J. D.,
Drexler, H., and Wollert, K. C. (2005). Attenuation of cardiac remodeling after
myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Zdisc. Proc. Natl. Acad. Sci. US, 102, 1655-1660.
[152] Barash, I. A., Mathew, L., Lahey, M., Greaser, M. L., and Lieber, R. L. (2005). Muscle
LIM protein plays both structural and functional roles in skeletal muscle. Am. J.
Physiol. Cell Physiol., 289, C1312-C1320.
200
Fuminori Kawano
[153] Kong, Y., Flick, M. J., Kudla, A. J., and Konieczny, S. F. (1997). Muscle LIM protein
promotes myogenesis by enhancing the activity of MyoD. Mol. Cell Biol., 17, 47504760.
[154] Barash, I. A., Mathew, L., Ryan, A. F., Chen, J., and Lieber, R. L. (2004). Rapid
muscle-specific gene expression changes after a single bout of eccentric contractions in
the mouse. Am. J. Physiol. Cell Physiol., 286, C355-C364.
[155] Hentzen, E. R., Lahey, M., Peters, D., Mathew, L., Barash, I. A., Friden, J., and Lieber,
R. L. (2006). Stress-dependent and -independent expression of the myogenic regulatory
factors and the MARP genes after eccentric contractions in rats. J. Physiol., 570, 157167.
[156] Schneider, A. G., Sultan, K. R. and Pette, D. (1999). Muscle LIM protein: expressed in
slowmuscle and induced in fast muscle by enhanced contractile activity. Am. J. Physiol.
Cell Physiol., 276, C900-C906.
[157] Willmann, R., Kusch, J., Sultan, K. R., Schneider, A. G., and Pette, D. (2001). Muscle
LIM protein is upregulated in fast skeletal muscle during transition toward slower
phenotypes. Am. J. Physiol. Cell Physiol., 280, C273-C279.
[158] Barash, I. A., Bang, M. L., Mathew, L., Greaser, M. L., Chen, J., and Lieber, R. L.
(2007). Structural and regulatory roles of muscle ankyrin repeat protein family in
skeletal muscle. Am. J. Physiol. Cell Physiol., 293, C218-C227.
[159] Ludolph, D. C. and Konieczny, S. F. (1995). Transcription factor families: muscling in
on the myogenic program. FASEB J., 9, 1595-1604.
[160] Buckingham, M. (1994). Muscle differentiation: which myogenic factors make muscle?
Curr. Biol., 4, 61-63.
[161] Emerson, C. P. (1993). Skeletal myogenesis: genetics and embryology to the fore. Curr.
Opin. Genet. Dev., 3, 265-274.
[162] Weintraub, H. (1993). The MyoD family and myogenesis: redundancy, networks, and
thresholds. Cell, 75, 1241-1244.
[163] Kaushal, S., Schneider, J. W., Nadal-Ginard, B., and Mahdavi, V. (1994). Activation of
the myogenic lineage by MEF2A, a factor that induces and cooperates with MyoD.
Science, 266, 1236-1240.
[164] Molkentin, J. D., Black, B. L., Martin, J. F., and Olson, E. N. (1995). Cooperative
activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell,
83,1125-1136.
[165] Naidu, P. S., Ludolph, D. C., To, R. Q., Hinterberger, T. J., and Konieczny, S. F.
(1995). Myogenin and MEF2 function synergistically to activate the MRF4 promoter
during myogenesis. Mol. Cell Biol., 15, 2707-2718.
[166] Clarkson, P. M. and Hubal, M. J. (2002). Exercise-induced muscle damage in humans.
Am. J. Phys. Med. Rehabil., 81, S52S69.
[167] Friden, J. and Lieber, R. L. (2001). Eccentric exercise-induced injuries to contractile
and cytoskeletal muscle fibre components. Acta Physiol. Scand., 171, 321-326.
[168] Friden, J. and Lieber, R. L. (1998). Segmental muscle fiber lesions after repetitive
eccentric contractions. Cell Tissue Res., 293, 165-171.
[169] Lieber, R. L., Thornell, L. E. and Friden, J. (1996). Muscle cytoskeletal disruption
occurs within the first 15 min of cyclic eccentric contraction. J. Appl. Physiol., 80, 278284.
201
[170] Yu, J. G., Frst, D. O. and Thornell, L. E. (2003). The mode of myofibril remodelling
in human skeletal muscle affected by DOMS induced by eccentric contractions.
Histochem. Cell Biol., 119, 383-393.
[171] Yu, J. G., Carlsson, L. and Thornell, L. E. (2004). Evidence for myofibril remodeling as
opposed to myofibril damage in human muscles with DOMS: an ultrastructural and
immunoelectron microscopic study. Histochem. Cell Biol., 121, 219-227.
[172] Yu, J. G., Malm, C. and Thornell, L. E. (2002). Eccentric contractions leading to
DOMS do not cause loss of desmin nor fibre necrosis in human muscle. Histochem.
Cell Biol., 118, 29-34.
[173] Yu, J. G., Thornell, L. E. and Malm, C. (2002). Desmin and actin alterations in human
muscles affected by delayed onset muscle soreness: a high resolution
immunocytochemical study. Histochem. Cell Biol., 118, 171-179.
[174] Otey, C. A., Rachlin, A., Moza, M., Arneman, D., and Carpen, O. (2005). The palladin/
myotilin/myopalladin family of actin-associated scaffolds. Int. Rev. Cytol., 246, 31-58.
[175] Salmikangas, P., Mykkanen, O. M., Gronholm, M., Heiska, L., Kere, J., and Carpen, O.
(1999). Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a
candidate gene for limb-girdle muscular dystrophy. Hum. Mol. Genet., 8, 1329-1336.
[176] Salmikangas, P., van der Ven, P. F., Lalowski, M., Taivainen, A., Zhao, F., Suila, H.,
Schrder, R., Lappalainen, P., Frst, D. O., and Carpn, O. (2003). Myotilin, the limbgirdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and
controls sarcomere assembly. Hum. Mol. Genet., 12, 189-203.
[177] Van der Ven, P. F., Wiesner, S., Salmikangas, P., Auerbach, D., Himmel, M., Kempa,
S., Hayess, K., Pacholsky, D., Taivainen, A., Schrder, R., Carpn, O., and Frst, D. O.
(2000). Indications for a novel muscular dystrophy pathway. gamma-filamin, the
muscle-specific filamin isoform, interacts with myotilin. J. Cell Biol., 151, 235-248.
[178] Carlsson, L., Yu, J. G., Moza, M., Carpn, O., and Thornell, L. E. (2007). Myotilin: a
prominent marker of myofibrillar remodelling. Neuromuscul. Disord., 17, 61-68.
[179] Hauser, M. A., Conde, C. B., Kowaljow, V., Zeppa, G., Taratuto, A. L., Torian, U. M.,
Vance, J., Pericak-Vance, M. A., Speer, M. C., and Rosa, A. L. (2002). Myotilin
Mutation found in second pedigree with LGMD1A. J. Hum. Genet., 1, 1428-1432.
[180] Hauser, M. A., Horrigan, S. K., Salmikangas, P., Torian, U. M., Viles, K. D., Dancel,
R., Tim, R. W., Taivainen, A., Bartoloni, L., Gilchrist, J. M. Stajich, J. M., Gaskell, P.
C., Gilbert, J. R., Vance, J. M., Pericak-Vance, M. A., Carpen, O., Westbrook, C. A.,
and Speer, M. C. (2000). Myotilin is mutated in limb girdle muscular dystrophy 1A.
Hum. Mol. Genet., 9, 2141-2147.
[181] Selcen, D. and Engel, A. G. (2004). Mutations in myotilin cause myofibrillar myopathy.
Neurology, 62, 1363-1371.
[182] Shalaby, S., Mitsuhashi, H., Matsuda, C., Minami, N., Noguchi, S., Nonaka, I., Nishino,
I., and Hayashi, Y. K. (2009). Defective myotilin homodimerization caused by a novel
mutation in MYOT exon 9 in the first Japanese limb girdle muscular dystrophy 1A
patient. J. Neuropathol. Exp. Neurol., 68, 701-707.
[183] Bang, M. L., Mudry, R. E., McElhinny, A. S., Trombitas, K., Geach, A. J., Yamasaki,
R., Sorimachi, H., Granzier, H., Gregorio, C. C., and Labeit, S. (2001). Myopalladin, a
novel 145-kilodalton sarcomeric protein with multiple roles in Z-disc and I-band
protein assemblies. J. Cell Biol., 153, 413-427.
202
Fuminori Kawano
[184] Garvey, S. M., Miller, S. E., Claflin, D. R., Faulkner, J. A., and Hauser, M. A. (2006).
Transgenic mice expressing the myotilin T57I mutation unite the pathology associated
with LGMD1A and MFM. Hum. Mol. Genet.,15, 2348-2362.
[185] Goto, K., Honda, M., Kabayashi, T., Uehara, K., Kojima, A., Akema, T., Sugiura, T.,
Yamada, S., Ohira, Y., and Yoshioka, T. (2004). Heat stress facilitates the recovery of
atrophied soleus muscle in rat. Jpn. J. Physiol., 54, 285-293.
[186] Huey, K. A. (2006). Regulation of HSP25 expression and phosphorylation in
functionally overloaded rat plantaris and soleus muscles. J. Appl. Physiol., 100, 451456.
[187] Huey, K. A., Thresher, J. S, Brophy, C. M., and Roy, R. R. (2004). Inactivity-induced
modulation of Hsp20 and Hsp25 content in rat hindlimb muscles. Muscle Nerve, 30, 95101.
[188] Lawler, J. M., Song, W. and Kwak, H. B. (2006). Differential response of heat shock
proteins to hindlimb unloading and reloading in the soleus. Muscle Nerve, 33, 200-207.
[189] Oishi, Y., Ogata, T., Ohira, Y., Taniguchi, K., and Roy, R. R. (2005). Calcineurin and
heat shock protein 72 in functionally overloaded rat plantaris muscle. Biochem.
Biophys. Res. Commun., 330, 706-713.
[190] Oishi, Y., Ogata, T., Tamamoto, K. I., Terada, M., Ohira, T., Ohira, Y., Taniguchi, K.,
and Roy, R. R. (2008). Cellular adaptations in soleus muscle during recovery after
hindlimb unloading. Acta Physiol., 192, 381-395.
[191] Golenhofen, N., Perng, M. D., Quinlan, R. A., and Drenckhahn, D. (2004). Comparison
of the small heat shock proteins B-crystallin, MKBP, HSP25, HSP20, and cvHSP in
heart and skeletal muscle. Histochem. Cell Biol., 122, 415-425.
[192] Huey, K. A., Roy, R. R., Zhong, H., and Lullo, C. (2008). Time-dependent changes in
caspase-3 activity and heat shock protein 25 after spinal cord transection in adult rats.
Exp. Physiol., 93, 415-425.
[193] Dodd, S. L., Hain, B., Senf, S. M., and Judge, A. R. (2009). Hsp27 inhibits IKKinduced NF-B activity and skeletal muscle atrophy. FASEB J., 23, 3415-3423.
[194] Sakurai, T., Fujita, Y., Ohto, E., Oguro, A., and Atomi, Y. (2005). The decrease of the
cytoskeleton tubulin follows the decrease of the associating molecular chaperone Bcrystallin in unloaded soleus muscle atrophy without stretch. FASEB J., 19, 1199-1201.
[195] Rogalla, T., Ehrnsperger, M., Preville, X., Kotlyarov, A., Lutsch, G., Ducasse, C., Paul,
C., Wieske, M., Arrigo, A. P., Buchner, J., and Gaestel, M. (1999). Regulation of hsp27
oligomerization, chaperone function, and protective activity against oxidative stress/
tumor necrosis factor
. J. Biol. Chem., 274, 18947-18956.
[196] Hayess, K. and Benndorf, R. (1997). Effect of protein kinase inhibitors on activity of
mammalian small heat-shock protein (HSP25) kinase. Biochem. Pharmacol., 53, 12391247.
[197] Hirano, S., Sun, X., DeGuzman, C. A, Ransom, R. F., McLeish, K. R., Smoyer, W. E.,
Shelden, E. A., Welsh, M. J., and Benndorf, R. (2005). p38 MAPK/HSP25 signaling
mediates cadmium-induced contraction of mesangial cells and renal glomeruli. Am. J.
Physiol. Renal. Physiol., 288, F1133-F1143.
[198] Golenhofen, N., Perng, M. D., Quinlan, R. A., and Drenckhahn, D. (2004). Comparison
of the small heat shock proteins B-crystallin, MKBP, HSP25, HSP20, and cvHSP in
heart and skeletal muscle. Histochem. Cell Biol., 122, 415-425.
203
[199] Ito, H., Okamoto, K., Nakayama, H., Isobe, T., and Kato, K. (1997). Phosphorylation of
B-crystallin in response to various types of stress. J. Biol. Chem., 272, 29934-29941.
[200] Koh, T. J. and Escobedo, J. (2004). Cytoskeletal disruption and small heat shock
protein translocation immediately after lengthening contractions. Am. J. Physiol. Cell
Physiol., 286, 713-722.
[201] Somara, S. and Bitar, K. N. (2004). Tropomyosin interacts with phosphorylated HSP27
in agonist-induced contraction of smooth muscle. Am. J. Physiol. Cell Physiol., 286,
C1290-C1301.
[202] Paulsen, G., Lauritzen, F., Bayer, M. L., Kalhovde, J. M., Ugelstad, I., Owe, S. G.,
Hallen, J., Bergersen, L. H., and Raastad, T. (2009). Subcellular movement and
expression of HSP27, B-crystallin, and HSP70 after two bouts of eccentric exercise in
humans. J. Appl. Physiol., 107, 570-582.
[203] Kawano, F., Fujita, R., Nakai, N., Terada, M., Ohira, T., and Ohira, Y. (2012). HSP25
can modulate myofibrillar desmin cytoskeleton following the phosphorylation at ser15
in rat soleus muscle. J. Appl. Physiol., 112, 176-186.
[204] Goto, K., Okuyama, R., Honda, M., Uchida, H., Akema, T., Ohira, Y., and Yoshioka,
T. (2003). Profiles of connectin (titin) in atrophied soleus muscle induced by unloading
of rats. J. Appl. Physiol., 94, 897-902.
[205] Ikemoto, M., Nikawa, T., Takeda, S., Watanabe, C., Kitano, T., Baldwin, K. M., Izumi,
R., Nonaka, I., Towatari, T., Teshima, S., Rokutan, K., and Kishi, K. (2001). Space
shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association
with activation of ubiquitin-proteasome pathway. FASEB J., 15, 1279-1281.
[206] Yimlamai, T., Dodd, S. L., Borst, S. E., and Park, S. (2005). Clenbuterol induces
muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome
pathway. J. Appl. Physiol., 99, 71-80.
[207] Alford, E. K., Roy, R. R., Hodgson, J. A., and Edgerton, V. R. (1987).
Electromyography of rat soleus, medial gastrocnemius, and tibialis anterior during
hindlimb suspension. Exp. Neurol., 96, 635-649.
[208] Allen, D. L., Linderman, J. K., Roy, R. R., Bigbee, A. J., Grindeland, R. E., Mukku, V.,
and Edgerton, V. R. (1997). Apoptosis: a mechanism contributing to remodeling of
skeletal muscle in response to hindlimb unweighting. Am. J. Physiol. Cell Physiol., 273,
C579-C587.
[209] Ohira, M., Hanada, H., Kawano, F., Nomura, T., Nonaka, I., and Ohira, Y. (2002).
Regulation of the properties of rat hindlimb muscles following gravitational unloading.
Jpn. J. Physiol., 52, 235-245.
[210] Ohira, Y., Jiang, B., Roy, R. R., Oganov, V., Ilyina-Kakueva, E., Martin, J. F., and
Edgerton, V. R. (1992). Rat soleus muscle fiber responses to 14 days of spaceflight and
hindlimb suspension. J. Appl. Physiol., 73, 51S-57S.
[211] Ohira, Y., Yasui, W., Roy, R. R., and Edgerton, V. R. (1997). Effects of muscle length
on the response to unloading. Acta Anat., 159, 90-98.
[212] Wang, X. D., Kawano, F., Matsuoka, Y., Fukunaga, K., Terada, M., Sudoh, M.,
Ishihara, A., and Ohira, Y. (2006). Mechanical load-dependent regulation of satellite
cell and fiber size in rat soleus muscle. Am. J. Physiol. Cell Physiol., 290, C981-C989.
[213] Kawano, F., Nomura, T., Ishihara, A, Nonaka, I., and Ohira, Y. (2002). Afferent inputassociated reduction of muscle activity in microgravity environment. Neuroscience,
114, 1133-1138.
204
Fuminori Kawano
[214] Ohira, Y., Yasui, W., Roy, R. R., and Edgerton, V. R. (1997). Effects of muscle length
on the response to unloading. Acta Anat., 159, 90-98.
[215] De-Doncker, L., Kasri, M., Picquet, F., and Falempin, M. (2005). Physiologically
adaptive changes of the L5 afferent neurogram and of the rat soleus EMG activity
during 14 days of hindlimb unloading and recovery. J. Exp. Biol., 208, 4585-4592.
[216] Ohira, Y., Nomura, T., Kawano, F., Sato, Y., Ishihara, A., and Nonaka, I. (2002).
Effects of nine weeks of unloading on neuromuscular activities in adult rats. J. Gravit.
Physiol., 9: 49-60.
[217] Shah, S. B., Peters, D., Jordan, K. A., Milner, D. J., Fridn, J., Capetanaki, Y., and
Lieber, R. L. (2001). Sarcomere number regulation maintained after immobilization in
desmin-null mouse skeletal muscle. J. Exp. Biol., 204, 1703-1710.
[218] De-Doncker, L., Picquet, F., Petit, J., and Falempin, M. (2003). Effects of
hypodynamia-hypokinesia on the muscle spindle discharges of rat soleus muscle. J.
Neurophysiol., 89, 3000-3007.
[219] Miller, T. A., Lesniewski, L. A., Muller-Delp, J. M., Majors, A. K., Scalise, D., and
Delp, M. D. (2001). Hindlimb unloading induces a collagen isoform shift in the soleus
muscle of the rat. Am. J. Physiol. Reg. Int. Comp. Physiol., 281, R1710-R1717.
[220] Toursel, T., Stevens, L., Granzier, H., and Mounier, Y. (2002). Passive tension of rat
skeletal muscle fibers: effects of unloading conditions. J. Appl. Physiol., 92, 1465-1472.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 8
Abstract
Skeletal muscle possesses a great degree of metabolic plasticity, which can be
controlled by exercise, cytokines, pharmaceuticals and nutrients. There are large
variations in the human skeletal muscle metabolic capacity, and they are linked with the
prevalence of chronic metabolic disorders such as obesity, type II diabetes mellitus,
hypertension and dyslipidemia, as well as exercise endurance.
The metabolic profiles of skeletal muscle have been investigated for several decades.
5-AMP-activated protein kinase (AMPK) is one of the most important metabolic
regulators in skeletal muscle. AMPK is also activated by energy deprivation (i.e., an
increasing AMP:ATP ratio) and served as a cellular energy sensor. AMPK is activated by
muscle contraction (e.g., exercise), drugs used to treat type 2 diabetes mellitus, cytokines,
nutrients, reactive oxygen species and other chemically synthesized activators.
Activated AMPK promotes the catabolic pathways that generate ATP (e.g., glucose
uptake, fatty acid uptake and oxidation, and mitochondrial respiration). AMPK promotes
the translocation of glucose transporter 4 (GLUT4) from the cytoplasm to the cell
membrane and the subsequent glucose uptake into a cell independent of the insulin
system. AMPK also accelerates the mitochondrial fatty acid uptake by inhibiting the
acetyl-coenzyme A carboxylase activity. AMPK phosphorylates several downstream
transcription factors and coactivators that regulate energy catabolism. AMPK activation
results in the upregulation and the direct phosphorylation of the peroxisome proliferatoractivated receptor coactivator-1 (PGC-1), which is an important regulator for
mitochondrial biogenesis. In addition, AMPK indirectly deacetylates PGC-1 via SIRT1.
206
Masataka Suwa
These characteristics make AMPK a valuable therapeutic target for chronic metabolic
diseases associated with insulin resistance.
Introduction
One of the unique characteristics of skeletal muscle is its considerable heterogeneity in
terms of its metabolic properties. Skeletal muscle plays an important role in regulating the
whole body energy expenditure due to its great capacity for glucose and lipid metabolism.
Skeletal muscle can account for 40~50% of body weight in non-obese subjects [1] and as
much as 30% of the total resting substrate oxidation [2].
An impaired skeletal muscle metabolic capacity is considered to be associated with the
development of chronic metabolic disorders such as obesity and type 2 diabetes mellitus [3-8]
that are increasing in worldwide. The metabolic profile in skeletal muscle is also a key
determinant of physical performance [9-11].
How the metabolic properties in skeletal muscle are controlled has been investigated for
several decades. It is known there are a number of signaling molecules that regulate metabolic
adaptations in skeletal muscle, and hundreds of reports have reached the general hypothesis
that 5-AMP-activated protein kinase (AMPK) is a central energy-sensing master regulator of
cellular metabolism. AMPK was first described in 1987 as a common protein kinase
regulating fatty acid and cholesterol synthesis [12]. AMPK is present in many tissues [13]. It
regulates the carbohydrate and lipid metabolism in a cell [14] and also regulates appetite via
orexigenic neuropeptides in the hypothalamus [15], and it can control the whole body energy
metabolism.
AMPK is also considered to regulate protein synthesis and degradation [16-19], cellular
polarity [20, 21], the cell cycle [22], apoptosis [23] and autophagy [24]. AMPK has a possible
link with a variety of disorders, such as obesity, insulin resistance, metabolic syndrome,
cardiovascular diseases, stroke, dementia and cancer [14, 25]. AMPK expression is associated
with an extended life span in C. elagans [26, 27], and thus, the gene encoding it is considered
to be one of the longevity genes [28].
Skeletal muscle AMPK is activated by many stimuli including muscle contraction,
caloric restriction, hormones and cytokines, drugs, nutrients, reactive oxygen species (ROS)
and other chemically synthesized activators.
In recent years, AMPK has emerged as a critical regulator of skeletal muscle glucose
transport, fatty acid oxidation and mitochondrial biogenesis as a result of its phosphorylation
of downstream targets. AMPK is therefore a potential therapeutic target for obesity and type
II diabetes mellitus. This chapter will focus on how the AMPK regulates the skeletal muscle
energy balance and metabolic adaptations that are associated with the prevention and
therapeutics for such diseases.
AMPK
207
Figure 1. The structure of AMPK. AMPK is composed of a catalytic -subunit and regulatory - and subunits. The -subunit consists of the NH2-terminal kinase domain and its auto-inhibition domain and
-subunit interacting domain. The catalytic domain can be phosphorylated by upstream AMPK kinase
on threonine 172. The -subunit consists of a glycogen binding domain and an - and -subunitsinteracting domain. The -subunit is composed of four repeating cystathione--synthase (CBS) domains
that can interact with ATP, ADP, and AMP.
208
Masataka Suwa
AMPK
209
sensor in cells. Increased AMP or ADP levels promote their binding to the AMPK -subunit,
which presumably results in a conformational change in the AMPK heterotrimer from the
inactive to the active conformation [56]. This allosteric regulation increases the AMPK
activity by only a few fold [56, 57]. However, the binding of AMP promotes the
phosphorylation of Thr172 in the -subunit by liver kinase B1 (LKB1) and Ca2+/calmodulindependent protein kinases (CaMKK) [58]. Once AMPK is phosphorylated, AMP can further
allosterically activate it and inhibit the dephosphorylation of Thr172 by protein phosphatases
[58, 59. 60].
210
Masataka Suwa
As mentioned above, AMPK acts as an energy sensor by sensing energy deprivation (i.e.
increased an AMP/ATP level). Exercise incorporates the muscle contraction which enhances
the energy consumption by up to ~ 100 fold from rested muscle [72]. When the consumption
of ATP exceeds the generation during contraction, the AMP/ATP ratio is elevated, which
triggers the activation of AMPK through allosteric regulation and phosphorylation by LKB1.
Ionized calcium is considered to be an important signaling ion in skeletal muscle [73, 74].
Increasing the intracellular Ca2+ concentration by caffeine treatment can result in AMPK
activation, which occurs at least partially via CaMKK, in isolated skeletal muscle [72, 75].
Such caffeine-induced change preferentially occurs in AMPK1 in comparison to the
AMPK2 [72, 76]. Because an increasing intracellular Ca2+ level is essential for muscle
contraction, it is possible that increasing the intracellular Ca2+ released from the SR during
muscle contraction may promote the phosphorylation of AMPK.
Superoxide anion radicals (O2-), one of the ROS, are continually produced in cells, and
the production of O2- increases substantially in contracting muscle [77, 78]. O2- is
immediately enzymatically dismutated to hydrogen peroxide (H2O2) by superoxide dismutase
[77]. In NIH-3T3 cells, H2O2 treatment phosphorylated the Thr172 in 1-subunit in a
concentration-dependent manner [79]. In addition, the contraction-induced AMPK activation
was partially blocked by the antioxidant, N-acetylcysteine, in isolated muscle [80, 81].
Collectively, these results suggest that ROS may activate AMPK during contraction [81].
H2O2-induced AMPK1 activation is not associated with increasing the AMP level or
decreasing the ATP/AMP ratio [80]. Although the mechanisms involved in AMPK activation
by ROS have been still unclear, the AMPK1 activation by acute ROS production may occur
via an adenosine nucleotides-independent mechanism.
Nitric oxide (NO) producion in a tissue is catalyzed by NO synthase (NOS). NO is
considered to be an important signaling molecule required for the metabolic adaptations in
skeletal muscle fibers [82, 83]. NOS is the primary source of NO in the contracting muscle
[84, 85]. The NOS activity and phosphorylation of neuronal NOS in skeletal muscle increased
with endurance exercise [86, 87]. The treatment of isolated skeletal muscle with NO donors
increases the AMPK1 activity, but does not affect AMPK2 [88, 89]. Therefore it is
possible that the exercise-induced activation of AMPK1 (as mentioned below) is partially
associated with the increase in NOS activity and NO production.
Mild heat stress is also associated with the AMPK activity in skeletal muscle. The
temperature of skeletal muscle reaches ~40C during exercise [90-92]. The exposure of rat
hepatocytes to heat shock increases the AMPK activity, which is considered to be a potential
protective response against the stress [93]. The AMPK phosphorylation occurring after mild
heat stress at 40C is significantly higher than that at 37C in C2C12 muscle cells [94].
Collectively, these findings indicate that it is likely that the elevated temperature of skeletal
muscle during exercise activates AMPK.
Recent studies have demonstrated that skeletal muscle expresses and secretes cytokines
(myokines) and hormones that can work in an autocrine, paracrine and endocrine fashion [95,
96]. In response to acute exercise, several myokines are released from skeletal muscle [97,
98]. Exercise and contraction induce the expression and secretion of interleukin-6 (IL-6) [99101] and brain-derived neurotrophic factor (BDNF) [102] in skeletal muscle cells. IL-6 has
been reported to be an inflammatory cytokine [103], and the plasma IL-6 concentraiton
increases by numerous inflammatory conditions and infection diseases. However, the
circulating IL-6 level increases more dramatically, up to 100-fold, in response to exercise
AMPK
211
[104]. IL-6 has been shown to activate AMPK [105, 106], and the AMPK activation in
skeletal muscle during exercise is diminished in IL-6 knockout mice, thus suggesting that IL6 at least partially controls the exercise-induced activation of AMPK in skeletal muscle.
BDNF is a member of the neurotrophin family, and can play an important role in
neuronal outgrowth, differentiation, synaptic connection and neuronal repair [107]. The
circulating BDNF level also increases during exercise [108]. BDNF can activate the AMPK
in skeletal muscle cells [102]. Therefore, IL-6 and BDNF are the potent candidates for
activating AMPK in skeletal muscle during exercise.
A major question has been what types of exercise(s) activate AMPK in the skeletal
muscle. The AMPK activation by endurance exercise seems to be intensity- and timedependent. Low-intensity endurance exercise (40 to 50% maximal O2 uptake) for 20 to 90
min fails to change the AMPK activity [109, 110]. On the other hand, prolonged low-intensity
endurance exercise (~45% maximal O2 uptake) until exhaustion (~3.5 h) increases the
AMPK2 activity, but not the AMPK1 activity [111]. Moderate-intensity exercise (60 to
80% maximal O2 uptake) for five to 60 min also preferentially activates the AMPK2 [54,
109, 110, 112]. It is therefore suggested that low- to moderate-intensity exercise is associated
with isoform-specific and intensity- and time-dependent increases in AMPK2 activity, but
not in AMPK1 activity. Exposure to further high-intensity exercise, such as sprint exercise,
in single or four bouts of exhausting sprint exercises for 30s, thus leads to increase in the both
the AMPK1 and 2 activities [110, 113]. Resistance exercise also increases the activity and
phosphorylation of AMPK [114-116].
3.3.2. Hypoxia
An inadequate oxygen supply (hypoxia) is considered to be another types of metabolic
stress. Hypoxia limits oxidative phosphorylation and leads to a decrease in ATP production
and the ATP/AMP ratio [117]. Hypoxia can generate ROS, and peroxynitrate is generated
from NO under hypoxic conditins [118, 119]. Under such conditions, AMPK can be rapidly
activated [119, 120]. Hypoxia promotes the activation of both AMPK1 and 2 in skeletal
muscle [47, 117, 121].
3.3.3. Secretory Factors
Beside the intracellular factors, several autocrine, paracrine and endocrine factors
including hormones and cytokines, regulate the AMPK activity [122]. Leptin, adiponectin,
and ciliary neurotrophic factor (CNTF) can all activate the skeletal muscle AMPK, as well as
IL-6 and BDNF, which were reviewed above in section 4.3.1.
Adipose tissue is currently recognized as a secretory organ, which secretes a variety of
biologically active molecules called adipocytokines. Adipocytokines play an important role
in regulating metabolism and inflammation [123]. Leptin was the first adipocytokine
identified, and it can act on central and peripheral tissues to regulate the food intake and
energy expenditure [124]. Skeletal muscle expresses leptin receptors, and the administration
of leptin to mice has been shown to promote AMPK2 activation in skeletal muscle [125].
Leptin preferentially activates the AMPK of type I muscle fibers rather than type II fibers
[125, 126]. There seems to be two ways by which leptin activates AMPK2. One is a direct
effect that occurs rapidly. Another later effect occurs through a primary action of leptin on the
hypothalamus and the subsequent secondary effects on skeletal muscle, which are mediated
by the sympathetic nervous system [125].
212
Masataka Suwa
AMPK
213
muscle [153, 154]. The action of metformin on the AMPK phosphorylation in skeletal muscle
is much milder than that of AICAR. A single injection of metformin takes for 5-6 h to
increase the phosphorylation of AMPK [154], whereas intraperitoneal injection of AICAR
into rats increased the AMPK phosphorylation within 30 min after the injection [155].
Collectively, these findings suggest that metformin and AICAR regulate AMPK via different
mechanisms.
The biochemical mechanisms by which metformin activates AMPK are unclear, but the
effects of metformin such as the inhibition of mitochondrial complex I of the respiratory
chain [156, 157], production of reactive nitrogen species [158] and inhibition of AMP
deaminase [159] are all considered to be potential candidates. Interestingly, the activation of
AMPK by metformin or phenformin treatment of isolated perfused rat heart is followed by an
increase in the cytosolic AMP concentration, without any change in the total AMP content or
AMP/ATP ratio [160], raising the possibility that metabolically active AMP regulates the
AMPK activity, and that the action of biguanides on AMPK occurs through such a
mechanism.
Thiazolidinediones are agonists of the transcription factor peroxisome proliferatoractivated receptor (PPAR). Thiazolidinediones can improve insulin sensitivity and reduce
the lipolysis and content of fatty acids in adipocytes through the binding and activation of
PPAR [161]. In addition, AMPK can be rapidly activated by thiazolidinediones in skeletal
muscle, with a coincident increase in the AMP level and a decrease in the ATP level [162,
163]. Long-term administration of thiazolidinediones in vivo also enhances the basal AMPK
activity in patients with type II diabetes mellitus [164, 165], and in rats [166] and mice [167].
Such treatment also increases the circulating adiponectin level and adiponectin secretion from
adipose tissue [168].
Interestingly, exposure of cultured myocytes to rosiglitazone enhances their adiponectin
production and AMPK2 phosphorylation [169], suggesting that thiazolidinediones promote
the autocrine or paracrine control of AMPK via the adiponectin secretion in skeletal muscle.
Additionally, the ablation of adiponectin abolishes the increase in AMPK activity induced by
thiazolidinediones both in vivo and in vitro [167, 169]. These results imply that AMPK
activation in the skeletal muscle by thiazolidinediones is at least partially mediated by
adiponectin signals.
Many nutraceuticals derived from foods, beverages, and herbal medicine can also
activate AMPK. It was reported that many compounds, including the polyphenol resveratrol
(present in the skin of red grapes and in red wine) [170], the flavonoid quercetin (present in
many fruits and vegetables) [171], berberine (present in genus Berberis used in Chinese
medicine) [172], compounds derived from bitter melon [173], epigallocatechin gallate
(present in green tea) [174], capsaicin (present in peppers) [175], -lipoic acid (present in the
internal organs of animals and vegetables) [176], the isoflavone genistein (present in many
plant) [177], the flavonoid tangeretin (present in the peel of citrus fruits) [178] and osmotin
(present in the skin of vegetables and fruits) [179] can activate AMPK. Resveratrol, quercetin
and berberine have all reported to increase the ADP:ATP ratio, which is accompanied by the
inhibition of mitochondrial ATP synthesis, which is associated with AMPK activation in
[180]. Osmotin is a ligand for AdipoR1 [179]. The mechanisms of action for the other
compounds are currently unknown.
214
Masataka Suwa
AMPK
215
Exposure of cultured bovine aortic endothelial cells to palmitate, a saturated free fatty acid,
decreases the AMPK phosphorylation due to an increase in the PP2A activity [200]. PP2A is
activated by ceramide [201], which is de novo synthesized from saturated free fatty acids
[202]. Additionally, a cell-permeable analog of ceramide can mimic the effects of palmitate
on AMPK phosphorylation [200]. Collectively, these data indicate that it is possible for an
excess of saturated free fatty acids to increase the intracellular ceramide concentration, which
activates the PP2A and leads to AMPK dephosphorylation.
The essential amino acid leucine is associated with AMPK activity and phosphorylation.
Treatment of C2C12 myoblasts with leucine decreased their AMPK activity and
phosphorylation [203]. Acute leucine administration to rats decreased the AMPK
phosphorylation and AMP/ATP ratio in the gastrocnemius muscle [204]. On the contrary, the
incubation of mouse extensor digitorum longus muscle with leucine also decreased the
AMPK phosphorylation and AMPK2 activity, but the concentration of adenine nucleotides
did not change [205].
3.4.4. Secretory Factors
Resistin is a newly-identified adipocytokine expressed in adipocytes and macrophages
that may play a role in obesity-induced insulin resistance [206, 207]. Chronic hyperresistinemia in rats induced by the intravenous administration of an adenovirus encoding
mouse resistin downregulated the AMPK phosphorylation in the skeletal muscle, liver and
adipose tissue [208]. Exposure of L6 muscle cells to resistin (50 nM, i.e., ~625 ng/ml, 24 h)
also decreased the AMPK phosphorylation [209]. In contrast, incubating L6 cells with a
physiological concentration of resistin (100 ng/ml, 4 h) did not affect the AMPK status [210].
Although the reason(s) for the discrepancies between these findings are still unclear, the
differences in the concentrations of resistin and the length of exposure might have led to the
inconsistent results. Tumor necrosis factor- (TNF-) is cleaved by a TNF- converting
enzyme primarily produced by macrophages [211]. TNF- is also an adipocytokine [212],
and its effects are mediated by two receptors: TNFR1 and TNFR2 [213]. TNF- can inhibit
AMPK through TNFR1 signaling in cultured skeletal muscle cells and the skeletal muscle of
mice [189, 214]. TNF- promotes the expression of PP2C, which decreases the AMPK
phosphorylation in L6 myotube [189].
216
Masataka Suwa
inhibiting the hepatic glucose production and output. On the other hand, the inhibition or
ablation of insulin signaling proteins such as phosphatidylinositol-3-kinase (PI3K) [215, 216],
insulin receptor substrate 1 (IRS1) [217], or the serine/threonine-specific protein kinase Akt2
[218] did not affect the contraction-stimulated glucose uptake in skeletal muscle.
Furthermore, the effect of insulin and contraction on glucose uptake was additive [219]. It is
therefore considered that further insulin-independent mechanisms controlling glucose uptake
during contraction exist.
A great deal of evidence suggests that AMPK is an important regulator of the skeletal
muscle glucose uptake during contraction, as well as a regulator of sucrose nonfermenting
AMPK-related kinase [220] and Ca2+ [221].
The skeletal muscle glucose uptake is mainly accomplished by the translocation of
glucose transporter 4 (GLUT4) from intracellular sites into the plasma membrane. Activation
of AMPK increases the GLUT4 translocation and glucose uptake of skeletal muscle both in
vivo and in vitro [222, 223].
Figure 2. The glucose uptake induced by insulin and AMPK signals in skeletal muscle. The
autophosphorylation and activation of insulin receptor substrate 1 (IRS1) and phosphoinositide 3-kinase
(PI3K) are induced by the binding of insulin to the insulin receptor (IR). PI3K converts
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) by
phosphorylation. PIP3 interacts with phosphoinositide-dependent kinase 1 (PDK1), which
phosphorylates and activates Akt2. Akt2 phosphorylates the Rab guanosine triphosphatases (GTPases)
tre-2/USP6, BUB2, cdc16 (TBC1) domain family proteins of member 1 (TBC1D1) and member 4
(TBC1D4), which bind to 14-3-3 protein and their activities are inhibited. AMPK is phosphorylated and
activated by liver kinase B1 (LKB1) and Ca2+/calmodulin-dependent protein kinases (CaMKK). AMPK
is subjected to allosteric regulation by AMP and ADP. AMPK also inhibits TBC1D1 and TBC1D4, the
same as insulin signals. As a result, the level of guanosine diphosphate (GDP)-bound Rab protein
decreases, and then GLUT4 is released from intracellular sites to the plasma membrane.
AMPK
217
Although the mechanisms underlying how AMPK controls the GLUT4 translocation
have not been fully elucidated, it has been speculated that the tre-2/USP6, BUB2, cdc16
(TBC1) domain family proteins of member 1 (TBC1D1) and member 4 (TBC1D4, formerly
known as Akt substrate of 160 kDa), that regulate the GLUT4 trafficking by their Rab
guanosine triphosphatase (GTPase) activity [224-226], mediate the action of AMPK. Both
TBC1D1 and TBC1D4 are phosphorylated by AMPK [224, 227-229]. When phosphorylated,
TBC1Ds bind to 14-3-3 proteins and their Rab GTPase activity is inhibited. As a result, the
level of guanosine triphosphate (GTP)-bound Rab protein increases, and GLUT4 is released
from intracellular sites to the plasma membrane [224, 225, 229-231] (Figure 2).
AMPK plays a putative role in improving the insulin sensitivity of skeletal muscle. The
activation of AMPK by AICAR treatment enhances the insulin-stimulated glucose transport
to fast-twitch muscles in vivo and ex vivo [232-234]. One possible explanation for these
finding is that AMPK can activate the insulin signaling proteins, IRS1 and PI3K. AMPK
activation induces the phosphorylation of IRS1 on Ser-789 in cell free assays and in C2C12
myotubes [235]. In addition, preincubation of C2C12 myotubes with AICAR increased the
insulin-stimulated IRS1-associated PI3K activity [235]. Treatment of rats with AICAR for
five days also increased the insulin-stimulated IRS1-associated PI3K activity in isolated
skeletal muscle [236]. However, it has also been suggested that the phosphorylation of IRS1
on Ser-789 is associated with insulin resistance in genetically insulin-resistant animal models
[237]. Therefore, further studies are required to elucidate the role of AMPK in insulin
sensitivity and the phosphorylation of Ser-789 of IRS1.
218
Masataka Suwa
Skeletal muscle GLUT4 expression is increased by AMPK activation both in vivo [241, 245]
and in vitro [246]. The GLUT4 gene promoter contains putative binding sites for the
transcription factors GLUT4 enhancer factor (GEF) and myocyte enhancer factor 2 (MEF2)
[247, 248]. GEF can bind to the domain I in the GLUT4 promoter, which is necessary for
GLUT4 promoter activity [248]. The MEF2 binding domain is also required for the
transcriptional regulation of GLUT4 [247, 248]. The full extent of the transcriptional activity
of the GLUT4 gene appears to depend on the interaction between GEF and MEF2A [250].
MEF2 and GEF interact with the transcriptional co-repressor, histone deacetylase 5
(HDAC5), which inhibits the GLUT4 promoter activity [251, 252]. In human skeletal muscle
cell culture, AMPK was observed to phosphorylate the HDAC5 [253]. This reduced the
association between HDAC5 and the GLUT4 promoter and nuclear content of HDAC5, and
coincidently increased the GLUT4 expression [253], suggesting that AMPK regulates the
GLUT4 expression by removing HDAC5 from the GLUT4 promoter. Furthermore, the
activation of AMPK by AICAR injection in rats induced the GEF phosphorylation, the
translocation of GEF and MEF2 into the nucleus, and the binding of these proteins to DNA,
which subsequently increased the GLUT4 mRNA expression in skeletal muscle [254].
Additionally, the removal of HDAC5 from GEF-MEF2 enables the recruitment of
transcriptional coactivators, such as peroxisome proliferator activated receptor coactivator1 (PGC-1), which is also activated by AMPK (as mentioned below), and upregulates the
GLUT4 transcription via the interaction with MEF2 [255]. Treatment of wild type mice with
AICAR for 28 consecutive days increased the GLUT4 protein expression, especially in the
white gastrocnemius and quadriceps muscles, whereas such changes are fully abolished in
PGC-1 knockout mice [256], thus suggesting that the AMPK-induced GLUT4 biogenesis
requires the PGC-1.
AMPK
219
220
Masataka Suwa
Figure 3. The role of AMPK in fatty acid (FA) metabolism in skeletal muscle cells. AMPK promotes
the translocation of FA transporter/CD36 (CD36) translocation from intracellular sites to the plasma
membrane and the subsequent FA uptake. Intracellular FAs are converted into fatty acyl coenzyme A
(FA-CoA) by FA-CoA synthase before mitochondrial uptake. FA-CoA transport to mitochondrial
intermembrane space is catalyzed by carnitine palmitoyltransferase-I (CPT-I), which converts the FACoA to acylcarnitine. The acylcarnitine can permeate the inner membrane via the carnitineacylcarnitine translocase (CAT) system. The acylcarnitine is reconverted into FA-CoA by CPT-II in the
mitochondrial matrix. CPT-I is inhibited by malonyl-CoA, which is carboxylated from acetyl-CoA by
acetyl-CoA carboxylase 2 (ACC2). When the ACC2 activity increases, an increase in the malonyl-CoA
level and a coincident decrease in CPT-I activity occur. AMPK can phosphorylate and inhibit ACC2,
which decreases the malonyl-CoA concentration and leads to an increase in CPT-I activity. Because
CPT-I is the rate-limiting enzyme for this process, the FA-CoA level in the matrix increases. The FACoA in the matrix is oxidized through -oxidation, the TCA cycle, and the electron transport chain
(ETC).
AMPK
221
Two isoforms of ACC have been identified (ACC1 and ACC2). The primary isoform of
ACC in skeletal muscle is ACC2, which is localized in the mitochondrial outer membrane
[282]. The activation of AMPK by AICAR increases the ACC2 phosphorylation and FA
oxidation, since it decreases the malonyl-CoA concentration in the skeletal muscle [222, 268,
269] (Figure 3).
FA-CoA in the mitochondrial matrix is oxidized through -oxidation, the TCA cycle, and
via electron transport chain processes by many oxidative enzymes. The mitochondrial
components involved in FA oxidation are increased by the chronic activation of AMPK in
skeletal muscle. Long-term AMPK activation in rats promoted an increase in mitochondrial
enzyme activity and protein expression in the skeletal muscle [261, 262, 283]. Such changes
of mitochondrial biogenesis would therefore positively contribute to enhancing the oxidative
capacity of FA.
222
Masataka Suwa
AMPK
223
224
Masataka Suwa
and activates PPAR and the proteins cooperate to induce the expression of genes involved in
mitochondrial fatty acid uptake and -oxidation [312]. As shown in Figure 4, PGC-1 can
promote the mitochondrial biogenesis via interactions with transcription factors as well as by
altering the glucose metabolism.
Conclusion
AMPK is a // heterotrimeric serine/threonine kinase. The AMPK activity is controlled
by upstream kinases, and also adenosine nucleotides also allosterically regulate the activity of
AMPK. In skeletal muscle cells, AMPK is activated by many types of stimuli, such as
exercise, secretory factors, nutrients, and chemical activators. AMPK regulates energy
metabolism via key signaling molecules, thereby controlling the energy homeostasis and gene
transcription. AMPK enhances the glucose and FA uptake, FA oxidation and mitochondrial
biogenesis and respiration in skeletal muscle cells. Further investigations about the
AMPK
225
mechanisms underlying AMPK activation and signaling will be important for better
understanding obesity and type II diabetes mellitus, and may lead to the development of novel
preventive or therapeutic strategies for these diseases.
Acknowledgments
This work was supported by a research Grant-in-Aid for Scientific Research (C) (No.
24500796) from the Ministry of Education, Science, Culture, Sports, Science and Technology
of Japan.
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
Owen, O. E., Reichard, G. A. Jr., Boden, G., Patel, M. S. & Trapp, V. E. (2012).
Interrelationships among key tissues in the utilization of metabolic substrates. In H. M.
Katzen & R. J. Mahler (Eds.), Advances in Modern Nutrition: Diabetes, Obesity, and
Vascular Disease: Metabolic and Molecular Interrelationships, Part 2 (Vol. 2, pp. 517550). New York, NY: Wiley.
Zurlo, F., Larson, K., Bogardus, C. & Ravussin, E. (1990). Skeletal muscle metabolism
is a major determinant of resting energy expenditure. J. Clin. Invest, 86, 1423-1427.
Kim, J. Y., Hickner, R. C., Cortright, R. L., Dohm, G. L. & Houmard, J. A. (2000).
Lipid oxidation is reduced in obese human skeletal muscle. Am. J. Physiol. Endocrinol.
Metab, 279, E1039-E1044.
Kelley, D. E., He, J., Menshikova, E. V. & Ritov, V. B. (2002). Dysfunction of
mitochondria in human skeletal muscle in type 2 diabetes. Diabetes, 51, 2944-2950.
DeFronzo, R. A., Gunnarsson, R., Bjrkman, O., Olsson, M. & Wahren, J. (1985).
Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulindependent (type II) diabetes mellitus. J. Clin. Invest, 76, 149-155.
Kelley, D. E., Mintun, M. A., Watkins, S. C., Simoneau, J. A., Jadali, F., Fredrickson,
A., Beattie, J. & Thriault, R. (1996). The effect of non-insulin-dependent diabetes
mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J.
Clin. Invest, 97, 2705-2713.
Ritov, V. B., Menshikova, E. V., Azuma, K., Wood, R., Toledo, F. G., Goodpaster, B.
H., Ruderman, N. B. & Kelley, D. E. (2010). Deficiency of electron transport chain in
human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am. J.
Physiol. Endocrinol. Metab, 298, E49-E58.
Suwa, M., Kumagai, S., Higaki, Y., Nakamura, T. & Katsuta, S. (2002). Dietary
obesity-resistance and muscle oxidative enzyme activities of the fast-twitch fibre
dominant rat. Int. J. Obes. Relat. Metab. Disord, 26, 830-837.
Tesch, P. A., Wright, J. E., Vogel, J. A., Daniels, W. L., Sharp, D. S. & Sjdin, B.
(1985). The influence of muscle metabolic characteristics on physical performance. Eur
J. Appl. Physiol, 54, 237-243.
226
Masataka Suwa
[10] Blomstrand, E., Rdegran, G. & Saltin, B. (1997). Maximum rate of oxygen uptake by
human skeletal muscle in relation to maximal activities of enzymes in the Krebs cycle.
J. Physiol, 501, 455-460.
[11] Seifert, E. L., Bastianelli, M., Aguer, C., Moffat, C., Estey, C., Koch, L. G., Britton, S.
L. & Harper, M. E. (2012). Intrinsic aerobic capacity correlates with greater inherent
mitochondrial oxidative and H2O2 emission capacities without major shifts in myosin
heavy chain isoform. J. Appl. Physiol, 113, 1624-1634.
[12] Carling, D., Zammit, V. A. & Hardie, D. G. (1987). A common bicyclic protein kinase
cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis.
FEBS Lett, 223, 217-222.
[13] Stapleton, D., Mitchelhill, K. I., Gao, G., Widmer, J., Michell, B. J., The, T., House, C.
M., Fernandez, C. S., Cox, T., Witters, L. A. & Kemp, B. E. (1996). Mammalian AMPactivated protein kinase subfamily. J. Biol. Chem, 271, 611-614.
[14] Steinberg, G. R. & Kemp, B. E. (2009). AMPK in Health and Disease. Physiol. Rev, 89,
1025-1078.
[15] Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y. B., Lee, A., Xue, B., Mu, J.,
Foufelle, F., Ferr, P., Birnbaum, M. J., Stuck, B. J. & Kahn, B. B. (2004). AMP-kinase
regulates food intake by responding to hormonal and nutrient signals in the
hypothalamus. Nature, 428, 569-574.
[16] Meley, D., Bauvy, C., Houben-Weerts, J. H., Dubbelhuis, P. F., Helmond, M. T.,
Codogno, P. & Meijer, A. J. (2006). AMP-activated protein kinase and the regulation of
autophagic proteolysis. J. Biol. Chem, 281, 34870-34879.
[17] Krawiec, B. J., Nystrom, G. J., Frost, R. A., Jefferson, L. S. & Lang, C. H. (2007).
AMP-activated protein kinase agonists increase mRNA content of the muscle-specific
ubiquitin ligases MAFbx and MuRF1 in C2C12 cells. Am. J. Physiol. Endocrinol.
Metab, 292, E1555-E1567.
[18] Nakashima, K. & Yakabe, Y. (2007). AMPK activation stimulates myofibrillar protein
degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO
transcription factors in C2C12 myotubes. Biosci. Biotechnol. Biochem, 71, 1650-1656.
[19] Nystrom, G. J. & Lang, C. H. (2008). Sepsis and AMPK Activation by AICAR
Differentially Regulate FoxO-1, -3 and -4 mRNA in Striated Muscle. Int. J. Clin. Exp.
Med, 1, 50-63.
[20] Lee, J. H., Koh, H., Kim, M., Kim, Y., Lee, S. Y., Karess, R. E., Lee, S. H., Shong, M.,
Kim, J. M., Kim, J. & Chung, J. (2007). Energy-dependent regulation of cell structure
by AMP-activated protein kinase. Nature, 447, 1017-1020.
[21] Mirouse, V., Swick, L. L., Kazgan, N., St Johnston, D. & Brenman, J. E. (2007). LKB1
and AMPK maintain epithelial cell polarity under energetic stress. J. Cell Biol, 177,
387-392.
[22] Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M. & Esumi, H. (2001). Cell cycle
regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5aminoimidazole- 4-carboxamide-1--D-ribofuranoside, in a human hepatocellular
carcinoma cell line. Biochem. Biophys. Res. Commun, 287, 562-567.
[23] Dagon, Y., Avraham, Y. & Berry, E. M. (2006). AMPK activation regulates apoptosis,
adipogenesis, and lipolysis by eIF2 in adipocytes. Biochem. Biophys. Res. Commun,
340, 43-47.
AMPK
227
[24] Wang, Z., Wilson, W. A., Fujino, M. A. & Roach, P. J. (2001). Antagonistic controls of
autophagy and glycogen accumulation by Snf1p, the yeast homolog of AMP-activated
protein kinase, and the cyclin-dependent kinase Pho85p. Mol. Cell Biol, 21, 5742-5752.
[25] Lage, R., Diguez, C., Vidal-Puig, A. & Lpez, M. (2008). AMPK: a metabolic gauge
regulating whole-body energy homeostasis. Trends Mol. Med, 14, 539-549.
[26] Apfeld, J., O'Connor, G., McDonagh, T., DiStefano, P. S. & Curtis, R. (2004). The
AMP-activated protein kinase AAK-2 links energy levels and insulin-like signals to
lifespan in C. elegans. Genes Dev, 18, 3004-3009.
[27] Greer, E. L., Dowlatshahi, D., Banko, M. R., Villen, J., Hoang, K., Blanchard, D., Gygi,
S. P. & Brunet, A. (2007). An AMPK-FOXO pathway mediates longevity induced by a
novel method of dietary restriction in C. elegans. Curr. Biol, 17, 1646-1656.
[28] Kenyon, C. J. (2010). The genetics of ageing. Nature, 464, 504-512.
[29] Hardie, D. G., Carling, D. & Carlson, M. (1998). The AMP-activated/SNF1 protein
kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem, 67,
821-855.
[30] Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D. &
Hardie, D. G. (1996). Characterization of the AMP-activated protein kinase kinase from
rat liver and identification of threonine 172 as the major site at which it phosphorylates
AMP-activated protein kinase. J. Biol. Chem, 271, 27879-27887.
[31] Xiao, B., Heath, R., Saiu, P., Leiper, F. C., Leone, P., Jing, C., Walker, P. A., Haire, L.,
Eccleston, J. F., Davis, C. T., Martin, S. R., Carling, D. & Gamblin, S. J. (2007).
Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature,
449, 496-500.
[32] Woods, A., Cheung, P. C., Smith, F. C., Davison, M. D., Scott, J., Beri, R. K. &
Carling, D. (1996). Characterization of AMP-activated protein kinase and subunits.
Assembly of the heterotrimeric complex in vitro. J. Biol. Chem, 26, 10282-10290.
[33] Polekhina, G., Gupta, A., Michell, B. J., van Denderen, B., Murthy, S., Feil, S. C.,
Jennings, I. G., Campbell, D. J., Witters, L. A., Parker, M. W., Kemp, B. E. &
Stapleton, D. (2003). AMPK subunit targets metabolic stress sensing to glycogen.
Curr. Biol, 13, 867-871.
[34] Machovic, M. & Janecek, S. (2006). The evolution of putative starch-binding domains.
FEBS Lett, 580, 6349-6356.
[35] Scott, J. W., Ross, F. A., Liu, J. K. & Hardie, D. G. (2007). Regulation of AMPactivated protein kinase by a pseudosubstrate sequence on the subunit. EMBO J, 26,
806-815.
[36] SantAna Pereira, J. A. A., Ennion, S., Sargeant, A. J., Moorman, A. F. M. &
Goldspink, G. (1997). Comparison of the molecular, antigenic and ATPase
determinants of fast myosin heavy chains in rat and human: a single-fibre study.
Pflgers Arch, 435, 151-163.
[37] LaFramboise, W. A., Daood, M. J., Guthrie, R. D., Moretti, P., Schiaffino. S. & Ontell,
M. (1990). Electrophoretic separation and immunological identification of type 2X
myosin heavy chain in rat skeletal muscle. Biochim. Biophys. Acta, 1035, 109-112.
[38] Termin, A., Staron, R. S. & Pette, D. (1989). Myosin heavy chain isoforms in
histochemically defined fiber types of rat muscle. Histochemistry, 92, 453-457.
228
Masataka Suwa
[39] Galler, S., Schmitt, T. L. & Pette, D. (1994). Stretch activation, unloaded shortening
velocity, and myosin heavy chain isoforms of rat skeletal muscle fibres. J. Physiol, 478,
513-521.
[40] Durante, P. E., Mustard, K. J., Park, S. H., Winder, W. W. & Hardie, D. G. (2002).
Effects of endurance training on activity and expression of AMP-activated protein
kinase isoforms in rat muscles. Am. J. Physiol. Endocrinol. Metab, 283, E178-E186.
[41] Mahlapuu, M., Johansson, C., Lindgren, K., Hjlm, G., Barnes, B. R., Krook, A.,
Zierath, J. R., Andersson, L. & Marklund, S. (2004). Expression profiling of the subunit isoforms of AMP-activated protein kinase suggests a major role for 3 in white
skeletal muscle. Am. J. Physiol. Endocrinol. Metab, 286, E194-E200.
[42] Yu, H., Fujii, N., Hirshman, M. F., Pomerleau, J. M. & Goodyear, L. J. (2004). Cloning
and characterization of mouse 5'-AMP-activated protein kinase 3 subunit. Am. J.
Physiol. Cell Physiol, 286, C283-C292.
[43] McGee, S. L., Mustard, K. J., Hardie, D. G. & Baar, K. (2008). Normal hypertrophy
accompanied by phosphoryation and activation of AMP-activated protein kinase 1
following overload in LKB1 knockout mice. J. Physiol, 586, 1731-1741.
[44] Mounier, R., Lantier, L., Leclerc, J., Sotiropoulos, A., Pende, M., Daegelen, D.,
Sakamoto, K., Foretz, M. & Viollet, B. (2009). Important role for AMPK in limiting
skeletal muscle cell hypertrophty. FASEB J, 23, 2264-2273.
[45] Rckl, K. S., Hirshman, M. F., Brandauer, J., Fujii, N., Witters, L. A. & Goodyear, L. J.
(2007). Skeletal muscle adaptation to exercise training: AMP-activated protein kinase
mediates muscle fiber type shift. Diabetes, 56, 2062-2069.
[46] Mu, J., Brozinick, Jr. J. T., Valladares, O., Mu, J., Brozinick, J. T. Jr., Valladares, O.,
Bucan, M. & Birnbaum, M. J. (2001). A role for AMP-activated protein kinase in
contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell, 7,
1085-1094.
[47] Jrgensen, S. B., Treebak, J. T., Viollet, B., Schjerling, P., Vaulont, S., Wojtaszewski,
J. F. & Richter, E. A. (2007). Role of AMPK2 in basal, training-, and AICAR-induced
GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle. Am. J.
Physiol. Endocrinol. Metab, 292, E331-E339.
[48] Fujii, N., Ho, R. C., Manabe, Y., Jessen, N., Toyoda, T., Holland, W. L., Summers, S.
A., Hirshman, M. F. & Goodyear, L. J. (2008). Ablation of AMP-activated protein
kinase 2 activity exacerbates insulin resistance induced by high-fat feeding of mice.
Diabetes, 57, 2958-2966.
[49] Nilsson, E. C., Long, Y. C., Martinsson, S., Glund, S., Garcia-Roves, P., Svensson, L.
T., Andersson, L., Zierath, J. R. & Mahlapuu, M. (2006). Opposite transcriptional
regulation in skeletal muscle of AMP-activated protein kinase 3 R225Q transgenic
versus knock-out mice. J. Biol. Chem, 281, 7244-7252.
[50] Barnes, B. R., Glund, S., Long, Y. C., Hjlm, G., Andersson, L. & Zierath, J. R. (2005).
5'-AMP-activated protein kinase regulates skeletal muscle glycogen content and
ergogenics. FASEB J, 19, 773-779.
[51] Garcia-Roves, P. M., Osler, M. E., Holmstrm, M. H. & Zierath, J. R. (2008). Gain-offunction R225Q mutation in AMP-activated protein kinase 3 subunit increases
mitochondrial biogenesis in glycolytic skeletal muscle. J. Biol. Chem, 283, 3572435734.
AMPK
229
[52] Crawford, S. A., Costford, S. R., Aguer, C., Thomas, S. C., deKemp, R. A., DaSilva, J.
N., Lafontaine, D., Kendall, M., Dent, R., Beanlands, R. S., McPherson, R. & Harper,
M. E. (2010). Naturally occurring R225W mutation of the gene encoding AMPactivated protein kinase (AMPK)3 results in increased oxidative capacity and glucose
uptake in human primary myotubes. Diabetologia, 53, 1986-1997.
[53] Wojtaszewski, J. F., Birk, J. B., Frsig, C., Holten, M., Pilegaard, H. & Dela, F. (2005).
5'AMP activated protein kinase expression in human skeletal muscle: effects of strength
training and type 2 diabetes. J. Physiol, 564, 563-573.
[54] Birk, J. B. & Wojtaszewski, J. F. (2006). Predominant 2/2/3 AMPK activation
during exercise in human skeletal muscle. J. Physiol, 577, 1021-1032.
[55] Oakhill, J. S., Scott, J. W. & Kemp, B. E. (2012). AMPK functions as an adenylate
charge-regulated protein kinase. Trends Endocrinol. Metab, 23, 125-132.
[56] Cheung, P. C., Salt, I. P., Davies, S. P., Hardie, D. G. & Carling, D. (2000).
Characterization of AMP-activated protein kinase -subunit isoforms and their role in
AMP binding. Biochem. J, 346, 659-669.
[57] Suter, M., Riek, U., Tuerk, R., Schlattner, U., Wallimann, T. & Neumann, D. (2006).
Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of
AMP-activated protein kinase. J. Biol. Chem, 281, 32207-32216.
[58] Oakhill, J. S., Chen, Z. P., Scott, J. W., Steel, R., Castelli, L. A., Ling, N., Macaulay, S.
L. & Kemp, B. E. (2010). -Subunit myristoylation is the gatekeeper for initiating
metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl. Acad.
Sci .U S A, 107, 19237-19241.
[59] Sanders, M. J., Grondin, P. O., Hegarty, B. D., Snowden, M. A. & Carling, D. (2007).
Investigating the mechanism for AMP activation of the AMP-activated protein kinase
cascade. Biochem. J, 403, 139-148.
[60] Xiao, B., Sanders, M. J., Underwood, E., Heath, R., Mayer, F. V., Carmena, D., Jing,
C., Walker, P. A., Eccleston, J. F., Haire, L. F., Saiu, P., Howell, S. A., Aasland, R.,
Martin, S. R., Carling, D. & Gamblin, S. J. (2011). Structure of mammalian AMPK and
its regulation by ADP. Nature, 472, 230-233.
[61] Boudeau, J., Baas, A. F., Deak, M., Morrice, N. A., Kieloch, A., Schutkowski, M.,
Prescott, A. R., Clevers, H. C. & Alessi, D. R. (2003). MO25/ interact with
STRAD/ enhancing their ability to bind, activate and localize LKB1 in the
cytoplasm. EMBO J, 22, 5102-5114.
[62] Zeqiraj, E., Filippi, B. M., Deak, M., Alessi, D. R. & van Aalten, D. M. (2009).
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of
kinase activation. Science, 326, 1707-1711.
[63] Sakamoto, K., McCarthy, A., Smith, D., Green, K. A., Grahame Hardie, D., Ashworth,
A. & Alessi, D. R. (2005). Deficiency of LKB1 in skeletal muscle prevents AMPK
activation and glucose uptake during contraction. EMBO J, 24, 1810-1820.
[64] Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M.,
Frenguelli, B. G. & Hardie, D. G. (2005). Calmodulin-dependent protein kinase kinase is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab, 2, 919.
[65] Hurley, R. L., Anderson, K. A., Franzone, J. M., Kemp, B. E., Means, A. R. & Witters,
L. A. (2005). The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated
protein kinase kinases. J. Biol. Chem, 280, 29060-29066.
230
Masataka Suwa
[66] Edelman, A. M., Mitchelhill, K. I., Selbert, M. A., Anderson, K. A., Hook, S. S.,
Stapleton, D., Goldstein, E. G., Means, A. R. & Kemp. B. E. (1996). Multiple Ca2+calmodulin-dependent protein kinase kinases from rat brain. Purification, regulation by
Ca2+-calmodulin, and partial amino acid sequence. J. Biol. Chem, 271, 10806-10810.
[67] Witczak, C. A., Fujii, N., Hirshman, M. F. & Goodyear, L. J. (2007). Ca2+/calmodulindependent protein kinase kinase- regulates skeletal muscle glucose uptake independent
of AMP-activated protein kinase and Akt activation. Diabetes, 56, 1403-1409.
[68] Kitani, T., Okuno, S. & Fujisawa, H. (1997). Molecular cloning of Ca2+/calmodulindependent protein kinase kinase . J. Biochem, 122, 243-250.
[69] Jensen, T. E., Rose, A. J., Jrgensen, S. B., Brandt, N., Schjerling, P., Wojtaszewski, J.
F. & Richter, E. A. (2007). Possible CaMKK-dependent regulation of AMPK
phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle
contraction. Am. J. Physiol. Endocrinol. Metab, 292, E1308-E1317.
[70] Jensen, T. E., Rose, A. J., Hellsten, Y., Wojtaszewski, J. F. & Richter, E. A. (2007).
Caffeine-induced Ca2+ release increases AMPK-dependent glucose uptake in rodent
soleus muscle. Am. J. Physiol. Endocrinol. Metab, 293, E286-E292.
[71] Winder, W. W. & Hardie, D. G. (1996). Inactivation of acetyl-CoA carboxylase and
activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol.
Endocrinol. Metab, 270, E299-E304.
[72] Sahlin, K., Tonkonogi, M. & Sderlund, K. (1998). Energy supply and muscle fatigue
in humans. Acta Physiol. Scand, 162, 261-266.
[73] Berchtold, M. W., Brinkmeier, H. & Mntener, M. (2000). Calcium ion in skeletal
muscle: its crucial role for muscle function, plasticity, and disease. Physiol. Rev, 80,
1215-1265.
[74] Al-Shanti, N. & Stewart, C. E. (2009). Ca2+/calmodulin-dependent transcriptional
pathways: potential mediators of skeletal muscle growth and development. Biol. Rev.
Camb. Philos. Soc, 84, 637-652.
[75] Raney, M. A. & Turcotte, L. P. (2008). Evidence for the involvement of CaMKII and
AMPK in Ca2+-dependent signaling pathways regulating FA uptake and oxidation in
contracting rodent muscle. J. Appl. Physiol, 104, 1366-1373.
[76] Egawa, T., Hamada, T., Ma, X., Karaike, K., Kameda, N., Masuda, S., Iwanaka, N. &
Hayashi, T. (2011). Caffeine activates preferentially 1-isoform of 5'AMP-activated
protein kinase in rat skeletal muscle. Acta Physiol, 201, 227-238.
[77] Murrant, C. L. & Reid, M. B. (2001). Detection of reactive oxygen and reactive
nitrogen species in skeletal muscle. Microsc. Res. Tech, 55, 236-248.
[78] Katz, A. (2007). Modulation of glucose transport in skeletal muscle by reactive oxygen
species. J. Appl. Physiol, 102, 1671-1676.
[79] Choi, S. L., Kim, S. J., Lee, K. T., Kim, J., Mu, J., Birnbaum, M. J., Soo, K. S. & Ha, J.
(2001). The regulation of AMP-activated protein kinase by H2O2. Biochem. Biophys.
Res. Commun, 287, 92-97.
[80] Toyoda, T., Hayashi, T., Miyamoto, L., Yonemitsu, S., Nakano, M., Tanaka, S.,
Ebihara, K., Masuzaki, H., Hosoda, K., Inoue, G., Otaka, A., Sato, K., Fushiki, T. &
Nakao, K. (2004). Possible involvement of the 1 isoform of 5'AMP-activated protein
kinase in oxidative stress-stimulated glucose transport in skeletal muscle. Am. J.
Physiol. Endocrinol. Metab, 287, E166-E173.
AMPK
231
[81] Sandstrm, M. E., Zhang, S. J., Bruton, J., Silva, J. P., Reid, M. B., Westerblad, H. &
Katz, A. (2006). Role of reactive oxygen species in contraction-mediated glucose
transport in mouse skeletal muscle. J. Physiol, 575, 251-262.
[82] Tengan, C. H., Rodrigues, G. S. & Godinho, R. O. (2012). Nitric oxide in skeletal
muscle: role on mitochondrial biogenesis and function. Int. J. Mol. Sci, 13, 1716017184.
[83] McConell, G. K., Rattigan, S., Lee-Young, R. S., Wadley, G. D. & Merry, T. L. (2012).
Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. Am
J. Physiol. Endocrinol. Metab, 303, E301-E317.
[84] Pattwell, D. M., McArdle, A., Morgan, J. E., Patridge, T. A. & Jackson, M. J. (2004).
Release of reactive oxygen and nitrogen species from contracting skeletal muscle cells.
Free Radic. Biol. Med, 37, 1064-1072.
[85] Hirschfield, W., Moody, M. R., O'Brien, W. E., Gregg, A. R., Bryan, R. M. Jr. & Reid,
M. B. (2000). Nitric oxide release and contractile properties of skeletal muscles from
mice deficient in type III NOS. Am. J. Physiol. Regul. Integr. Comp. Physiol, 278, R95R100.
[86] Chen, Z. P., Stephens, T. J., Murthy, S., Canny, B. J., Hargreaves, M., Witters, L. A.,
Kemp, B. E. & McConell, G. K. (2003). Effect of exercise intensity on skeletal muscle
AMPK signaling in humans. Diabetes, 52, 2205-2212.
[87] Roberts, C. K., Barnard, R. J., Jasman, A. & Balon, T. W. (1999). Acute exercise
increases nitric oxide synthase activity in skeletal muscle. Am. J. Physiol. Endocrinol.
Metab, 277, E390-E394.
[88] Deshmukh, A. S., Long, Y. C., de Castro Barbosa, T., Karlsson, H. K., Glund, S.,
Zavadoski, W. J., Gibbs, E. M., Koistinen, H. A., Wallberg-Henriksson, H. & Zierath,
J. R. (2010). Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase
(AMPK)1-specific activity and glucose transport in human skeletal muscle.
Diabetologia, 53, 1142-1150.
[89] Higaki, Y., Hirshman, M. F., Fujii, N. & Goodyear, L. J. (2001). Nitric oxide increases
glucose uptake through a mechanism that is distinct from the insulin and contraction
pathways in rat skeletal muscle. Diabetes, 50, 241-247.
[90] Morton, J. P., MacLaren, D. P., Cable, N. T., Bongers, T., Griffiths, R. D., Campbell, I.
T, Evans, L., Kayani, A., McArdle, A. & Drust, B. (2006). Time course and differential
responses of the major heat shock protein families in human skeletal muscle following
acute nondamaging treadmill exercise. J. Appl. Physiol, 101, 1760-1712.
[91] Saltin, B., Gagge, A. P., Bergh, U. & Stolwijk, J. A. (1972). Body temperatures and
sweating during exhaustive exercise. J. Appl. Physiol, 32, 635-643.
[92] Saltin, B., Gagge, A. P. & Stolwijk, J. A. (1968). Muscle temperature during
submaximal exercise in man. J. Appl. Physiol, 25, 679-688.
[93] Corton, J. M., Gillespie, J. G. & Hardie, D. G. (1994). Role of the AMP-activated
protein kinase in the cellular stress response. Curr. Biol, 4, 315-324.
[94] Liu, C. T. & Brooks, G. A. (2012). Mild heat stress induces mitochondrial biogenesis in
C2C12 myotubes. J. Appl. Physiol, 112, 354-361.
[95] Pedersen, B. K. & Febbraio, M. A. (2012). Muscles, exercise and obesity: skeletal
muscle as a secretory organ. Nat. Rev. Endocrinol, 8, 457-465.
[96] Pedersen, B. K. (2011). Muscles and their myokines. J. Exp. Biol, 214, 337-346.
232
Masataka Suwa
[97] Pedersen, B. K., Akerstrm, T. C., Nielsen, A. R. & Fischer, C. P. (2007). Role of
myokines in exercise and metabolism. J. Appl. Physiol, 103, 1093-1098.
[98] Scheele, C., Nielsen, S. & Pedersen, B. K. (2009). ROS and myokines promote muscle
adaptation to exercise. Trends Endocrinol. Metab, 20, 95-99.
[99] Hiscock, N., Chan, M. H., Bisucci, T., Darby, I. A. & Febbraio, M. A. (2004). Skeletal
myocytes are a source of interleukin-6 mRNA expression and protein release during
contraction: evidence of fiber type specificity. FASEB J, 18, 992-994.
[100] Steensberg, A., van Hall, G., Osada, T., Sacchetti, M., Saltin, B. & Pedersen, B. K.
(2000). Production of interleukin-6 in contracting human skeletal muscles can account
for the exercise-induced increase in plasma interleukin-6. J. Physiol, 529, 237-242.
[101] Steensberg, A., Keller, C., Starkie, R. L., Osada, T., Febbraio, M. A. & Pedersen, B. K.
(2002). IL-6 and TNF- expression in, and release from, contracting human skeletal
muscle. Am. J. Physiol. Endocrinol. Metab, 283, E1272-E1278.
[102] Matthews, V. B., Astrm, M. B., Chan, M. H., Bruce, C. R., Krabbe, K. S., Prelovsek,
O., Akerstrm, T., Yfanti, C., Broholm, C., Mortensen, O. H., Penkowa, M., Hojman,
P., Zankari, A., Watt, M. J., Bruunsgaard, H., Pedersen, B. K. & Febbraio, M. A.
(2009). Brain-derived neurotrophic factor is produced by skeletal muscle cells in
response to contraction and enhances fat oxidation via activation of AMP-activated
protein kinase. Diabetologia, 52, 1409-1418.
[103] Naka, T., Nishimoto, N. & Kishimoto, T. (2002). The paradigm of IL-6: from basic
science to medicine. Arthritis Res, 3, S233-S242.
[104] Fischer, C. P. (2006). Interleukin-6 in acute exercise and training: what is the biological
relevance? Exerc. Immunol. Rev, 12, 6-33.
[105] Ruderman, N. B., Keller, C., Richard, A. M., Saha, A. K., Luo, Z., Xiang, X., Giralt,
M., Ritov, V. B., Menshikova, E. V., Kelley, D. E., Hidalgo, J., Pedersen, B. K. &
Kelly, M. (2006). Interleukin-6 regulation of AMP-activated protein kinase. Potential
role in the systemic response to exercise and prevention of the metabolic syndrome.
Diabetes, 55, S48-S54.
[106] Kelly, M., Gauthier, M. S., Saha, A. K. & Ruderman, N. B. (2009). Activation of AMPactivated protein kinase by interleukin-6 in rat skeletal muscle: association with
changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes, 58, 19531960.
[107] Lewin, G. R. & Barde, Y. A. (1996). Physiology of the neurotrophins. Annu. Rev.
Neurosci, 19, 289-317.
[108] Nofuji, Y., Suwa, M., Sasaki, H., Ichimiya, A., Nishichi, R. & Kumagai, S. (2012).
Different circulating brain-derived neurotrophic factor responses to acute exercise
between physically active and sedentary subjects. J. Sports Sci. Med, 11, 83-88.
[109] Wojtaszewski, J. F., Nielsen, P., Hansen, B. F., Richter, E. A. & Kiens B. (2000).
Isoform-specific and exercise intensity-dependent activation of 5'-AMP-activated
protein kinase in human skeletal muscle. J. Physiol, 528, 221-226.
[110] Chen, Z. P., McConell, G. K., Michell, B. J., Snow, R. J., Canny, B. J. & Kemp, B. E.
(2000). AMPK signaling in contracting human skeletal muscle: acetyl-CoA carboxylase
and NO synthase phosphorylation. Am. J. Physiol. Endocrinol. Metab, 279, E1202E1206.
AMPK
233
[111] Wojtaszewski, J. F., Mourtzakis, M., Hillig, T., Saltin, B. & Pilegaard, H. (2002).
Dissociation of AMPK activity and ACC phosphorylation in human muscle during
prolonged exercise. Biochem. Biophys. Res. Commun, 298, 309-316.
[112] Fujii, N., Hayashi, T., Hirshman, M. F., Smith, J. T., Habinowski, S. A., Kaijser, L.,
Mu, J., Ljungqvist, O., Birnbaum, M. J., Witters, L. A., Thorell, A. & Goodyear, L. J.
(2000). Exercise induces isoform-specific increase in 5'AMP-activated protein kinase
activity in human skeletal muscle. Biochem. Biophys. Res. Commun, 273, 1150-1155.
[113] Gibala, M. J., McGee, S. L., Garnham, A. P., Howlett, K. F., Snow, R. J. & Hargreaves,
M. (2009). Brief intense interval exercise activates AMPK and p38 MAPK signaling
and increases the expression of PGC-1 in human skeletal muscle. J. Appl. Physiol,
106, 929-934.
[114] Wang, L., Mascher, H., Psilander, N., Blomstrand, E. & Sahlin, K. (2011). Resistance
exercise enhances the molecular signaling of mitochondrial biogenesis induced by
endurance exercise in human skeletal muscle. J. Appl. Physiol, 111, 1335-1344.
[115] Dreyer, H. C., Fujita, S., Cadenas, J. G., Chinkes, D. L., Volpi, E. & Rasmussen, B. B.
(2006). Resistance exercise increases AMPK activity and reduces 4E-BP1
phosphorylation and protein synthesis in human skeletal muscle. J. Physiol, 576, 613624.
[116] Koopman, R., Zorenc, A. H., Gransier, R. J., Cameron-Smith, D. & van Loon, L. J.
(2006). Increase in S6K1 phosphorylation in human skeletal muscle following
resistance exercise occurs mainly in type II muscle fibers. Am. J. Physiol. Endocrinol.
Metab, 290, E1245-E1252.
[117] Hayashi, T., Hirshman, M. F., Fujii, N., Habinowski, S. A., Witters, L. A. & Goodyear,
L. J. (2000). Metabolic stress and altered glucose transport: activation of AMPactivated protein kinase as a unifying coupling mechanism. Diabetes, 49, 527-531.
[118] Hardie, D. G. & Hawley, S. A. (2001). AMP-activated protein kinase: the energy
charge hypothesis revisited. Bioessays, 23, 1112-1119.
[119] Zou, M. H., Shi, C. & Cohen, R. A. (2002). Oxidation of the zinc-thiolate complex and
uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest, 109,
817-826.
[120] Zou, M. H., Shi, C. & Cohen, R. A. (2002). High glucose via peroxynitrite causes
tyrosine nitration and inactivation of prostacyclin synthase that is associated with
thromboxane/prostaglandin H2 receptor-mediated apoptosis and adhesion molecule
expression in cultured human aortic endothelial cells. Diabetes, 51, 198-203.
[121] Wright, D. C., Geiger, P. C., Holloszy, J. O. & Han, D. H. (2005). Contraction- and
hypoxia-stimulated glucose transport is mediated by a Ca2+-dependent mechanism in
slow-twitch rat soleus muscle. Am. J. Physiol. Endocrinol. Metab, 288, E1062-E1066.
[122] Steinberg, G. R., Watt, M. J. & Febbraio, M. A. (2009). Cytokine regulation of AMPK
signalling. Front Biosci, 14, 1902-1916.
[123] Greenberg, A. S. & Obin, M. S. (2006). Obesity and the role of adipose tissue in
inflammation and metabolism. Am. J. Clin. Nutr, 83, 461S-465S.
[124] Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D.,
Lallone, R. L., Burley, S. K. & Friedman, J. M. (1995). Weight-reducing effects of the
plasma protein encoded by the obese gene. Science, 269, 543-546.
234
Masataka Suwa
[125] Minokoshi, Y., Kim, Y. B., Peroni, O. D., Fryer, L. G., Mller, C., Carling, D. & Kahn,
B. B. (2002). Leptin stimulates fatty-acid oxidation by activating AMP-activated
protein kinase. Nature, 415, 339-343.
[126] Tanaka, T., Hidaka, S., Masuzaki, H., Yasue, S., Minokoshi, Y., Ebihara, K., Chusho,
H., Ogawa, Y., Toyoda, T., Sato, K., Miyanaga, F., Fujimoto, M., Tomita, T.,
Kusakabe, T., Kobayashi, N., Tanioka, H., Hayashi, T., Hosoda, K., Yoshimatsu, H.,
Sakata, T. & Nakao, K. (2005). Skeletal muscle AMP-activated protein kinase
phosphorylation parallels metabolic phenotype in leptin transgenic mice under dietary
modification. Diabetes, 54, 2365-2374.
[127] Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S.,
Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P.,
Carling, D., Kimura, S., Nagai, R., Kahn, B. B. & Kadowaki, T. (2002). Adiponectin
stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated
protein kinase. Nat. Med, 8, 1288-1295.
[128] Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., Funahashi,
T., Ouchi, N. & Walsh, K. (2005). Adiponectin protects against myocardial ischemiareperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med, 11,
1096-1103.
[129] Kubota, N., Yano, W., Kubota, T., Yamauchi, T., Itoh, S., Kumagai, H., Kozono, H.,
Takamoto, I., Okamoto, S., Shiuchi, T., Suzuki, R., Satoh, H., Tsuchida, A., Moroi, M.,
Sugi, K., Noda, T., Ebinuma, H., Ueta, Y., Kondo, T., Araki, E., Ezaki, O., Nagai, R.,
Tobe, K., Terauchi, Y., Ueki, K., Minokoshi, Y. & Kadowaki, T. (2007). Adiponectin
stimulates AMP-activated protein kinase in the hypothalamus and increases food intake.
Cell Metab, 6, 55-68.
[130] Kadowaki, T., Yamauchi, T. & Kubota, N. (2008). The physiological and
pathophysiological role of adiponectin and adiponectin receptors in the peripheral
tissues and CNS. FEBS Lett, 582, 74-80.
[131] Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T.,
Miyagishi, M., Hara, K., Tsunoda, M., Murakami, K., Ohteki, T., Uchida, S.,
Takekawa, S., Waki, H., Tsuno, N. H., Shibata, Y., Terauchi, Y., Froguel, P., Tobe, K.,
Koyasu, S., Taira, K., Kitamura, T., Shimizu, T., Nagai, R. & Kadowaki, T. (2003).
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature,
423, 762-769.
[132] Iwabu, M., Yamauchi, T., Okada-Iwabu, M., Sato, K., Nakagawa, T., Funata, M.,
Yamaguchi, M., Namiki, S., Nakayama, R., Tabata, M., Ogata, H., Kubota, N.,
Takamoto, I., Hayashi, Y. K., Yamauchi, N., Waki, H., Fukayama, M., Nishino, I.,
Tokuyama, K., Ueki, K., Oike, Y., Ishii, S., Hirose, K., Shimizu, T., Touhara, K. &
Kadowaki, T. (2010). Adiponectin and AdipoR1 regulate PGC-1 and mitochondria by
Ca2+ and AMPK/SIRT1. Nature, 464, 1313-1319.
[133] Yamauchi, T. & Kadowaki, T. (2008). Physiological and pathophysiological roles of
adiponectin and adiponectin receptors in the integrated regulation of metabolic and
cardiovascular diseases. Int. J. Obes, 32, S13S18.
[134] Yamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., OkadaIwabu, M., Kawamoto, S., Kubota, N., Kubota, T., Ito, Y., Kamon, J., Tsuchida, A.,
Kumagai, K., Kozono, H., Hada, Y., Ogata, H., Tokuyama, K., Tsunoda, M., Ide, T.,
Murakami, K., Awazawa, M., Takamoto, I., Froguel, P., Hara, K., Tobe, K., Nagai, R.,
AMPK
235
Ueki, K. & Kadowaki, T. (2007). Targeted disruption of AdipoR1 and AdipoR2 causes
abrogation of adiponectin binding and metabolic actions. Nat. Med, 13, 332-339.
[135] Helgren, M. E., Squinto, S. P., Davis, H. L., Parry, D. J., Boulton, T. G., Heck, C. S.,
Zhu, Y., Yancopoulos, G. D., Lindsay, R. M. & DiStefano, P. S. (1994). Trophic effect
of ciliary neurotrophic factor on denervated skeletal muscle. Cell, 76, 493-504.
[136] Forger, N. G., Roberts, S. L., Wong, V. & Breedlove, S. M. (1993). Ciliary
neurotrophic factor maintains motoneurons and their target muscles in developing rats.
J. Neurosci, 13, 4720-4726.
[137] Ohta, K., Hara, H., Hayashi, K., Itoh, N., Ohi, T. & Ohta, M. (1995). Tissue expression
of rat ciliary neurotrophic factor (CNTF) mRNA and production of the recombinant
CNTF. Biochem. Mol. Biol. Int, 35, 283-290.
[138] Sleeman, M. W., Anderson, K. D., Lambert, P. D., Yancopoulos, G. D. & Wiegand, S.
J. (2000). The ciliary neurotrophic factor and its receptor, CNTFR . Pharm. Acta Helv,
74, 265-272.
[139] Andreassen, C. S., Jakobsen, J., Flyvbjerg, A. & Andersen, H. (2009). Expression of
neurotrophic factors in diabetic muscle--relation to neuropathy and muscle strength.
Brain, 132, 2724-2733.
[140] Steinberg, G. R., Watt, M. J., Ernst, M., Birnbaum, M. J., Kemp, B. E. & Jrgensen, S.
B. (2009). Ciliary neurotrophic factor stimulates muscle glucose uptake by a PI3kinase-dependent pathway that is impaired with obesity. Diabetes, 58, 829-839.
[141] Watt, M. J., Dzamko, N., Thomas, W. G., Rose-John, S., Ernst, M., Carling, D., Kemp,
B. E., Febbraio, M. A. & Steinberg, G. R. (2006). CNTF reverses obesity-induced
insulin resistance by activating skeletal muscle AMPK. Nat. Med, 12, 541-548.
[142] Galianes, M., Mullane, K. M., Bullough, D. & Hearse, D. J. (1992). Acadesine and
myocardial protection. Studies of time of administration and dose-response relations in
the rat. Circulation, 86, 598-608.
[143] Bolling, S. F., Groh, M. A., Mattson, A. M., Grinage, R. A. & Gallagher, K. P. (1992).
Acadesine (AICA-riboside) improves postischemic cardiac recovery. Ann. Thorac.
Surg, 54, 93-98.
[144] Mullane, K., Bullough, D. & Shapiro, D. (1993). From academic vision to clinical
reality A case study of acadesine. Trends Cardiovasc. Med, 3, 227-234.
[145] Sullivan, J. E., Brocklehurst, K. J., Marley, A. E., Carey, F., Carling, D. & Beri, R. K.
(1994). Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a
cell-permeable activator of AMP-activated protein kinase. FEBS Lett, 353, 33-36.
[146] Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. (1995). 5aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMPactivated protein kinase in intact cells? Eur. J. Biochem, 229, 558-565.
[147] Guigas, B., Bertrand, L., Taleux, N., Foretz, M., Wiernsperger, N., Vertommen, D.,
Andreelli, F., Viollet, B. & Hue, L. (2006). 5-Aminoimidazole-4-carboxamide-1--Dribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMPactivated protein kinase-independent effect on glucokinase translocation. Diabetes, 55,
865-874.
[148] Longnus, S. L., Wambolt, R. B., Parsons, H. L., Brownsey, R. W. & Allard, M. F.
(2003). 5-Aminoimidazole-4-carboxamide 1--D-ribofuranoside (AICAR) stimulates
myocardial glycogenolysis by allosteric mechanisms. Am. J. Physiol. Regul. Integr.
Comp. Physiol, 284, R936-R944.
236
Masataka Suwa
[149] Vincent, M. F., Erion, M. D., Gruber, H. E. & Van den Berghe, G. (1996).
Hypoglycaemic effect of AICAriboside in mice. Diabetologia, 39, 1148-1155.
[150] Cool, B., Zinker, B., Chiou, W., Kifle, L., Cao, N., Perham, M., Dickinson, R., Adler,
A., Gagne, G., Iyengar, R., Zhao, G., Marsh, K., Kym, P., Jung, P., Camp, H. S. &
Frevert, E. (2006). Identification and characterization of a small molecule AMPK
activator that treats key components of type 2 diabetes and the metabolic syndrome.
Cell Metab, 3, 403-416.
[151] Treebak, J. T., Birk, J. B., Hansen, B. F., Olsen, G. S. & Wojtaszewski, J. F. (2009). A769662 activates AMPK 1-containing complexes but induces glucose uptake through a
PI3-kinase-dependent pathway in mouse skeletal muscle. Am. J. Physiol. Cell Physiol,
297, C1041-C1052.
[152] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J.,
Doebber, T., Fujii, N., Musi, N., Hirshman, M. F., Goodyear, L. J. & Moller, D. E.
(2001). Role of AMP-activated protein kinase in mechanism of metformin action. J.
Clin. Invest, 108, 1167-1174.
[153] Musi, N., Hirshman, M. F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O.,
Zhou, G., Williamson, J. M., Ljunqvist, O., Efendic, S., Moller, D. E., Thorell, A., &
Goodyear, L. J. (2002). Metformin increases AMP-activated protein kinase activity in
skeletal muscle of subjects with type 2 diabetes. Diabetes, 51, 2074-2081.
[154] Suwa, M., Egashira, T., Nakano, H., Sasaki, H. & Kumagai, S. (2006). Metformin
increases the PGC-1 protein and oxidative enzyme activities possibly via AMPK
phosphorylation in skeletal muscle in vivo. J. Appl. Physiol, 101, 1685-1692.
[155] Aschenbach, W. G., Hirshman, M. F., Fujii, N., Sakamoto, K., Howlett, K. F. &
Goodyear, L. J. (2002). Effect of AICAR treatment on glycogen metabolism in skeletal
muscle. Diabetes, 51, 567-573.
[156] Owen, M. R., Doran, E. & Halestrap, A. P. (2000). Evidence that metformin exerts its
anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory
chain. Biochem. J, 348, 607-614.
[157] El-Mir, M. Y., Nogueira, V., Fontaine, E., Avret, N., Rigoulet, M. & Leverve, X.
(2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the
respiratory chain complex I. J. Biol. Chem, 275, 223-228.
[158] Zou, M. H., Kirkpatrick, S. S., Davis, B. J., Nelson, J. S., Wiles, W. G. 4th, Schlattner,
U., Neumann, D., Brownlee, M., Freeman, M. B. & Goldman, M. H. (2004). Activation
of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role
of mitochondrial reactive nitrogen species. J. Biol. Chem, 279, 43940-43951.
[159] Ouyang, J., Parakhia, R. A. & Ochs, R. S. (2011). Metformin activates AMP kinase
through inhibition of AMP deaminase. J. Biol. Chem, 286, 1-11.
[160] Zhang, L., He, H. & Balschi, J. A. (2007). Metformin and phenformin activate AMPactivated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J.
Physiol. Heart Circ. Physiol, 293, H457-H466.
[161] Schimmack, G., Defronzo, R. A. & Musi, N. (2006). AMP-activated protein kinase:
Role in metabolism and therapeutic implications. Diabetes Obes. Metab, 8, 591-602.
[162] Fryer, L. G., Parbu-Patel, A. & Carling, D. (2002). The Anti-diabetic drugs
rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct
signaling pathways. J. Biol. Chem, 277, 25226-25232.
AMPK
237
[163] LeBrasseur, N. K., Kelly, M., Tsao, T. S., Farmer, S. R., Saha, A. K., Ruderman, N. B.
& Tomas, E. (2006). Thiazolidinediones can rapidly activate AMP-activated protein
kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab, 291, E175-E181.
[164] Bajaj, M., Suraamornkul, S., Hardies, L. J., Glass, L., Musi, N. & DeFronzo, R. A.
(2007). Effects of peroxisome proliferator-activated receptor (PPAR)- and PPAR-
agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Diabetologia, 50, 1723-1731.
[165] Coletta, D. K., Sriwijitkamol, A., Wajcberg, E., Tantiwong, P., Li, M., Prentki, M.,
Madiraju, M., Jenkinson, C. P., Cersosimo, E., Musi, N. & Defronzo, R. A. (2009).
Pioglitazone stimulates AMP-activated protein kinase signalling and increases the
expression of genes involved in adiponectin signalling, mitochondrial function and fat
oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia, 52, 723732.
[166] Lessard, S. J., Chen, Z. P., Watt, M. J., Hashem, M., Reid, J. J., Febbraio, M. A., Kemp,
B. E. & Hawley, J. A. (2006). Chronic rosiglitazone treatment restores AMPK2
activity in insulin-resistant rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab, 290,
E251-E257.
[167] Kubota, N., Terauchi, Y., Kubota, T., Kumagai, H., Itoh, S., Satoh, H., Yano, W.,
Ogata, H., Tokuyama, K., Takamoto, I., Mineyama, T., Ishikawa, M., Moroi, M., Sugi,
K., Yamauchi, T., Ueki, K., Tobe, K., Noda, T., Nagai, R. & Kadowaki, T. (2006).
Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent
and -independent pathways. J. Biol. Chem, 281, 8748-8755.
[168] Rasouli, N., Yao-Borengasser, A., Miles, L. M., Elbein, S. C. & Kern, P. A. (2006).
Increased plasma adiponectin in response to pioglitazone does not result from increased
gene expression. Am. J. Physiol. Endocrinol. Metab, 290, E42-E46.
[169] Amin, R. H., Mathews, S. T., Camp, H. S., Ding, L. & Leff, T. (2010). Selective
activation of PPAR in skeletal muscle induces endogenous production of adiponectin
and protects mice from diet-induced insulin resistance. Am. J. Physiol. Endocrinol.
Metab, 298, E28-E37.
[170] Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu,
V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., Pistell, P. J., Poosala, S., Becker, K.
G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K. W., Spencer, R. G.,
Lakatta. E. G., Le Couteur, D., Shaw, R. J., Navas, P., Puigserver, P., Ingram, D. K., de
Cabo, R. & Sinclair, D. A. (2006). Resveratrol improves health and survival of mice on
a high-calorie diet. Nature, 444, 337-342.
[171] Eid, H. M., Martineau, L. C., Saleem, A., Muhammad, A., Vallerand, D., BenhaddouAndaloussi, A., Nistor, L., Afshar, A., Arnason, J. T. & Haddad, P. S. (2010).
Stimulation of AMP-activated protein kinase and enhancement of basal glucose uptake
in muscle cells by quercetin and quercetin glycosides, active principles of the
antidiabetic medicinal plant Vaccinium vitis-idaea. Mol. Nutr. Food Res, 54, 991-1003.
[172] Gomes, A. P., Duarte, F. V., Nunes, P., Hubbard, B. P., Teodoro, J. S., Varela, A. T.,
Jones, J. G., Sinclair, D. A., Palmeira, C. M. & Rolo, A. P. (2012). Berberine protects
against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1dependent mitochondrial biogenesis. Biochim. Biophys. Acta, 1822, 185-195.
[173] Tan, M. J., Ye, J. M., Turner, N., Hohnen-Behrens, C., Ke, C. Q., Tang, C. P., Chen, T.,
Weiss, H. C., Gesing, E. R., Rowland, A., James, D. E. & Ye, Y. (2008). Antidiabetic
238
Masataka Suwa
activities of triterpenoids isolated from bitter melon associated with activation of the
AMPK pathway. Chem. Biol, 15, 263-273.
[174] Li, Y., Zhao, S., Zhang, W., Zhao, P., He, B., Wu, N. & Han, P. (2011).
Epigallocatechin-3-O-gallate (EGCG) attenuates FFAs-induced peripheral insulin
resistance through AMPK pathway and insulin signaling pathway in vivo. Diabetes
Res. Clin. Pract, 93, 205-214.
[175] Hwang, J. T., Park, I. J., Shin, J. I., Lee, Y. K., Lee, S. K., Baik, H. W., Ha, J. & Park,
O. J. (2005). Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process
via activating AMP-activated protein kinase. Biochem. Biophys. Res. Commun, 338,
694-699.
[176] Lee, W. J., Song, K. H., Koh, E. H., Won, J. C., Kim, H. S., Park, H. S., Kim, M. S.,
Kim, S. W., Lee, K. U. & Park, J. Y. (2005). -lipoic acid increases insulin sensitivity
by activating AMPK in skeletal muscle. Biochem. Biophys. Res. Commun, 332, 885891.
[177] Hsu, M. H., Savas, U., Lasker, J. M. & Johnson, E. F. (2011). Genistein, resveratrol,
and 5-aminoimidazole-4-carboxamide-1--D-ribofuranoside induce cytochrome P450
4F2 expression through an AMP-activated protein kinase-dependent pathway. J.
Pharmacol. Exp. Ther, 337, 125-136.
[178] Kim, M. S., Hur, H. J., Kwon, D. Y. & Hwang, J. T. (2012). Tangeretin stimulates
glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes and
improves glucose tolerance in high-fat diet-induced obese mice. Mol. Cell Endocrinol,
358, 127-134.
[179] Narasimhan, L. M., Coca, M. A., Jin, J., Yamauchi, T., Ito, Y., Kadowaki, T., Kim, K.
K., Pardo, J. M., Damsz, B., Bressan, R. A. & Yun, D. J. (2005). Osmotin is a homolog
of mammalian adiponectin and controls apoptosis in yeast through a homolog of
mammalian adiponectin receptor. Mol. Cell, 17, 171-180.
[180] Hawley, S. A., Ross, F. A., Chevtzoff, C., Green, K. A., Evans, A., Fogarty, S., Towler,
M. C., Brown, L. J., Ogunbayo, O. A., Evans, A. M. & Hardie, D. G. (2010). Use of
cells expressing subunit variants to identify diverse mechanisms of AMPK activation.
Cell Metab, 11, 554-565.
[181] Fontana, L., Partridge, L. & Longo, V. D. (2010). Extending healthy life spanfrom
yeast to humans. Science, 328, 321-326.
[182] Palacios, O. M., Carmona, J. J., Michan, S., Chen, K. Y., Manabe, Y., Ward, J. L. 3rd,
Goodyear, L. J. & Tong, Q. (2009). Diet and exercise signals regulate SIRT3 and
activate AMPK and PGC-1 in skeletal muscle. Aging, 1, 771-783.
[183] Wang, P., Zhang, R. Y., Song, J., Guan, Y. F., Xu, T. Y., Du, H., Viollet, B. & Miao, C.
Y. (2012). Loss of AMP-activated protein kinase-2 impairs the insulin-sensitizing
effect of calorie restriction in skeletal muscle. Diabetes, 61, 1051-1061.
[184] Lendoye, E., Sibille, B., Rousseau, A. S., Murdaca, J., Grimaldi, P. A. & Lopez, P.
(2011). PPAR activation induces rapid changes of both AMPK subunit expression and
AMPK activation in mouse skeletal muscle. Mol. Endocrinol, 25, 1487-1498.
[185] Gonzalez, A. A., Kumar, R., Mulligan, J. D., Davis, A. J., Weindruch, R. & Saupe, K.
W. (2004). Metabolic adaptations to fasting and chronic caloric restriction in heart,
muscle, and liver do not include changes in AMPK activity. Am. J. Physiol. Endocrinol.
Metab, 287, E1032-E1037.
AMPK
239
[186] Draznin, B., Wang, C., Adochio, R., Leitner, J. W. & Cornier, M. A. (2012). Effect of
dietary macronutrient composition on AMPK and SIRT1 expression and activity in
human skeletal muscle. Horm. Metab. Res, 44, 650-655.
[187] Davies, S. P., Helps, N. R., Cohen, P. T. & Hardie, D. G. (1995). 5'-AMP inhibits
dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein
kinase. Studies using bacterially expressed human protein phosphatase-2C and native
bovine protein phosphatase-2AC. FEBS Lett, 377, 421-425.
[188] Suterm, M., Riek, U., Tuerk, R., Schlattner, U., Wallimann, T. & Neumann, D. (2006).
Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of
AMP-activated protein kinase. J. Biol. Chem, 281, 32207-32216.
[189] Steinberg, G. R., Michell, B. J., van Denderen, B. J., Watt, M. J., Carey, A. L., Fam, B.
C., Andrikopoulos, S., Proietto, J., Grgn, C. Z., Carling, D., Hotamisligil, G. S.,
Febbraio, M. A., Kay, T. W. & Kemp, B. E. (2006). Tumor necrosis factor -induced
skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell
Metab, 4, 465-474.
[190] Hardie, D. G. & Carling, D. (1997). The AMP-activated protein kinase--fuel gauge of
the mammalian cell? Eur. J. Biochem, 246, 259-273.
[191] Fryer, L. G., Parbu-Patel, A. & Carling, D. (2002). Protein kinase inhibitors block the
stimulation of the AMP-activated protein kinase by 5-amino-4-imidazolecarboxamide
riboside. FEBS Lett, 531, 189-192.
[192] Funai, K. & Cartee, G. D. (2009). Inhibition of contraction-stimulated AMP-activated
protein kinase inhibits contraction-stimulated increases in PAS-TBC1D1 and glucose
transport without altering PAS-AS160 in rat skeletal muscle. Diabetes, 58, 1096-1104.
[193] Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I.,
Arthur, J. S., Alessi, D. R. & Cohen, P. (2007). The selectivity of protein kinase
inhibitors: a further update. Biochem. J, 408, 297-315.
[194] Kraegen, E. W., Saha, A. K., Preston, E., Wilks, D., Hoy, A. J., Cooney, G. J. &
Ruderman, N. B. (2006). Increased malonyl-CoA and diacylglycerol content and
reduced AMPK activity accompany insulin resistance induced by glucose infusion in
muscle and liver of rats. Am. J. Physiol. Endocrinol. Metab, 290, E471-E479.
[195] Guerra, B., Guadalupe-Grau, A., Fuentes, T., Ponce-Gonzlez, J. G., Morales-Alamo,
D., Olmedillas, H., Guilln-Salgado, J., Santana, A. & Calbet, J. A. (2010). l. SIRT1,
AMP-activated protein kinase phosphorylation and downstream kinases in response to a
single bout of sprint exercise: influence of glucose ingestion. Eur. J. Appl. Physiol, 109,
731-743.
[196] Wojtaszewski, J. F., Jrgensen, S. B., Hellsten, Y., Hardie, D. G. & Richter, E. A.
(2002). Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)riboside on AMP-activated protein kinase and glycogen synthase activities in rat
skeletal muscle. Diabetes, 51, 284-292.
[197] McBride, A., Ghilagaber, S., Nikolaev, A. & Hardie, D. G. (2009). The glycogenbinding domain on the AMPK subunit allows the kinase to act as a glycogen sensor.
Cell Metab, 9, 23-34.
[198] Liu, Y., Wan, Q., Guan, Q., Gao, L. & Zhao, J. (2006). High-fat diet feeding impairs
both the expression and activity of AMPKa in rats' skeletal muscle. Biochem. Biophys.
Res. Commun, 339, 701-707.
240
Masataka Suwa
[199] Martin, T. L., Alquier, T., Asakura, K., Furukawa, N., Preitner, F. & Kahn, B. B.
(2006). Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal
muscle. J. Biol. Chem, 281, 18933-18941.
[200] Wu, Y., Song, P., Xu, J., Zhang, M. & Zou, M. H. (2007). Activation of protein
phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J. Biol. Chem, 282,
9777-9788.
[201] Ruvolo, P. P., Deng, X., Ito, T., Carr, B. K. & May, W. S. (1999). Ceramide induces
Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J. Biol. Chem,
274, 20296-20300.
[202] Chavez, J. A., Knotts, T. A., Wang, L. P., Li, G., Dobrowsky, R. T., Florant, G. L. &
Summers, S. A. (2003). A role for ceramide, but not diacylglycerol, in the antagonism
of insulin signal transduction by saturated fatty acids. J. Biol. Chem, 278, 10297-10303.
[203] Du, M., Shen, Q. W., Zhu, M. J. & Ford, S. P. (2007). Leucine stimulates mammalian
target of rapamycin signaling in C2C12 myoblasts in part through inhibition of
adenosine monophosphate-activated protein kinase. J. Anim. Sci, 85, 919-927.
[204] Wilson, G. J., Layman, D. K., Moulton, C. J., Norton, L. E., Anthony, T. G., Proud, C.
G., Rupassara, S. I. & Garlick, P. J. (2011). Leucine or carbohydrate supplementation
reduces AMPK and eEF2 phosphorylation and extends postprandial muscle protein
synthesis in rats. Am. J. Physiol. Endocrinol. Metab, 301, E1236-E1242.
[205] Saha, A. K., Xu, X. J., Lawson, E., Deoliveira, R., Brandon, A. E., Kraegen, E. W. &
Ruderman, N. B. (2010). Downregulation of AMPK accompanies leucine- and glucoseinduced increases in protein synthesis and insulin resistance in rat skeletal muscle.
Diabetes, 59, 2426-2434.
[206] Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M.,
Patel, H. R., Ahima, R. S. & Lazar, M. A. (2001). The hormone resistin links obesity to
diabetes. Nature, 409, 307-312.
[207] Patel, L., Buckels, A. C., Kinghorn, I. J., Murdock, P. R., Holbrook, J. D., Plumpton,
C., Macphee, C. H. & Smith, S. A. (2003). Resistin is expressed in human macrophages
and directly regulated by PPAR activators. Biochem. Biophys. Res. Commun, 300,
472-476.
[208] Satoh, H., Nguyen, M. T., Miles, P. D., Imamura, T., Usui, I. & Olefsky, J. M. (2004).
Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in
normal rats. J. Clin. Invest, 114, 224-231.
[209] Palanivel, R. & Sweeney, G. (2005). Regulation of fatty acid uptake and metabolism in
L6 skeletal muscle cells by resistin. FEBS Lett, 579, 5049-5054.
[210] Jrgensen, S. B., Honeyman, J., Oakhill, J. S., Fazakerley, D., Stckli, J., Kemp, B. E.
& Steinberg, G. R. (2009). Oligomeric resistin impairs insulin and AICAR-stimulated
glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am. J.
Physiol. Endocrinol. Metab, 297, E57-E66.
[211] Marques, L. J., Zheng, L., Poulakis, N., Guzman, J. & Costabel, U. (1999).
Pentoxifylline inhibits TNF- production from human alveolar macrophages. Am. J.
Respir. Crit. Care Med, 159, 508-511.
[212] Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. (1993). Adipose expression of
tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science, 259,
87-91.
AMPK
241
[213] Liu, Z. G. & Han, J. (2001). Cellular responses to tumor necrosis factor. Curr. Issues
Mol. Biol, 3, 79-90.
[214] Zhang, Z., Zhao, M., Li, Q., Zhao, H., Wang, J. & Li, Y. (2009). Acetyl-l-carnitine
inhibits TNF--induced insulin resistance via AMPK pathway in rat skeletal muscle
cells. FEBS Lett, 583, 470-474.
[215] Wojtaszewski, J. F., Lynge, J., Jakobsen, A. B., Goodyear, L. J. & Richter, E. A.
(1999). Differential regulation of MAP kinase by contraction and insulin in skeletal
muscle: metabolic implications. Am. J. Physiol. Endocrinol. Metab, 277, E724-E732.
[216] Brozinick, J. T. Jr. & Birnbaum, M. J. (1998). Insulin, but not contraction, activates
Akt/PKB in isolated rat skeletal muscle. J. Biol. Chem, 273, 14679-14682.
[217] Dumke, C. L., Wetter, A. C., Arias, E. B., Kahn, C. R. & Cartee, G. D. (2001). Absence
of insulin receptor substrate-1 expression does not alter GLUT1 or GLUT4 abundance
or contraction-stimulated glucose uptake by mouse skeletal muscle. Horm. Metab. Res,
33, 696-700.
[218] Sakamoto, K., Arnolds, D. E., Fujii, N., Kramer, H. F., Hirshman, M. F. & Goodyear,
L. J. (2006). Role of Akt2 in contraction-stimulated cell signaling and glucose uptake in
skeletal muscle. Am. J. Physiol. Endocrinol. Metab, 291, E1031-E1037.
[219] Gao, J., Ren, J., Gulve, E. A. & Holloszy, J. O. (1994). Additive effect of contractions
and insulin on GLUT-4 translocation into the sarcolemma. J. Appl. Physiol, 77, 15971601.
[220] Koh, H. J., Toyoda, T., Fujii, N., Jung, M. M., Rathod, A., Middelbeek, R. J., Lessard,
S. J., Treebak, J. T., Tsuchihara, K., Esumi, H., Richter, E. A., Wojtaszewski, J. F.,
Hirshman, M. F. & Goodyear, L. J. (2010). Sucrose nonfermenting AMPK-related
kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal
muscle. Proc. Natl. Acad. Sci. U S A, 107, 15541-15546.
[221] Holloszy, J. O. (2003). A forty-year memoir of research on the regulation of glucose
transport into muscle. Am. J. Physiol. Endocrinol. Metab, 284, E453-E467.
[222] Merrill, G. F., Kurth, E. J., Hardie, D. G. & Winder, W. W. (1997). AICA riboside
increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat
muscle. Am. J. Physiol. Endocrinol. Metab, 273, E1107-E1112.
[223] Kurth-Kraczek, E. J., Hirshman, M. F., Goodyear, L. J. & Winder, W. W. (1999). 5'
AMP-activated protein kinase activation causes GLUT4 translocation in skeletal
muscle. Diabetes, 48, 1667-1671.
[224] Chen, S., Murphy, J., Toth, R., Campbell, D. G., Morrice, N. A. & Mackintosh, C.
(2008). Complementary regulation of TBC1D1 and AS160 by growth factors, insulin
and AMPK activators. Biochem. J, 409, 449-459.
[225] Sano, H., Kane, S., Sano, E., Minea, C. P., Asara, J. M., Lane, W. S., Garner, C. W. &
Lienhard, G. E. (2003). Insulin-stimulated phosphorylation of a Rab GTPase-activating
protein regulates GLUT4 translocation. J. Biol. Chem, 278, 14599-14602.
[226] Roach, W. G., Chavez, J. A., Minea, C. P. & Lienhard, G. E. (2007). Substrate
specificity and effect on GLUT4 translocation of the Rab GTPase-activating protein
Tbc1d1. Biochem J, 403, 353-358.
[227] Pehmller, C., Treebak, J. T., Birk, J. B., Chen, S., Mackintosh, C., Hardie, D. G.,
Richter, E. A. & Wojtaszewski, J. F. (2009). Genetic disruption of AMPK signaling
abolishes both contraction- and insulin-stimulated TBC1D1 phosphorylation and 14-3-3
binding in mouse skeletal muscle. Am. J. Physiol. Endocrinol. Metab, 297, E665-E675.
242
Masataka Suwa
[228] Treebak, J. T., Taylor, E. B., Witczak, C. A., An, D., Toyoda, T., Koh, H. J., Xie, J.,
Feener, E. P., Wojtaszewski, J. F., Hirshman, M. F. & Goodyear, L. J. (2010).
Identification of a novel phosphorylation site on TBC1D4 regulated by AMP-activated
protein kinase in skeletal muscle. Am. J. Physiol. Cell Physiol, 298, C377-C385.
[229] Kramer, H. F., Witczak, C. A., Fujii, N., Jessen, N., Taylor, E. B., Arnolds, D. E.,
Sakamoto, K., Hirshman, M. F. & Goodyear, L. J. (2006). Distinct signals regulate
AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse
skeletal muscle. Diabetes, 55, 2067-2076.
[230] An, D., Toyoda, T., Taylor, E. B., Yu, H., Fujii, N., Hirshman, M. F. & Goodyear, L. J.
(2010). TBC1D1 regulates insulin- and contraction-induced glucose transport in mouse
skeletal muscle. Diabetes, 59, 1358-1365.
[231] Ishikura, S. & Klip, A. (2008). Muscle cells engage Rab8A and myosin Vb in insulindependent GLUT4 translocation. Am. J. Physiol. Cell Physiol, 295, C1016-C1025.
[232] Buhl, E. S., Jessen, N., Schmitz, O., Pedersen, S. B., Pedersen, O., Holman, G. D. &
Lund, S. (2001). Chronic treatment with 5-aminoimidazole-4-carboxamide-1--Dribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in
rat skeletal muscles in a fiber type-specific manner. Diabetes, 50, 12-17.
[233] Iglesias, M. A., Ye, J. M., Frangioudakis, G., Saha, A. K., Tomas, E., Ruderman, N. B.,
Cooney, G. J. & Kraegen, E. W. (2002). AICAR administration causes an apparent
enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats.
Diabetes, 51, 2886-2894.
[234] Fisher, J. S., Gao, J., Han, D. H., Holloszy, J. O. & Nolte, L. A. (2002). Activation of
AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol.
Endocrinol. Metab, 282, E18-E23.
[235] Jakobsen, S. N., Hardie, D. G., Morrice, N. & Tornqvist, H. E. (2001). 5'-AMPactivated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in
response to 5-aminoimidazole-4-carboxamide riboside. J. Biol. Chem, 276, 4691246916.
[236] Jessen, N., Pold, R., Buhl, E. S., Jensen, L. S., Schmitz, O. & Lund, S. (2003). Effects
of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4
content in rat muscles. J. Appl. Physiol, 94, 1373-1379.
[237] Qiao, L. Y., Zhande, R., Jetton, T. L., Zhou, G. & Sun, X. J. (2002). In vivo
phosphorylation of insulin receptor substrate 1 at serine 789 by a novel serine kinase in
insulin-resistant rodents. J. Biol. Chem, 277, 26530-26539.
[238] Skurat, A. V., Wang, Y. & Roach, P. J. (1994). Rabbit skeletal muscle glycogen
synthase expressed in COS cells. Identification of regulatory phosphorylation sites. J.
Biol. Chem, 269, 25534-25542.
[239] Carling, D. & Hardie, D. G. (1989). The substrate and sequence specificity of the AMPactivated protein kinase. Phosphorylation of glycogen synthase and phosphorylase
kinase. Biochim. Biophys. Acta, 1012, 81-86.
[240] Jrgensen, S. B., Nielsen, J. N., Birk, J. B., Olsen, G. S., Viollet, B., Andreelli, F.,
Schjerling, P., Vaulont, S., Hardie, D. G., Hansen, B. F., Richter, E. A. &
Wojtaszewski, J. F. (2004). The 2-5'AMP-activated protein kinase is a site 2 glycogen
synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes, 53,
3074-3081.
AMPK
243
[241] Holmes, B. F., Kurth-Kraczek, E. J. & Winder, W. W. (1999). Chronic activation of 5'AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle.
J. Appl. Physiol, 87, 1990-1995.
[242] Hansen, P. A., Gulve, E. A., Marshall, B. A., Gao, J., Pessin, J. E., Holloszy, J. O. &
Mueckler, M. (1995). Skeletal muscle glucose transport and metabolism are enhanced
in transgenic mice overexpressing the Glut4 glucose transporter. J. Biol. Chem, 270,
1679-1684.
[243] Zisman, A., Peroni, O. D., Abel, E. D., Michael, M. D., Mauvais-Jarvis, F., Lowell, B.
B., Wojtaszewski, J. F., Hirshman, M. F., Virkamaki, A., Goodyear, L. J., Kahn, C. R.
& Kahn, B. B. (2000). Targeted disruption of the glucose transporter 4 selectively in
muscle causes insulin resistance and glucose intolerance. Nat. Med, 6, 924-928.
[244] Kim, J. K., Zisman, A., Fillmore, J. J., Peroni, O. D., Kotani, K., Perret, P., Zong, H.,
Dong, J., Kahn, C. R., Kahn, B. B. & Shulman, G. I. (2001). Glucose toxicity and the
development of diabetes in mice with muscle-specific inactivation of GLUT4. J. Clin.
Invest, 108, 153-160.
[245] Suwa, M., Nakano, H., Radak, Z. & Kumagai, S. (2011). Short-term adenosine
monophosphate-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-D-ribofuranoside treatment increases the sirtuin 1 protein expression in skeletal
muscle. Metabolism, 60, 394-403.
[246] Ojuka, E. O., Jones, T. E., Nolte, L. A., Chen, M., Wamhoff, B. R., Sturek, M. &
Holloszy, J. O. (2002). Regulation of GLUT4 biogenesis in muscle: evidence for
involvement of AMPK and Ca2+. Am. J. Physiol. Endocrinol. Metab, 282, E1008E1013.
[247] Thai, M. V., Guruswamy, S., Cao, K. T., Pessin, J. E. & Olson, A. L. (1998). Myocyte
enhancer factor 2 (MEF2)-binding site is required for GLUT4 gene expression in
transgenic mice. Regulation of MEF2 DNA binding activity in insulin-deficient
diabetes. J. Biol. Chem, 273, 14285-14292.
[248] Oshel, K. M., Knight, J. B., Cao, K. T., Thai, M. V. & Olson, A. L. (2000).
Identification of a 30-base pair regulatory element and novel DNA binding protein that
regulates the human GLUT4 promoter in transgenic mice. J. Biol. Chem, 275, 2366623673.
[249] Olson, A. L. & Pessin, J. E. (1995). Transcriptional regulation of the human GLUT4
gene promoter in diabetic transgenic mice. J. Biol. Chem, 270, 23491-23495.
[250] Knight, J. B., Eyster, C. A., Griesel, B. A. & Olson, A. L. (2003). Regulation of the
human GLUT4 gene promoter: interaction between a transcriptional activator and
myocyte enhancer factor 2A. Proc. Natl. Acad. Sci. U S A, 100, 14725-14730.
[251] Sparling, D. P., Griesel, B. A., Weems, J. & Olson, A. L. (2008). GLUT4 enhancer
factor (GEF) interacts with MEF2A and HDAC5 to regulate the GLUT4 promoter in
adipocytes. J. Biol. Chem, 283, 7429-7437.
[252] Lemercier, C., Verdel, A., Galloo, B., Curtet, S., Brocard, M. P. & Khochbin, S. (2000).
mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A
transcriptional activity. J. Biol. Chem, 275, 15594-15599.
[253] McGee, S. L., van Denderen, B. J., Howlett, K. F., Mollica, J., Schertzer, J. D., Kemp,
B. E. & Hargreaves, M. (2008). AMP-activated protein kinase regulates GLUT4
transcription by phosphorylating histone deacetylase 5. Diabetes, 57, 860-867.
244
Masataka Suwa
[254] Holmes, B. F., Sparling, D. P., Olson, A. L., Winder, W. W. & Dohm, G. L. (2005).
Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMPactivated protein kinase. Am. J. Physiol. Endocrinol. Metab, 289, E1071-E1076.
[255] Michael, L. F., Wu, Z., Cheatham, R. B., Puigserver, P., Adelmant, G., Lehman, J. J.,
Kelly, D. P. & Spiegelman, B. M. (2001). Restoration of insulin-sensitive glucose
transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator
PGC-1. Proc. Natl. Acad. Sci. U S A, 98, 3820-3825.
[256] Leick, L., Fentz, J., Biens, R. S., Knudsen, J. G., Jeppesen, J., Kiens, B.,
Wojtaszewski, J. F. & Pilegaard, H. (2010). PGC-1 is required for AICAR-induced
expression of GLUT4 and mitochondrial proteins in mouse skeletal muscle. Am. J.
Physiol. Endocrinol. Metab, 299, E456-E465.
[257] Grossbard, L. & Schimke, R. T. (1966). Multiple hexokinases of rat tissues. Purification
and comparison of soluble forms. J. Biol. Chem, 241, 3546-3560.
[258] Fueger, P. T., Heikkinen, S., Bracy, D. P., Malabanan, C. M., Pencek, R. R., Laakso,
M. & Wasserman, D. H. (2003). Hexokinase II partial knockout impairs exercisestimulated glucose uptake in oxidative muscles of mice. Am. J. Physiol. Endocrinol.
Metab, 285, E958-E963.
[259] Halseth, A. E., Bracy, D. P. & Wasserman, D. H. (1999). Overexpression of hexokinase
II increases insulin and exercise-stimulated muscle glucose uptake in vivo. Am. J.
Physiol. Endocrinol. Metab, 276, E70-E77.
[260] Halseth, A. E., Bracy, D. P. & Wasserman, D. H. (2001). Functional limitations to
glucose uptake in muscles comprised of different fiber types. Am. J. Physiol.
Endocrinol. Metab, 280, E994- E999.
[261] Suwa, M., Nakano, H. & Kumagai, S. (2003). Effects of chronic AICAR treatment on
fiber composition, enzyme activity, UCP3, and PGC-1 in rat muscles. J. Appl. Physiol,
95, 960-968.
[262] Winder, W. W., Holmes, B. F., Rubink, D. S., Jensen, E. B., Chen, M. & Holloszy, J.
O. (2000). Activation of AMP-activated protein kinase increases mitochondrial
enzymes in skeletal muscle. J. Appl. Physiol, 88, 2219-2226.
[263] Bamford, J. A., Lopaschuk, G. D., MacLean, I. M., Reinhart, M. L., Dixon, W. T. &
Putman, C. T. (2003). Effects of chronic AICAR administration on the metabolic and
contractile phenotypes of rat slow- and fast-twitch skeletal muscles. Can. J. Physiol.
Pharmacol, 81, 1072-1082.
[264] Ojuka, E. O., Nolte, L. A. & Holloszy, J. O. (2000). Increased expression of GLUT-4
and hexokinase in rat epitrochlearis muscles exposed to AICAR in vitro. J. Appl.
Physiol, 88, 1072-1075.
[265] Osawa, H., Robey, R. B., Printz, R. L. & Granner, D. K. (1996). Identification and
characterization of basal and cyclic AMP response elements in the promoter of the rat
hexokinase II gene. J. Biol. Chem, 271, 17296-17303.
[266] Lee, M. G. & Pedersen, P. L. (2003). Glucose metabolism in cancer: importance of
transcription factor-DNA interactions within a short segment of the proximal region of
the type II hexokinase promoter. J. Biol. Chem, 278, 41047-41058.
[267] Thomson, D. M., Herway, S. T., Fillmore, N., Kim, H., Brown, J. D., Barrow, J. R. &
Winder, W. W. (2008). AMP-activated protein kinase phosphorylates transcription
factors of the CREB family. J. Appl. Physiol, 104, 429-438.
AMPK
245
[268] Merrill, G. F., Kurth, E. J., Rasmussen, B. B. & Winder, W. W. (1998). Influence of
malonyl-CoA and palmitate concentration on rate of palmitate oxidation in rat muscle.
J. Appl. Physiol, 85, 1909-1914.
[269] Smith, A. C., Bruce, C. R. & Dyck, D. J. (2005). AMP kinase activation with AICAR
simultaneously increases fatty acid and glucose oxidation in resting rat soleus muscle.
J. Physiol, 565, 537-546.
[270] Abumrad, N. A., el-Maghrabi, M. R., Amri, E. Z., Lopez, E. & Grimaldi. P. A. (1993).
Cloning of a rat adipocyte membrane protein implicated in binding or transport of longchain fatty acids that is induced during preadipocyte differentiation. Homology with
human CD36. J. Biol. Chem, 268, 17665-17668.
[271] Stremmel, W., Lotz, G., Strohmeyer, G. & Berk, P. D. (1985). Identification, isolation,
and partial characterization of a fatty acid binding protein from rat jejunal microvillous
membranes. J. Clin. Invest, 75, 1068-1076.
[272] Kim, J. K., Gimeno, R. E., Higashimori, T., Kim, H. J., Choi, H., Punreddy, S., Mozell,
R. L., Tan, G., Stricker-Krongrad, A., Hirsch, D. J., Fillmore, J. J., Liu, Z. X., Dong, J.,
Cline, G., Stahl, A., Lodish, H. F. & Shulman, G. I. (2004). Inactivation of fatty acid
transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J. Clin.
Invest, 113, 756-763.
[273] DiRusso, C. C., Li, H., Darwis, D., Watkins, P. A., Berger, J. & Black, P. N. (2005).
Comparative biochemical studies of the murine fatty acid transport proteins (FATP)
expressed in yeast. J. Biol. Chem, 280, 16829-16837.
[274] Luiken, J. J., Coort, S. L., Willems, J., Coumans, W. A., Bonen, A., van der Vusse, G.
J. & Glatz, J. F. (2003). Contraction-induced fatty acid translocase/CD36 translocation
in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling.
Diabetes, 52, 1627-1634.
[275] Samovski, D., Su, X., Xu, Y., Abumrad, N. A. & Stahl, P. D. (2012). Insulin and
AMPK regulate FA translocase/CD36 plasma membrane recruitment in cardiomyocytes
via Rab GAP AS160 and Rab8a Rab GTPase. J. Lipid. Res, 53, 709-717.
[276] Bonen, A., Luiken, J. J., Arumugam, Y., Glatz, J. F. & Tandon, N. N. (2000). Acute
regulation of fatty acid uptake involves the cellular redistribution of fatty acid
translocase. J. Biol. Chem, 275, 14501-14508.
[277] Turcotte, L. P., Raney, M. A. & Todd, M. K. (2005). ERK1/2 inhibition prevents
contraction-induced increase in plasma membrane FAT/CD36 content and FA uptake in
rodent muscle. Acta Physiol. Scand, 184, 131-139.
[278] Abbott, M. J., Edelman, A. M. & Turcotte, L. P. (2009). CaMKK is an upstream signal
of AMP-activated protein kinase in regulation of substrate metabolism in contracting
skeletal muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol, 297, R1724-R1732.
[279] Jeppesen, J., Albers, P. H., Rose, A. J., Birk, J. B., Schjerling, P., Dzamko, N.,
Steinberg, G. R. & Kiens, B. (2011). Contraction-induced skeletal muscle FAT/CD36
trafficking and FA uptake is AMPK independent. J. Lipid Res, 52, 699-711.
[280] Bonen, A., Han, X. X., Habets, D. D., Febbraio, M., Glatz, J. F. & Luiken, J. J. (2007).
A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin- and
AICAR-stimulated fatty acid metabolism. Am. J. Physiol. Endocrinol. Metab, 292,
E1740-E1749.
246
Masataka Suwa
AMPK
247
[292] Jrgensen, S. B., Wojtaszewski, J. F., Viollet, B., Andreelli, F., Birk, J. B., Hellsten, Y.,
Schjerling, P., Vaulont, S., Neufer, P. D., Richter, E. A. & Pilegaard, H. (2005). Effects
of -AMPK knockout on exercise-induced gene activation in mouse skeletal muscle.
FASEB J, 19, 1146-1148.
[293] Czubryt, M. P., McAnally, J., Fishman, G. I. & Olson, E. N. (2003). Regulation of
peroxisome proliferator-activated receptor coactivator 1 (PGC-1) and
mitochondrial function by MEF2 and HDAC5. Proc. Natl. Acad. Sci. U S A, 100, 17111716.
[294] Handschin, C., Rhee, J., Lin, J., Tarr, P. T. & Spiegelman, B. M. (2003). An
autoregulatory loop controls peroxisome proliferator-activated receptor coactivator 1
expression in muscle. Proc. Natl. Acad. Sci. U S A, 100, 7111-7116.
[295] Akimoto, T., Sorg, B. S. & Yan, Z. (2004). Real-time imaging of peroxisome
proliferator-activated receptor- coactivator-1 promoter activity in skeletal muscles of
living mice. Am. J. Physiol. Cell Physiol, 287, C790-C796.
[296] Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A.,
Cinti, S., Lowell, B., Scarpulla, R. C. & Spiegelman, B. M. (1999). Mechanisms
controlling mitochondrial biogenesis and respiration through the thermogenic
coactivator PGC-1. Cell, 98, 115-124.
[297] Schreiber, S. N., Emter, R., Hock, M. B., Knutti, D., Cardenas, J., Podvinec, M.,
Oakeley, E. J. & Kralli, A. (2004). The estrogen-related receptor (ERR) functions in
PPAR coactivator 1 (PGC-1)-induced mitochondrial biogenesis. Proc. Natl. Acad.
Sci. U S A, 101, 6472-6477.
[298] Hondares, E., Pineda-Torra, I., Iglesias, R., Staels, B., Villarroya, F. & Giralt, M.
(2007). PPAR, but not PPAR, activates PGC-1 gene transcription in muscle.
Biochem. Biophys. Res. Commun, 354, 1021-1027.
[299] Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F.,
Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P. &
Auwerx, J. (2006). Resveratrol improves mitochondrial function and protects against
metabolic disease by activating SIRT1 and PGC-1. Cell, 127, 1109-1122.
[300] Gerhart-Hines, Z., Rodgers, J. T., Bare, O., Lerin, C., Kim, S. H., Mostoslavsky, R.,
Alt, F. W., Wu, Z. & Puigserver, P. (2007). Metabolic control of muscle mitochondrial
function and fatty acid oxidation through SIRT1/PGC-1. EMBO J, 26, 1913-1923.
[301] Fulco, M., Cen, Y., Zhao, P., Hoffman, E. P., McBurney, M. W., Sauve, A. A. &
Sartorelli, V. (2008). Glucose restriction inhibits skeletal myoblast differentiation by
activating SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell, 14, 661673.
[302] Cant, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C.,
Elliott, P. J., Puigserver, P. & Auwerx, J. (2009). AMPK regulates energy expenditure
by modulating NAD+ metabolism and SIRT1 activity. Nature, 458, 1056-1060.
[303] Cant, C., Jiang, L. Q., Deshmukh, A. S., Mataki, C., Coste, A., Lagouge, M., Zierath,
J. R. & Auwerx, J. (2010). Interdependence of AMPK and SIRT1 for metabolic
adaptation to fasting and exercise in skeletal muscle. Cell Metab, 11, 213-219.
[304] Lan, F., Cacicedo, J. M., Ruderman, N. & Ido, Y. (2008). SIRT1 modulation of the
acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMPactivated protein kinase activation. J. Biol. Chem, 283, 27628-27635.
248
Masataka Suwa
[305] Breen, D. M., Sanli, T., Giacca, A. & Tsiani, E. (2008). Stimulation of muscle cell
glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res.
Commun, 374, 117-122.
[306] Jger, S., Handschin, C., St-Pierre, J. & Spiegelman, B. M. (2007). AMP-activated
protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1.
Proc. Natl. Acad. Sci. U S A, 104, 12017-12022.
[307] Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M. & Spiegelman, B. M.
(1998). A cold-inducible coactivator of nuclear receptors linked to adaptive
thermogenesis. Cell, 92, 829-839.
[308] Lin, J., Handschin, C. & Spiegelman, B. M. (2005). Metabolic control through the
PGC-1 family of transcription coactivators. Cell Metab, 1, 361-370.
[309] Virbasius, J. V. & Scarpulla, R. C. (1994). Activation of the human mitochondrial
transcription factor A gene by nuclear respiratory factors: a potential regulatory link
between nuclear and mitochondrial gene expression in organelle biogenesis. Proc. Natl.
Acad. Sci. U S A, 91, 1309-1313.
[310] Scarpulla, R. C. (1997). Nuclear control of respiratory chain expressionin mammalian
cells. J. Bioenerg. Biomembr, 29, 109-119.
[311] Schreiber, S. N., Knutti, D., Brogli, K., Uhlmann, T. & Kralli, A. (2003). The
transcriptional coactivator PGC-1 regulates the expression and activity of the orphan
nuclear receptor estrogen-related receptor (ERR). J. Biol. Chem, 278, 9013-9018.
[312] Vega, R. B., Huss, J. M. & Kelly, D. P. (2000). The coactivator PGC-1 cooperates with
peroxisome proliferator-activated receptor in transcriptional control of nuclear genes
encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell Biol, 20, 1868-1876.
[313] DeFronzo, R. A. (2004). Pathogenesis of type 2 diabetes mellitus. Med. Clin. North Am,
88, 787-835.
[314] Mogensen, M., Sahlin, K., Fernstrm, M., Glintborg, D., Vind, B. F., Beck-Nielsen, H.
& Hjlund, K. (2007). Mitochondrial respiration is decreased in skeletal muscle of
patients with type 2 diabetes. Diabetes, 56, 1592-1599.
[315] Bruce, C. R., Anderson, M. J., Carey, A. L., Newman, D. G., Bonen, A., Kriketos, A.
D., Cooney, G. J. & Hawley, J. A. (2003). Muscle oxidative capacity is a better
predictor of insulin sensitivity than lipid status. J. Clin. Endocrinol. Metab, 88, 54445451.
[316] Grski, J. (2012). Ceramide and insulin resistance: how should the issue be
approached? Diabetes, 61, 3081-3083.
[317] Amati, F., Dub, J. J., Alvarez-Carnero, E., Edreira, M. M., Chomentowski, P., Coen,
P. M., Switzer, G. E., Bickel, P. E., Stefanovic-Racic, M., Toledo, F. G. & Goodpaster,
B. H. (2011). Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin
resistance: another paradox in endurance-trained athletes? Diabetes, 60, 2588-2597.
[318] Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y.,
Kohane, I., Costello, M., Saccone, R., Landaker, E. J., Goldfine, A. B., Mun, E.,
DeFronzo, R., Finlayson, J., Kahn, C. R. & Mandarino, L. J. (2003). Coordinated
reduction of genes of oxidative metabolism in humans with insulin resistance and
diabetes: Potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. U S A, 100, 84668471.
[319] Mensink, M., Hesselink, M. K., Russell, A. P., Schaart, G., Sels, J. P. & Schrauwen, P.
(2007). Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1
AMPK
249
and PPAR / gene expression upon rosiglitazone treatment in obese patients with type
2 diabetes mellitus. Int. J. Obes, 31, 1302-1310.
[320] Steinberg, G. R., Smith, A. C., Van Denderen, B. J., Chen, Z., Murthy, S., Campbell, D.
J., Heigenhauser, G. J., Dyck, D. J. & Kemp, B. E. (2004). AMP-activated protein
kinase is not down-regulated in human skeletal muscle of obese females. J. Clin.
Endocrinol. Metab, 89, 4575-4580.
[321] Musi, N., Fujii, N., Hirshman, M. F., Ekberg, I., Frberg, S., Ljungqvist, O., Thorell, A.
& Goodyear, L. J. (2001). AMP-activated protein kinase (AMPK) is activated in
muscle of subjects with type 2 diabetes during exercise. Diabetes, 50, 921-927.
[322] Hjlund, K., Mustard, K. J., Staehr, P., Hardie, D. G., Beck-Nielsen, H., Richter, E. A.
& Wojtaszewski, J. F. (2004). AMPK activity and isoform protein expression are
similar in muscle of obese subjects with and without type 2 diabetes. Am. J. Physiol.
Endocrinol. Metab, 286, E239-E244.
[323] Sriwijitkamol, A., Coletta, D. K., Wajcberg, E., Balbontin, G. B., Reyna, S. M.,
Barrientes, J., Eagan, P. A., Jenkinson, C. P., Cersosimo, E., DeFronzo, R. A.,
Sakamoto, K. & Musi, N. (2007). Effect of acute exercise on AMPK signaling in
skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study.
Diabetes, 56, 836-848.
[324] Chen, M. B., McAinch, A. J., Macaulay, S. L., Castelli, L. A., O'brien, P. E., Dixon, J.
B., Cameron-Smith, D., Kemp, B. E. & Steinberg, G. R. (2005). Impaired activation of
AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human
skeletal muscle of obese type 2 diabetics. J. Clin. Endocrinol. Metab, 90, 3665-3672.
[325] Koistinen, H. A., Galuska, D., Chibalin, A. V., Yang, J., Zierath, J. R., Holman, G. D.
& Wallberg-Henriksson, H. (2003). 5-amino-imidazole carboxamide riboside increases
glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with
type 2 diabetes. Diabetes, 52, 1066-1072.
[326] Song, X. M., Fiedler, M., Galuska, D., Ryder, J. W., Fernstrm, M., Chibalin, A. V.,
Wallberg-Henriksson, H. & Zierath, J. R. (2002). 5-Aminoimidazole-4-carboxamide
ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic
(ob/ob) mice. Diabetologia, 45, 56-65.
[327] Halseth, A. E., Ensor, N. J., White, T. A., Ross, S. A. & Gulve, E. A. (2002). Acute and
chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose
concentrations. Biochem. Biophys. Res. Commun, 294, 798-805.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 9
Abstract
Mitochondria serve a critical function in the maintenance of cellular energy supplies,
calcium homeostasis, and cell death. Aside from these major roles, several lines of
evidence suggest that mitochondria are involved in cell cycle control, cell growth and
differentiation in a wide variety of cell types including myogenic cells.
When the myoblasts differentiate into myotubes, the abundance, morphology, and
functional properties of mitochondria is being dynamically altered. Mitochondrial mass,
mitochondrial DNA content, mitochondrial enzyme activities, and mitochondrial
respiration are markedly increased during myogenesis.
This strongly suggests that myogenesis is accompanied by increased mitochondrial
biogenesis and that the metabolic shift from glycolysis to oxidative phosphorylation as
the major energy source occurs during myogenesis. Intriguingly, when myoblasts are
exposed to mitochondrial genetic and metabolic stress, they fail to differentiate into
multinucleated myotubes, suggesting that mitochondria may play a certain role in
myogenesis.
The process is relatively well understood phenomenologically, but the underlying
molecular mechanisms have been surprisingly slow to emerge. Understanding how
mitochondria are involved in myogenesis will provide a valuable insight into the
underlying mechanisms that regulate the maintenance of cellular homeostasis. Here we
will summarize the current knowledge regarding the role of mitochondria as a potential
regulator of myogenesis.
252
Akira Wagatsuma
1. Introduction
Mitochondria not only generate most of the energy necessary for cellular function via
oxidative phosphorylation (OXPHOS) but also are involved in calcium homeostasis, reactive
oxygen species (ROS)-redox control, multiple cellular signaling pathways, and cell death.
Alterations in mitochondrial function are involved in a range of inherited and acquired human
diseases and in the aging process [1]. Therefore, proper mitochondrial function is required for
the maintenance of both cellular and tissue integrity.
There is growing evidence that mitochondrial activity are linked to cell cycle control, cell
growth and differentiation, as have been shown in a wide variety of cell types including
adipocytes [2, 3], erythroblasts [4], erythroleukemia cells [5], dendritic cells [6], epidermal
keratinocyte [7], intestinal epithelial cells [8], mastocytoma cells [9], mesoangioblasts [10],
neurons [11-13], embryonic stem cells (ESCs) [14-18], and induced pluripotent stem cells
(iPSCs) [19], and myoblasts [20-29].
Skeletal muscle comprises approximately 40% of the normal adult male and 30% of the
female body weight [30]. The skeletal muscle possesses the unique ability to increase
metabolic rate nearly 100-fold during the transition form a basal resting state to near-maximal
contractile activity [31]. Therefore, skeletal muscle is a key metabolic tissue, which is
composed of highly specialized postmitotic, multinucleated myofibers. The molecular and
cellular processes leading to the fusion of myoblast cells to form multinucleated myofibers
have been extensively studied. Myogenesis is characterized by mononucleated myoblasts
withdrawing from the cell cycle, initiating muscle specific gene expression, and subsequently
fusing with each other and with existing myotubes to form syncytial myofibers [32]. It is
orchestrated through a series of transcriptional controls governed by the myogenic regulatory
factors (MRFs). The MRFs, a group of basic helix-loop-helix (bHLH) transcription factors
consisting of MyoD, Myf-5, myogenin, and MRF4, play important regulatory functions in the
skeletal muscle developmental program [33]. MRF4 and Myf5 act in a genetic pathway
upstream of MyoD to direct embryonic cells into the myogenic lineage [34]. Myogenin,
which acts in a genetic pathway downstream of MyoD and Myf-5 [35], directly controls the
differentiation process, including the formation of myotubes [36, 37].
After the onset of myogenic differentiation, mitochondrial enzyme activity is drastically
increased [38-40]. Similarly, muscle regeneration, which proceeds through a molecular
cascade resembling embryonic muscle development, is also accompanied by an increased
mitochondrial enzyme activity [41-43]. These findings suggest that the metabolic shift from
glycolysis to OXPHOS as the major energy source occurs during myogenesis. Intriguingly,
this metabolic shift has been also reported in ESCs [15, 16] and iPSCs [19]. iPSCs have low
mitochondrial activity, relying predominantly on glycolysis for ATP generation and maintains
a state of dedifferentiation, while differentiation is accompanied by increased mitochondrial
activity [19]. Therefore, metabolic shift may be a key event initiating cell differentiation. This
shift requires an activation of mitochondrial biogenesis through coordinated expression of
nuclear and mitochondrial genomes. Mitochondrial biogenesis is tightly controlled by
transcriptional coactivators, transcription factors, and nuclear receptors [1, 44-47]. Their
expression is induced during myogenesis [39, 40] and muscle regeneration [41, 43].
The effects of impairment of mitochondrial function and activity on myogenic cells have
been investigated using antimycin [48], azide [48-51], chloramphenicol [24, 26-29], carbonyl
253
254
Akira Wagatsuma
255
mtDNA, as shown in mtDNA harboring large-scale deletions [101]; (b) a high population of
mutant mtDNA initially present in ovum; (c) a nonrandom sampling of the mtDNA
population in embryological development [99]. Meanwhile, a sporadic patient with chronic
progressive external ophthalmoplegia, ptosis, limb weakness, sensorineural hearing loss, and
a pigmentary retinopathy that has previously been only found in association with large-scale
deletions or the A3243G mutation in the tRNAleu(UUR) gene, has shown evidence of abnormal
proliferation of mitochondria [102]. Satellite cells from the patient's skeletal muscle contain
homoplasmic wild-type mtDNA and a low or negligible amount of mutated mtDNA [102,
103]. Therefore, activation of satellite cells in adult muscle could function in the shifting of
normal mitochondrial templates to mature myofiber and restoration of a more normal
mitochondrial genotype and biochemical function [102, 103]. For instance, muscle injury
induces restoration of a wild-type mtDNA genotype in regenerating myofibers in patients
with a Kearns-Sayre Syndrome (KSS), a sporadic disease associated with large-scale mtDNA
deletions, and in sporadic patients with tRNA point mutations [104]. Resistance training also
increases the ratio of wild-type to mutant mtDNAs, in the proportion of myofibers with
normal respiratory chain activity in patient with a phenotype similar to KSS [105]. These
findings suggest that normalization of the mtDNA genotype in mature myofibers in a patient
with mitochondrial myopathy could be brought by enhancing the incorporation of satellite
cells into the myofibers with mutated mtDNA through regeneration following injury and
resistance training.
256
Akira Wagatsuma
mtDNA; (4) selective degradation of mitochondria by autophagy (mitophagy) [46, 108, 109].
When it is not indicated, in this article, mitochondrial biogenesis will be referred to as an
increase in mitochondrial volume and changes in organelle composition per tissue or cell
[108].
257
in increased mitochondrial biogenesis and oxygen consumption [118]. Skeletal musclespecific PGC-1 transgenic mice exhibit increased mtDNA amount, mitochondrial content,
mitochondrial enzyme activity [119]. Mice lacking PGC-1 show a reduced numbers of
mitochondria, decreased respiration function, and decreased expression of mitochondrial
genes [120]. Taken together, PRC and/or PGC-1 may functionally replace PGC-1 during
muscle regeneration. However, the possibility cannot be excluded that PGC-1 may
contribute to the mitochondrial biogenesis during muscle regeneration, as has been shown in
gain-of-function and loss-of-function studies [121-125]. Other studies [39, 40] also report that
PGC-1 expression increases in vitro culture system using C2C12 myoblasts. Accordingly,
further studies are required to elucidate the role of PGC-1 in mitochondrial biogenesis
during muscle regeneration.
258
Akira Wagatsuma
259
260
Akira Wagatsuma
investigate their fusion capacity [22]. The fusion capacity of mtDNA-depleted myoblasts falls
to one-third of control myoblasts when initiating cell differentiation in the absence of EtBr
[22]. Subsequently, Sobreira et al. investigate the extent to which myoblasts fuse into
multinucleated myotubes in respiration-deficient myogenic cybrids produced by
transmitochondrial cybrid technology [52]. They produced viable myoblasts harboring
exclusively mtDNA with large-scale deletions by treating wild-type myoblasts with
rhodamine 6G and fusing them with cytoplasts homoplasmic for two different mutated
mtDNAs. Three cell lines were used as mitochondrial donors: 143B.TK-, 206/FLP 32.39, and
206/CW 420-115. The wild-type 143B.TK- cell line contains normally respiring mitochondria
[148]. Rhodamine 6G-treated myoblasts fused with 143B.TK- cytoplasts were used as
controls. The transmitochondrial cell line 206/FLP 32.39 was obtained by fusing mtDNA less
143B206 rho0 cells with enucleated fibroblasts from KSS patient K11 [149] harboring a 1,902
bp mtDNA deletion encompassing the region between nucleotides 7846 and 9748 of mtDNA.
The transmitochondrial cell line 206/CW 420-115 was obtained by fusing mtDNA less
143B206 rho0 cells with cytoplasts from KSS patient K13 [149] harboring a 5,790 bp deletion
situated between nucleotides 10155 and 15945 of mtDNA. It has previously been
demonstrated that the threshold for normal respiratory chain function in cultured cells
harboring mtDNA with deletions is relatively high, requiring the presence of at least 15%
wild-type mtDNA [101, 150]. The residual levels of wild-type mtDNA are less than 0.005%
and 0.025% of total mtDNA, respectively for the 206/FLP 32.39 and 206/CW 420-115
myogenic cybrids, which are insufficient to sustain normal respiratory chain activity, as
shown in very low levels of their COX activity when compared to control myogenic cybrid
[52]. The cell proliferation capacity of these myogenic cybrids nearly equals to that of control
myogenic cybrid [52], suggesting that the introduction of intact mitochondria is sufficient to
overcome the growth arrest of respiratory-deficient cells and the absence of ATP generated
by OXPHOS does not impair myoblast proliferation. The myotubes derived from myogenic
cybrids harboring mtDNAs with deletions have fewer nuclei (less than 4 nuclei) than that
from control myogenic cybrid [52]. The rate of myoblast fusion is reduced, ranging from 19%
to 50% and from 13% to 28% of the control myogenic cybrid, respectively for the 206/FLP
32.39 and 206/CW 420-115 myogenic cybrids [52]. These finding suggest that myogenic
differentiation might progress to some extent depending exclusively on inefficient energy
production via glycolysis, instead of relying primarily on more efficient energy production
through OXPHOS. However, one can argue that respiratory chain activity is required for
sustaining normal myogenesis. Importantly, it should be noted that myoblast fusion is
suppressed to a greater extent than the expression of sarcomeric myosin heavy chain in
myogenic cybrids containing mutated mtDNAs, [52] suggesting that mitochondrial activity
might either directly or indirectly modulate myoblast fusion.
Myoblast fusion is a highly regulated process that is a typical and essential feature of
myogenesis [151-153]. It occurs through the sequential events including cell elongation, cell
migration, cell-cell recognition/adhesion, and membrane fusion [154]. Recent studies have
identified cell surface, extracellular, and intracellular molecules in myoblast fusion in
mammals [152, 153, 155, 156]. For instance, integrins comprise a large family of /
heterodimeric cell surface glycoproteins involved in cell-cell and cell-matrix interactions. The
integrin 1A, and 1D subunits and its partners 1, 3, 4, 5, 6, 7A, 7B, and v are expressed
in vertebrate skeletal muscle in a developmentally regulated fashion [157, 158]. Integrin 3
and 91 are observed at membrane cell surface and at close cell-cell contact of fusing
261
myoblasts [159, 160]. The function of 3 integrin and 9 integrin being attenuated using
specific antibodies, myoblast fusion is suppressed in vitro [159, 160]. The 1 integrindeficient myoblasts from transgenic mice have an impaired ability to undergo cell fusion
[161]. The 1 integrin-null mice exhibit the accumulation of unfused myoblasts in skeletal
muscle [161]. Intriguingly, mtDNA-depleted myoblasts fail to form multinucleated myotubes
and show markedly reduced levels of 51 integrins around the plasma membrane [162]. 51
integrins also have been reported to regulate myogenesis [163, 164]. When myoblasts began
to fuse, 5 integrin is distributed in small adhesion plaques along the lateral edges of the
postmitotic myoblasts and early myotubes and subsequently 51 integrins is localized to
parallel streaks underneath their entire substrate surface of mature myotubes [163]. When
myoblasts are treated with a monoclonal antibody of enhancing the binding of 51 integrins
for its ligand fibronectin, it interfers with cell migration and normal myoblast fusion [164]. In
view of the suggested role of integrins in myogenesis, mitochondrial genetic stress may
suppress myoblast fusion by dysregulating integrins-mediated cell adhesion and migration.
Myoferlin, which is identified as a protein highly homologous to dysferlin [165], is highly
expressed in myoblasts undergoing fusion, and is expressed at the site of myoblasts fusing to
myotubes [166]. Myoferlin-deficient myoblasts undergo initial fusion events, but they form
large myotubes less efficiently in vitro and myoferlin null muscle lacks large diameter
myofibers [166]. Nuclear factor of activated T cells (NFAT) is a family of transcription
factors in regulating early gene transcription in response to T cell receptor-mediated signals in
lymphocytes [167]. Despite their name, the member of NFAT isoforms (NFATc1-4) is
expressed in myogenic cells and differentially translocate at different stages of muscle
development [168]. The NFATc2 isoform is activated only in newly formed or nascent
myotubes [168] where it plays a crucial role in the myotube growth [169]. NFATc2 regulates
myoblast fusion through the cytokine, interleukin-4 (IL-4), which is secreted by newly
formed myotubes, interacts with IL-4 receptor present on surrounding myoblasts, promoting
their fusion to pre-existing myotubes [170], probably through enhancing the migration of
myoblasts [171]. Prostaglandin F2 also recruits the additional myoblast fusion with preexisting myotubes via an NFATc2-dependent pathway [170]. The fusion events of myoblasts
occur in two well-characterized phases. In the first phase, mononucleated myoblasts fuse with
one another to form a nascent myotube (myoblast/myoblast fusion events). During the second
phase, additional myoblasts fuse with pre-existing myotubes to form a large and mature
myotube (myoblast/myotube fusion events) [152]. Therefore, these findings suggest that
NFATc2 signaling is involved in regulating myoblast/myotube fusion events. Actin
regulatory molecules also play key roles in myoblast fusion. Defects in neural WiskottAldrich syndrome protein (NWASP), which is important regulators of the actin cytoskeleton
and WASP-interacting protein (WIP) leads to impaired myoblast fusion [173]. Until now, the
relationship between the expression of these molecules involved in regulating cell fusion and
mitochondrial activity during myogenesis is largely unknown.
262
Akira Wagatsuma
the initiation of differentiation. This finding is inconsistent with other studies [24, 26-29]. It is
possible that lab-to-lab variability in experimental conditions including such as cell type
(primary or immortalized cells), cell density, culture time, and drug exposure times may have
contributed to this discrepancy.
Korohoda et al. [24] have reported that chloramphenicol inhibits the fusion of myoblasts
isolated from chick embryo skeletal muscle. This is among the first study to show the
inhibitory effect of chloramphenicol on myogenesis. They show that tryptose phosphate broth
and nucleosides can restore the cell capacity to proliferate but not to fuse and differentiate in
the presence of chloramphenicol [24].
Subsequently, it has been demonstrated that mitochondrial activity is an important
regulator of myogenesis in quail myoblasts of the QM7 cell line and mouse myoblasts of the
C2C12 cell line [26, 28, 29]. Chloramphenicol-treated myoblasts proliferate at a slower rate
than control myoblasts without inducing any alteration of cell viability [26]. However, a
strong reduction in ATP levels is observed in chloramphenicol-treated myoblasts during cell
proliferation [26].
This finding raises the possibility that ATP depletion observed in chloramphenicoltreated myoblasts during the early period of cell culture could be responsible for the inhibition
of myogenic differentiation. This possibility seems to be excluded for the following the
reasons: (1) glycolysis fully compensates for mitochondrial impairment just before and during
terminal differentiation, as shown in a marked accumulation of L-lactate in the culture
medium [25, 26]; (2) myogenic differentiation is repressed especially when myoblasts are
exposed to chloramphenicol at the onset of terminal differentiation [26]. These findings
indicate that mitochondrial activity regulates myogenesis independently of their implication
in ATP synthesis [26].
6.1. Myogenin
Cabellos research group has investigated the relationship mitochondrial activity and
myogenesis using chloramphenicol [26, 28, 29]. Chloramphenicol treatment inhibits
myogenesis and downregulates the expression of myogenin but not other MRFs, Myf5 and
MyoD [26, 28]. Conversely, chloramphenicol removal rejuvenates the capacity for
differentiation into myotubes and leads to the restoration of myogenin expression [26].
263
Reagents
Target
Results
EtBr
mtDNA
EtBr
mtDNA
Rhodamine 6G
mtDNA
Protein
translation
Protein
Rifampicin
translation
Protein
Chloramphenicol
translation
Chloramphenicol
Protein
translation
QM7 (Quail)
Chloramphenicol
Protein
translation
Protein
translation
QM7 (Quail)
Chloramphenicol
Protein
translation
Protein
translation
Skeletal muscle
Protein
Chloramphenicol
(Mouse)
translation
QM7 (Quail)
Oligomycin
QM7 (Quail)
FCCP
ATP synthase
Oxidative
Decreased myoblast fusion and differentiation
phosphorylation
No difference in the extent of myoblast fusion
Cytochrome c
and expression of sMyHC between control and
oxidase
treated cultures
Inhibition of myoblast fusion
ATP synthase
Downregulation of myogenin
NADH
Inhibition of myoblast fusion
dehydrogenase Downregulation of myogenin
Cytochrome bc 1 Inhibition of myoblast fusion
complex
Downregulation of myogenin
References
Brunk et al.,
1976
Herzberg et
al., 1993
Sobreira et
al., 1999
Brunk et al.,
1976
Brunk et al.,
1976
Korohoda et
al., 1993
Hamai et al.,
1997
Rochard et
al., 2000
Pawlikowska
et al., 2006
Seyer et al.,
2006
Seyer et al.,
2011
Wagatsuma
et al., 2011
Rochard et
al., 2000
Rochard et
al., 2000
Yun et al.,
2005
Pawlikowska
et al., 2006
Pawlikowska
et al., 2006
Pawlikowska
et al., 2006
EtBr, ethidium bromide; CK, creatine kinase; TnI, troponin I; troponin T, TnT; AChR, acetylcholine
receptor subunit; sMyHC, sarcomeric myosin heavy chain; FCCP, carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone.
264
Akira Wagatsuma
The functions of myogenin have been well investigated. When transfecting mesenchymal
cell line C3H10T1/2 with myogenin, it can convert them to myoblasts [174]. Mice lacking
myogenin exhibit a normal number of myoblasts but die immediately after birth because of an
absence of myofibers [36, 37]. They differ from mice lacking either Myf5 or MyoD, which
have normal skeletal muscle [175, 176]. Therefore, myogenin has a crucial role during
myogenesis [36, 37] and both Myf5 and MyoD cannot compensate for its deficit [35].
Intriguingly, similar downregulation of myogenin is commonly observed in FCCP,
myxothiazol [27], rotenone [27], and oligomycin [26, 27], which affect mitochondria at
different levels. These findings suggest that myogenin is a specific target of mitochondrial
activity. How is myogenin expression regulated by mitochondrial activity? The measurement
of half-life of myogenin mRNA after transcription inhibition with actinomycin D reveals that
chloramphenicol have no effect on myogenin mRNA stability [26], suggesting that
mitochondrial activity could regulate myogenin expression at the transcriptional level.
Unfortunately, the molecular mechanisms regulating the expression and activity of myogenin
by mitochondrial activity remain to be elucidated, although they are not only transcriptionally
regulated but also by mRNA stability, translation efficiency, protein stability, and protein
phosphorylation [177]. For instance, myogenin is a short-lived protein [178] and can be
ubiquitinated and degraded through the von Hippel-Lindau protein (pVHL)-E3 ubiquitin
ligase pathway [179]. Myogenin protein can be stabilized by interacting with EGLN3 (EGL
nine homolog 3), which encodes an intracellular prolyl hydroxylase that is involved in the
cellular response to oxygen availability by hydroxylating hypoxia inducible factor 1 (HIF1) protein [180, 181]. EGLN3 can prevent myogenin protein from pVHL-mediated
unbiquitination and degradation, leading to stabilization of myogenin protein that promotes
myogenesis [179]. Myogenin activity can be suppressed by calcium/calmodulin-dependent
protein kinase II-mediated phosphorylation [182]. Considering the role of myogenin in
myogenesis, it is expected that forced expression of myogenin can rescue cell differentiation
in chloramphenicol-treated myoblasts. However, overexpression of myogenin fails to restore
their differentiation potential in the presence of chloramphenicol [26]. This indicates that
mitochondrial activity could regulate myogenesis by decaying ability of MRFs via other
regulators and/or negative regulators of myogenesis.
265
downregulates MyoD, myogenin, and Myf5 expression [189]. Cotransfection of c-Myc with
MyoD and myogenin in NIH 3T3 cells inhibits myogenic differentiation [187]. While these
findings are compelling, a role of c-Myc should be carefully considered for a number of
reasons as follows. First, nuclear runoff transcription assay demonstrates that c-Myc and
skeletal muscle-specific genes could be simultaneously transcribed in both biochemically
differentiated myoblasts (no fusion) and terminally differentiated myotubes [185]. c-Myctransformed C2C12 cells retain the ability to undergo commitment and biochemical
differentiation but they are strikingly unable to fuse into multinucleated myotubes with no
change in the expression of MyoD, myogenin, and myosin heavy chain [188]. These findings
suggest that irreversible repression of c-Myc is not necessary for myogenic differentiation and
its expression is insufficient to suppress the differentiated phenotype. Secondly, c-Myc
represses p21Cip1/WAF1 expression through transcriptional activator, Miz-1 (c-Myc interacting
zinc-finger protein-1)-dependent interaction with p21Cip1/WAF1 core promoter [191]. In
addition, c-Myc interacts with Miz-1 and recruits DNA methyltransferase 3A to p21Cip1/WAF1
promoter to silence p21 transcription [192]. The expression of p21 Cip1/WAF1 is known to be a
key event triggering the withdrawal of myoblasts from the cell cycle to G0, a prerequisite to
myogenic differentiation [193]. Chloramphenicol or c-Myc overexpression decrease the
proportion of myoblasts in the G0-G1 phase whereas overexpression of p43 exerts opposite
influence [28]. These findings suggest the possibility that mitochondrial activity could
regulate myoblast cell cycle withdrawal by modulating expression of p21 Cip1/WAF1 through cMyc/Miz-1 complex. Therefore, not only c-Myc, but also Miz-1 expression levels need to be
explored in myogenic cells treated with chloramphenicol. Thirdly, Myc is a member of the
Myc/Max (Myc-associated factor X)/Mad (MAX dimerization protein) transcriptional
network comprises a group of widely expressed transcription factors [194]. For instance, cMyc/Max heterodimers transactivate its downstream genes by binding to the E-box sequence
5-CACGTG-3 in the target promoter, whereas Mad/Max heterodimers act as transcriptional
repressors at the same E-box-related DNA-binding sites [194]. Therefore, c-Myc/Max
heterodimers act by competing with Mad/Max heterodimers, resulting in controlling the
expression of their target genes. Intriguingly, a switching from Myc/Max to Mad/Max
heterodimers occurs in the process of cell differentiation. For instance, Max can interact with
Myc but not Mad in the undifferentiated U937 monocyte cell line and Mad:Max complexes
begin to accumulate rapidly 2 hr after induction of macrophage differentiation [195],
suggesting that cell differentiation is accompanied by a change in the composition of Max
heterocomplexes. The c-Myc/Max complex is readily detected in exponentially proliferating
HL60 cells but Mad is strongly induced in differentiated HL60 cells [196]. In addition, these
changes are closely associated with human telomerase reverse transcriptase (hTERT), the
catalytic subunit of telomerase/telomerase activity [196]. c-Myc induces the hTERT promoter
activity and gene expression [197] whereas Mad1 represses them [198]. Most recent
biochemical and genetic evidence suggest that the maintenance of telomere length by
telomerase is critical to sustain the proliferative ability of cells. These findings suggest that
the Myc/Max/Mad transcriptional network may constitute a molecular switch where the
abundance of Myc- versus Mad-containing heterodimers determines whether cells enter a
differentiation pathway or remain in a proliferative, undifferentiated state. Therefore, same
molecular switching may occur during myogenesis. However, this hypothesis is highly
speculative. Further studies are required to validate it in myogenic cells. Finally, a new mode
of Myc regulation has been recently reported in myogenesis. Myc protein is cleaved by a
266
Akira Wagatsuma
267
of Id1 and Id3 [204]. Taken together, mitochondrial activity may regulate myogenesis
through calcineurin-mediated myogenin and Id expression.
In contrast to the finding from myoblasts treated with chloramphenicol, calcineurin is
upregulated in mtDNA-depleted myoblasts [48, 162]. This upregulation seems to be
associated with elevated steady-state cytosolic Ca2+ level ([Ca2+]i). Myogenic cell lines
containing partially depleted mtDNA are established by chronically treated with EtBr for ~70
growth cycles, followed by single cell cloning [48]. Depletion of mtDNA leads to the
disruption of mitochondrial membrane potential and then results in elevated steady-state
cytosolic Ca2+ level ([Ca2+]i) possibly due to reduced ATP levels affecting Ca2+ efflux
through the plasma membrane [48]. Under these conditions, calcineurin A and NFATc are
strongly induced concomitant with a modest increase in calcineurin B [48]. Intriguingly, all
these changes are normalized in genetically reverted myoblasts which contain near-normal
mtDNA levels by growing mtDNA-depleted cells in normal medium, lacking EtBr, for ~30
growth cycles [48]. Therefore, calcineurin signaling may be increased in mtDNA-depleted
myoblasts. What role does calcineurin signaling play in mtDNA-depleted myoblasts? One
possibility would be that calcineurin is involved in activation of nuclear factor-B (NF-B)
signaling, which has been known to repress myogenesis [213]. In support of this hypothesis,
Alzuherri et al. [214] report that stable expression of constitutively active calcineurin in
myoblasts strongly activates NF-B. However, this finding perplexes us because previous
studies have consistently shown that calcineurin promotes myogenesis. To explain this
discrepancy, they propose a model for the dual actions of calcineurin on myogenesis:
transient activation of calcineurin promotes myogenesis, whereas prolonged activation of
calcineurin inhibits it [214]. If that's the case, chronic activation of calcineurin observed in
mtDNA-depleted myoblasts may lead to NF-B activation, resulting in interfering with
myogenesis.
268
Akira Wagatsuma
proteasome, allowing NF-B dimmers to translocate into the nucleus where they regulate
target gene expression [213, 220, 221]. In the non-canonical pathway, the p52 and RelB
heterodimers are frequently activated [211, 220, 221]. IKK homodimer is activated by the
NF-B-inducing kinase. Once activated, IKK phosphorylates p100 subunit, followed by 26S
proteasome-dependent processing of p100 to p52, which can lead to the activation of
p52/RelB heterodimers that translocate to the nucleus to transactivate NF-B target genes that
may be distinct from the classical pathway [213].
NF-B DNA binding activity is decreased during myogenic differentiation [216, 217,
225-227]. Guttridge et al., investigate the relative levels and subunit composition of NFB/Rel complexes found in undifferentiated and differentiated C2C12 cell cultures [217].
They report that p65 and p50 subunits of NF-B contain abundant DNA binding activities
using an electrophoretic mobility shift assay and NF-B transcriptional activity falls by nearly
50% with initiation of myogenic differentiation [217]. Subsequently, Guttridges research
group have shown that myogenesis is enhanced in MyoD-expressing fibroblasts deficient in
p65, IKK, or IKK and in myoblasts lacking p65 or IKK [213]. Skeletal muscles from p65
or IKK mutant mice also contain higher myofiber numbers [227]. These findings suggest
that canonical NF-B signaling functions to repress myogenesis [227].
The NF-B pathway is likely to be activated in mtDNA-depleted myoblasts [162, 228].
Indeed, p50 and c-Rel is abundant in the nuclear fractions from mtDNA-depleted myoblasts
concomitant with increased NF-B DNA binding activity [162, 228]. It is, however,
debatable as to whether the levels of p65 are increased or decreased in mtDNA-depleted
myoblasts [48, 228]. Because c-Rel can form heterodimers with p50 and p65 [229], at least cRel/p50 and/or p50/p50 nuclear translocation can occur, leading to activation of NF-B
pathway in mtDNA-depleted myoblasts. Avadhanis research group focus on the role of
calcineurin in the process of NF-B activation in response to mitochondrial genetic stress.
[228]. The nuclear p65, p50, and c-Rel levels are decreased in skeletal muscles from mice
lacking calcineurin A, compared to wild-type mice [228]. When C2C12 cells are transfected
with cDNA containing calcineurin A, it enhances the levels of p65, p50, and c-Rel in the
nuclear fraction whereas FK506, (calcineurin inhibitor) decreases their levels [228]. The
DNA-bound complex supershifted with antibodies against p65, p50, and cRel is observed in
transfected myoblasts and the complex formation is decreased by treating with FK506 [228].
The NF-B DNA binding activity of transfected myoblasts is comparable to that of mtDNAdepleted myoblasts [228]. Taken together, calcineurin could contribute to activation of NF-B
signaling by modulating the levels of NF-B/Rel proteins. The same research group further
investigates the mechanism of activation of NF-B pathway in mtDNA-depleted myoblasts.
NF-B/Rel proteins (p50, c-Rel, p65) bound IB can form a ternary complex with
calcineurin, as revealed by chemical cross-linking and coimmunoprecipitation experiments.
Calcineurin can dephosphorylate IB at the C-terminal PEST (polypeptide sequences
enriched in proline, glutamate, serine, and threonine) region, which has been shown to be
important for the function of IB [230-232]. Dephosphorylation of IB by calcineurin is
inhibited by RII peptide (a specific substrate of calcineurin) in a dose-dependent manner
[228]. These findings suggest that IB is inactivated through calcineurin-mediated
dephosphorylation, thereby releasing p50/Rel complex to translocate into the nucleus, leading
to activation of target genes.
Although the levels of p50 and c-Rel are increased in mtDNA-depleted myoblasts [162,
228], we think carefully whether NF-B (p50/c-Rel) functions as a repressor of myogenesis
269
because there is a report that DNA-binding activity of the NF-B subunit c-Rel cannot be
detected during myogenesis [217]. However, given that NF-B (p50/c-Rel) serves in a way
comparable to NF-B (p50/p65), they might play a role in myogenesis in response to
mitochondrial genetic stress. NF-B, which consists mostly of p50/p65, seems to interfere
with myogenesis through multiple mechanisms [227]. For instance, NF-B activates the
expression of cyclin D1 [217], which itself is capable of suppressing myogenic differentiation
[233, 234]. NF-B transcriptionally regulates cyclin D1 through direct binding of NF-B to
multiple sites in the cyclin D1 promoter [217]. Furthermore, p65 has shown to be able to
interact with cyclin D1, which contribute to cyclin D1 protein stability [235]. NF-B seems to
regulate MyoD expression through posttranscriptional gene silencing mechanism. Activation
of NF-B through p65 can destabilize MyoD mRNA levels through an mRNA cis-regulatory
motif (5-ACUACAG-3) [236, 237]. NF-B can also posttranslationally regulate MyoD.
Activation of the NF-B pathway by coexpression of IKK, IKK, or p65 modulates
myogenesis probably through its role in MyoD protein stability [238]. Tumor necrosis factor and tumor necrosis factor-like weak inducer of apoptosis activates NF-B pathway,
resulting in inhibition of myogenesis probably through destabilizing MyoD protein [238,
239]. NF-B pathway is likely to regulate myogenesis through Yin Yang1 (YY1) which is
known to be a negative regulator in myogenesis by directly repressing skeletal musclespecific genes [240-242]. NF-B regulates YY1 expression at the transcriptional levels
through direct binding of the p50/p65 heterodimer complex to the YY1 promoter and YY1
binds and inhibits myofibrillar promoters by recruiting the Polycomb group member, histone
methyltransferase (Enhancer of zente homolog 2; Ezh2) as well as histone deacethylase 1
(HDAC1) [243]. Furthermore, NF-B works in concert with YY1 to regulate microRNAs
(miRNAs). NF-B and YY1 negatively regulate the expression of miR-29b/c, which
accerilates myogenic differentiation [243]. Other miRNAs are also regulated by NF-B
through YY1 [245]. Although miR-1 and miR-133 are simultaneously induced during
myogenic differentiation, their effects are functionally antagonistic [247]. miR-1 facilitates
cell differentiation by targeting HDAC4 whereas miR-133 enhances cell proliferation by
repressing serum response factor [247]. These regulation mediated by NF-B seems to be
mostly dependent on p65 activity. Therefore, further studies may be required to determine
whether NF-B (p50/c-Rel) suppress myogenesis in response to mitochondrial genetic stress.
Conclusion
This paper provides the current knowledge about the role for mitochondria as a potential
regulator of myogenesis. Previous studies have highlighted that mitochondria play a role in
myogenesis. Several molecules have been identified as mitochondrial target. In particular,
myogenin, that is essential for myogenic differentiation, may be an important target of
mitochondrial activity because its downregulation is commonly observed in myogenic cells in
response to mitochondrial stress caused by antibiotics and chemical compounds, which affect
the organelle at different levels. In addition, NF-B may function as a suppressor of
myogenesis in mtDNA-depleted myoblasts. Guttridges research group has proposed the
model for NF-B signaling pathways during myogenesis [227]. According to them, a
temporal switch occurs between NF-B canonical and non-canonical signaling pathways
270
Akira Wagatsuma
Acknowledgments
This research was supported by the MEXT (The Ministry of Education, Culture, Sports,
Science and Technology) (Grant-in Aid for Scientific Research (C), 22500658), Japan.
References
[1]
[2]
[3]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
271
Kaneko, T., Watanabe, T. & Oishi, M. (1988). Effect of mitochondrial protein synthesis
inhibitors on erythroid differentiation of mouse erythroleukemia (Friend) cells. Mol.
Cell Biol., 8, 3311-3315.
Levenson, R., Macara, I. G., Smith, R. L., Cantley, L. & Housman, D. (1982). Role of
mitochondrial membrane potential in the regulation of murine erythroleukemia cell
differentiation. Cell, 28, 855-863.
Zaccagnino, P., Saltarella, M., Maiorano, S., Gaballo, A., Santoro, G., Nico, B.,
Lorusso, M. & Del Prete, A. (2012). An active mitochondrial biogenesis occurs during
dendritic cell differentiation. Int. J. Biochem. Cell Biol., 44, 1962-1969.
Hamanaka, R. B., Glasauer, A., Hoover, P., Yang, S, Blatt, H., Mullen, A. R., Getsios,
S., Gottardi, C. J., Deberardinis, R. J., Lavker, R. M. & Chandel, N. S. (2013).
Mitochondrial reactive oxygen species promote epidermal differentiation and hair
follicle development. Sci. Signal, 6, ra8.
Santandreu, F. M., Oliver, J. & Roca, P. (2011). Improvement of mitochondrial energy
and oxidative balance during intestinal differentiation. Mitochondrion, 11, 89-96.
Laeng, H., Schneider, E., Bolli, R., Zimmermann, A., Schaffner, T. & Schindler R.
(1988). Participation of mitochondrial proliferation in morphological differentiation of
murine mastocytoma cells. Exp. Cell Res., 179, 222-232.
San Martin, N., Cervera, A. M., Cordova, C., Covarello, D., McCreath, K. J. & Galvez,
B. G. (2011). Mitochondria determine the differentiation potential of cardiac
mesoangioblasts. Stem Cells, 29, 1064-1074.
Vayssire, J. L., Cordeau-Lossouarn, L., Larcher, J. C., Basseville, M., Gros, F. &
Croizat, B. (1992). Participation of the mitochondrial genome in the differentiation of
neuroblastoma cells. In Vitro Cell Dev. Biol., 28A, 763-772.
Mattson, M. P. & Partin, J. (1999). Evidence for mitochondrial control of neuronal
polarity. J. Neurosci. Res., 56, 8-20.
Wang, G., Qi, C., Fan, G. H., Zhou, H. Y. & Chen, S. D. (2005). PACAP protects
neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial
complex I inhibitor, rotenone. FEBS Lett., 579, 4005-4011.
Spitkovsky, D., Sasse, P., Kolossov, E., Bttinger, C., Fleischmann, B. K., Hescheler, J.
& Wiesner, R. J. (2004). Activity of complex III of the mitochondrial electron transport
chain is essential for early heart muscle cell differentiation. FASEB J., 18, 13001302.
Chung, S., Dzeja, P.P., Faustino, R.S., Perez-Terzic, C., Behfar, A. & Terzic, A. (2007).
Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem
cells. Nat. Clin. Pract. Cardiovasc. Med., 4 Suppl 1, S60-S67.
Chung, S., Dzeja, P. P., Faustino, R. S. & Terzic, A. (2008). Developmental
restructuring of the creatine kinase system integrates mitochondrial energetics with
stem cell cardiogenesis. Ann. NY Acad. Sci., 1147, 254-263.
Varum, S., Momcilovi, O., Castro, C., Ben-Yehudah, A., Ramalho-Santos, J. &
Navara, C. S. (2009). Enhancement of human embryonic stem cell pluripotency through
inhibition of the mitochondrial respiratory chain. Stem Cell Res., 3, 142-156.
Birket, M. J., Orr, A. L., Gerencser, A. A., Madden, D. T., Vitelli, C., Swistowski, A.,
Brand, M. D. & Zeng, X. (2011). A reduction in ATP demand and mitochondrial
activity with neural differentiation of human embryonic stem cells. J. Cell Sci., 124,
348-358.
272
Akira Wagatsuma
[19] Folmes, C. D., Nelson, T. J., Martinez-Fernandez, A., Arrell, D. K., Lindor, J. Z.,
Dzeja, P. P., Ikeda, Y., Perez-Terzic, C. & Terzic, A. (2011). Somatic oxidative
bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear
reprogramming. Cell Metab., 14, 264-271.
[20] Brunk, C. F. & Yaffe, D. (1976). The reversible inhibition of myoblast fusion by
ethidium bromide (EB). Exp. Cell Res., 99, 310-318.
[21] Duguez, S., Sabido, O. & Freyssenet, D. (2004). Mitochondrial-dependent regulation of
myoblast proliferation. Exp. Cell Res., 299, 27-35.
[22] Herzberg, N. H., Zwart, R., Wolterman, R. A., Ruiter, J. P., Wanders, R. J., Bolhuis, P.
A. & van den Bogert, C. (1993). Differentiation and proliferation of respirationdeficient human myoblasts. Biochim. Biophys. Acta, 1181, 63-67.
[23] Herzberg, N. H., Middelkoop, E., Adorf, M., Dekker, H. L., Van Galen, M. J., Van den
Berg, M., Bolhuis, P. A. & Van den Bogert, C. (1993). Mitochondria in cultured human
muscle cells depleted of mitochondrial DNA. Eur. J. Cell Biol., 61, 400-408.
[24] Korohoda, W., Pietrzkowski, Z. & Reiss, K. (1993). Chloramphenicol, an inhibitor of
mitochondrial protein synthesis, inhibits myoblast fusion and myotube differentiation.
Folia Histochem. Cytobiol., 31, 9-13.
[25] Hamai, N., Nakamura, M. & Asano, A. (1997). Inhibition of mitochondrial protein
synthesis impaired C2C12 myoblast differentiation. Cell Struct. Funct., 22, 421-431.
[26] Rochard, P., Rodier, A., Casas, F., Cassar-Malek, I., Marchal-Victorion, S., Daury, L.,
Wrutniak, C. & Cabello, G. (2000). Mitochondrial activity is involved in the regulation
of myoblast differentiation through myogenin expression and activity of myogenic
factors. J. Biol. Chem., 275, 2733-2744.
[27] Pawlikowska, P., Gajkowska, B., Hocquette, J. F. & Orzechowski, A. (2006). Not only
insulin stimulates mitochondriogenesis in muscle cells, but mitochondria are also
essential for insulin-mediated myogenesis. Cell Prolif., 39, 127-145.
[28] Seyer, P., Grandemange, S., Busson, M., Carazo, A., Gamalri, F., Pessemesse, L.,
Casas, F., Cabello, G. & Wrutniak-Cabello, C. (2006). Mitochondrial activity regulates
myoblast differentiation by control of c-Myc expression. J. Cell Physiol., 207, 75-86.
[29] Seyer, P., Grandemange, S., Rochard, P., Busson, M., Pessemesse, L., Casas, F.,
Cabello, G. & Wrutniak-Cabello, C. (2011) P43-dependent mitochondrial activity
regulates myoblast differentiation and slow myosin isoform expression by control of
calcineurin expression. Exp. Cell Res., 317, 2059-2071.
[30] Woodard, H. Q. & White, D. R. (1986). The composition of body tissues. Br. J. Radiol.,
59, 1209-1218.
[31] Lanza, I. R. & Sreekumaran Nair, K. (2010). Regulation of skeletal muscle
mitochondrial function: genes to proteins. Acta Physiol., 199, 529-547.
[32] Horsley, V. & Pavlath, G. K. (2004). Forming a multinucleated cell: molecules that
regulate myoblast fusion. Cells Tissues Organs, 176, 67-78.
[33] Weintraub, H., Davis, R., Tapscott, S., Thayer, M., Krause, M., Benezra, R., Blackwell,
T. K., Turner, D., Rupp, R., Hollenberg, S., Zhuang, Y. & Lassar, A. (1991). The myoD
gene family: nodal point during specification of the muscle cell lineage. Science, 251,
761-766.
[34] Kassar-Duchossoy, L., Gayraud-Morel, B., Goms, D., Rocancourt, D., Buckingham,
M., Shinin, V. & Tajbakhsh, S. (2004). Mrf4 determines skeletal muscle identity in
Myf5:Myod double-mutant mice. Nature, 431, 466-471.
273
[35] Rawls, A., Morris, J. H., Rudnicki, M., Braun, T., Arnold, H. H., Klein, W. H. & Olson,
E. N. (1995). Myogenin's functions do not overlap with those of MyoD or Myf-5 during
mouse embryogenesis. Dev. Biol., 172, 37-50.
[36] Hasty, P., Bradley, A., Morris, J. H., Edmondson, D. G., Venuti, J. M., Olson, E. N. &
Klein, W. H. (1993). Muscle deficiency and neonatal death in mice with a targeted
mutation in the myogenin gene. Nature, 364, 501-506.
[37] Nabeshima, Y., Hanaoka, K., Hayasaka, M., Esumi, E., Li, S., Nonaka, I. &
Nabeshima, Y. (1993). Myogenin gene disruption results in perinatal lethality because
of severe muscle defect. Nature, 364, 532-535.
[38] Moyes, C. D., Mathieu-Costello, O. A., Tsuchiya, N., Filburn, C. & Hansford, R. G.
(1997). Mitochondrial biogenesis during cellular differentiation. Am. J. Physiol., 272,
C1345-C1351.
[39] Remels, A. H., Langen, R. C., Schrauwen, P., Schaart, G., Schols, A. M. & Gosker, H.
R. (2010). Regulation of mitochondrial biogenesis during myogenesis. Mol. Cell
Endocrinol., 315, 113-120.
[40] Barbieri, E., Battistelli, M., Casadei, L., Vallorani, L., Piccoli, G., Guescini, M.,
Gioacchini, A. M., Polidori, E., Zeppa, S., Ceccaroli, P., Stocchi, L., Stocchi, V. &
Falcieri, E. (2011). Morphofunctional and biochemical Aapproaches for studying
mitochondrial changes during myoblasts differentiation. J. Aging Res., 2011, 845379.
[41] Duguez, S., Fasson, L., Denis, C. & Freyssenet, D. (2002). Mitochondrial biogenesis
during skeletal muscle regeneration. Am. J. Physiol., 282, E802-E809.
[42] Fink, E., Fortin, D., Serrurier, B., Ventura-Clapier, R. & Bigard, A. X. (2003).
Recovery of contractile and metabolic phenotypes in regenerating slow muscle after
notexin-induced or crush injury. J. Muscle Res. Cell Motil., 24, 421-429.
[43] Wagatsuma, A., Kotake, N. & Yamada, S. (2011). Muscle regeneration occurs to
coincide with mitochondrial biogenesis. Mol. Cell Biochem., 349, 139-147.
[44] Ryan, M. T. & Hoogenraad, N. J. (2007). Mitochondrial-nuclear communications.
Annu. Rev. Biochem., 76, 701-722.
[45] Scarpulla, R. C. (2008). Transcriptional paradigms in mammalian mitochondrial
biogenesis and function. Physiol. Rev., 88, 611-638.
[46] Hock M. B. & Kralli A. (2009). Transcriptional control of mitochondrial biogenesis and
function. Annu. Rev. Physiol., 71, 177-203.
[47] Scarpulla, R. C. (2011). Metabolic control of mitochondrial biogenesis through the
PGC-1 family regulatory network. Biochim. Biophys. Acta, 1813, 1269-1278.
[48] Biswas, G., Adebanjo, O. A., Freedman, B. D., Anandatheerthavarada, H. K.,
Vijayasarathy, C., Zaidi, M., Kotlikoff, M. & Avadhani, N. G. (1999). Retrograde Ca2+
signaling in C2C12 skeletal myocytes in response to mitochondrial genetic and
metabolic stress: a novel mode of inter-organelle crosstalk. EMBO J., 18, 522-533.
[49] Leary, S. C., Battersby, B. J., Hansford, R. G. & Moyes, C. D. (1998). Interactions
between bioenergetics and mitochondrial biogenesis. Biochim. Biophys. Acta, 1365,
522-530.
[50] Leary, S. C., Hill, B. C., Lyons, C. N., Carlson, C. G., Michaud, D., Kraft, C. S., Ko,
K., Glerum, D. M. & Moyes, C. D. (2002). Chronic treatment with azide in situ leads to
an irreversible loss of cytochrome c oxidase activity via holoenzyme dissociation. J.
Biol. Chem., 277, 11321-11328.
274
Akira Wagatsuma
[51] Yun, Z., Lin, Q. & Giaccia, A. J. (2005). Adaptive myogenesis under hypoxia. Mol.
Cell Biol., 25, 3040-3055.
[52] Sobreira, C., King, M. P., Davidson, M. M., Park, H., Koga, Y. & Miranda, A. F.
(1999). Long-term analysis of differentiation in human myoblasts repopulated with
mitochondria harboring mtDNA mutations. Biochem. Biophys. Res. Commun., 266,
179-186.
[53] Richter, C., Park, J. W. & Ames, B. N. (1988). Normal oxidative damage to
mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. U S A, 85, 64656467.
[54] Ames, B. N., Shigenaga, M. K. & Hagen, T. M. (1993). Oxidants, antioxidants, and the
degenerative diseases of aging. Proc. Natl. Acad. Sci. U S A, 90, 7915-7922.
[55] Linnane, A. W., Marzuki, S., Ozawa, T. & Tanaka, M. (1989). Mitochondrial DNA
mutations as an important contributor to ageing and degenerative diseases. Lancet, 1,
642-645.
[56] Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H., Coulson, A. R., Drouin,
J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., Schreier, P. H., Smith, A. J.,
Staden, R. & Young, I. G. (1981). Sequence and organization of the human
mitochondrial genome. Nature, 290, 457-465.
[57] Alexeyev, M. F., LeDoux, S. P. & Wilson, G. L. (2004). Mitochondrial DNA and
aging. Clin. Sci., 107, 355364.
[58] McKenzie, D., Bua, E., McKiernan, S., Cao, Z., Wanagat, J. & Aiken, J. M. (2002).
Mitochondrial DNA deletion mutations: a causal role in sarcopenia. Eur. J. Biochem.,
269, 2010-2015.
[59] Engel, W. K. & Cunningham, G. G. (1963). Rapid examination of muscle tissue:
an improved trichrome method for fresh-frozen biopsy sections. Neurology, 13, 919
923.
[60] Holt, I. J., Harding, A. E. & Morgan-Hughes, J. A. (1988). Deletions of muscle
mitochondrial DNA in patients with mitochondrial myopathies. Nature, 331, 717719.
[61] Aspnes, L. E., Lee, C. M., Weindruch, R., Chung, S. S., Roecker, E. B. & Aiken, J. M.
(1997). Caloric restriction reduces fiber loss and mitochondrial abnormalities in aged
rat muscle. FASEB J., 11, 573-581.
[62] Lee, C. M., Lopez, M. E., Weindruch, R. & Aiken, J. M. (1998). Association of agerelated mitochondrial abnormalities with skeletal muscle fiber atrophy. Free Radic Biol.
Med., 25, 964-972.
[63] Lee, C. M., Aspnes, L. E., Chung, S. S., Weindruch, R. & Aiken, J. M. (1998).
Influences of caloric restriction on age-associated skeletal muscle fiber characteristics
and mitochondrial changes in rats and mice. Ann. N Y Acad. Sci., 854, 182-191.
[64] Lopez, M. E., Van Zeeland, N. L., Dahl, D. B., Weindruch, R. & Aiken, J. M. (2000).
Cellular phenotypes of age-associated skeletal muscle mitochondrial abnormalities in
rhesus monkeys. Mutat. Res., 452, 123-138.
[65] Cao, Z., Wanagat, J., McKiernan, S. H. & Aiken, J. M. (2001). Mitochondrial DNA
deletion mutations are concomitant with ragged red regions of individual, aged muscle
fibers: analysis by laser-capture microdissection. Nucleic Acids Res., 29, 4502-4508.
[66] Pesce, V., Cormio, A., Fracasso, F., Vecchiet, J., Felzani, G., Lezza, A. M., Cantatore,
P. & Gadaleta, M. N. (2001). Age-related mitochondrial genotypic and phenotypic
alterations in human skeletal muscle. Free Radic Biol. Med., 30, 1223-1233.
275
[67] Wanagat, J., Cao, Z., Pathare, P. & Aiken, J. M. (2001). Mitochondrial DNA deletion
mutations colocalize with segmental electron transport system abnormalities, muscle
fiber atrophy, fiber splitting, and oxidative damage in sarcopenia. FASEB J., 15, 322332.
[68] Bua, E. A., McKiernan, S. H., Wanagat, J., McKenzie, D. & Aiken, J. M. (2002).
Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia. J.
Appl. Physiol., 92, 2617-2624.
[69] Fayet, G., Jansson, M., Sternberg, D., Moslemi, A. R., Blondy, P., Lombs, A.,
Fardeau, M. & Oldfors, A. (2002). Ageing muscle: clonal expansions of mitochondrial
DNA point mutations and deletions cause focal impairment of mitochondrial function.
Neuromuscul. Disord., 12, 484-493.
[70] Pak, J. W., Herbst, A., Bua, E., Gokey, N., McKenzie, D. & Aiken, J. M. (2003).
Mitochondrial DNA mutations as a fundamental mechanism in physiological declines
associated with aging. Aging Cell, 2, 1-7.
[71] Bua, E., McKiernan, S. H. & Aiken, J. M. (2004). Calorie restriction limits the
generation but not the progression of mitochondrial abnormalities in aging skeletal
muscle. FASEB J., 18, 582-584.
[72] Gokey, N. G., Cao, Z., Pak, J. W., Lee, D., McKiernan, S. H., McKenzie, D.,
Weindruch, R. & Aiken, J. M. (2004). Molecular analyses of mtDNA deletion
mutations in microdissected skeletal muscle fibers from aged rhesus monkeys. Aging
Cell, 3, 319-326.
[73] Bua, E., Johnson, J., Herbst, A., Delong, B., McKenzie, D., Salamat, S. & Aiken, J. M.
(2006) Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental
levels in aged human skeletal muscle fibers. Am. J. Hum. Genet., 79, 469-480.
[74] Herbst, A., Pak, J. W., McKenzie, D., Bua, E., Bassiouni, M. & Aiken, J. M. (2007).
Accumulation of mitochondrial DNA deletion mutations in aged muscle fibers:
evidence for a causal role in muscle fiber loss. J. Gerontol., 62, 235-245.
[75] McKiernan, S. H., Colman, R., Lopez, M., Beasley, T. M., Weindruch, R. & Aiken, J.
M. (2009). Longitudinal analysis of early stage sarcopenia in aging rhesus monkeys.
Exp. Gerontol., 44, 170-176.
[76] McKiernan, S. H., Colman, R. J., Lopez, M., Beasley, T. M., Aiken, J. M., Anderson,
R. M. & Weindruch, R. (2011). Caloric restriction delays aging-induced cellular
phenotypes in rhesus monkey skeletal muscle. Exp. Gerontol., 46, 23-29.
[77] McKiernan, S. H., Colman, R. J., Aiken, E., Evans, T. D., Beasley, T. M., Aiken, J. M.,
Weindruch, R. & Anderson, R. M. (2012). Cellular adaptation contributes to calorie
restriction-induced preservation of skeletal muscle in aged rhesus monkeys. Exp.
Gerontol., 47, 229-236.
[78] Rifai, Z., Welle, S., Kamp, C. & Thornton, C. A. (1995). Ragged red fibers in normal
aging and inflammatory myopathy. Ann. Neurol., 37, 24-29.
[79] Shoffner, J. M., Lott, M. T., Lezza, A. M., Seibel, P., Ballinger, S. W. & Wallace, D. C.
(1990). Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a
mitochondrial DNA tRNA(Lys) mutation. Cell, 61, 931937.
[80] Goto, Y., Nonaka, I. & Horai, S. (1990). A mutation in the tRNA(Leu)(UUR) gene
associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature,
348, 651653.
276
Akira Wagatsuma
[81] Mauro, A. (1961). Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol.,
9, 493-495.
[82] Hawke, T. J. & Garry, D. J. (2001). Myogenic satellite cells: physiology to molecular
biology. J. Appl. Physiol., 91, 534-551.
[83] Charg, S. B. & Rudnicki, M. A. (2004). Cellular and molecular regulation of muscle
regeneration. Physiol. Rev., 84, 209-238.
[84] Rudnicki, M. A., Le Grand, F., McKinnell, I. & Kuang, S. (2008). The molecular
regulation of muscle stem cell function. Cold Spring Harb. Symp. Quant. Biol., 73, 323331.
[85] Wang, Y. X. & Rudnicki, M. A. (2011). Satellite cells, the engines of muscle repair.
Nat. Rev. Mol. Cell Biol., 13, 127-133.
[86] Yin, H., Price, F. & Rudnicki, M. A. (2013). Satellite cells and the muscle stem cell
niche. Physiol. Rev., 93, 23-67.
[87] Muir, A. R., Kanji, A. H. & Allbrook, D. (1965). The structure of the satellite cells in
skeletal muscle. J. Anat., 99, 435-44.
[88] Shafiq, S. A. & Gorycki, M. A. (1965). Regeneration in skeletal muscle of mouse: some
electron-microscope observations. J. Pathol. Bacteriol., 90, 123-127.
[89] Reger, J. F. & Craig, A. S. (1968). Studies on the fine structure of muscle fibers and
associated satellite cells in hypertrophic human deltoid muscle. Anat. Rec., 162, 483500.
[90] Tervinen, H. (1970). Satellite cells of striated muscle after compression injury so
slight as not to cause degeneration of the muscle fibres. Z. Zellforsch. Mikrosk. Anat.,
103, 320-327.
[91] Stahlberger, R. & Friede, R. L. (1977). Fine structure of myomedulloblastoma. Acta
Neuropathol., 37, 43-48.
[92] Roth, S. M., Martel, G. F., Ivey, F. M., Lemmer, J. T., Metter, E. J., Hurley, B. F. &
Rogers, M. A. (2000). Skeletal muscle satellite cell populations in healthy young and
older men and women. Anat. Rec., 260, 351-358.
[93] Bayona-Bafaluy, M. P., Blits, B., Battersby, B. J., Shoubridge, E. A. & Moraes, C. T.
(2005). Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by
a mitochondrially targeted restriction endonuclease. Proc. Natl. Acad. Sci. U S A, 102,
14392-14397.
[94] Piao, Y. J., Seo, Y. H., Hong, F., Kim, J. H., Kim, Y. J., Kang, M. H., Kim, B. S., Jo, S.
A., Jo, I., Jue, D. M., Kang, I, Ha, J. & Kim, S. S. (2005). Nox 2 stimulates muscle
differentiation via NF-kappaB/iNOS pathway. Free Radic Biol. Med., 38, 989-1001.
[95] Lee, S., Tak, E., Lee, J., Rashid, M. A., Murphy, M. P., Ha, J. & Kim, S. S. (2011).
Mitochondrial H2O2 generated from electron transport chain complex I stimulates
muscle differentiation. Cell Res., 21, 817-834.
[96] Malinska, D., Kudin, A. P, Bejtka, M. & Kunz, W. S. (2012). Changes in mitochondrial
reactive oxygen species synthesis during differentiation of skeletal muscle cells.
Mitochondrion, 12, 144-148.
[97] Wei, Y. H. (1998). Oxidative stress and mitochondrial DNA mutations in human aging.
Proc. Soc. Exp. Biol. Med., 217, 53-63.
[98] Shokolenko, I., Venediktova, N., Bochkareva, A., Wilson, G. L. & Alexeyev, M. F.
(2009). Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids
Res., 37, 2539-2548.
277
[99] Boulet, L., Karpati, G. & Shoubridge, E. A. (1992). Distribution and threshold
expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic
epilepsy and ragged-red fibers (MERRF). Am. J. Hum. Genet., 51, 1187-1200.
[100] Chomyn, A., Martinuzzi, A., Yoneda, M., Daga, A., Hurko, O., Johns, D., Lai, S. T.,
Nonaka, I., Angelini, C. & Attardi, G. (1992). MELAS mutation in mtDNA binding site
for transcription termination factor causes defects in protein synthesis and in respiration
but no change in levels of upstream and downstream mature transcripts. Proc. Natl.
Acad. Sci. U S A, 89, 4221-4225.
[101] Hayashi, J., Ohta, S., Kikuchi, A., Takemitsu, M., Goto, Y. & Nonaka, I. (1991).
Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking
mitochondrial DNA results in mitochondrial dysfunction. Proc. Natl. Acad. Sci. U S A,
88, 10614-10618.
[102] Fu, K., Hartlen, R., Johns, T., Genge, A., Karpati, G. & Shoubridge, E. A. (1996). A
novel heteroplasmic tRNAleu(CUN) mtDNA point mutation in a sporadic patient with
mitochondrial encephalomyopathy segregates rapidly in skeletal muscle and suggests
an approach to therapy. Hum. Mol. Genet., 5, 1835-1840.
[103] Clark. K. M., Bindoff. L. A., Lightowlers. R. N., Andrews. R. M., Griffiths. P. G.,
Johnson. M. A., Brierley. E. J. & Turnbull. D. M. (1997). Reversal of a mitochondrial
DNA defect in human skeletal muscle. Nat. Genet., 16, 222-224.
[104] Shoubridge, E. A., Johns, T. & Karpati, G. (1997). Complete restoration of a wild-type
mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation
and mitochondrial encephalomyopathy. Hum. Mol. Genet., 6, 2239-2242.
[105] Taivassalo, T., Fu, K., Johns, T., Arnold, D., Karpati, G. & Shoubridge, E. A. (1999).
Gene shifting: a novel therapy for mitochondrial myopathy. Hum. Mol. Genet., 8, 10471052.
[106] Hood, D. A. (2001). Invited Review: contractile activity-induced mitochondrial
biogenesis in skeletal muscle. J. Appl. Physiol., 90, 1137-1157.
[107] Terman, A., Kurz, T., Navratil, M., Arriaga, E. A. & Brunk, U. T. (2010).
Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondriallysosomal axis theory of aging. Antioxid. Redox. Signal, 12, 503-535.
[108] Hood, D. A., Irrcher, I., Ljubicic, V. & Joseph, A. M. (2006). Coordination of
metabolic plasticity in skeletal muscle. J. Exp. Biol., 209, 2265-2275.
[109] Kim, I., Rodriguez-Enriquez, S. & Lemasters, J. J. (2007). Selective degradation of
mitochondria by mitophagy. Arch. Biochem. Biophys., 462, 245-253.
[110] Zhao, P. & Hoffman, E. P. (2004). Embryonic myogenesis pathways in muscle
regeneration. Dev. Dyn., 229, 380-392.
[111] Kanai A. J., Pearce L. L., Clemens P. R., Birder L. A., VanBibber M. M., Choi S. Y.,
de Groat W. C. & Peterson, J. (2001). Identification of a neuronal nitric oxide synthase
in isolated cardiac mitochondria using electrochemical detection. Proc. Natl. Acad. Sci.
U S A, 98, 14126-14131.
[112] Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A.,
Cinti, S., Lowell, B., Scarpulla, R. C. & Spiegelman, B. M. (1999). Mechanisms
controlling mitochondrial biogenesis and respiration through the thermogenic
coactivator PGC-1. Cell, 98, 115-124.
278
Akira Wagatsuma
[113] Kraft, C. S., LeMoine, C. M., Lyons, C. N., Michaud, D., Mueller, C. R. & Moyes, C.
D. (2006). Control of mitochondrial biogenesis during myogenesis. Am. J. Physiol.,
290, C1119-C1127.
[114] Andersson, U. & Scarpulla, R. C. (2001). Pgc-1-related coactivator, a novel, seruminducible coactivator of nuclear respiratory factor 1-dependent transcription in
mammalian cells. Mol. Cell Biol., 21, 3738-3749.
[115] Gleyzer, N., Vercauteren, K. & Scarpulla, R. C. (2005). Control of mitochondrial
transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors
(NRF-1 and NRF-2) and PGC-1 family coactivators. Mol. Cell Biol, 25, 1354-1366.
[116] Shao, D., Liu, Y., Liu, X., Zhu, L., Cui, Y., Cui, A., Qiao, A., Kong, X., Liu, Y., Chen,
Q., Gupta, N., Fang, F. & Chang, Y. (2010). PGC-1 beta-regulated mitochondrial
biogenesis and function in myotubes is mediated by NRF-1 and ERR alpha.
Mitochondrion, 10, 516-527.
[117] Philp, A., Belew, M. Y., Evans, A., Pham, D., Sivia, I., Chen, A., Schenk, S. & Baar, K.
(2011). The PGC-1-related coactivator promotes mitochondrial and myogenic
adaptations in C2C12 myotubes. Am. J. Physiol., 301, R864-R872.
[118] St-Pierre, J., Lin, J., Krauss, S., Tarr, P. T., Yang, R., Newgard, C. B. & Spiegelman, B.
M. (2003). Bioenergetic analysis of peroxisome proliferator-activated receptor gamma
coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J. Biol.
Chem., 278, 26597-26603.
[119] Arany, Z., Lebrasseur, N., Morris, C., Smith, E., Yang, W., Ma, Y., Chin, S. &
Spiegelman, B. M. (2007). The transcriptional coactivator PGC-1beta drives the
formation of oxidative type IIX fibers in skeletal muscle. Cell Metab., 5, 35-46.
[120] Lelliott, C. J., Medina-Gomez, G., Petrovic, N., Kis, A., Feldmann, H. M., Bjursell, M.,
Parker, N., Curtis, K., Campbell, M., Hu, P., Zhang, D., Litwin, S. E., Zaha, V. G.,
Fountain, K. T., Boudina, S., Jimenez-Linan, M., Blount, M., Lopez, M., Meirhaeghe,
A., Bohlooly-Y, M., Storlien, L., Strmstedt, M., Snaith, M., Oresic, M., Abel, E. D.,
Cannon, B. & Vidal-Puig, A. (2006). Ablation of PGC-1beta results in defective
mitochondrial activity, thermogenesis, hepatic function, and cardiac performance. PLoS
Biol., 4, e369.
[121] Lin, J., Wu, H., Tarr, P. T., Zhang, C. Y., Wu, Z., Boss, O., Michael, L. F., Puigserver,
P., Isotani, E., Olson, E. N., Lowell, B. B., Bassel-Duby, R. & Spiegelman, B. M.
(2002). Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch
muscle fibres. Nature, 418, 797-801.
[122] Leone, T. C., Lehman, J. J., Finck, B. N., Schaeffer, P. J., Wende, A. R., Boudina, S.,
Courtois, M., Wozniak, D. F., Sambandam, N., Bernal-Mizrachi, C., Chen, Z.,
Holloszy, J. O., Medeiros, D. M., Schmidt, R. E., Saffitz, J. E., Abel, E. D.,
Semenkovich, C. F. & Kelly, D. P. (2005). PGC-1alpha deficiency causes multi-system
energy metabolic derangements: muscle dysfunction, abnormal weight control and
hepatic steatosis. PLoS Biol., 3, e101.
[123] Handschin, C., Choi, C. S., Chin, S., Kim, S., Kawamori, D., Kurpad, A. J., Neubauer,
N., Hu, J., Mootha, V. K., Kim, Y. B., Kulkarni, R. N., Shulman, G. I. & Spiegelman,
B. M. (2007). Abnormal glucose homeostasis in skeletal muscle-specific PGC-1alpha
knockout mice reveals skeletal muscle-pancreatic beta cell crosstalk. J. Clin. Invest.,
117, 3463-3474.
279
[124] Handschin, C., Chin, S., Li, P., Liu, F., Maratos-Flier, E. Lebrasseur, N. K., Yan, Z. &
Spiegelman, B. M. (2007). Skeletal muscle fiber-type switching, exercise intolerance,
and myopathy in PGC-1alpha muscle-specific knock-out animals. J. Biol. Chem., 282,
30014-30021.
[125] Calvo, J. A., Daniels, T. G., Wang, X., Paul, A., Lin, J., Spiegelman, B. M., Stevenson,
S. C. & Rangwala, S. M. (2008). Muscle-specific expression of PPARgamma
coactivator-1alpha improves exercise performance and increases peak oxygen uptake. J.
Appl. Physiol., 104, 1304-1312.
[126] Saada, A., Shaag, A. & Elpeleg, O. (2003). mtDNA depletion myopathy: elucidation of
the tissue specificity in the mitochondrial thymidine kinase (TK2) deficiency. Mol.
Genet. Metab., 79, 1-5.
[127] Meierhofer, D., Mayr, J. A., Foetschl, U., Berger, A., Fink, K., Schmeller, N., Hacker,
G. W., Hauser-Kronberger, C., Kofler, B. & Sperl, W. (2004). Decrease of
mitochondrial DNA content and energy metabolism in renal cell carcinoma.
Carcinogenesis, 25, 1005-1010.
[128] Singh, K. K., Kulawiec, M., Still, I., Desouki, M. M., Geradts, J. & Matsui, S. (2005).
Inter-genomic cross talk between mitochondria and the nucleus plays an important role
in tumorigenesis. Gene, 354, 140-146.
[129] Brunk, C. F. (1981). Mitochondrial proliferation during myogenesis. Exp. Cell Res.,
136, 305-309.
[130] Yamamoto, H., Morino, K., Nishio, Y., Ugi, S., Yoshizaki, T., Kashiwagi, A. &
Maegawa, H. (2012). MicroRNA-494 regulates mitochondrial biogenesis in skeletal
muscle through mitochondrial transcription factor A and Forkhead box j3. Am. J.
Physiol., 303, E1419-E1427.
[131] Handschin, C. (2009). The biology of PGC-1 and its therapeutic potential. Trends
Pharmacol. Sci., 30, 322-329.
[132] Taanman, J. W., Herzberg, N. H., De Vries, H., Bolhuis, P. A. & Van den Bogert, C.
(1992). Steady-state transcript levels of cytochrome c oxidase genes during human
myogenesis indicate subunit switching of subunit VIa and co-expression of subunit
VIIa isoforms. Biochim. Biophys. Acta, 1139, 155162.
[133] Franko, A., Mayer, S., Thiel, G., Mercy, L., Arnould, T., Hornig-Do, H. T., Wiesner, R.
J. & Goffart, S. (2008). CREB-1alpha is recruited to and mediates upregulation of the
cytochrome c promoter during enhanced mitochondrial biogenesis accompanying
skeletal muscle differentiation. Mol. Cell Biol., 28, 2446-2459.
[134] Rossi, C. A., Pozzobon, M., Ditadi, A., Archacka, K., Gastaldello, A., Sanna, M.,
Franzin, C., Malerba, A., Milan, G., Cananzi, M., Schiaffino, S., Campanella, M.,
Vettor, R. & De Coppi, P. (2010). Clonal characterization of rat muscle satellite cells:
proliferation, metabolism and differentiation define an intrinsic heterogeneity. PLoS
One, 5, e8523.
[135] Jash, S. & Adhya, S. (2010). Induction of muscle regeneration by RNA-mediated
mitochondrial restoration. FASEB J., 26, 4187-4197.
[136] Clark-Walker, G. D. & Linnane, A. W. (1996). In vivo differentiation of yeast
cytoplasmic and mitochondrial protein synthesis with antibiotics. Biochem. Biophys.
Res. Commun., 25, 8-13.
280
Akira Wagatsuma
281
[155] Horsley, V. & Pavlath, G. K. (2004). Forming a multinucleated cell: molecules that
regulate myoblast fusion. Cells Tissues Organs, 176, 67-78.
[156] Richardson, B. E., Nowak, S. J. & Baylies, M. K. (2008). Myoblast fusion in fly and
vertebrates: new genes, new processes and new perspectives. Traffic, 9, 1050-1059.
[157] Gullberg, D., Velling, T., Lohikangas, L. & Tiger, C. F. (1998) Integrins during muscle
development and in muscular dystrophies. Front Biosci., 3, D1039-D1050.
[158] Mayer, U. (2003). Integrins: redundant or important players in skeletal muscle? J. Biol.
Chem., 278, 14587-14590.
[159] Lafuste, P., Sonnet, C., Chazaud, B., Dreyfus, P. A., Gherardi, R. K., Wewer, U. M. &
Authier, F. J. (2005). ADAM12 and alpha9beta1 integrin are instrumental in human
myogenic cell differentiation. Mol. Biol. Cell, 16, 861-870.
[160] Brzska, E., Bello, V., Darribre, T. & Moraczewski, J. (2006). Integrin alpha3 subunit
participates in myoblast adhesion and fusion in vitro. Differentiation, 74, 105-118.
[161] Schwander, M., Leu, M., Stumm, M., Dorchies, O. M., Ruegg, U. T., Schittny, J. &
Mller, U. (2003). Beta1 integrins regulate myoblast fusion and sarcomere assembly.
Dev. Cell, 4, 673-685.
[162] Biswas, G., Tang, W., Sondheimer, N., Guha, M., Bansal, S. & Avadhani, N. G. (2008).
A distinctive physiological role for IkappaBbeta in the propagation of mitochondrial
respiratory stress signaling. J. Biol. Chem, 283, 12586-12594.
[163] Enomoto, M. I., Boettiger, D. & Menko, A. S. (1993). Alpha 5 integrin is a critical
component of adhesion plaques in myogenesis. Dev. Biol., 155, 180-197.
[164] Boettiger, D., Enomoto-Iwamoto, M., Yoon, H. Y., Hofer, U., Menko, A. S. & ChiquetEhrismann, R. (1995). Regulation of integrin alpha 5 beta 1 affinity during myogenic
differentiation. Dev. Biol., 169, 261-272.
[165] Davis, D. B., Delmonte, A. J., Ly, C. T. & McNally, E. M. (2000). Myoferlin, a
candidate gene and potential modifier of muscular dystrophy. Hum. Mol. Genet., 9,
217-226.
[166] Doherty, K. R., Cave, A., Davis, D. B., Delmonte, A. J., Posey, A., Earley, J. U.,
Hadhazy, M. & McNally, E. M. (2005). Normal myoblast fusion requires myoferlin.
Development, 132, 5565-5575.
[167] Rao, A., Luo, C. & Hogan, P. G. (1997). Transcription factors of the NFAT family:
regulation and function. Annu. Rev. Immunol., 15, 707-747.
[168] Abbott, K. L., Friday, B. B., Thaloor, D., Murphy, T. J. & Pavlath, G. K. (1998).
Activation and cellular localization of the cyclosporine A-sensitive transcription factor
NF-AT in skeletal muscle cells. Mol. Biol. Cell, 9, 2905-2916.
[169] Horsley, V., Friday, B. B., Matteson, S., Kegley, K. M., Gephart, J. & Pavlath, G. K.
(2001). Regulation of the growth of multinucleated muscle cells by an NFATC2dependent pathway. J. Cell Biol., 153, 329-338.
[170] Horsley. V., Jansen. K. M., Mills. S. T. & Pavlath. G. K. (2003). IL-4 acts as a
myoblast recruitment factor during mammalian muscle growth. Cell, 113, 483-494.
[171] Lafreniere, J. F., Mills, P., Bouchentouf, M. & Tremblay, J. P. (2006). Interleukin-4
improves the migration of human myogenic precursor cells in vitro and in vivo. Exp.
Cell Res., 312, 1127-1141.
[172] Horsley, V. & Pavlath, G. K. (2003). Prostaglandin F2(alpha) stimulates growth of
skeletal muscle cells via an NFATC2-dependent pathway. J. Cell Biol., 161, 111-118.
282
Akira Wagatsuma
[173] Kim, S., Shilagardi, K., Zhang, S., Hong, S. N., Sens, K. L., Bo, J., Gonzalez, G. A. &
Chen, E. H. (2007). A critical function for the actin cytoskeleton in targeted exocytosis
of prefusion vesicles during myoblast fusion. Dev. Cell, 12, 571-586.
[174] Wright, W. E., Sassoon, D. A. & Lin, V. K. (1989). Myogenin, a factor regulating
myogenesis, has a domain homologous to MyoD. Cell, 56, 607-617.
[175] Braun, T., Rudnicki, M., Arnold, H. H. & Jaenisch, R. (1992). Targeted inactivation of
the muscle regulatory gene Myf-5 results in abnormal rib development and perinatal
death. Cell, 71, 369-382.
[176] Rudnicki, M. A., Braun, T., Hinuma, S. & Jaenisch, R. (1992). Inactivation of MyoD in
mice leads to up-regulation of the myogenic HLH gene Myf-5 and results in apparently
normal muscle development. Cell, 71, 383-390.
[177] Neville, C. M. & Rosenthal, N. Transcriptional regulation of skeletal myogenesis.
Goodbourn, S. In: Eukariotic Gene Transcription. Oxford: Oxford University Press,
1996, 192-233.
[178] Edmondson, D. G., Brennan, T. J. & Olson, E. N. (1991). Mitogenic repression of
myogenin autoregulation. J. Biol. Chem., 266, 21343-21346.
[179] Fu, J., Menzies, K., Freeman, R. S. & Taubman, M. B. (2007). EGLN3 prolyl
hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. J.
Biol. Chem., 282, 12410-12418.
[180] Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D.
R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., Tian, Y. M., Masson, N.,
Hamilton, D. L., Jaakkola, P., Barstead, R., Hodgkin, J., Maxwell, P. H., Pugh, C. W.,
Schofield, C. J. & Ratcliffe, P. J. (2001). C. elegans EGL-9 and mammalian homologs
define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107,
43-54.
[181] Bruick, R. K. & McKnight, S. L. (2001). A conserved family of prolyl-4-hydroxylases
that modify HIF. Science, 294, 1337-1340.
[182] Tang, H., Macpherson, P., Argetsinger, L. S., Cieslak, D., Suhr, S. T., Carter-Su, C. &
Goldman, D. (2004). CaM kinase II-dependent phosphorylation of myogenin
contributes to activity-dependent suppression of nAChR gene expression in developing
rat myotubes. Cell Signal, 16, 551-563.
[183] Dang, C. V., O'Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C. & Li, F. (2006).
The c-Myc target gene network. Semin. Cancer Biol., 16, 253-264.
[184] Sejersen, T., Smegi, J. & Ringertz, N. R. (1985). Density-dependent arrest of DNA
replication is accompanied by decreased levels of c-myc mRNA in myogenic but not in
differentiation-defective myoblasts. J. Cell Physiol., 125, 465-470.
[185] Endo, T. & Nadal-Ginard, B. (1986). Transcriptional and posttranscriptional control of
c-myc during myogenesis: its mRNA remains inducible in differentiated cells and does
not suppress the differentiated phenotype. Mol. Cell Biol., 6, 1412-1421.
[186] Denis, N., Blanc, S., Leibovitch, M. P., Nicolaiew, N., Dautry, F., Raymondjean, M.,
Kruh, J. & Kitzis, A. (1987). c-myc oncogene expression inhibits the initiation of
myogenic differentiation. Exp. Cell Res., 172, 212-7.
[187] Miner, J. H. & Wold, B. J. (1991). c-myc inhibition of MyoD and myogenin-initiated
myogenic differentiation. Mol. Cell Biol., 11, 2842-2851.
283
[188] Crescenzi, M., Crouch, D. H. & Tat, F. (1994). Transformation by myc prevents
fusion but not biochemical differentiation of C2C12 myoblasts: mechanisms of
phenotypic correction in mixed culture with normal cells. J. Cell Biol., 125, 1137-1145.
[189] La Rocca, S. A., Crouch, D. H. & Gillespie, D. A. (1994). c-Myc inhibits myogenic
differentiation and myoD expression by a mechanism which can be dissociated from
cell transformation. Oncogene, 9, 3499-3508.
[190] Yeilding, N. M., Procopio, W. N., Rehman, M. T. & Lee, W. M. (1998) c-myc mRNA
is down-regulated during myogenic differentiation by accelerated decay that depends
on translation of regulatory coding elements. J. Biol. Chem., 273, 15749-15757.
[191] Wu, S., Cetinkaya, C., Munoz-Alonso, M. J., von der Lehr, N., Bahram, F., Beuger, V.,
Eilers, M., Leon, J. & Larsson, L. G. (2003). Myc represses differentiation-induced
p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter.
Oncogene, 22, 351-360.
[192] Brenner, C., Deplus, R., Didelot, C., Loriot, A., Vir, E., De Smet, C., Gutierrez, A.,
Danovi, D., Bernard, D., Boon, T., Pelicci, P. G., Amati, B., Kouzarides, T., de Launoit,
Y., Di Croce, L. & Fuks, F. (2005). Myc represses transcription through recruitment of
DNA methyltransferase corepressor. EMBO J., 24, 336-346.
[193] Andrs, V. & Walsh, K. (1996). Myogenin expression, cell cycle withdrawal, and
phenotypic differentiation are temporally separable events that precede cell fusion upon
myogenesis. J. Cell Biol., 132, 657-666.
[194] Grandori, C., Cowley, S. M., James, L. P. & Eisenman, R. N. (2000). The
Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell
Dev. Biol., 16, 653-699.
[195] Ayer, D. E. & Eisenman, R. N. (1993). A switch from Myc:Max to Mad:Max
heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev., 7,
2110-2119.
[196] Xu, D., Popov, N., Hou, M., Wang, Q., Bjrkholm, M., Gruber, A., Menkel, A. R. &
Henriksson, M. (2001). Switch from Myc/Max to Mad1/Max binding and decrease in
histone acetylation at the telomerase reverse transcriptase promoter during
differentiation of HL60 cells. Proc. Natl. Acad. Sci. U S A, 98, 3826-3831.
[197] Wu, K. J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J. &
Dalla-Favera, R. (1999). Direct activation of TERT transcription by c-MYC. Nat.
Genet., 21, 220-224.
[198] Gnes, C., Lichtsteiner, S., Vasserot, A. P. & Englert, C. (2000). Expression of the
hTERT gene is regulated at the level of transcriptional initiation and repressed by
Mad1. Cancer Res., 60, 2116-2121.
[199] Conacci-Sorrell, M., Ngouenet, C. & Eisenman, R. N. (2010). Myc-nick: a cytoplasmic
cleavage product of Myc that promotes alpha-tubulin acetylation and cell
differentiation. Cell, 142, 480-493.
[200] Rusnak, F. & Mertz, P. (2000). Calcineurin: form and function. Physiol. Rev., 80, 14831521.
[201] Delling, U., Tureckova, J., Lim, H. W., De Windt, L. J., Rotwein, P. & Molkentin, J. D.
(2000). A calcineurin-NFATc3-dependent pathway regulates skeletal muscle
differentiation and slow myosin heavy-chain expression. Mol. Cell Biol., 20, 66006611.
284
Akira Wagatsuma
[202] Friday, B. B., Horsley, V. & Pavlath G. K. (2000). Calcineurin activity is required for
the initiation of skeletal muscle differentiation. J. Cell Biol., 149, 657-666.
[203] Friday, B. B. & Pavlath, G. K. (2001). A calcineurin- and NFAT-dependent pathway
regulates Myf5 gene expression in skeletal muscle reserve cells. J. Cell Sci., 114, 303310.
[204] Friday, B. B., Mitchell, P. O., Kegley, K. M. & Pavlath G. K. (2003). Calcineurin
initiates skeletal muscle differentiation by activating MEF2 and MyoD. Differentiation,
71, 217-227.
[205] Scicchitano, B. M., Spath, L., Musar, A., Molinaro, M., Rosenthal, N., Nervi, C. &
Adamo, S. (2005). Vasopressin-dependent myogenic cell differentiation is mediated by
both Ca2+/calmodulin-dependent kinase and calcineurin pathways. Mol. Biol. Cell, 16,
3632-3641.
[206] Armand, A. S., Bourajjaj, M., Martnez-Martnez, S., el Azzouzi, H., da Costa Martins,
P. A., Hatzis, P., Seidler, T., Redondo, J. M. & De Windt, L. J. (2008). Cooperative
synergy between NFAT and MyoD regulates myogenin expression and myogenesis. J.
Biol. Chem., 283, 29004-29010.
[207] Hardiman, O., Sklar, R. M. & Brown, R. H. Jr. (1993). Direct effects of cyclosporin A
and cyclophosphamide on differentiation of normal human myoblasts in culture.
Neurology, 43, 1432-1434.
[208] Yokoyama, S. & Asahara, H. (2011). The myogenic transcriptional network. Cell Mol.
Life Sci., 68, 1843-1849.
[209] Benezra, R., Davis, R. L., Lockshon, D., Turner, D. L. & Weintraub, H. (1990). The
protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell, 61, 4959.
[210] Jen, Y., Weintraub, H. & Benezra, R. (1992). Overexpression of Id protein inhibits the
muscle differentiation program: in vivo association of Id with E2A proteins. Genes
Dev., 6, 1466-1479.
[211] Atherton, G. T., Travers, H., Deed, R. & Norton, J. D. (1996). Regulation of cell
differentiation in C2C12 myoblasts by the Id3 helix-loop-helix protein. Cell Growth
Differ., 7, 1059-1066.
[212] Melnikova, I. N. & Christy, B. A. (1996). Muscle cell differentiation is inhibited by the
helix-loop-helix protein Id3. Cell Growth Differ., 7, 1067-1079.
[213] Bakkar, N. & Guttridge, D. C. (2010). NF-kappaB signaling: a tale of two pathways in
skeletal myogenesis. Physiol. Rev., 90, 495-511.
[214] Alzuherri, H & Chang, K. C. (2003). Calcineurin activates NF-kappaB in skeletal
muscle C2C12 cells. Cell Signal, 15, 471-478.
[215] Sen, R. & Baltimore, D. (1986). Inducibility of kappa immunoglobulin enhancerbinding protein Nf-kappa B by a posttranslational mechanism. Cell, 47, 921-928.
[216] Lehtinen, S. K., Rahkila, P., Helenius, M., Korhonen, P. & Salminen, A. (1996). Downregulation of transcription factors AP-1, Sp-1, and NF-kappa B precedes myocyte
differentiation. Biochem. Biophys. Res. Commun., 229, 36-43.
[217] Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G. & Baldwin, A. S. Jr.
(1999). NF-kappaB controls cell growth and differentiation through transcriptional
regulation of cyclin D1. Mol. Cell Biol., 19, 5785-5799.
[218] Siebenlist, U., Franzoso, G. & Brown, V. (1994). Structure, regulation and function of
NF-kappa B. Annu. Rev. Cell Biol., 10, 405-455.
285
[219] Ghosh, S., May, M. J. & Kopp, E. B. (1998). NFB and Rel proteins: evolutionarily
conserved mediators of immune responses. Annu. Rev. Immunol., 16, 225-260.
[220] Perkins, N.D. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK
function. Nat. Rev. Mol. Cell Biol., 8, 49-62.
[221] Baud, V. & Karin, M. (2009). Is NF-kappaB a good target for cancer therapy? Hopes
and pitfalls. Nat. Rev. Drug Discov., 8, 33-40.
[222] Karin, M. & Lin, A. (2002). NF-kappaB at the crossroads of life and death. Nat.
Immunol., 3, 221-227.
[223] Woronicz, J. D., Gao, X., Cao, Z., Rothe, M. & Goeddel, D. V. (1997). IB kinase-:
NF-B activation and complex formation with IB kinase- and NIK. Science, 278,
866-869.
[224] Rothwarf, D. M., Zandi, E., Natoli, G. & Karin, M. (1998). IKK- is an essential
regulatory subunit of the IB kinase complex. Nature, 395, 297-300.
[225] Catani, M. V., Savini, I., Duranti, G., Caporossi, D., Ceci, R., Sabatini, S. & Avigliano,
L. (2004). Nuclear factor kappaB and activating protein 1 are involved in
differentiation-related resistance to oxidative stress in skeletal muscle cells. Free Radic
Biol. Med., 37, 1024-1036.
[226] Bakkar, N., Wackerhage, H. & Guttridge, D. C. (2005). Myostatin and NF-B regulate
skeletal myogenesis through distinct signaling pathways. Signal Transduction, 4, 202210.
[227] Bakkar, N., Wang, J., Ladner, K. J., Wang, H., Dahlman, J. M., Carathers, M.,
Acharyya, S., Rudnicki, M. A., Hollenbach, A. D. & Guttridge, D. C. (2008). IKK/NFkappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation
and promote mitochondrial biogenesis. J. Cell Biol., 180, 787-802.
[228] Biswas, G., Anandatheerthavarada, H. K., Zaidi, M. & Avadhani, N. G. (2003).
Mitochondria to nucleus stress signaling: a distinctive mechanism of NFkappaB/Rel
activation through calcineurin-mediated inactivation of IkappaBbeta. J. Cell Biol., 161,
507-519.
[229] Hayden M. S. & Ghosh, S. (2004). Signaling to NF-kappaB. Genes Dev., 18, 21952224.
[230] Chu, Z. L., McKinsey, T. A., Liu, L., Qi, X. & Ballard, D. W. (1996). Basal
phosphorylation of the PEST domain in the I(kappa)B(beta) regulates its functional
interaction with the c-rel proto-oncogene product. Mol. Cell Biol., 16, 5974-5984.
[231] McKinsey, T. A., Chu, Z. L. & Ballard, D. W. (1997). Phosphorylation of the PEST
domain of IkappaBbeta regulates the function of NF-kappaB/IkappaBbeta complexes.
J. Biol. Chem., 272, 22377-22380.
[232] Tran, K., Merika, M. & Thanos, D. (1997). Distinct functional properties of IkappaB
alpha and IkappaB beta. Mol. Cell Biol., 17, 5386-5399.
[233] Rao, S. S., Chu, C. & Kohtz, D. S. (1994). Ectopic expression of cyclin D1 prevents
activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol.
Cell Biol., 14, 5259-5267.
[234] Skapek, S. X., Rhee, J., Spicer, D. B. & Lassar, A. B. (1995). Inhibition of myogenic
differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science, 267,
1022-1024.
286
Akira Wagatsuma
[235] Dahlman, J. M., Wang, J., Bakkar, N. & Guttridge, D. C. (2009). The RelA/p65 subunit
of NF-kappaB specifically regulates cyclin D1 protein stability: implications for cell
cycle withdrawal and skeletal myogenesis. J. Cell Biochem., 106, 42-51.
[236] Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C. Y. & Baldwin, A. S. Jr.
(2000). NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle
decay and cachexia. Science, 289, 2363-2366.
[237] Sitcheran, R., Cogswell, P. C. & Baldwin, A. S. Jr. (2003). NF-kappaB mediates
inhibition of mesenchymal cell differentiation through a posttranscriptional gene
silencing mechanism. Genes Dev., 17, 2368-2373.
[238] Langen, R. C., Van Der Velden, J. L., Schols, A. M., Kelders, M. C., Wouters, E. F. &
Janssen-Heininger, Y. M. (2004). Tumor necrosis factor-alpha inhibits myogenic
differentiation through MyoD protein destabilization. FASEB J., 18, 227-237.
[239] Dogra, C., Changotra, H., Mohan, S. & Kumar, A. (2006). Tumor necrosis factor-like
weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of
nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem., 281, 1032710336.
[240] Lee, T. C., Shi, Y. & Schwartz, R. J. (1992). Displacement of BrdUrd-induced YY1 by
serum response factor activates skeletal alpha-actin transcription in embryonic
myoblasts. Proc. Natl. Acad. Sci. U S A, 89, 9814-9818.
[241] Vincent, C. K., Gualberto, A., Patel, C. V. & Walsh, K. (1993). Different regulatory
sequences control creatine kinase-M gene expression in directly injected skeletal and
cardiac muscle. Mol. Cell Biol., 13, 1264-1272.
[242] Caretti, G., Di Padova, M., Micales, B., Lyons, G. E. & Sartorelli, V. (2004). The
Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal
muscle differentiation. Genes Dev., 18, 2627-2638.
[243] Wang, H., Hertlein, E., Bakkar, N., Sun, H., Acharyya, S., Wang, J., Carathers, M.,
Davuluri, R. & Guttridge, D. C. (2007). NF-kappaB regulation of YY1 inhibits skeletal
myogenesis through transcriptional silencing of myofibrillar genes. Mol. Cell Biol., 27,
4374-4387.
[244] Wang, H., Garzon, R., Sun, H., Ladner, K. J., Singh, R., Dahlman, J., Cheng, A., Hall,
B. M., Qualman, S. J., Chandler, D. S., Croce, C. M. & Guttridge, D. C. (2008). NFkappaB-YY1-miR-29
regulatory circuitry in
skeletal
myogenesis
and
rhabdomyosarcoma. Cancer Cell, 14, 369381.
[245] Lu, L., Zhou, L., Chen, E. Z., Sun, K., Jiang, P., Wang, L., Su, X., Sun, H. & Wang, H.
(2012). A Novel YY1-miR-1 regulatory circuit in skeletal myogenesis revealed by
genome-wide prediction of YY1-miRNA network. PLoS One, 7, e27596.
[246] Chen, J. F., Mandel, E. M., Thomson, J. M., Wu, Q., Callis, T. E., Hammond, S. M.,
Conlon, F. L. & Wang, D. Z. (2006). The role of microRNA-1 and microRNA-133 in
skeletal muscle proliferation and differentiation. Nat. Genet., 38, 228-233.
[247] Wenz, T., Diaz, F., Spiegelman, B. M. & Moraes, C. T. (2008). Activation of the
PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a
mitochondrial myopathy phenotype. Cell Metab., 8, 249-56.
[248] Rosenberg, I. H. (1997). Sarcopenia: origins and clinical relevance. J. Nutr., 127, 990S991S.
287
[249] Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M. & Moraes, C. T. (2009).
Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic
disease during aging. Proc. Natl. Acad. Sci. U S A, 106, 20405-20410.
In: Basic Biology and Current Understanding of Skeletal Muscle ISBN: 978-1-62808-367-5
Editor: Kunihiro Sakuma
2013 Nova Science Publishers, Inc.
Chapter 10
Abstract
The plasticity of skeletal muscle facilitates adaptation to various stimuli. Exercise
training induces skeletal muscle adaptation such as muscle strength and hypertrophy,
while inactivity leads to muscle atrophy such as sarcopenia. Sex steroid hormones
(androgens and estrogens) often mediate muscle plasticity. Indeed, these hormones
induce various effects including growth, strength, metabolism, and antioxidant levels as
well as muscle atrophy. Though sex steroid hormones play an important role in skeletal
muscular homeostasis, the role of the endocrine system in muscle plasticity is unknown.
Sex steroid hormones are produced by various peripheral target tissues including the
kidney, liver, and brain in addition to endocrine organs such as the testis or ovary. Sex
steroid hormones are synthesized from cholesterol by steroidogenic enzymes, such as
cholesterol side-chain cleavage (P450scc), cytochrome P450 enzyme 17-hydroxylase
(P450c17), 3-hydroxysteroid dehydrogenase (HSD), and 17-HSD, with testosterone
being irreversibly converted to estrogen by aromatase cytochrome P450 (P450arom).
Testosterone is also converted into its bioactive metabolite dihydrotestosterone (DHT) by
5-reductase.
The functional importance of sex steroid hormones derived from extragonadal
tissues has been gaining support in recent years. For instance, steroidogenic enzymes
expressed in skeletal muscle have been reported to locally synthesize sex steroid
hormones from circulating dehydroepiandrosterone (DHEA) or testosterone in response
to exercise. Thus, local steroidogenesis in skeletal muscle may play an important role in
the plasticity of skeletal muscle. This review focuses on the steroidogenesis of skeletal
muscle and discusses the physiological significance of the sex steroid hormone network
of circulation and skeletal muscle.
Address correspondence and reprint requests to: Katsuji Aizawa, Ph. D. Senshu University Institute of Sport, 2-11, Higashimita, Tama-ku, Kawasaki-shi, Kanagawa 214-8580, Japan. (TEL) +81 44 911 1024. (FAX) +81 44
911 1032. E-mail: katsuji.aizawa@gmail.com.
290
Katsuji Aizawa
1. Introduction
Skeletal muscle is plastic due in part to a balance between protein synthesis and
degradation. For example, exercise leads to muscular hypertrophy due to increased protein
synthesis, while inactivity or disuse leads to muscle atrophy due to protein catabolism. Thus,
the maintenance of skeletal muscle homeostasis is beneficial in the prevention of many
chronic diseases and can improve quality of life; however, the mechanism of skeletal muscle
plasticity is still poorly understood.
Sex steroid hormones, such as testosterone and estradiol, play important roles in
developing both strength and mass of skeletal muscle. Chronic exercise induces increases in
muscle size, strength, energy metabolism, and antioxidant capacity, as well as changes in
muscle fiber type [1, 2]. Sex steroid hormones partly contribute to these exercise-induced
muscular adaptations [3, 4, 5]. Interestingly, testosterone administration increases muscle
strength and mass, while estrogen administration has little effect on muscle development and
mass. On the other hand, loss of skeletal muscle mass with aging, known as sarcopenia, is
associated with decreased blood androgens levels. Thus, it is likely that sex steroid hormones
may be involved in the mechanism of skeletal muscular adaptation.
Sex steroid hormones are mainly secreted by the ovary, testis, and adrenal cortex and
regulate a variety of physiological processes in their target tissues, which include
reproductive tissues, bone, liver, cardiovascular tissues, brain, and skeletal muscle [6, 7].
Both classes of sex steroid hormones, androgens and estrogens, are synthesized from
cholesterol by steroidogenic enzymes, such as cholesterol side-chain cleavage (P450scc),
cytochrome P450 enzyme 17-hydroxylase (P450c17), 3-hydroxysteroid dehydrogenase
(3-HSD), 17-HSD, 5-reductase, and cytochrome P450 (P450arom) [7]. Previous reports
have shown that sex steroid hormones are secreted not only by the ovary, testis, and adrenal
gland, but also by various peripheral tissues, including bone, liver, and brain [8, 9, 10].
Recent findings indicate that skeletal muscle produces local sex steroid hormones [11] and is
activated by exercise stimulation [12]. Since sex steroid hormones participate in skeletal
muscular adaptation, local muscular steroidogenesis may have an important role in skeletal
muscle homeostasis. This review focuses on the steroidogenesis of skeletal muscle and
discusses the physiological significance of the sex steroid hormone network of circulation and
skeletal muscle.
291
292
Katsuji Aizawa
Muscle atrophy can be caused by diverse medical conditions and results from accelerated
catabolism of muscle proteins. Ubiquitin ligases that regulate muscle proteolysis, such as
atrogin-1/MAFbx/FBXO32 [34] and Murf-1/trim63 [35], are specifically upregulated during
muscle atrophy. Overexpression of atrogin-1 leads to atrophy of cultured myotubes, whereas
atrogin-1 or Murf-1 knockout animals are resistant to muscle atrophy. Thus, the levels of
atrogin-1/Murf-1 appear to determine the extent of muscle loss.
Low testosterone levels have been associated with decreased muscle mass in humans, and
testosterone administration has been successful in improving general muscle function in
elderly men [36]. A previous study reported that testosterone deprivation induced a 31-fold
increase in testosterone-dependent fast-twitch levator ani muscle atrogin-1 mRNA and 18fold increase in Murf-1 mRNA, which were detected after 2 and 7 days of castration,
respectively [37]. Testosterone administration in the model above inhibited mRNA
expression of atrogin-1 and Murf-1 in androgen-sensitive rat skeletal muscles in vivo [37].
Testosterone also repressed MAFbx expression via association of the AR and Oct-1 with the
5 untranslated region of MAFbx just upstream of the first codon. Thus, prevention of muscle
atrophy by testosterone may be mediated by the regulation of ubiquitin ligases that control
muscle proteolysis [38].
293
Figure 1. A pathway showing sex steroid hormone metabolism, and associated steroidogenic enzymes.
DHEA: dehydroepiandrosterone, DHT: dihydrotestosterone, P450scc: cholesterol side-chain cleavage,
17-HSD: 17-hydroxysteroid dehydrogenase, 3-HSD: 3-hydroxysteroid dehydrogenase, P450arom:
aromatase cytochrome P450, AR: androgen receptor, ER: estrogen receptor
294
Katsuji Aizawa
local autocrine and/or paracrine system of testosterone and estrogen action in skeletal muscle
cells.
Figure 2. Skeletal muscle expresses steroidogenic enzymes (ref. [11]). A: mRNA expression of
steroidogenic enzymes in various rat tissues. Expression of 3-HSD, 17-HSD type I, and P450arom
mRNA was revealed by RT-PCR gels in skeletal muscle [gastrocnemius (gastro)] of the rat compared
with positive control tissues, namely ovary, testis, liver, kidney, and brain. -Actin mRNA was used as
an internal control. B: Localization of steroidogenic enzymes via protein expression from the muscle of
the rat. Representative images of immunofluorescence for P450arom in skeletal muscle (gastrocnemius)
of male rats (AD). Aromatase is stained red, and immunoreactivity is clearly seen in the cytoplasm
and cytoplasmic membrane (AD) at a magnification of 200. E: Positive staining was also observed in
blood vessels (magnification 200). F: Omission of primary antibody showed no immunoreactivity in the
skeletal muscle, indicating the specificity of the antibody (magnification 200).
Figure 3. Local steroidogenesis when DHEA and testosterone are added to cultured muscle cells (ref.
[11]). Intracellular concentration of total testosterone (A and C), and estradiol (B and D) formed after
the addition of either DHEA or testosterone (10, 100, 300, and 500 M, respectively) in cultured
muscle cells. The muscle cells treated with vehicle (0.1% ethanol) were used as a control.
295
296
Katsuji Aizawa
exercise enhances the local metabolism of bioactive androgens in skeletal muscle, which may
play a role in compensating for the low level of circulating testosterone in females. In
contrast, the level of muscle estradiol is increased by exercise in males, but not in females
(Figure 4B) [12]. Furthermore, it has been shown that expression of P450arom, which is
important for metabolizing androgens into estrogens [40], is increased in males but decreased
in females by a single bout of exercise [12]. Thus, 5-reductase and P450arom expression in
skeletal muscle is inversely correlated with the response to exercise in the two sexes. Since
the physiological balance between sex steroid hormones is largely controlled by aromatase or
5-reductase in exercising skeletal muscle, estrogen synthesis may increase in males while
testosterone synthesis increases in females. Thus, sex differences in the regulation of 5reductase and P450arom by exercise may in part compensate for insufficient local levels of
sex steroid hormones in skeletal muscle for each sex. Moreover, the highly effective local
synthesis of sex steroid hormones in skeletal muscle contributes to the differential capacity
for sex steroid hormone synthesis.
Figure 4. Muscular concentrations of DHT (A) and estradiol (B) in the skeletal muscle of male and
female rats with acute exercise (ref. [12, 52]).
297
Conclusion
In summary, skeletal muscle can be considered an endocrine organ that produces sex
steroid hormones. We, and others, have found that exercise locally stimulates muscle
steroidogenic enzymes, thereby activating sex steroid hormone production. Furthermore, the
age-related decrease in sex steroid hormone levels is involved in the reduction of muscle
function. Thus, enhancement of muscle steroidogenesis by exercise may play an important
role in skeletal muscle homeostasis and maintenance in aging. Finally, the interaction
between circulating and muscular sex steroid hormones may contribute to skeletal muscular
adaptation.
References
[1]
[2]
[3]
298
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
Katsuji Aizawa
Ramamani, A., Aruldhas, M. M. and Govindarajulu, P. (1999). Impact of testosterone
and oestradiol on region specificity of skeletal muscle-ATP, creatine phosphokinase
and myokinase in male and female Wistar rats. Acta Physiol. Scand., 166, 91-97.
Sinha-Hikim, I., Roth, S. M., Lee, M. I. and Bhasin, S. (2003). Testosterone-induced
muscle hypertrophy is associated with an increase in satellite cell number in healthy,
young men. Am. J. Physiol. Endocrinol. Metab., 285, E197-E205.
Simpson, E. R. (2002). Aromatization of androgens in women: current concepts and
findings. Fertil. Steril., 77, 6-10.
Labrie, F., Luu-The, V., Lin, S. X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G. and
Blanger, A. (2000). Intracrinology: role of the family of 17 beta-hydroxysteroid
dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25, 1-16.
van der Eerden, B. C., van de Ven, J., Lowik, C. W., Wit, J. M. and Karperien, M.
(2002). Sex steroid metabolism in the tibial growth plate of the rat. Endocrinology, 143,
4048-4055.
Vianello, S., Waterman, M. R., Dalla Valle, L. and Colombo, L. (1997).
Developmentally regulated expression and activity of 17alpha-hydroxylase/C-17,20lyase cytochrome P450 in rat liver. Endocrinology, 138, 3166-3174.
Zwain, I. H. and Yen, S. S. (1999) Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology, 140, 3843-3852.
Aizawa, K., Iemitsu, M., Maeda, S., Jesmin, S., Otsuki, T., Mowa, C. N., Miyauchi T.
and Mesaki, N. (2007). Expression of steroidogenic enzymes and synthesis of sex
steroid hormones from DHEA in skeletal muscle of rats. Am. J. Physiol. Endocrinol.
Metab., 292, E577-E584.
Aizawa, K., Iemitsu, M., Otsuki, T., Maeda, S., Miyauchi T. and Mesaki, N. (2008).
Sex differences in steroidogenesis in skeletal muscle following a single bout of exercise
in rats. J. Appl. Physiol., 104, 67-74.
Labrie, F., Belanger, A., and Simard, J. (1995). DHEA and peripheral androgen and
estrogen formation: intracrinology. Ann. N Y Acad. Sci., 774, 16-28.
Labrie, F., Luu-The, V., Blanger, A., Lin, S. X., Simard, J., Pelletier, G. and Labrie, C.
(2005). Is dehydroepiandrosterone a hormone? J. Endocrinol., 187, 169-196.
Morales, A. J., Haubrich, R. H., Hwang, J. Y., Asakura, H. and Yen, S. S. (1998). The
effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone
(DHEA) on circulating sex steroids, body composition and muscle strength in ageadvanced men and women. Clin. Endocrinol. (Oxf), 49, 421-432.
Glenmark, B., Nilsson, M., Gao, H., Gustafsson, J. A., Dahlman-Wright, K. and
Westerblad, H. (2004) Difference in skeletal muscle function in males vs. females: role
of estrogen receptor-beta. Am. J. Physiol. Endocrinol. Metab., 287, 1125-1131.
Lee, W. J., Thompson, R. W., McClung, J. M. and Carson, J. A. (2003). Regulation of
androgen receptor expression at the onset of functional overload in rat plantaris muscle.
Am. J. Physiol. Regul. Integr. Comp. Physiol., 285, R1076-R1085.
Ihemelandu, E. C. (1980). Effect of oestrogen on muscle development of female
rabbits. Acta Anat. (Basel), 108, 310-315.
Skelton, D. A., Phillips, S. K., Bruce, S. A., Naylor, C. H. and Woledge, R. C. (1999).
Hormone replacement therapy increases isometric muscle strength of adductor pollicis
in post-menopausal women. Clin. Sci. (Lond), 96, 357-364.
299
[20] Urban, R. J., Bodenburg, Y. H., Gilkison, C., Foxworth, J., Coggan, A. R., Wolfe, R. R.
and Ferrando, A. (1995). Testosterone administration to elderly men increases skeletal
muscle strength and protein synthesis. Am. J. Physiol., 269, E820-E826.
[21] Villareal, D. T., Holloszy, J. O. and Kohrt, W. M. (2000). Effects of DHEA
replacement on bone mineral density and body composition in elderly women and men.
Clin. Endocrinol. (Oxf), 53, 561-568.
[22] Antonio, J., Wilson, J. D. and George, F. W. (1999). Effects of castration and androgen
treatment on androgen-receptor levels in rat skeletal muscles. J. Appl. Physiol., 87,
2016-2019.
[23] Yoshioka, M., Boivin, A., Ye, P., Labrie, F. and St-Amand, J. (2006). Effects of
dihydrotestosterone on skeletal muscle transcriptome in mice measured by serial
analysis of gene expression. J. Mol. Endocrinol., 36, 247-259.
[24] Phillips, S. K., Rook, K. M., Siddle, N. C., Bruce, S. A. and Woledge, R. C. (1993).
Muscle weakness in women occurs at an earlier age than in men, but strength is
preserved by hormone replacement therapy. Clin. Sci. (Lond), 84, 95-98.
[25] Greising, S. M., Baltgalvis, K. A., Lowe, D. A. and Warren, G. L. (2009). Hormone
therapy and skeletal muscle strength: a meta-analysis. J. Gerontol. A. Biol. Sci. Med.
Sci., 64, 1071-1081.
[26] Armstrong, A. L., Oborne, J., Coupland, C. A., Macpherson, M. B., Bassey, E. J. and
Wallace, W. A. (1996). Effects of hormone eplacement therapy on muscle performance
and balance in post-menopausal women. Clin. Sci. (Lond), 91, 685-690.
[27] Baltgalvis, K. A., Greising, S. M., Warren, G. L. and Lowe, D. A. (2010). Estrogen
regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle.
PLoS One, 5, e10164.
[28] Lamberts, S. W., van den Beld, A. W. and van der Lely, A. J. (1997). The
endocrinology of aging. Science, 278, 419-424.
[29] Labrie, F., Blanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J. L.
and Candas, B. (1998). DHEA and the intracrine formation of androgens and estrogens
in peripheral target tissues: its role during aging. Steroids, 63, 322-328.
[30] Simpson, E. R. (2003). Sources of estrogen and their importance. J. Steroid Biochem.
Mol. Biol., 86, 225-230.
[31] Greeves, J. P., Cable, N. T., Reilly, T. and Kingsland, C. (1999). Changes in muscle
strength in women following the menopause: a longitudinal assessment of the efficacy
of hormone replacement therapy. Clin. Sci. (Lond), 97, 79-84.
[32] Meeuwsen, I. B., Samson, M. M. and Verhaar, H. J. (2000). Evaluation of the
applicability of HRT as a preservative of muscle strength in women. Maturitas, 36,
49-61.
[33] Vermeulen, A. (2000). Andropause. Maturitas, 34, 5-15.
[34] Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. and Goldberg, A. L. (2001).
Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.
Proc. Natl. Acad. Sci. U S A, 98, 14440-14445.
[35] Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K., Nunez, L., Clarke, B. A.,
Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., Pan, Z. Q., Valenzuela, D.
M., DeChiara, T. M., Stitt, T. N., Yancopoulos, G. D. and Glass, D. J. (2001).
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294,
1704-1708.
300
Katsuji Aizawa
[36] Ferrando, A. A., Sheffield-Moore, M., Yeckel, C. W., Gilkison, C., Jiang, J., Achacosa,
A., Lieberman, S. A., Tipton, K., Wolfe, R. R. and Urban, R. J. (2002). Testosterone
administration to older men improves muscle function: molecular and physiological
mechanisms. Am. J. Physiol. Endocrinol. Metab., 282, E601-E607.
[37] Pires-Oliveira, M., Maragno, A. L., Parreiras-e-Silva, L. T., Chiavegatti, T., Gomes, M.
D. and Godinho, R. O. (2010). Testosterone represses ubiquitin ligases atrogin-1 and
Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo. J. Appl.
Physiol., 108, 266-273.
[38] Zhao, W., Pan, J., Wang, X., Wu, Y., Bauman, W. A. and Cardozo, C. P. (2008).
Expression of the muscle atrophy factor muscle atrophy F-box is suppressed by
testosterone. Endocrinology, 149, 5449-5460.
[39] Labrie, F. (2004). Adrenal androgens and intracrinology. Semin. Reprod. Med., 22, 299309.
[40] Conley, A. and Hinshelwood, M. (2001). Mammalian aromatases. Reproduction, 121,
685-695.
[41] Mindnich, R., Mller, G. and Adamski, J. (2004). The role of 17 beta-hydroxysteroid
dehydrogenases. Mol. Cell Endocrinol., 218, 7-20.
[42] Puranen, T., Poutanen, M., Ghosh, D., Vihko, P. and Vihko, R. (1997). Origin of
substrate specificity of human and rat 17beta-hydroxysteroid dehydrogenase type 1,
using chimeric enzymes and site-directed substitutions. Endocrinology, 138, 35323539.
[43] Bruchovsky, N. and Wilson, J. D. (1968). The intranuclear binding of testosterone and
5-alpha-androstan-17-beta-ol-3-one by rat prostate. J. Biol. Chem., 243, 5953-5960.
[44] Hiipakka, R. A. and Liao, S. (1998). Molecular mechanism of androgen action. Trends
Endocrinol. Metab., 9, 317-324.
[45] George, F. W. and Noble, J. F. (1984). Androgen receptors are similar in fetal and adult
rabbits. Endocrinology, 115, 1451-1458.
[46] Russell, D. W. and Wilson, J. D. (1994). Steroid 5 alpha-reductase: two genes/two
enzymes. Annu. Rev. Biochem., 63, 25-61.
[47] Normington, K. and Russell, D. W. (1992). Tissue distribution and kinetic
characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct
physiological functions. J. Biol. Chem., 267, 19548-19554.
[48] Wigley, W. C., Prihoda, J. S., Mowszowicz, I., Mendonca, B. B., New, M. I., Wilson, J.
D. and Russell, D. W. (1994). Natural mutagenesis study of the human steroid 5 alphareductase 2 isozyme. Biochemistry, 33, 1265-1270.
[49] Abbaszade, I. G., Arensburg, J., Park, C. H., Kasa-Vubu, J. Z., Orly, J. and Payne, A.
H. (1997). Isolation of a new mouse beta-hydroxysteroid dehydrogenase isoform,
3beta-HSD VI, expressed during early pregnancy. Endocrinology, 138, 1392-1399.
[50] Ueyama, T., Shirasawa, N., Numazawa, M., Yamada, K., Shelangouski, M., Ito, T. and
Tsuruo, Y. (2002). Gastric parietal cells: potent endocrine role in secreting estrogen as a
possible regulator of gastro-hepatic axis. Endocrinology, 143, 3162-3170.
[51] Pllnen, E., Sipil, S., Alen, M., Ronkainen, P. H., Ankarberg-Lindgren, C., Puolakka,
J., Suominen, H., Hmlinen, E., Turpeinen, U., Konttinen, Y. T. and Kovanen, V.
(2011). Differential influence of peripheral and systemic sex steroids on skeletal muscle
quality in pre- and postmenopausal women. Aging Cell, 10, 650-660.
301
[52] Aizawa, K., Iemitsu, M., Maeda, S., Otsuki, T., Sato, K., Ushida, T., Mesaki, N. and
Akimoto, T. (2010). Acute exercise activates local bioactive androgen metabolism in
skeletal muscle. Steroids, 75, 219-223.
[53] Aizawa, K., Iemitsu, M., Maeda, S. Mesaki, N., Ushida, T. and Akimoto, T. (2011).
Endurance exercise training enhances local sex steroidogenesis in skeletal muscle. Med.
Sci. Sports Exerc., 43, 2072-2080.
[54] Vingren, J. L., Kraemer, W. J., Hatfield, D. L., Anderson, J. M., Volek, J. S., Ratamess,
N. A., Thomas, G. A., Ho, J. Y., Fragala, M. S. and Maresh, C. M. (2008). Effect of
resistance exercise on muscle steroidogenesis. J. Appl. Physiol., 105, 1754-1760.
[55] Kraemer, W. J., Gordon, S. E., Fleck, S. J., Marchitelli, L. J., Mello, R., Dziados, J. E.,
Friedl, K., Harman, E., Maresh, C. and Fry, A. C. (1991). Endogenous anabolic
hormonal and growth factor responses to heavy resistance exercise in males and
females. Int. J. Sports Med., 12, 228-235.
[56] Kraemer, W. J., Fleck, S. J., Dziados, J. E., Harman, E. A., Marchitelli, L. J., Gordon,
S. E., Mello, R. and Frykman, P. N. (1993). Changes in hormonal concentrations after
different heavy-resistance exercise protocols in women. J. Appl. Physiol., 75, 594-604.
[57] Cureton, K. J., Collins, M. A., Hill, D. W. and McElhannon, F. M. Jr. (1988). Muscle
hypertrophy in men and women. Med. Sci. Sports Exerc., 20, 338-344.
[58] Staron, R. S., Karapondo, D. L., Kraemer, W. J., Fry, A. C., Gordon, S. E., Falkel, J. E.,
Hagerman, F. C. and Hikida, R. S. (1994). Skeletal muscle adaptations during early
phase of heavy-resistance training in men and women. J. Appl. Physiol., 76, 1247-1255.
[59] Villareal, D. T. and Holloszy, J. O. (2006). DHEA enhances effects of weight training
on muscle mass and strength in elderly women and men. Am. J. Physiol. Endocrinol.
Metab., 291, E1003-E1008.
[60] Hawkins, V. N., Foster-Schubert, K., Chubak, J., Sorensen, B., Ulrich, C. M., Stancyzk,
F. Z., Plymate, S., Stanford, J., White, E., Potter, J. D. and McTiernan, A. (2008).
Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial.
Med. Sci. Sports Exerc., 40, 223-233.
Index
A
Abraham, 77, 78
abuse, 80
accessibility, 144
acetylation, 247, 283
acetylcholine, 263
activation state, 31
active site, 133, 196
acute infection, 33
acute stress, 151
adaptation(s), vii, x, 31, 37, 83, 91, 108, 109, 111,
118, 121, 124, 133, 134, 135, 137, 138, 141, 145,
151, 165, 166, 176, 188, 189, 190, 194, 197, 202,
206, 208, 210, 221, 228, 232, 238, 247, 275, 278,
289, 290, 295, 296, 297, 301
adductor, 185, 298
adductor longus, 185
adenine, 131, 215, 223
adenosine, 42, 91, 208, 210, 212, 224, 240, 243
adenosine triphosphate, 91
adenovirus, 215
adenylate kinase, 131
adhesion, 11, 60, 66, 76, 77, 78, 83, 126, 127, 233,
260, 281
adipocyte, 139, 212, 238, 245, 270
adiponectin, 128, 139, 211, 212, 213, 234, 235, 237,
238, 249
adipose, 61, 93, 102, 128, 131, 132, 170, 213, 215,
223, 233, 293
adipose tissue, 61, 93, 102, 128, 131, 132, 170, 213,
215, 223, 233, 293
adiposity, 99, 169
ADP, 207, 208, 213, 216, 229, 256
adrenal gland, 290, 291, 293
adulthood, 98
adults, vii, 2, 3, 4, 6, 7, 12, 21, 22, 47, 48, 85, 89, 92,
94, 95, 99, 102, 106, 107, 108, 109, 111, 113,
116, 119, 137, 290
aerobic capacity, 92, 176, 226, 296
aerobic exercise, 35, 92, 105, 124, 142
afferent nerve, 187, 188
afferent nerve fiber, 188
age-related diseases, 124
aggregation, 148, 185
aging process, ix, 94, 96, 97, 103, 123, 124, 155, 252
agonist, 203
alanine, 93
aldehydes, 102
allele, 185
alters, 85, 112, 135, 144, 165, 194, 240
alveolar macrophage, 240
American Heart Association, 106, 109
amino, viii, 24, 26, 27, 32, 39, 40, 43, 46, 47, 48, 55,
56, 57, 58, 59, 64, 67, 74, 75, 76, 87, 88, 89, 93,
94, 98, 99, 104, 110, 111, 125, 126, 180, 190,
215, 230, 239, 249
amino acid(s), viii, 24, 26, 27, 32, 39, 40, 43, 46, 47,
48, 55, 56, 57, 58, 59, 64, 67, 74, 75, 87, 88, 89,
93, 94, 98, 99, 104, 110, 111, 125, 126, 180, 190,
215, 230
amniotic fluid, 74
amplitude, 181, 182, 198
amyotrophic lateral sclerosis (ALS), viii, 53, 54, 59,
61, 62, 63, 100, 111
anabolic steroids, 84
anabolism, 32, 46, 48
anchorage, 77, 181, 185
anchoring, 197
androgen(s), xi, 84, 97, 115, 289, 290, 291, 292, 293,
295, 296, 298, 299, 300, 301
angiogenesis, 78, 101, 109
angiotensin converting enzyme, 118
anorexia, 103
304
Index
B
basal lamina, vii, 1, 2, 11, 67
basal metabolic rate, 130
base, 55, 243, 253, 254
base pair, 55, 243, 253
basement membrane, 254
beneficial effect, 94, 101, 135, 160, 270, 291
benefits, ix, 90, 93, 94, 95, 97, 101, 123, 154, 159,
162
beverages, 213
binding globulin, 291
biological activities, 69
biological fluids, 80
biological roles, 56, 60, 159, 292
biomarkers, ix, 50, 113, 123
biopsy, 93, 274
C
C reactive protein, 33
Ca2+, ix, 27, 40, 41, 82, 103, 130, 136, 140, 143, 144,
155, 158, 171, 174, 175, 178, 180, 181, 182, 191,
198, 209, 210, 212, 216, 229, 230, 233, 234, 243,
256, 266, 267, 273, 284
Ca2+ signals, 266
cachexia, 29, 33, 49, 90, 95, 97, 99, 100, 107, 113,
115, 117, 118, 286
cadmium, 202
caffeine, 209, 210
calcineurin, ix, 64, 66, 71, 82, 96, 135, 164, 171,
178, 181, 182, 183, 195, 198, 199, 263, 266, 267,
268, 272, 283, 284, 285
calcitonin, 2
calcium, x, 28, 64, 102, 110, 130, 133, 140, 144,
165, 181, 196, 198, 210, 251, 252, 264, 266
calcium homeostasis, x, 130, 251, 252
caliber, 16
caloric restriction, 206, 238, 274
calorie, 78, 88, 103, 121, 141, 237, 238, 275
calpain-3, ix, 171, 178, 179, 180, 189
CAM, 14
Index
cancer, 17, 33, 38, 49, 60, 95, 97, 100, 101, 113, 120,
125, 136, 206, 244, 285
cancer therapy, 120, 285
candidates, 26, 30, 99, 104, 156, 162, 211, 213, 222
capillary, 60
carbohydrate(s), 32, 48, 49, 74, 93, 110, 131, 159,
206, 208, 240
carbon, 95
carboxyl, 55, 56, 76
carcinoma, 76
cardiac muscle, 30, 176, 286
cardiomyopathy, 198, 199
cardiovascular disease(s), 95, 101, 106, 108, 128,
206, 234
cardiovascular disorders, 291, 296
carpal tunnel syndrome, 99
cartilage, viii, 9, 53, 61
cascades, 15, 54, 64, 66, 71, 141
case study, 235
casein, 81
caspases, 158
casting, 187, 188
castration, 292, 299
catabolic, viii, x, 21, 22, 28, 29, 49, 50, 93, 102, 120,
205
catabolism, x, 28, 29, 34, 139, 205, 290, 292
catabolized, 125
CBS, 207
CDK inhibitor, 118
cDNA, 30, 268
cell biology, 5, 12
cell culture, 69, 74, 218, 223, 255, 262, 268
cell cycle, x, 11, 12, 13, 35, 66, 67, 77, 83, 84, 206,
251, 252, 265, 283, 286
cell death, x, 16, 82, 148, 155, 158, 166, 170, 251,
252
cell differentiation, 13, 30, 86, 113, 252, 260, 263,
264, 265, 269, 271, 281, 283, 284, 286
cell division, 6, 7, 8, 10, 11, 17
cell fate, 3, 6, 12, 15, 17, 18, 259, 280
cell fusion, 261, 283
cell line(s), 2, 65, 69, 75, 81, 152, 156, 158, 226,
260, 262, 264, 265, 266, 267, 272
cell signaling, 241, 291
cell size, 25, 37
cell surface, 57, 60, 63, 64, 65, 66, 77, 260
cellular energy, x, 27, 38, 205, 208, 209, 251
cellular homeostasis, x, 251
cellular signaling pathway, 252
ceramide, 65, 214, 215, 224, 240
cerebral cortex, 298
Chad, 111, 112
challenges, 38
305
306
Index
conjugation, 119
connective tissue, 14, 22, 77, 78, 93, 188, 258, 263
connectivity, 94
consensus, 97, 114, 176, 183
construction, 189
consumption, 130, 145, 210
control group, 92
controlled trials, 102, 121
controversial, 34, 97, 98, 99, 106, 162, 209
cooperation, 215, 296
COPD, 117
corepressor, 283
coronary heart disease, 113
correlation, 27, 67, 191
cortex, 290
CPT, 131, 132, 136, 219, 220
creatine, 88, 93, 95, 111, 112, 127, 138, 151, 154,
263, 271, 286, 298
creatine phosphokinase, 151, 298
cross-sectional study, 105, 115
cross-validation, 35
CRP, 33
cues, viii, 21
culture, 3, 5, 6, 8, 10, 62, 63, 68, 70, 71, 81, 84, 257,
262, 283, 284, 293
culture conditions, 63, 70
culture medium, 262
cure, 158
cyanide, 253, 263
cycles, 158, 267
cycling, 12, 18, 85, 115, 132, 143, 148, 174
cyclophosphamide, 284
cyclosporine, 266, 281
cysteine, 56, 57, 60, 63, 125, 126, 132, 144, 178, 266
cytochrome, xi, 108, 130, 158, 221, 238, 254, 257,
273, 279, 289, 290, 293, 298
cytokines, x, 12, 22, 33, 60, 61, 78, 98, 99, 126, 127,
128, 132, 138, 141, 142, 205, 206, 209, 210, 211,
267
cytoplasm, x, 29, 125, 127, 130, 137, 179, 186, 205,
229, 267, 294
cytosine, 185
cytoskeleton, 36, 172, 179, 198, 202, 203, 261, 282
cytotoxicity, 166
D
daily living, 106
damages, 67, 68
deacetylation, 221, 223
decay, 113, 283, 286
defects, 15, 36, 253, 254, 277
deficiency(s), 22, 62, 63, 79, 95, 102, 103, 120, 162,
176, 179, 191, 193, 194, 196, 199, 270, 273, 278,
279, 291
deficit, 109, 145, 148, 185, 264, 286
degradation, viii, 21, 22, 23, 28, 29, 30, 33, 34, 43,
64, 66, 67, 74, 96, 101, 126, 127, 128, 129, 130,
137, 139, 140, 153, 156, 158, 165, 178, 192, 203,
206, 226, 254, 255, 264, 276, 277, 286, 290
degradation rate, 128, 153
dehydroepiandrosterone, xi, 88, 115, 289, 290, 293,
298
deltoid, 276
dementia, 206
denaturation, 155
dendritic cell, 252, 271
deoxyribonucleic acid, 81
dependent variable, 109
dephosphorylation, viii, 27, 42, 54, 66, 71, 95, 209,
215, 239, 240, 268
deposition, 9
depression, 103, 159
deprivation, x, 26, 29, 44, 169, 194, 205, 210, 292
desensitization, 180
detectable, 58
detection, 277
developmental change, 164
developmental process, 60, 71
diabetes, ix, x, 29, 94, 97, 100, 101, 108, 130, 131,
135, 137, 145, 147, 148, 159, 160, 161, 162, 169,
170, 205, 206, 212, 213, 217, 224, 225, 237, 240,
243, 248
diabetic patients, 113, 131, 138, 141, 159, 160, 161,
224
diacylglycerol, 180, 239, 240
diaphragm, 111, 137, 140, 143, 177, 185, 195
diet, 132, 142, 159, 160, 169, 214, 237, 238, 239
dimerization, 185, 265
diploid, 77
disability, vii, 22, 34, 35, 49, 89, 106
discharges, 204
discs, 172, 176, 177, 178, 181, 182, 183, 184, 185,
186
disease progression, 15
diseases, vii, x, 21, 22, 33, 95, 124, 125, 129, 206,
210, 225, 252, 254, 270, 274
disorder, 158, 175
displacement, 183
dissociation, 135, 186, 273
distribution, 38, 54, 56, 79, 86, 89, 194, 197, 199,
207, 246, 292, 300
diversity, 54, 71, 190
DNA, vii, 1, 6, 7, 11, 12, 17, 18, 22, 26, 57, 60, 64,
65, 79, 91, 108, 124, 126, 127, 130, 146, 155,
Index
156, 165, 167, 183, 218, 243, 244, 253, 257, 265,
268, 269, 274, 275, 277, 280, 282, 283, 284
DNA damage, 22, 26, 91, 146
DNA repair, 253
docosahexaenoic acid, 113
domain structure, 193
donors, 133, 210, 260
dosage, 97
dose-response relationship, 47
down-regulation, 9, 13, 135
drug discovery, viii, 87, 115
drugs, x, 97, 205, 206, 212, 236, 262
dyslipidemia, x, 205
dystrophy, ix, 3, 12, 13, 15, 16, 36, 87, 88, 90, 92,
102, 109, 136, 147, 158, 168, 179, 196, 197, 201,
281
E
ECM, 57, 60, 63, 64, 70, 75, 78
edema, 99
eicosapentaenoic acid, 88, 113
eIF4A, 24
elderly population, viii, 33, 34, 50, 87
elders, 91, 108
election, 109
electron, ix, 2, 91, 96, 123, 131, 155, 167, 172, 176,
219, 220, 221, 223, 225, 253, 256, 257, 271, 275,
276
electron microscopy, 2
ELISA, 115
elongation, 25, 31, 37, 156, 162, 258, 260
elucidation, 279
embryogenesis, 177, 273
embryology, 200
embryonic stem cells (ESCs), 252, 271
EMG, 204
emission, 226
encoding, 79, 91, 101, 126, 127, 158, 206, 209, 215,
223, 229, 248, 253, 257, 259, 264, 292
endocrine, viii, xi, 53, 54, 61, 72, 210, 211, 289, 296,
297, 300
endocrine glands, 296
endocrine system, xi, 289
endocrinology, 299
endonuclease, 276
endothelial cells, 60, 77, 78, 126, 215, 233
endothelium, 54, 63, 91, 124
endurance, x, 85, 91, 92, 94, 96, 104, 108, 109, 132,
135, 143, 144, 145, 148, 176, 194, 205, 208, 210,
211, 221, 228, 233, 248, 295, 296
energy, vii, x, 24, 26, 27, 41, 42, 44, 89, 99, 103,
105, 110, 112, 130, 131, 132, 135, 141, 205, 206,
307
209, 210, 211, 224, 225, 227, 232, 233, 246, 247,
251, 252, 258, 260, 271, 278, 279, 280, 290
energy consumption, vii, 130, 210
energy expenditure, 141, 206, 211, 225, 247
enlargement, 180
environment(s), 3, 9, 15, 54, 186, 187, 189, 203
environmental factors, 102
environmental stress, 148
enzyme(s), x, xi, 69, 88, 91, 108, 118, 119, 125, 127,
130, 131, 135, 137, 144, 160, 178, 190, 212, 215,
219, 220, 221, 224, 225, 226, 236, 244, 248, 251,
252, 256, 257, 266, 280, 289, 289, 290, 291, 292,
293, 294, 295, 297, 298, 300
enzyme inhibitors, 118, 119
EPA, ix, 87, 88, 95, 96, 104, 113
epidemic, 106
epidermis, 17
epididymis, 292
epilepsy, 95, 254, 275, 277
epithelial cells, 60, 252
erosion, 102
erythrocyte membranes, 192
ESCs, 252
estrogen, xi, 98, 222, 223, 247, 248, 256, 289, 290,
291, 292, 293, 296, 298, 299, 300
ethanol, 294
etiology, 22
eukaryotic, 24, 30, 39, 47, 88, 93, 151, 227, 266
eukaryotic cell, 151, 227
evidence, ix, x, 3, 5, 6, 7, 18, 27, 32, 33, 66, 69, 79,
85, 89, 91, 95, 99, 101, 102, 114, 123, 125, 128,
148, 154, 159, 160, 161, 162, 169, 170, 191, 194,
216, 232, 243, 251, 252, 253, 255, 256, 257, 258,
259, 265, 275
evolution, 193, 227
excitability, 168
excitation, 133
exclusion, 152
exercise performance, 118, 133, 145, 221, 246, 279
exocytosis, 282
exons, 54, 55, 58
experimental condition, 262
exposure, 140, 144, 187, 210, 213, 215, 259, 262
extensor, 3, 5, 16, 83, 90, 174, 185, 188, 208, 212,
215, 221
extensor digitorum, 3, 5, 16, 83, 174, 185, 188, 208,
212, 215, 221
extracellular matrix, 57, 60, 69, 74, 75, 77, 119, 177
extraocular muscles, 4
eye movement, 4
308
Index
F
facial expression, 4
facial muscles, 4
families, 28, 29, 148, 200, 231
family members, 18, 29, 72, 256
fasting, 29, 94, 101, 110, 156, 159, 160, 214, 223,
238, 247
fasting glucose, 160
fat, 22, 89, 92, 94, 106, 113, 130, 132, 139, 141, 159,
160, 169, 214, 228, 232, 237, 238, 239, 242, 245
fatty acids, 89, 95, 106, 112, 113, 132, 213, 215, 245
female rat, 296
fertility, 86
fiber bundles, 133
fibroblast growth factor, 82
fibroblasts, 14, 60, 64, 77, 80, 81, 82, 126, 260, 268
fibrosis, 102, 177, 185, 194
fibula, 150
filament, ix, 28, 45, 171, 173, 174, 175, 177, 179,
181, 182, 184, 185, 191, 192, 195
fish, 95
fish oil, 95
flank, 174
flexibility, 92
flight, 139, 156, 187, 203
fluid, 63
follicle, 114
food, 99, 136, 142, 194, 211, 226, 234
Food and Drug Administration, 102
food intake, 99, 211, 226, 234
force, vii, 3, 100, 121, 132, 133, 143, 146, 148, 154,
155, 166, 172, 174, 175, 176, 179, 184, 185, 186,
187, 188, 191
Ford, 240
formation, 9, 15, 24, 29, 48, 60, 75, 77, 125, 133,
136, 174, 175, 176, 177, 179, 181, 186, 196, 246,
252, 253, 255, 259, 263, 268, 278, 280, 285, 298,
299
fractures, 121
fragments, 9, 58, 59, 64, 76, 179, 185
free radicals, 131, 254
freezing, 256
fruits, 213
functional food, 136
fusion, 9, 67, 69, 194, 252, 253, 255, 259, 260, 261,
262, 263, 265, 272, 280, 281, 282, 283
G
gait, 90
gamma-tocopherol, 142
309
Index
108, 111, 112, 115, 116, 118, 128, 241, 267, 295,
301
growth hormone, 54, 72, 73, 78, 79, 80, 88, 111, 116,
117
GTPases, 24, 26, 40, 216
guanine, 24, 259
H
hair, 18, 271
hair follicle, 271
half-life, 153, 154, 264
harmony, 70
health, vii, ix, 21, 22, 30, 43, 91, 95, 102, 109, 110,
116, 122, 123, 140, 145, 147, 162, 237
health status, 30
heart failure, 101, 108
heat shock protein, vii, 148, 163, 164, 165, 166, 167,
168, 169, 170, 189, 202, 203, 231
hematopoietic stem cells, 7, 18
heme, 170, 257
heme oxygenase, 170
hepatocellular carcinoma, 226
hepatocytes, 83, 210, 212
herbal medicine, 94, 213
heterogeneity, vii, 1, 4, 5, 6, 12, 13, 16, 17, 103, 206,
279
high fat, 237
hip fractures, 120
hippocampus, 168
histidine, 132
histological examination, 102
histone(s), 18, 29, 218, 223, 243, 253, 269, 283
histone deacetylase, 29, 218, 223, 243
history, 6, 17
HIV, 100, 117
homeostasis, viii, x, xi, 6, 7, 12, 18, 37, 87, 88, 93,
99, 102, 110, 124, 130, 137, 158, 170, 217, 224,
227, 246, 249, 251, 252, 278, 289, 290, 297
hormone(s), xi, 22, 79, 84, 98, 114, 115, 116, 139,
149, 206, 209, 210, 211, 240, 289, 290, 291, 292,
293, 295, 296, 297, 298, 299
hormone levels, 297
host, 2, 3, 5, 9
House, 226
HPC, 258
hTERT, 265, 283
human body, vii, 21, 22, 88
human health, 88
human milk, 75
human skin, 77
human subjects, 35, 46, 103, 110, 132
Hunter, 44, 84
I
ideal, 212
identification, 14, 42, 136, 198, 227
identity, 272, 292
IFN, 33, 49
images, 8, 294
immobilization, ix, 29, 140, 147, 148, 154, 156, 157,
188, 204
immune response, 285
immunofluorescence, 294
immunoglobulin, 60, 61, 196, 284
immunoreactivity, 294
improvements, 91, 95, 101, 108, 111, 135
in vitro, 9, 10, 11, 12, 16, 17, 27, 42, 62, 66, 68, 71,
79, 84, 85, 95, 104, 127, 132, 196, 212, 213, 216,
218, 227, 244, 257, 258, 259, 261, 266, 281, 293
in vivo, 2, 3, 5, 8, 9, 10, 12, 17, 23, 27, 35, 45, 46,
69, 71, 74, 79, 82, 85, 94, 114, 129, 141, 157,
161, 191, 196, 198, 212, 213, 214, 216, 217, 218,
219, 221, 236, 237, 238, 240, 244, 246, 255, 257,
258, 281, 284, 291, 292, 293, 300
incidence, 17, 99, 103, 169
increased workload, 182
independence, viii, 22, 87, 190
indirect effect, 236
indirect measure, 101
individual character, 136
individual characteristics, 136
individuals, 30, 31, 33, 34, 70, 94, 128, 142
inducer, 49, 166, 167, 269, 286
induction, 10, 44, 83, 99, 101, 129, 138, 156, 158,
160, 161, 162, 177, 180, 181, 183, 223, 256, 257,
263, 264
ineffectiveness, 99
infancy, 73
310
Index
infection, 210
inflammation, ix, 33, 34, 35, 50, 72, 91, 109, 123,
125, 126, 127, 128, 135, 148, 158, 159, 160, 162,
170, 211, 233, 270
inflammatory bowel disease, 95
inflammatory disease, 22, 33
inflammatory mediators, 126, 127
inflammatory responses, 159
ingestion, 32, 46, 48, 49, 93, 110, 111, 136, 214, 239
inhibitor, ix, 23, 26, 31, 36, 38, 60, 61, 81, 87, 88,
100, 102, 104, 118, 121, 135, 141, 143, 157, 209,
214, 223, 253, 259, 266, 267, 268, 271, 272
initiation, viii, 24, 25, 31, 37, 39, 45, 47, 48, 53, 55,
71, 88, 93, 110, 131, 257, 262, 268, 282, 283, 284
injections, 100
injury(s), viii, 2, 3, 7, 8, 9, 14, 19, 35, 54, 67, 87,
106, 138, 148, 150, 154, 155, 156, 165, 200, 212,
234, 255, 256, 258, 270, 273, 276
insects, 207
insertion, 178, 258
insulin resistance, ix, x, 92, 99, 106, 109, 116, 126,
128, 130, 131, 132, 136, 138, 139, 141, 142, 145,
147, 159, 160, 161, 162, 163, 169, 170, 206, 215,
217, 224, 228, 235, 237, 238, 239, 240, 241, 243,
245, 248, 291
insulin sensitivity, 100, 111, 131, 132, 135, 148, 161,
162, 169, 213, 217, 221, 238, 246, 248, 270
insulin signaling, 85, 128, 136, 161, 169, 216, 217,
224, 238, 270
insulin system, x, 205
integration, 27, 177, 185
integrin(s), 2, 11, 14, 57, 58, 60, 63, 65, 66, 71, 74,
78, 81, 83, 177, 179, 260, 281
integrity, 148, 177, 194, 252, 270
interference, 92, 152
interferon, 33
intervention, 34, 103, 135, 169
intestine, 7
intoxication, 40
intracellular calcium, 133
intramuscular injection, 256
intravenously, 99
involution, 86
ion channels, 257
iron, 113
irradiation, 67, 68, 83
ischemia, 168
isoflavone, 213
isoforms, viii, 53, 54, 55, 56, 62, 67, 68, 69, 71, 73,
82, 148, 166, 173, 174, 175, 176, 180, 190, 191,
194, 196, 207, 208, 209, 212, 218, 221, 227, 228,
229, 257, 261, 279
isolation, 13, 185, 245
isoleucine, 93
isomerization, 144
isotope, 137
isozyme(s), 197, 292, 295, 300
issues, vii, 21, 94
J
Japan, 1, 21, 53, 87, 105, 123, 147, 171, 205, 225,
251, 270, 289
joints, 187, 188
Jordan, 204
K
keratinocyte, 252
kidney(s), xi, 62, 93, 111, 112, 207, 223, 289, 293,
294
kinase activity, 36, 63, 141, 207, 209, 233, 236, 240
kinetics, 46, 112, 189, 197
Krebs cycle, 226
L
labeling, 133, 137
lactic acid, 254
L-arginine, 111
lead, 24, 25, 26, 58, 70, 96, 100, 126, 128, 130, 131,
135, 162, 172, 181, 184, 185, 186, 207, 217, 221,
225, 254, 256, 258, 267, 268, 291, 295
lean body mass, 95, 97, 98, 99, 111
legs, 99, 117
leptin, 117, 211, 234
lesions, 184, 186, 200, 254
leucine, 26, 32, 40, 42, 46, 47, 48, 49, 89, 93, 111,
112, 215, 240, 266
levator, 5, 16, 292
life cycle, 162
life expectancy, 89
ligand, 58, 63, 75, 81, 99, 213, 261
light, 30, 133, 172, 175, 258
limb weakness, 255
linoleic acid, 131
lipid metabolism, 131, 132, 135, 136, 159, 206, 208,
237
lipid peroxidation, 125, 131, 132, 138, 141, 155
lipid peroxides, 126, 143
lipids, 96, 115, 124, 131, 255
lipolysis, 213, 226, 235
liver, viii, xi, 42, 53, 54, 55, 61, 62, 65, 73, 78, 79,
89, 93, 95, 121, 128, 190, 192, 207, 209, 212,
Index
215, 216, 223, 227, 238, 239, 242, 257, 289, 290,
293, 294, 298
localization, 57, 58, 66, 72, 78, 144, 174, 178, 180,
181, 182, 197, 247, 266, 281, 292
locomotor, 175
locus, 3, 6
longevity, 206, 227
long-term health, vii, 21, 22
Louisiana, 106
low-grade inflammation, 33, 128
Luo, 165, 198, 232, 281
luteinizing hormone, 114
lymphocytes, 261
lymphoid, 78, 158
lysine, 125, 131, 132, 137, 142
M
machinery, 23, 29, 36, 37, 186, 257
Mackintosh, 241
macromolecules, 96
macrophages, 95, 126, 128, 168, 215, 240
magnetic resonance, 93
magnetic resonance imaging, 93
magnitude, 31, 187
majority, 2, 3, 5, 7, 8, 9, 11, 14, 99, 103
malnutrition, vii, 21, 22
mammalian cells, 41, 153, 248, 254, 258, 278
mammalian tissues, 237
mammals, 23, 172, 174, 207, 260, 290
man, 105, 138, 231
manipulation, 100
mapping, 76, 78, 192, 193
mass, vii, viii, ix, x, 5, 21, 22, 23, 33, 35, 47, 69, 85,
87, 88, 89, 91, 92, 94, 97, 98, 99, 105, 106, 111,
115, 117, 118, 123, 130, 137, 141, 156, 246, 251,
270, 290, 291
mass spectrometry, 137
masseter, 4, 5, 16
matrix, 77, 81, 155, 191, 219, 220, 221, 254, 260
matter, 16, 106
measurement(s), 99, 264
meat, 93
mechanical stress, ix, 32, 127, 171, 172, 176, 177,
179, 181, 183, 184, 185, 186, 187, 188, 189
mechano growth factor, viii, 53, 79, 85
mediation, 174
medical, 292
medicine, 232
MEK, 24, 25
mellitus, 100, 206, 212, 213, 224, 225
melon, 213, 238
membranes, 148, 180, 194, 245
311
312
Index
morphogenesis, 15
morphology, vii, x, 184, 251
mortality, vii, 22, 34, 89, 106
Moses, 112
motif, 28, 56, 58, 63, 71, 183, 269
mRNA(s), 4, 24, 26, 39, 44, 47, 54, 55, 56, 60, 62,
68, 69, 70, 71, 72, 73, 78, 79, 84, 85, 91, 94, 101,
107, 112, 116, 119, 151, 152, 153, 159, 160, 170,
183, 196, 212, 218, 221, 226, 232, 235, 246, 259,
264, 269, 282, 283, 292, 293, 294, 295
mtDNA, 253, 254, 256, 257, 259, 261, 262, 263,
267, 268, 269, 274, 275, 277, 279, 280
multinucleated, x, 8, 9, 11, 251, 252, 253, 260, 261,
265, 272, 281
multiple factors, 22
multiple myeloma, 36
multipotent, 7
multi-protein complexes, 23
muscle contraction, x, 88, 91, 127, 133, 149, 155,
159, 174, 176, 180, 185, 205, 206, 209, 210, 291
muscle performance, 93, 299
muscle relaxation, 133
muscle stem cells, vii, 1, 2, 15, 118
muscle strength, x, 31, 33, 50, 88, 90, 91, 92, 97, 99,
101, 102, 110, 115, 116, 118, 119, 158, 235, 289,
290, 291, 298, 299
muscular dystrophy, ix, 3, 12, 13, 15, 87, 88, 90, 92,
102, 109, 147, 158, 168, 179, 196, 197, 201, 281
musculoskeletal, 107, 120
musculoskeletal system, 120
mutagenesis, 58, 75, 81, 300
mutant, 65, 66, 81, 182, 214, 254, 268, 272, 280
mutation(s), 4, 6, 7, 12, 15, 58, 64, 70, 76, 86, 101,
155, 156, 167, 175, 184, 185, 196, 201, 202, 223,
228, 229, 245, 253, 254, 255, 273, 274, 275, 276,
277
myoblasts, x, 1, 2, 6, 9, 10, 17, 60, 65, 66, 68, 69, 70,
84, 86, 140, 163, 167, 168, 178, 215, 240, 251,
252, 253, 256, 257, 259, 261, 262, 263, 264, 266,
267, 268, 269, 272, 273, 274, 282, 283, 284, 285,
286
myocardial infarction, 199
myocardial ischemia, 234
myocardium, 175
myoclonus, 254
myocyte, 84, 156, 181, 190, 218, 222, 243, 244, 266,
284
myofibres, vii, 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 12
myofibril, ix, 171, 172, 175, 176, 185, 192, 196, 201
myogenesis, x, 4, 7, 9, 13, 15, 77, 82, 83, 84, 86,
106, 115, 177, 183, 199, 200, 251, 252, 253, 255,
256, 257, 259, 260, 262, 263, 264, 266, 267, 268,
269, 270, 272, 273, 274, 277, 278, 279, 280, 281,
282, 283, 284, 285, 286
myogenic progeny, vii, 1, 7, 9
myoglobin, 182
myopathy, 23, 36, 92, 109, 120, 145, 174, 191, 197,
201, 254, 255, 270, 275, 277, 279, 286
myosin, 2, 30, 45, 46, 79, 82, 102, 128, 129, 133,
139, 144, 149, 166, 174, 175, 176, 177, 188, 191,
192, 193, 195, 198, 203, 208, 226, 227, 228, 242,
260, 263, 265, 272, 283
myotubes, x, 2, 3, 7, 8, 9, 10, 11, 38, 42, 60, 66, 67,
68, 69, 95, 102, 128, 129, 130, 137, 141, 168,
195, 217, 226, 229, 231, 238, 242, 251, 252, 253,
254, 256, 257, 260, 261, 262, 264, 278, 282, 292
N
NAD, 222, 223, 247
NADH, 144, 263
National Health and Nutrition Examination Survey,
109
natural compound, 107, 112
necrosis, 28, 44, 50, 89, 113, 158, 201, 215, 239,
256, 269, 286
negative consequences, 147
negative effects, 135, 262
nerve, 93, 181, 182, 212, 223
nervous system, 212
neuroblastoma, 271
neuronal apoptosis, 93
neurons, 168, 252, 298
neuropathy, 235
neuropeptides, 206
neurotoxicity, 271
neurotrophic factors, 235
neutral, 17, 165
neutrophils, 128
nicotinamide, 222, 223
nitric oxide, 133, 143, 146, 231, 233, 277
nitric oxide synthase, 143, 231, 233, 277
nitrogen, 93, 125, 126, 213, 230, 231, 236
nonsense mutation, 194
normal aging, 121, 275
Norway, 166
NRF, 246, 256, 257, 278
Nrf2, 135, 145
nuclear genome, 253
nuclear magnetic resonance (NMR), 58, 76
nuclear receptors, 248, 252, 255, 256
nucleation, 177
nuclei, 67, 177, 182, 185, 260
nucleotides, 131, 208, 210, 215, 224, 260
Index
nucleus, 9, 58, 126, 127, 130, 135, 137, 179, 181,
183, 218, 266, 268, 279, 285
null, 61, 70, 86, 100, 175, 177, 182, 188, 192, 204,
219, 245, 246, 261
nursing, 90, 103
nursing home, 90, 103
nutraceutical, 114
nutrient(s), viii, x, 21, 23, 29, 30, 32, 34, 36, 40, 135,
205, 206, 224, 226, 255
nutrition, 97
O
obesity, ix, x, 50, 89, 91, 106, 116, 128, 139, 147,
159, 160, 163, 205, 206, 215, 224, 225, 231, 235,
240, 291
oil, 95
old age, 89, 141
oligomerization, 202
omega-3, 95, 107, 113
opportunities, 38
orbit, 96
organ(s), vii, xi, 21, 22, 72, 86, 124, 174, 211, 213,
231, 289, 297
organelle(s), 133, 155, 156, 194, 248, 253, 255, 269,
273
osteomalacia, 102
osteoporosis, 102, 103
ovaries, 291, 296
overlap, 23, 273
ovum, 255
oxidation, x, 94, 125, 126, 133, 136, 139, 140, 142,
143, 144, 155, 205, 206, 219, 220, 221, 223, 224,
225, 230, 232, 234, 237, 241, 245, 246, 247, 248,
249, 256
oxidative damage, 92, 96, 108, 124, 155, 164, 167,
254, 274, 275
oxidative stress, ix, 4, 22, 89, 93, 97, 103, 113, 114,
123, 124, 125, 126, 127, 128, 129, 130, 131, 132,
133, 134, 135, 136, 137, 138, 139, 140, 141, 142,
144, 145, 148, 150, 151, 154, 160, 163, 165, 166,
169, 202, 230, 254, 285
oxygen, ix, 91, 96, 108, 123, 124, 130, 131, 145,
169, 211, 221, 226, 246, 257, 264, 279
oxygen consumption, ix, 123, 124, 257
P
pain, 127
pancreas, 93, 161
pancreatic cancer, 95
parallel, 24, 177, 191, 261
313
parathyroid, 102
parathyroid hormone, 102
patella, 107
pathogenesis, 38, 111, 124, 131, 133, 136, 159, 179
pathology, 4, 33, 158, 159, 185, 202
pathophysiological, 234
pathophysiological roles, 234
pathophysiology, 82, 107, 293
pathways, viii, x, 16, 23, 30, 37, 43, 53, 64, 66, 82,
91, 93, 97, 128, 135, 162, 172, 177, 190, 205,
230, 231, 237, 267, 269, 277, 284, 285
PDZ domains, 180
pedigree, 185, 201
peptidase, 102
peptide(s), viii, 53, 55, 56, 66, 69, 72, 73, 79, 85, 98,
99, 102, 117, 144, 268
percentage of fat, 89
perinatal, 39, 273, 282
peroxidation, 160, 297
peroxide, 130, 195
peroxisome, ix, x, 87, 88, 91, 135, 205, 212, 213,
218, 222, 237, 247, 248, 256, 278
peroxynitrite, 137, 140, 144, 233
phagocyte, 127, 128, 135
pharmaceutical(s), x, 205, 224
pharmacological treatment, 104
phenotype(s), 2, 3, 4, 5, 85, 122, 135, 145, 176, 177,
182, 200, 234, 244, 255, 258, 265, 270, 273, 274,
275, 282, 286
phosphate, 63, 80, 111, 151, 217, 262
phosphocreatine, 93
phosphorus, 102
physical activity, viii, 21, 22, 30, 35, 50, 87, 89, 90,
91, 157
physical exercise, 124, 145
physiological, 116, 234
physiological mechanisms, 23, 114, 300
physiology, 116, 169, 191, 253, 276, 291, 293, 298
pioglitazone, 212, 237
pituitary gland, 98
placebo, 97, 99, 113, 119
plants, 94, 207
plaque, 185
plasma membrane, 11, 25, 216, 217, 219, 220, 245,
254, 261, 267
plasmid, 157
plasticity, x, xi, 205, 230, 277, 289, 290
playing, 34
point mutation, 58, 254, 255, 275, 277
polarity, 17, 206, 226, 271
polymerase, 254
polymerase chain reaction (PCR), 6, 153, 254, 257,
294
314
Index
polymerization, 175
polymorphism, 176, 194
polypeptide(s), 56, 148, 162, 253, 268
polyunsaturated fat, 95
polyunsaturated fatty acids, 95
pools, 6
population, vii, 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16,
18, 33, 89, 176, 194, 255, 258
positive correlation, 5, 6, 132
positive feedback, 222, 223
positive relationship, 98
postnatal muscle, vii, 1, 2, 9
post-transcriptional regulation, 56, 152
potassium, 143
PRC, 256
precursor cells, 16, 22, 67, 69, 85, 177, 281
prediction models, 35
pregnancy, 300
preservation, 92, 115, 155, 156, 275
preservative, 299
prevention, 95, 101, 107, 110, 113, 121, 154, 155,
156, 159, 162, 206, 232, 290, 292
principles, 237
probe, 81
professionals, 106
progenitor cells, 4, 15, 17, 259, 280
pro-inflammatory, 22, 29, 33, 98, 162
proliferation, viii, 2, 3, 4, 5, 6, 7, 9, 17, 18, 25, 37,
50, 53, 54, 60, 62, 64, 65, 66, 67, 69, 70, 71, 73,
77, 78, 86, 89, 91, 255, 258, 260, 262, 263, 269,
271, 272, 279, 286, 291
proline, 23, 36, 38, 268
promoter, 29, 33, 55, 127, 151, 200, 218, 222, 223,
243, 244, 247, 257, 265, 266, 269, 279, 283, 291
propagation, 281
prostate cancer, 97
prostate specific antigen, 58, 75, 81
prosurvival, ix, 147
proteasome, ix, 27, 29, 30, 33, 34, 43, 51, 87, 101,
102, 107, 119, 120, 125, 128, 129, 137, 139, 140,
141, 147, 148, 153, 156, 157, 158, 162, 165, 178,
195, 203, 268
protection, 92, 103, 104, 148, 149, 154, 155, 158,
162, 163, 168, 186, 235
protective role, 154
protein components, 30, 172, 191
protein family, 200, 222
protein folding, 148, 158, 159
protein kinase C, 126, 137, 181, 197
protein kinases, 208, 209, 214, 216
protein oxidation, 137
protein structure, 81, 148
proteinase, 60, 61, 74, 266
Q
quadriceps, 107, 208, 218, 295
quality of life, vii, viii, 21, 22, 87, 95, 115, 290
quercetin, 114, 213, 237
R
Rab, 216, 217, 219, 241, 245
race, 18
radiation, 83, 161
radicals, 96, 131, 210
ramp, 62, 68
reactions, 124, 156
reactive oxygen, vii, x, 96, 121, 124, 137, 140, 141,
142, 147, 165, 205, 206, 230, 231, 252, 259, 267,
271, 276
reactivity, 96, 125
reading, 55
reagents, 143
reality, 235
receptors, viii, 2, 9, 33, 53, 54, 56, 63, 66, 69, 71, 80,
86, 95, 98, 99, 116, 211, 212, 215, 234, 293, 299,
300
recognition, 260
recommendations, 107, 110
reconstruction, 191
recovery, 2, 154, 155, 156, 163, 166, 173, 183, 202,
204, 235, 256, 259
recovery process, 183
recruiting, 67, 269
red wine, 213
redistribution, 197, 245
redundancy, 193, 200
regenerate, 4, 263, 266
regeneration, vii, 1, 2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 17, 23, 69, 72, 82, 85, 106, 139, 155, 158,
Index
159, 177, 188, 252, 253, 254, 255, 256, 258, 270,
273, 276, 277, 279
regenerative capacity, 2, 5, 89
regrowth, 154, 164
rehabilitation, 112, 114, 154
relaxation, 168, 291
relevance, 97, 232, 286
remodelling, 201
renal cell carcinoma, 279
repair, vii, 1, 2, 3, 7, 9, 10, 11, 14, 18, 67, 73, 77, 99,
148, 149, 189, 211, 254, 263, 266, 276
repetitions, 148, 295
replication, 7, 12, 255, 257, 259, 262, 282
repression, 27, 265, 282
repressor, 24, 25, 121, 135, 141, 218, 268
requirements, 105
researchers, 89, 99, 100
residues, 24, 25, 27, 56, 57, 58, 59, 64, 75, 125, 126,
132, 133, 207
resolution, 201
respiration, x, 205, 224, 236, 247, 248, 251, 253,
256, 257, 258, 259, 272, 277
respiratory rate, 256
responsiveness, 22
restoration, 16, 106, 162, 168, 248, 255, 262, 277,
279
restructuring, 271
resveratrol, 97, 114, 213, 223, 238, 248
retardation, 54, 61
reticulum, 130, 136, 137, 140, 143, 144, 155, 158,
161, 170, 209, 255, 256
retina, 111
retinoblastoma, 84
retinopathy, 255
reverse transcriptase, 265, 283
ribosomal RNA, 35, 253
ribosome, 37, 258
risk(s), vii, viii, 12, 22, 34, 87, 89, 97, 102, 120, 121,
291, 296
RNA(s), 253, 258, 259, 266, 275, 279, 280
rodents, viii, 28, 31, 53, 68, 91, 101, 155, 185, 186,
208, 214, 219, 224, 242, 295
root, 163
rosiglitazone, 212, 213, 236, 237, 249
roundworms, 207
rowing, 70
runoff, 265
S
salmon, 95
satellite cells, vii, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, 62, 67, 83, 84, 89, 91,
315
94, 100, 105, 115, 128, 157, 253, 255, 258, 259,
266, 276, 279, 280
saturated fat, 240
saturated fatty acids, 240
scavengers, 133
schema, 24, 161
science, 232
sclerosis, 25, 38, 39, 88
secrete, 56
secretion, 14, 32, 62, 69, 80, 98, 99, 210, 213, 291,
296
sedentary lifestyle, ix, 123, 128
segregation, 7, 17
selectivity, 239
seminal vesicle, 292
senescence, 35, 157
sensing, ix, 39, 171, 172, 206, 210, 227, 229
sensitivity, 126, 162, 174, 175, 217, 242
sensorineural hearing loss, 255
sensors, 227
sepsis, 43, 49, 101
sequencing, 111
serine, 23, 27, 58, 60, 61, 64, 65, 76, 77, 160, 165,
169, 180, 181, 207, 216, 224, 242, 266, 268
serum, 61, 62, 70, 77, 80, 85, 89, 95, 104, 106, 114,
115, 116, 118, 158, 159, 198, 269, 278, 286, 291,
296, 301
sex, xi, 22, 80, 98, 115, 116, 289, 290, 291, 292, 293,
295, 296, 297, 298, 300, 301
sex differences, 296
sex hormones, 98, 290, 301
sex steroid, xi, 115, 116, 289, 290, 291, 293, 295,
296, 297, 298, 300, 301
sex steroid hormones, xi, 289, 290, 291, 293, 295,
296, 297, 298
shock, ix, 136, 147, 151, 156, 162, 163, 164, 165,
167, 169, 170, 202, 210
showing, 3, 4, 6, 30, 33, 95, 184, 293
side chain, 126
side effects, 97, 99, 103
signal peptide, 56
signal transduction, vii, x, 37, 125, 126, 132, 134,
136, 158, 161, 162, 168, 171, 176, 179, 181, 182,
186, 240
signaling pathway, viii, 21, 29, 31, 33, 42, 64, 66, 71,
72, 77, 82, 84, 95, 101, 118, 125, 128, 130, 132,
144, 148, 172, 190, 194, 230, 236, 238, 269, 285
signalling, 4, 9, 10, 18, 35, 36, 37, 38, 39, 41, 48,
138, 168, 199, 233, 237, 285
signals, 23, 36, 42, 49, 55, 62, 68, 79, 104, 125, 172,
180, 186, 189, 198, 213, 215, 216, 226, 227, 238,
242, 261
signs, 95, 138
316
Index
single chain, 56
siRNA, 9, 26
skeleton, 116
skin, 7, 17, 213
sleep apnea, 97
smooth muscle, 64, 65, 80, 81, 203
smooth muscle cells, 64, 80, 81
soleus, 5, 16, 41, 85, 119, 133, 148, 149, 150, 154,
156, 157, 164, 166, 167, 168, 173, 174, 177, 185,
186, 187, 188, 189, 202, 203, 204, 208, 209, 212,
218, 230, 233, 245, 246
solution, 32
somatic cell, 280
specialization, 164
species, vii, ix, x, 88, 96, 121, 123, 124, 125, 126,
137, 141, 142, 147, 165, 169, 193, 205, 206, 208,
213, 214, 230, 231, 236, 252, 259, 267, 271, 276,
293, 295
spin, 132
spinal cord, 158, 168, 185, 187, 202
spinal cord injury, 168
spindle, 204
Spring, 13, 191, 276
stability, 59, 88, 264, 269, 282, 286
stabilization, 81, 91, 95, 185, 192, 264
starch, 227
starvation, 28, 44, 115, 139
state(s), 2, 4, 7, 10, 12, 19, 26, 27, 50, 62, 68, 69, 89,
132, 133, 156, 182, 232, 252, 254, 256, 257, 258,
265, 267, 279
stem cells, vii, 1, 4, 5, 6, 7, 11, 16, 17, 18, 67, 72,
100, 139, 252, 271
steroidogenic, xi, 289, 290, 292, 293, 294, 295, 297,
298
steroids, 291, 295
stimulation, 2, 9, 32, 41, 46, 48, 64, 66, 77, 99, 131,
143, 148, 149, 153, 154, 155, 162, 178, 180, 182,
183, 184, 198, 223, 229, 239, 290, 295, 296
stimulus, 3, 26, 31, 172
stomach, 99, 117
storage, 131
strength training, 67, 91, 109, 112, 229
stress response, ix, 26, 155, 162, 171, 179, 183, 231
stressors, 148, 151, 154, 162
stretching, 179, 187, 188
stroke, 101, 120, 206, 254
structural gene, 177
structural protein, 148
structure, ix, 5, 16, 45, 56, 57, 58, 59, 74, 101, 118,
131, 154, 166, 171, 172, 173, 175, 176, 186, 191,
193, 195, 197, 207, 226, 276
style, 22, 34, 124
substitution, 58, 185, 300
substrate(s), 23, 25, 29, 30, 36, 37, 38, 102, 105, 132,
140, 160, 178, 181, 206, 212, 216, 217, 225, 241,
242, 245, 261, 268, 292, 300
sucrose, 207, 216
sulfate, 61, 115, 290
Sun, 38, 39, 49, 72, 141, 144, 169, 202, 242, 286
supplementation, ix, 32, 34, 48, 87, 93, 94, 95, 96,
97, 98, 99, 102, 103, 107, 110, 111, 112, 113,
114, 115, 121, 137, 142, 240
suppression, 25, 41, 49, 135, 155, 158, 197, 220,
239, 282
survival, viii, 36, 38, 41, 44, 53, 63, 65, 66, 72, 86,
148, 152, 179, 237
susceptibility, 22, 148, 155
Sweden, 106
sympathetic nervous system, 211
symptoms, ix, 87, 97, 98, 224
synergistic effect, 93, 157
synthesis, 23, 25, 27, 30, 31, 32, 37, 46, 47, 48, 57,
60, 64, 65, 66, 83, 91, 93, 95, 96, 104, 110, 128,
131, 132, 156, 165, 206, 213, 215, 217, 220, 253,
255, 258, 259, 262, 276, 280, 290, 291, 295, 296,
298
synthesized activators, x, 205, 206
T
T cell(s), 117, 181, 261
T cell receptor, 261
tamoxifen, 15
target, x, xi, 9, 10, 21, 23, 30, 36, 37, 38, 39, 40, 42,
43, 45, 47, 54, 66, 68, 82, 88, 91, 98, 107, 118,
125, 127, 131, 133, 136, 144, 152, 159, 161, 178,
206, 235, 240, 264, 266, 268, 269, 282, 285, 289,
290, 291, 299
techniques, 182
technology, 259, 260
telomere, 265
temperature, 149, 153, 163, 165, 210, 231, 255
tendon, 101, 107, 179
tensile strength, 194
tension, 116, 173, 175, 176, 177, 187, 188, 190, 204
testis, xi, 289, 290, 293, 294, 296
testosterone, xi, 40, 54, 79, 97, 98, 99, 104, 114, 115,
116, 289, 290, 291, 292, 293, 294, 295, 298, 300
therapeutic approaches, 90
therapeutic effects, 111
therapeutic interventions, viii, 21, 32
therapeutic targets, viii, 87, 159
therapeutics, 206
therapy, 43, 97, 99, 158, 159, 160, 161, 163, 169,
277, 291, 298, 299
thermal treatment, 159
317
Index
thiazolidinediones, 212, 213
threonine, 23, 27, 42, 180, 181, 207, 216, 224, 227,
266, 268
thyroglobulin, 57, 74
thyroid, 149
tibialis anterior, 5, 100, 119, 149, 187, 188, 203, 218
tissue, vii, 5, 6, 7, 11, 54, 56, 60, 61, 72, 73, 77, 84,
88, 98, 99, 102, 113, 127, 130, 139, 159, 196,
207, 210, 211, 246, 252, 256, 274, 279, 291, 292,
293, 295
tissue homeostasis, 6, 7
titin, ix, 30, 45, 171, 173, 174, 176, 178, 179, 180,
183, 184, 188, 189, 190, 195, 197, 203
TNF-alpha, 44, 49, 121, 189
TNF-, 88, 95, 96, 98, 99, 103, 113, 128, 132, 215,
232, 240, 241
tonic, 172, 182, 187, 188
toxicity, 243
toxin, 3
trafficking, 217, 219, 245
transcription factors, x, 44, 66, 119, 125, 126, 135,
151, 167, 198, 205, 218, 221, 222, 223, 226, 244,
252, 255, 256, 257, 261, 265, 266, 284
transcripts, 28, 54, 55, 56, 70, 85, 108, 277
transduction, 77, 136, 192
transection, 158, 202
transfection, 159, 259
transfer RNA, 253
transformation, x, 80, 156, 167, 171, 181, 182, 198,
283
transforming growth factor (TGF), 9, 27, 60, 77, 83,
100, 117
translation, viii, 24, 25, 31, 37, 39, 45, 47, 48, 53, 55,
71, 110, 151, 152, 196, 253, 254, 257, 258, 259,
262, 263, 264, 283
translocation, x, 26, 96, 127, 131, 149, 154, 166,
178, 180, 181, 182, 183, 186, 199, 203, 205, 216,
217, 218, 219, 220, 235, 240, 241, 242, 245, 268
transmission, 177, 178, 179, 180, 188
transplantation, 2, 3, 5, 8, 9, 15, 18, 85, 168
transport, ix, 54, 56, 63, 91, 99, 123, 131, 133, 155,
167, 206, 217, 219, 220, 221, 223, 224, 225, 228,
230, 231, 233, 239, 241, 242, 243, 245, 249, 253,
256, 257, 271, 275, 276
trapezius, 83
trial, 90, 97, 107, 108, 109, 113, 116, 119, 120, 121,
237, 301
triggers, 156, 158, 175, 176, 186, 210
triglycerides, 106, 224, 248
triiodothyronine, 264
trypsin, 102
tumor, 14, 27, 29, 38, 39, 40, 41, 50, 60, 77, 78, 81,
88, 95, 114, 128, 137, 140, 158, 163, 202, 240,
241, 269
tumor cells, 81
tumor necrosis factor (TNF), 29, 33, 44, 49, 88, 95,
96, 98, 99, 103, 113, 121, 128, 129, 130, 132,
140, 189, 202, 215, 232, 240, 241, 269
tumorigenesis, 279
turnover, 17, 23, 43, 54, 56, 86, 120, 177, 178, 179,
208, 277
type 2 diabetes, x, 89, 131, 138, 142, 159, 163, 169,
170, 205, 206, 225, 229, 236, 237, 248, 249
tyrosine, 63, 75, 95, 112, 131, 133, 233
U
ubiquitin, ix, 23, 28, 29, 33, 34, 43, 44, 45, 51, 101,
119, 127, 128, 129, 139, 140, 141, 147, 148, 153,
156, 157, 158, 162, 165, 167, 171, 178, 189, 194,
195, 203, 226, 264, 292, 299, 300
ubiquitin-proteasome system, 23, 102, 140
ultrastructure, 190, 291
underlying mechanisms, x, 156, 251
uniform, 256
united, 95
United States, 95
untranslated regions, 152
ursolic acid, ix, 87, 88, 94, 96, 104, 112
V
valine, 47, 93
variations, x, 205
vascular cell adhesion molecule, 14
vascularization, 91
vastus lateralis, 89, 103, 139, 166, 218
VCAM, 2
vector, 209
vegetables, 213
velocity, 90, 143, 208, 228
ventilation, 194
versatility, 18
vertebrates, 4, 187, 281
vessels, 60, 78
vision, 235
vitamin C, 135, 145
vitamin D, 102, 104, 120, 121
vitamin D deficiency, 102
vitamin E, 132, 135, 143
volleyball, 194
318
Index
W
walking, 101
water, 93, 94, 162
weakness, viii, 11, 22, 34, 59, 87, 89, 102, 103, 104,
116, 135, 148, 155, 156, 179, 191, 299
web, 176, 193
weight control, 278
weight loss, 139
weight management, 105
western blot, 151, 153
wild type, 154, 174, 177, 180, 218, 219, 221, 223,
280
Wiskott-Aldrich syndrome, 261
withdrawal, 67, 80, 265, 283, 286
Wnt signaling, 77
workload, 172
worldwide, 102, 206
Y
yeast, 23, 30, 42, 207, 214, 227, 238, 245, 258, 279,
280
yolk, 192
young adults, 22, 30, 89, 91, 98
Z
zinc, 233, 265